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VII. Abbreviations	  
4EBP1	   	   eukaryotic	  translation	  initiation	  factor	  4E-­‐binding	  protein	  
AGC	   	   protein	  kinase	  A,	  protein	  kinase	  G,	  protein	  kinase	  C	  
Akt	  	   	   v-­‐akt	  murine	  thymoma	  viral	  oncogene	  homologue	  1	  (PKB)	  
AMPK	  	   	   AMP-­‐activated	  protein	  kinase	  
AS160	   	   Akt	  substrate	  of	  160kDa	  
ATP	   	   adenosine	  triphosphate	  
Bad	   	   Bcl-­‐2	  antagonist	  of	  cell	  death	  
BSA	   	   bovine	  serum	  albumin	  
cAMP	   	   cyclic	  adenosine	  monophosphate	  
CHAPS	   	   3-­‐[(3-­‐Cholamidopropyl)dimethylammonio]-­‐1-­‐propanesulfonate	  
C.	  elegans	   Caenorhabditis	  elegans	  
cpm	   	   counts	  per	  minute	  
C-­‐terminal	   carboxy-­‐terminal	  
Da	   	   Dalton	  
Deptor	   	   DEP	  domain	  containing	  mTOR	  interacting	  protein	  
DMEM	   	   Dulbecco's	  Modified	  Eagle's	  Medium	  
DMP	  	   	   dimethyl	  pimelimidate	  
DMSO	   	   dimethyl	  sulphoxide	  
DNA	  	   	   deoxyribonucleic	  acid	  
DSTT	   	   Division	  of	  Signal	  Transduction	  Therapy	  
DTT	  	   	   dithiothreitol	  
E.	  coli	   	   Escherichia	  coli	  
ECL	  	   	   enhanced	  chemiluminescence	  
EDTA	   	   ethylenediamine	  tetra	  acetic	  acid	  
EGF	  	   	   epidermal	  growth	  factor	  
EGTA	  	   	   ethyleneglycol	  bis	  (2-­‐aminoethylether)-­‐N,	  N-­‐tetra	  acetic	  acid	  
ERK	   	   extracellular	  signal	  regulated	  kinase	  
FBS	  	   	   foetal	  bovine	  serum	  
ENaC	   	   epithelial	  sodium	  channel	  
FOXO	  	   	   forkhead	  box	  O	  
GPCR	   	   G-­‐protein	  coupled	  receptor	  
GSK	  	   	   glycogen	  synthase	  kinase	  
GST	  	   	   glutathione	  S-­‐transferase	  
HA	  	   	   YPYDVPDYA	  peptide	  (haemagglutinin)	  
HEK293	  	   human	  embryonic	  kidney	  293	  
HeLa	   	   Henrietta	  Lacks	  
HPLC	  	   	   high	  performance	  liquid	  chromatography	  
HRP	  	   	   horseradish	  peroxidase	  
IB	   	   immunoblot	  
IC50	  	   	   concentration	  required	  for	  50%	  inhibition	  of	  enzyme	  activity	  
IGF1	   	   insulin-­‐like	  growth	  factor	  
IGFR	  	   	   insulin-­‐like	  growth	  factor	  receptor	  
IgG	  	   	   immunoglobulin	  G	  
IP	   	   immunoprecipitation	  
IRS	   	   insulin	  receptor	  substrate	   	  
ki	   kinase	  inactive	  
LPA	   lysophosphatidic	  acid	  
MAGI	   membrane-­‐associated	  guanylate	  kinase,	  WW	  and	  PDZ	  domain-­‐containing	  protein	  	  	  
MDM2	   	   mouse	  double	  minute	  2	  homolog	  
MEF	  	   	   mouse	  embryonic	  fibroblast	  
Mg-­‐ATP	  	   magnesium	  adenosine	  5'-­‐triphosphate	  complex	  
mLST8	  	   	   mammalian	  lethal	  with	  SEC13	  protein	  8	  
mRNA	  	   	   messenger	  ribonucleic	  acid	  
MS/MS	  	  	   tandem	  mass	  spectrometry	  
mTOR	  	   	   mammalian	  target	  of	  Rapamycin	  
NDRG1	  	  	   N-­‐myc	  downregulated	  protein	  1	  
Nedd	   Neural	  Precursor	  Cell-­‐Expressed	  Developmentally	  Down-­‐Regulated	  Protein	  	  
NHE	   	   sodium	  hydrogen	  exchanger	  	  
N-­‐terminal	   amino-­‐terminal	  
PBS	  	   	   phosphate	  buffered	  saline	  
PDGFR	   	   platelet-­‐derived	  growth	  factor	  receptor	  
PDK1	  	   	   3-­‐phosphoinositide-­‐dependent	  kinase	  1	  
PH	  	   	   pleckstrin	  homology	  
PI3K	  	   	   phosphoinositide	  3-­‐kinase	  
PIF	   	   PDK1	  interacting	  fragment	  
PKA	  	   	   protein	  kinase	  A	  (cAMP-­‐dependent	  protein	  kinase)	  
PKB	  	   	   protein	  kinase	  B	  (also	  known	  as	  Akt)	  
PKC	   	   protein	  kinase	  C	  
PMSF	  	   	   phenylmethanesulphonylfluoride	  
PPAR	   	   peroxisome	  proliferator-­‐activated	  receptors	  
PRAS40	  	   proline-­‐rich	  Akt	  substrate	  of	  40	  kDa	  
Protor	  	   	   protein	  observed	  with	  Rictor	  
PtdIns	   	   phosphatidylinositol	  
PTEN	   	   phosphatase	  and	  tensin	  homolog	  
PX	   	   phox	  homology	  domain	  
qRT-­‐PCR	   quantitative	  reverse	  transcription-­‐polymerase	  chain	  reaction	   	   	   	  
Raptor	  	  	   regulatory	  associated	  protein	  of	  mTOR	  
Rictor	  	   	   Rapamycin-­‐insensitive	  companion	  of	  mTOR	  
rpm	  	   	   revolutions	  per	  minute	  
RTK	   	   receptor	  tyrosine	  kinase	  
S6	  	   	   ribosomal	  S6	  protein	  
S6K	  	   	   p70	  ribosomal	  S6	  kinase	  
S.	  cerevisiae	  	   Saccharomyces	  cerevisiae	  
SDS	  	   	   sodium	  dodecyl	  sulphate	  
SDS-­‐PAGE	   sodium	  dodecyl	  sulphate	  polyacrylamide	  gel	  electrophoresis	  
SGK	  	   	   serum-­‐	  and	  glucocorticoid-­‐regulated	  protein	  kinase	  
Sin1	  	   	   SAPK-­‐interacting	  protein	  1	  
shRNA	  	   	   short	  hairpin	  RNA	  
TBST	   	   Tris-­‐buffered	  saline/tween	  
TFEB	   	   transcription	  factor	  EB	  
Tris	  	   	   Tris(hydroxymethyl)methylamine	   	  
TSC	   	   tuberous	  sclerosis	  
Tween	   	   polyethylene	  glycol	  sorbitan	  monolaurate	  
UTR	   	   untranslated	  region	  
wt	   	   wild	  type	  
w/v	  	   	   weight	  to	  volume	  
	  VIII. Amino	  Acid	  Code	  
Amino	  acid	   	   	   Three	  letter	  symbol	   	   One	  letter	  symbol	  
alanine	  	   	   	   	   Ala	   	   	   	   A	  
arginine	  	   	   	   	   Arg	  	   	   	   	   R	  
asparagine	  	   	   	   	   Asn	  	   	   	   	   N	  
aspartate	  	   	   	   	   Asp	  	   	   	   	   D	  
cysteine	  	   	   	   	   Cys	  	   	   	   	   C	  
glutamate	  	   	   	   	   Glu	  	   	   	   	   E	  
glutamine	   	   	   	   Gln	  	   	   	   	   Q	  
glycine	  	   	   	   	   Gly	  	   	   	   	   G	  
histidine	   	   	   	   His	   	   	   	   H	  
isoleucine	   	   	   	   Ile	   	   	   	   I	  
leucine	  	   	   	   	   Leu	  	   	   	   	   L	  
lysine	  	   	   	   	   	   Lys	  	   	   	   	   K	  
methionine	  	   	   	   	   Met	  	   	   	   	   M	  
phenylalanine	  	   	   	   Phe	   	   	   	   F	  
proline	  	   	   	   	   Pro	   	   	   	   P	  
serine	   	   	   	   	   Ser	   	   	   	   S	  
threonine	   	   	   	   Thr	   	   	   	   T	  
tryptophan	   	   	   	   Trp	   	   	   	   W	  
tyrosine	   	   	   	   Tyr	   	   	   	   Y	  
valine	   	   	   	   	  	  	  	   Val	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   V	  
any	  amino	  acid	  	  	  	  	  	  	  	   	   	   Xaa	   	   	   	   X	  
	   	  
IX. Summary	  
Phosphatidylinositide	   3-­‐kinase	   (PI3K)	   signalling	   pathway	   is	   a	   pivotal	   regulator	   of	   cell	  
growth,	   proliferation	   and	   survival	   and	   over	   70%	   of	   breast	   cancers	   harbour	   mutations	  
within	   this	   pathway.	   Accordingly,	   key	   components	   of	   this	   pathway	   have	   emerged	   as	  
promising	  targets	  for	  cancer	  drug	  discovery.	  Much	  research	  has	  focused	  on	  the	  role	  of	  Akt	  
as	   being	   the	   major	   mediator	   of	   PI3K	   in	   driving	   proliferation	   of	   tumour	   cells	   and	   by	  
comparison	  the	  closely	  related	  serum-­‐	  and	  glucocorticoid-­‐regulated	  kinase	  (SGK)	  isoforms	  
have	   received	   little	   attention.	   Understanding	   signaling	   mechanisms	   that	   have	   the	  
potential	  to	  confer	  resistance	  to	  cancer	  therapies	  is	  of	  great	  clinical	  relevance.	  The	  central	  
theme	  of	  my	  PhD	  work	  has	  focused	  on	  studying	  the	  roles	  that	  SGK	  isoforms	  play	  in	  breast	  
cancer	  cells	  that	  are	  either	  sensitive	  or	  resistant	  to	  Akt	  inhibitors.	  
In	  the	  first	  part	  of	  this	  thesis	  I	  describe	  the	  development	  of	  tools	  that	  were	  instrumental	  in	  
enabling	   the	   study	  of	   endogenous	   SGK	   isoforms	   in	   subsequent	   parts	   of	  my	  work.	   I	   first	  
utilized	   the	   novel	   antibody	   tools	   to	   the	   study	   the	   role	   of	   Protor,	   a	   recently	   identified	  
component	   of	   mTOR	   complex	   2	   (mTORC2),	   in	   the	   activation	   of	   SGK	   by	   mTORC2.	   I	  
demonstrate	   that	   in	  mice	   lacking	   both	   Protor	   isoforms	   activation	   of	   SGK	   is	   significantly	  
impaired	  in	  the	  kidney	  but	  not	  in	  other	  tissues	  or	  cells	  studied.	  mTORC2	  kinase	  activity	  is	  
not	   affected	   by	   the	   loss	   of	   Protor	   suggesting	   that	   Protor	   may	   act	   as	   a	   scaffold	   that	  
presents	  SGK	  for	  mTORC2	  in	  vivo.	  
In	   the	   second	   part	   of	   the	   present	   thesis	   I	   show	   that	   breast	   cancer	   cells	   that	   possess	  
elevated	  levels	  of	  SGK1	  mRNA	  and	  protein	  are	  inherently	  resistant	  to	  Akt	  inhibitors.	  These	  
findings	  indicate	  that	  elevation	  of	  SGK1	  expressions	  represents	  a	  mechanism	  of	  predicting	  
Akt	   inhibitor	   resistance	   and	   is	   therefore	   of	   significant	   relevance	   to	   the	   ongoing	  
development	   of	   Akt	   inhibitors	   for	   the	   treatment	   of	   cancer.	   Patients	   whose	   tumours	  
possess	  elevated	  levels	  of	  SGK1	  might	  be	  better	  treated	  with	  a	  combination	  of	  inhibitors	  
that	  suppress	  the	  activation	  of	  both	  SGK	  and	  Akt	  isoforms.	  I	  also	  show	  that	  in	  the	  absence	  
of	   significant	   SGK	   activity	   Akt	   can	   mediate	   phosphorylation	   of	   NDRG1,	   which	   has	  
previously	   been	   reported	   to	   comprise	   an	   SGK-­‐specific	   substrate.	   Therefore	   my	   work	  
emphasises	   that	   caution	   is	   required	  when	   employing	  NDRG1	   as	   a	   surrogate	  marker	   for	  
SGK	  activity.	  
In	  the	  third	  part	  of	  this	  thesis	  I	  show	  that	  Akt	  negatively	  regulates	  the	  levels	  and	  activity	  of	  
SGK3.	  Consequently,	  following	  prolonged	  Akt	  inhibition	  the	  activity	  and	  levels	  of	  SGK3	  are	  
elevated.	  Furthermore,	  I	  also	  present	  evidence	  that	  the	  induction	  of	  SGK3	  as	  a	  response	  to	  
chronic	  Akt	  inhibition	  represents	  a	  compensatory	  signaling	  mechanism	  as	  SGK3	  induction	  
reduces	   the	   ability	   of	   Akt	   inhibitors	   to	   suppress	   cell	   proliferation.	   Finally,	   my	   work	  
presented	   in	   Chapter	   5	   also	   indicates	   that	   the	   precise	   molecular	   mechanisms	   of	   SGK3	  
activation	  may	  need	  to	  be	  re-­‐evaluated	  in	  future	  work.	  
	   1	  
1. Introduction	  
1.1 	  Regulatory	  role	  of	  reversible	  protein	  phosphorylation	  
1.1.1 The	  role	  of	  protein	  phosphorylation	  in	  signal	  transduction	  
Living	   cells	   must	   appropriately	   receive	   and	   respond	   to	   extracellular	   signals	   in	   order	   to	  
undergo	  process	  such	  as	  cell	  differentiation,	  division	  or	  death.	  To	  achieve	  this,	  a	  cellular	  
signalling	   cascade	   is	   typically	   initiated	   by	   the	   binding	   of	   an	   external	   signalling	  molecule	  
such	   as	   a	   growth	   factor	   to	   a	   receptor	   embedded	   in	   the	   cell’s	   plasma	   membrane.	  
Subsequent	   activation	   of	   the	   receptor	   triggers	   activation	   of	   cellular	   enzymes	   ultimately	  
leading	  to	  a	  response.	  In	  order	  to	  propagate	  signals,	  activated	  enzymes	  frequently	  modify	  
cellular	  substrates	  by,	  for	  example,	  proteolytic	  cleavage	  or	  the	  covalent	  attachment	  of,	  for	  
instance,	  phosphate	  or	  carbohydrate	  groups.	  Phosphorylation	  is	  a	  key	  component	  of	  most	  
signal	   transduction	   cascades	   and	   is	   carried	   out	   by	   a	   group	   of	   enzymes	   termed	   kinases.	  
Typically	  protein	  kinases	  catalyse	  the	  transfer	  of	  γ-­‐phosphate	  of	  ATP	  to	  a	  Ser,	  Thr	  or	  Tyr	  
residue	  within	  the	  substrate	  protein.	  The	  global	  importance	  of	  protein	  phosphorylation	  is	  
illustrated	   by	   the	   facts	   that	   majority	   of	   human	   proteins	   are	   expected	   to	   be	  
phosphorylated,	   phosphorylation	   is	   an	   evolutionarily	   conserved	   mechanism	   found	  
amongst	  bacteria,	  archaea	  and	  eukaryotes	  and	  many	  diseases	  are	  caused	  by	  perturbations	  
of	  protein	  phosphorylation.	  	  	  
Phosphorylation	  is	  involved	  in	  the	  regulation	  of	  every	  conceivable	  cellular	  process.	  Despite	  
being	  a	  very	  simple	  process,	  phosphorylation	  is	  an	  excellent	  means	  for	  signal	  transduction.	  
Firstly,	   phosphorylation	   is	   reversible	   because	   the	   action	   of	   kinases	   can	   be	   reversed	   by	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another	   class	   of	   enzymes,	   termed	   phosphatases	   (Figure	   1.1A).	   Secondly,	   because	   a	  
phosphate	   group	   carries	   two	   negative	   charges,	   the	   addition	   of	   a	   phosphate	   group	  
introduces	  a	   considerable	   local	   charge	   change	   in	   the	   substrate	  protein.	  Phosphorylation	  
can	  thereby	  induce	  a	  conformational	  change	  that	  may	  affect	  the	  substrate	  in	  a	  number	  of	  
ways	  (Figure	  1.1B).	  For	  instance,	  if	  the	  substrate	  itself	  is	  an	  enzyme,	  phosphorylation	  can	  
alter	   its	  activity.	   In	   fact,	   the	  activity	  of	  many	  kinases	   is	   regulated	  by	  phosphorylation.	   In	  
addition	   phosphorylation	   may	   affect	   the	   ability	   of	   the	   protein	   to	   interact	   with	   other	  
proteins	  leading	  to	  altered	  localisation,	  stability	  or	  function	  (Figure	  1.1B).	  	  
	  
	  
Figure	  1.1	  Protein	  phosphorylation	  and	  its	  consequences	  on	  target	  proteins	  
(A)	  Protein	  kinases	  catalyse	  the	  transfer	  of	  the	  γ-­‐phosphate	  of	  ATP	  to	  an	  amino	  acid	  side	  
chain.	   The	   reverse	   reaction	   is	   catalysed	   by	   protein	   phosphatases.	   (B)	   Protein	  
phosphorylation	  can	  have	  wide-­‐ranging	  effects	  on	  the	  target	  protein	  including	  a	  change	  in	  
catalytic	  activity,	  protein:protein	  interactions,	  stability,	  function	  or	  localisation.	  
	  
The	   first	   description	   of	   a	   signalling	   system	   controlled	   by	   phosphorylation	   dates	   back	   to	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termed	   glycogen	   phosphorylase	   (Fischer	   and	   Krebs,	   1955;	   Krebs	   and	   Fischer,	   1956;	  
Sutherland	   and	  Wosilait,	   1955).	   Subsequently	   Protein	   kinase	   A	   (PKA)	  was	   shown	   to	   act	  
upstream	  of	  phosphorylase	  kinase	  (Walsh	  et	  al.,	  1968)	  thus	  explaining	  how	  adrenaline	  can	  
trigger	   glycogen	   breakdown	   in	   the	   muscle	   (Figure	   1.2).	   Analogous	   roles	   for	   protein	  
phosphorylation	   in	   controlling	   signal	   transduction	   cascades	   have	   since	   been	   widely	  
described.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1.2	  Signalling	  cascade	  leading	  to	  glycogen	  breakdown	  
Adrenaline	   binds	   to	  β-­‐adrenergic	   receptor,	   a	  G	   protein-­‐coupled	   receptor	   triggering	  GTP	  
loading	   of	   the	  α-subunit	   of	   heterotrimeric	   G	   proteins.	   GTP	   loaded	  α-­‐subunit	   associates	  
with	   and	   activates	   adenylate	   cyclase.	   The	   resulting	   cAMP	   activates	   PKA,	   which	  
phosphorylates	   and	   activates	   phosphorylase	   kinase,	   which	   in	   turn	   phosphorylates	   and	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1.1.2 Protein	  kinases	  –	  the	  human	  kinome	  
The	   human	   genome	   contains	  more	   than	   500	   protein	   kinases	   that	   comprise	   the	   kinome	  
(Figure	   1.3).	   Kinases	   share	   a	   similar	   catalytic	   region	   of	   approximately	   250-­‐300	   residues	  
(kinase	  domain)	  (Hanks	  et	  al.,	  1988)	  but	  vary	  considerably	  outside	  the	  kinase	  domain	  and	  
these	   variable	   regions	   tend	   to	   contain	   additional	   domains	   that	   frequently	   dictate	  
specificity,	  localisation	  and	  regulation.	  Based	  on	  sequence	  similarity	  the	  kinome	  is	  divided	  
into	   eight	   groups:	   AGC	   (PKA,	   PKG	   and	   PKC	   family),	   CAMK	   (Ca2+/Calmodulin-­‐dependent	  
kinases),	   CK1	   (Casein	   kinase	   1	   family),	   CMGC	   (CDK,	   MAPK,	   GSK3	   and	   CLK	   family),	   STE	  
(homologues	   of	   the	   yeast	   Sterile	   kinases	   family),	   TK	   (Tyrosine	   kinases	   family),	   TKL	  
(Tyrosine	  kinase-­‐like	   kinases	   family)	   and	  atypical	   kinases	   family	   (Manning	  et	   al.,	   2002b).	  
Members	   of	   the	   same	   group	   typically	   have	   similar	   substrate	   preferences	   and	   may	   be	  
regulated	  similarly.	  The	  atypical	  kinases	  do	  not	  share	  significant	  similarity	  with	  the	  kinase	  
domain	   but	   do	   posses	   kinase	   activity.	   One	   such	   kinase	   is	   the	   mammalian	   target	   of	  
rapamycin	   (mTOR).	   Interestingly,	   approximately	   10%	  of	  members	  of	   the	  human	  kinome	  
are	   pseudokinases	   that	   have	   retained	   the	   kinase	   fold	   but	   have	   lost	   residues	   that	   are	  
required	  for	  catalysis.	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Figure	  1.3	  The	  human	  kinome	  
About	  500	  kinases	  constitute	  the	  human	  kinome.	  This	  phylogenetic	  tree	  of	  the	  kinome	  is	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1.1.3 General	  features	  of	  a	  protein	  kinase	  
Structural	  insights	  into	  protein	  kinases	  were	  first	  gained	  when	  the	  catalytic	  domain	  of	  PKA	  
was	   crystallised	   (Knighton	   et	   al.,	   1991).	   Subsequent	   studies	   have	   found	   that	   the	   kinase	  
fold	  is	  remarkably	  well	  conserved.	  The	  kinase	  domain	  consists	  of	  12	  subdomains	  organised	  
into	   two	   lobes	   (Figure	   1.4).	   The	   smaller	   N-­‐terminal	   lobe	   (N-­‐lobe)	   (subdomains	   I-­‐IV)	   is	  
composed	  of	  a	   five-­‐stranded	  β-­‐sheet	  and	  one	  α-­‐helix	   (C-­‐helix)	  while	   the	  C-­‐terminal	   lobe	  
(C-­‐lobe)	  is	  α-­‐helical.	  A	  hinge	  region	  links	  the	  two	  domains	  and	  the	  interface	  between	  the	  
two	  lobes	  forms	  an	  important	  part	  of	  the	  active	  site.	  The	  N-­‐lobe	  is	  involved	  in	  the	  binding	  
and	   coordination	   of	   ATP	   and	   the	   C-­‐lobe	   plays	   a	   role	   in	   substrate	   binding	   and	   provides	  
residues	  that	  are	  essential	  for	  catalysis	  [reviewed	  in	  (Endicott	  et	  al.,	  2012)].	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1.4	  General	  features	  of	  a	  kinase	  domain	  and	  structure	  of	  SGK1	  kinase	  domain	  
(A)	  Subdomain	  organisation	  of	  protein	  kinases	  and	  key	  residues	  and	  motifs.	  (B)	  Structure	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Figure	  1.4B	  shows	  the	  crystal	  structure	  of	   inactive	  SGK1	  kinase	  domain.	  The	  structure	  of	  
SGK1	   catalytic	   domain	   closely	   resembles	   the	   canonical	   kinase	   domain	   fold	   but	   the	  
structure	  around	   the	  active	   site	   is	  unusual	   (discussed	  below)	   (Zhao	  et	  al.,	   2007).	  Within	  
the	   N-­‐lobe	   subdomain	   I	   contains	   a	   conserved	   a	   GxGxxG	   motif	   that	   binds	   to	   the	   non-­‐
transferable	  α-­‐	   and	  β-­‐	   phosphates	   of	   ATP.	   Subdomain	   II	   contains	  VAIK	  motif	  whose	   Lys	  
(Lys127	   in	   SGK1)	   binds	   and	   positions	   ATP,	   an	   interaction	   stabilised	   by	   residues	   within	  
subdomain	   III.	   Within	   subdomain	   VIB	   the	   C-­‐lobe	   contains	   the	   catalytic	   loop	   HRDxxxxN	  
motif,	   whose	   Asp	   functions	   as	   a	   proton	   acceptor	   for	   the	   phosphotransfer	   and	   the	   Asn	  
coordinates	  an	  Mg2+	  ion.	  	  	  Within	  subdomain	  VII	  the	  C-­‐lobe	  also	  contains	  DFG	  motif,	  which	  
coordinates	  a	  second	  Mg2+	   ion	  thereby	   facilitating	   the	  orientation	  of	   the	  γ-­‐phosphate	  of	  
ATP	   for	   transfer,	   and	  APE	  motif	  whose	  Glu	   forms	   a	   salt	   bridge	  with	   a	   conserved	  Arg	   in	  
subdomain	  XI,	  to	  promote	  stability	  of	  the	  C-­‐lobe.	  Between	  the	  DFG	  and	  APE	  motifs	  there	  
is	   a	   regulatory	   region	   called	   the	   activation	   loop	   (or	   T-­‐loop).	   Kinases	   are	   frequently	  
activated	  by	  phosphorylation	  within	  the	  T-­‐loop,	  which	  allows	  for	  the	  displacement	  of	  αC-­‐
helix	   and	   stabilisation	   of	   the	   N-­‐	   and	   C-­‐lobes	   in	   the	   active	   conformation	   permitting	   the	  
proper	  orientation	  of	   the	   substrate	   (Hanks	  and	  Hunter,	  1995;	   Johnson	  et	  al.,	   1998).	   For	  
SGK1	  and	  other	  related	  AGC-­‐family	  kinases	  phosphorylation	  of	  a	  conserved	  residue	  within	  
the	  T-­‐loop	  is	  required	  for	  activation.	  In	  SGK1	  the	  residue	  is	  Thr256	  and	  is	  phosphorylated	  
by	  3-­‐phosphoinositide	  dependent	  protein	  kinase-­‐1	  (PDK1)	  (Kobayashi	  and	  Cohen,	  1999).	  A	  
striking	   difference	   between	   structure	   of	   SGK1	   and	   that	   of	   other	   AGC	   kinases	   is	   the	  
absence	  of	  a	  clearly	  defined	  αC-­‐helix	  in	  SGK1	  (Zhao	  et	  al.,	  2007).	  A	  further	  unique	  feature	  
of	  SGK1	  is	  the	  conformation	  around	  the	  T-­‐loop.	  The	  conserved	  DFG	  motif	  of	  SGK1	  forms	  a	  
short	  β-­‐sheet	  with	  a	  region	  that	  corresponds	  to	  a	  part	  of	  αC-­‐helix	  of	  other	  kinases.	  The	  key	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residue	  required	  for	  activation	  of	  SGK1,	  Thr256,	  is	  located	  on	  the	  surface	  of	  SGK1.	  In	  the	  
inactive	  SGK1	  structure	  the	  T-­‐loop	  is	  in	  a	  conformation	  that	  would	  be	  expected	  to	  hinder	  
the	   binding	   of	   the	   substrate	   (Zhao	   et	   al.,	   2007).	   As	   of	   now	   it	   is	   unclear	   whether	   the	  
unusual	   features	   described	   are	   a	   true	   representation	   of	   the	   in	   vivo	   fold	   of	   SGK1	   or	  
whether	  they	  represent	  crystallisation	  artifacts.	  	  
In	   order	   to	   create	   kinase	   inactive	   mutants	   by	   site-­‐directed	   mutagenesis	   a	   number	   of	  
approaches	  can	  be	  taken.	  Commonly	  either	  (1)	  the	  Lys	  of	  VAIK	  motif,	  (2)	  the	  Asp	  of	  DFG	  or	  
(3)	  the	  Thr/Ser	  of	  T-­‐loop	  is	  mutated	  to	  an	  alanine.	  For	  example,	  for	  SGK1	  Lys127Ala	  (VAIK	  
motif)	  mutation	  is	  used	  in	  this	  study.	  	  
	  
1.1.4 Phosphorylation	  and	  human	  disease	  
Regulation	   of	   signal	   transduction	   by	   protein	   and	   lipid	   phosphorylation	   affects	   probably	  
every	   conceivable	   cellular	   process.	   Accordingly,	   mutations	   within	   enzymes	   that	   control	  
phosphorylation	   are	   linked	   to	   a	   wide	   spectrum	   of	   diseases.	   A	   number	   of	   hereditary	  
conditions	   are	   linked	   to	   mutations	   in	   kinases	   and	   these	   are	   listed	   in	   Table	   1.1.	  
Furthermore,	  sporadic	  and	  hereditary	  mutations	  in	  protein	  and	  lipid	  kinases	  are	  extremely	  
frequent	  in	  cancers	  and	  commonly	  described	  mutations	  are	  listed	  in	  Table	  1.2.	  The	  initial	  
observations	  linking	  kinases	  and	  human	  disease	  came	  from	  studies	  with	  viral	  oncogenes.	  
For	  example,	  v-­‐Src	  encoded	  by	  the	  Rous	  sarcoma	  virus	  is	  the	  constitutively	  active	  version	  
of	   the	   human	   proto-­‐oncogene	   c-­‐Src,	   which	   is	   a	   Tyr	   kinase	   (Hunter	   and	   Sefton,	   1980;	  
Stehelin	   et	   al.,	   1977).	   The	   importance	   of	   protein	   phosphorylation	   in	   human	   disease	   is	  
highlighted	  by	  the	  significant	  effort	  that	  has	  been	  devoted	  for	  the	  development	  of	  protein	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kinase	   inhibitors	   for	   the	   treatment	  of	   cancer	  and	  many	  “druggable”	  kinase	   targets	  have	  
also	   been	   identified	   to	   play	   critical	   roles	   in	   inflammation,	   auto-­‐immunity,	   hypertension	  
and	  Parkinson’s	  disease	  (Cohen	  and	  Alessi,	  2013).	  
Gene	  	   Protein	  name/function	   Disease	  
ACVR1	   ALK2	  (receptor	  	  Ser/Thr	  kinase)	   Fibrodysplasia	  ossificans	  progressiva	  	  
ACVRL1	   ALK1	  (receptor	  	  Ser/Thr	  kinase)	   Hereditary	  haemorrhagic	  telangiectasia	  type	  2	  	  
AKT2	   Akt2	  (Ser/Thr	  kinase)	   Atypical	  lipodystrophy	  	  
ALK	   ALK	  (receptor	  Tyr	  kinase)	   Neuroblastoma	  
AMHR2	   AMHR2	  (receptor	  Ser/Thr	  kinase)	   Persistent	  Mullerian	  duct	  syndrome	  type	  2	  
ATM	   ATM	  (Ser/Thr	  kinase)	   Ataxia	  telangiectasia	  
ATR	   ATR	  (Ser/Thr	  kinase)	   Seckel	  syndrome	  
BMPR1B	   ALK6	  (receptor	  Ser/Thr	  kinase)	   Brachydactyly	  type	  2A	  	  
BMPR2	   BMPR2	  (receptor	  Ser/Thr	  kinase)	   Primary	  pulmonary	  hypertension	  1	  	  
BRAF	   B-­‐Raf	  (Ser/Thr	  kinase)	   Cardio–facio–cutaneous	  syndrome	  	  
BTK	   BTK	  (Tyr	  kinase)	   Agammaglobulinemia	  
CASK	   CASK	  (Ser	  kinase)	   X-­‐linked	  mental	  retardation	  
CDKL5	   CDK5	  (Ser/Thr	  kinase)	   Early	  infantile	  epileptic	  encephalopathy	  type	  2	  	  
CHEK2	   CHK2	  (Ser/Thr	  kinase)	   Li–Fraumeni	  syndrome	  2	  	  
EIF2AK3	   EIF2AK3	  (Ser/Thr	  kinase)	   Wolcott-­‐Rallison	  syndrome	  
ERBB3	   ErbB-­‐3	  (receptor	  Tyr	  kinase)	   Lethal	  congenital	  contractural	  syndrome	  type	  2	  
FGFR1	   FGFR1	  (receptor	  Tyr	  kinase)	   Osteoglophonic	   dysplasia,	   Pfeiffer	   syndrome	   and	  
hypogonadotropic	  hypogonadism	  	  
FGFR2	   FGFR2	  (receptor	  Tyr	  kinase)	   Pfeiffer	   syndrome,	   Apert	   syndrome,	   Crouzon	  
syndrome	   and	   lacrimoauriculodentodigital	  
syndrome	  	  
FGFR3	   FGFR3	  (receptor	  Tyr	  kinase)	   Achondrodysplasia,	   thanatophoric	   dysplasia	   types	  
1	  and	  2	  and	  Muenke	  syndrome	  
FLT4	   FLT4	  (VEGFR3	  receptor	  Tyr	  kinase)	   Hereditary	  lymphedema	  type	  1A	  
GRK1	   GRK1	  (Ser/Thr	  kinase)	   Oguchi	  disease	  1	  	  
GRK4	   GRK4	  (Ser/Thr	  kinase)	   Hypertension	  
ICK	   ICK	  (Ser/Thr	  kinase)	   Endocrine–cerebro–osteodysplasia	  	  
IKBKG	   NEMO	   (regulatory	   subunit	   of	   IκB	  
kinase)	  
Hypohidrotic	   ectodermal	   dysplasia	   and	  
incontinentia	  pigmenti	  type	  2	  
INSR	   InsR	  (receptor	  Tyr	  kinase)	   Insulin-­‐resistant	   diabetes	   with	   acanthosis,	  	  
Donahue	  syndrome	  
IRAK4	   IRAK4	  (Ser/Thr	  kinase)	   Invasive	   pneumococcal	   disease	   and	   pyogenic	  
bacterial	  infections	  	  
JAK3	   JAK3	  (Tyr	  kinase)	   Severe	  combined	  immunodeficiency	  
KIT	   KIT	  (Tyr	  kinase)	   Piebaldism	  
LRRK2	   LRRK2	  (Ser/Thr	  kinase)	   Parkinson	  disease	  
LTK	   LTK(receptor	  Tyr	  kinase)	   Systemic	  lupus	  erythematosus	  
MAPK10	   JNK3	  (Ser/Thr	  kinase)	   Epileptic	  encephalopathy	  Lennox–Gaustaut	  type	  
MAP2K1	   MEK1	  (dual	  specificity	  protein	  kinase)	   Cardio–facio–cutaneous	  syndrome	  	  
MAP2K2	   MEK2	  (dual	  specificity	  protein	  kinase)	   Cardio–facio–cutaneous	  syndrome	  	  
MERTK	   MERTK	  (receptor	  Tyr	  kinase)	   Retinitis	  pigmentosa	  38	  
MUSK	   MuSK	  (receptor	  Tyr	  kinase)	   Myasthenic	  syndrome	  
NTRK1	   TrkA	  (receptor	  Tyr	  kinase)	   Congenital	  insensitivity	  to	  pain	  with	  anhidrosis	  
NTRK2	   TrkB	  (receptor	  Tyr	  kinase)	   Early	  obesity,	  hyperphagia,	  developmental	  delay	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PDGFRA	   PDGFRA	  (receptor	  Tyr	  kinase)	   Gastrointestinal	  stromal	  tumour	  
PHKA2	   Phosphorylase	  kinase	  α	  subunit	   Glycogen	  storage	  disease	  type	  9A	  (types	  1	  and	  2)	  	  
PHKG2	   Phosphorylase	  kinase	  γ	  subunit	   Glycogen	  storage	  disease	  type	  9C	  	  
PINK1	   PINK1	  (Ser/Thr	  kinase)	   Early-­‐onset	  Parkinson	  disease	  	  
PRKAA1	  
PRKAA2	  
AMPK	   α1/	   α	   2	   catalytic	   subunit	  
(Ser/Thr	  kinase)	  
Wolff-­‐Parkinson-­‐White	  syndrome	  
PRKAR1A	   PRKAR1A	  (regulatory	  subunit	  of	  cAMP-­‐
dependent	  protein	  kinases)	  
Primary	  pigmented	  nodular	  adrenocortical	  disease	  
and	  Carney	  complex	  	  
PRKCG	   PKC-­‐γ (Ser/Thr	  kinase)	   Spinocerebellar	  ataxia	  type	  14	  	  
RAF1	   c-­‐Raf	  (Ser/Thr	  kinase)	   Noonan	  syndrome	  type	  5	  and	  LEOPARD	  syndrome	  
type	  2	  	  
RET	   RET	  (receptor	  Tyr	  kinase)	   Multiple	   endocrine	   neoplasia	   type	   2B,	   familial	  
medullary	   thyroid	   carcinoma,	   familial	  
pheochromocytoma	   and	   Hirschsprung	   disease,	  
Congenital	   failure	   of	   autonomic	   control,	   renal	  
dysplasia	  
ROR2	   ROR2	  (receptor	  Tyr	  kinase)	   Robinow	  syndrome	  
RPS6KA3	   RSK2	  (Ser/Thr	  kinase)	   Coffin–Lowry	  syndrome	  	  
STK11	   LKB1	  (Ser/Thr	  kinase)	   Peutz–Jeghers	  syndrome	  	  
TEK	   TEK/Tie-­‐2	  (receptor	  Tyr	  kinase)	   Cutaneous	  and	  mucosal	  venous	  malformations	  
TTBK2	   TTBK2	  (Ser/Thr	  kinase)	   Spinocerebellar	  ataxia	  type	  11	  
TGFBR1	   TGFβ	  receptor	  1	  (Ser/Thr	  kinase)	   Loeys–Dietz	  syndrome	  (types	  1A	  and	  2A)	  	  
TGFBR2	   TGFβ	  receptor	  2	  (Ser/Thr	  kinase)	   Loeys–Dietz	  syndrome	  (types	  1B	  and	  2B)	  	  
TRPM7	   TRPM7	  (ion	  channel	  and	  kinase)	   Amyotrophic	  lateral	  sclerosis–Parkinsonism	  	  
WNK1/4	   WNK1/4	  (Ser/Thr	  kinase)	   Pseudohypo-­‐aldosteronism	  type	  2	  	  
ZAP70	   ZAP70	  (Tyr	  kinase)	   Severe-­‐combined	   immunodeficiency	   (T	   cell-­‐
negative)	  
	  
Table	  1.1	  Kinases	  mutated	  in	  human	  disease	  
	  Adapted	  from	  (Lahiry	  et	  al.,	  2010;	  Ortutay	  et	  al.,	  2005).	  
	  
Gene	  	   Protein	  name/function	   Alteration	  
AKT1/2/3	   Akt1/2/3	  (Ser/Thr	  kinase)	   Activation	  
ALK	   ALK	  (receptor	  Tyr	  kinase)	   Activation	  
BCR-­‐ABL	   BCR-­‐ABL	  (fusion	  Tyr	  kinase)	   Activation	  
(translocation)	  
BRAF	   B-­‐Raf	  (Ser/Thr	  kinase)	   Activation	  
CDK4/6	   CDK4	  (Ser/Thr	  kinase)	   Activation	  
CDK12	   CDK12	  (Ser/Thr	  kinase)	   Inactivation	  
EGFR	   EGFR2	  (receptor	  Tyr	  kinase)	   Activation	  
ERBB2	   HER-­‐2	  (receptor	  Tyr	  kinase)	   Activation	  
FGFR2	   FGFR2	  (receptor	  Tyr	  kinase)	   Activation	  
FGFR3	   FGFR3	  (receptor	  Tyr	  kinase)	   Activation	  
FLT3	   Fms-­‐related	  tyrosine	  kinase	  3	   Activation	  
ITK	   ITK	  (Tyr	  kinase)	   Activation	  
JAK1/2/3	   JAK2	  (Ser/Thr	  kinase)	   Activation	  
KDR	   VEGFR2	  (receptor	  Tyr	  kinase)	   Activation	  
KIT	   SCFR	  (receptor	  Tyr	  kinase)	   Activation	  
LCK	   LCK	  (Tyr	  kinase)	   Activation	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MAP2K1/2	   MEK1/2	  (dual	  specificity	  kinase)	   Activation	  
MAP2K4	   MEK4	  (dual	  specificity	  kinase)	   Inactivation	  
MET	   HGFR	  (receptor	  Tyr	  kinase)	   Activation	  
NTRK1/3	   Trk-­‐A/C	  (receptor	  Tyr	  kinase)	   Activation	  
PDGFRA	   PDGFRA	  (receptor	  Tyr	  kinase)	   Activation	  
PI3KCA	   PI3K	  (Catalytic	  	  subunit	  of	  Phosphoinositide-­‐3	  kinase)	  	   Activation	  
PI3KR1	   PI3K	  (Regulatory	  subunit	  of	  Phosphoinositide-­‐3	  kinase)	   Inactivation	  
PTEN	   PTEN	  (phospholipid	  PtdIns(3,4,5)P3	  3-­‐phosphatase	  and	  dual-­‐specificity	  
protein	  phosphatase)	  
Inactivation	  
STK11	   LKB1	  (Ser/Thr	  kinase)	   Inactivation	  	  
SYK	   SYK	  (Tyr	  kinase)	   Activation	  
	  
Table	  1.2	  Protein	  and	  lipid	  kinases	  and	  phosphatases	  frequently	  mutated	  in	  cancer	  
Adapted	  from	  (Forbes	  et	  al.,	  2011;	  Futreal	  et	  al.,	  2004).	  
	  
1.2 	  Overview	  of	  breast	  cancer	  
1.2.1 Acquired	  capacities	  of	  cancer	  cells	  
A	  seminal	  review	  published	  in	  2000	  proposed	  six	  acquired	  capacities	  that	  are	  fundamental	  
for	  the	  development	  of	  malignancies:	  (1)	  self-­‐sufficiency	  in	  growth	  signals,	  (2)	  insensitivity	  
to	   anti-­‐growth	   signals,	   (3)	   evasion	   of	   apoptosis,	   (4)	   tissue	   invasion	   &	   metastasis,	   (5)	  
limitless	   replicative	   potential	   and	   (6)	   sustained	   angiogenesis	   (Hanahan	   and	   Weinberg,	  
2000).	   Over	   the	   last	   decade	   four	   new	   hallmarks	   have	   emerged	   to	   complement	   earlier	  
understanding:	  (7)	  deregulation	  of	  cellular	  energetics,	  (8)	  evasion	  of	  immune	  destruction,	  
(9)	  genomic	  instability	  and	  (10)	  tumour	  promoting	  inflammation	  (Hanahan	  and	  Weinberg,	  
2011).	   These	   hallmarks,	   illustrated	   in	   Figure	   1.5,	   represent	   acquired	   alterations	   of	   cell	  
physiology	   that	   collectively	   enable	   the	   multistage	   development	   of	   malignant	   growth.	  	  
Genomic	   instability	   enables	   the	   phenotypic	   changes	   that	   give	   a	   selective	   advantage	   to	  
cancer	   cells	   to	   be	   acquired	   via	   a	   number	   of	   ways	   including:	   (1)	  mutations	   within	   gene	  
coding	   DNA	   sequences,	   (2)	   genomic	   alterations	   such	   as	   deletions,	   amplifications	   or	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translocations	   that	   result	   in	   altered	   gene	   expression,	   (3)	   epigenetic	   changes	   such	   as	  
changes	  to	  DNA	  methylation	  or	  histone	  acetylation	  that	  alter	  gene	  expression	  or	  (4)	  other	  
non-­‐mutational	  changes	  affecting	  gene	  expression.	  
	  
Figure	  1.5	  Multistage	  development	  of	  cancer	  
Ten	  hallmarks	  of	  cancer	  cells,	  adapted	  from	  (Hanahan	  and	  Weinberg,	  2011).	  	  
	  
One	   of	   the	   fundamental	   properties	   of	   cancer	   cells	   is	   the	   ability	   sustain	   chronic	  
proliferation.	   In	   normal	   tissues	   the	   release	   of	   growth	   promoting	   signals	   and	   the	   signal	  
transduction	   pathways	   activated	   by	   them	   are	   tightly	   controlled	   to	   ensure	   that	   cells	  
progress	   through	   the	   cell	   division	   cycle	   appropriately.	   This	   ensures	   the	  maintenance	   of	  
normal	  tissue	  architecture	  and	  function.	  In	  order	  to	  evade	  normal	  control	  of	  proliferation	  
cancer	  cells	  may,	   for	  example,	  produce	  their	  own	  growth	  factors	   for	  which	  they	  express	  
cognate	  receptors,	  stimulate	  normal	  cells	  within	  the	  tumour-­‐surrounding	  stroma	  to	  supply	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receptors	  or	  downstream	  signalling	  pathways	  or	  alter	  negative	  feedback	  loops	  which	  self-­‐
limit	  proliferative	  signal	  transduction	  (Figure	  1.6)	  (Hanahan	  and	  Weinberg,	  2011).	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1.6	  Cancer	  cells	  acquire	  the	  capacity	  to	  sustain	  limitless	  proliferation	  
In	  order	   to	  sustain	   limitless	  proliferation	  cancer	  cells	  may	  (A)	  produce	  their	  own	  growth	  
factors	   (B)	   stimulate	   surrounding	   stromal	   cells	   to	   supply	   growth	   factors	   (C)	   elevate	   the	  
expression	  and/or	  activity	  of	  growth	  factor	  receptors	   (D)	  elevate	  activity	  of	  downstream	  
signalling	  pathways	  or	  alter	  negative	  feedback	  loops	  that	  limit	  signal	  transduction.	  
	  
1.2.2 Classification	  and	  mutation	  analysis	  of	  breast	  cancers	  
Breast	   cancer	   is	   the	   most	   common	   cancer	   and	   remains	   the	   principle	   cause	   of	   cancer-­‐
related	  mortality	  in	  women	  worldwide	  accounting	  for	  23%	  of	  cancer	  diagnoses	  and	  14%	  of	  
cancer	  deaths	  globally	  in	  2008	  (Ferlay	  et	  al.,	  2010;	  Jemal	  et	  al.,	  2011).	  Like	  most	  cancers,	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according	   to	   their	   characteristic	   molecular	   features.	   The	   gene-­‐expression	   profiles	   that	  
breast	  cancers	  are	  most	  commonly	  classified	  according	  to	  are:	  luminal	  A,	  luminal	  B,	  Her2-­‐
enriched	  (human	  epidermal	  growth	  factor	  receptor	  2,	  also	  known	  as	  Neu	  or	  ERBB2)	  and	  
triple	   negative	   (also	   known	   as	   basal-­‐like)	   (Sorlie	   et	   al.,	   2001;	   Sorlie	   et	   al.,	   2003).	   This	  
classification,	   however,	   is	   not	   exhaustive	   and	   in	   reality	  many	   subclasses	  with	  distinctive	  
characteristics	   are	   proposed	   to	   exist.	   The	   key	   features	   of	   the	   main	   subtypes	   are	  
summarised	  in	  Table	  1.3.	   	  Understanding	  the	  driving	  genetic	  alterations	  of	  breast	  cancer	  
subtypes	  has	   led	  to	  the	  development	  of	  targeted	  therapies,	  some	  of	  which	  are	  currently	  
used	   in	   the	   clinic.	   The	   first	   targeted	   therapy	   for	   breast	   cancer	   dates	   back	   to	   the	   1970s	  
when	   a	   failed	   contraceptive	   ICI46474	   (Harper	   and	   Walpole,	   1966),	   which	   is	   an	   anti-­‐
oestrogenic,	  was	  reinvented	  as	  tamoxifen	  and	  targeted	  towards	  oestrogen	  receptor	  (ER)	  
positive	  tumours	  (Jordan	  and	  Koerner,	  1975).	  Since	  the	  development	  of	  tamoxifen	  many	  
other	   endocrine	   therapies	   that	   target	   the	   action	   of	   oestrogen	   have	   been	   described	   but	  
their	  efficacy	  is	  often	  found	  to	  be	  limited	  due	  to	  the	  emergence	  of	  resistance	  [reviewed	  in	  
(Musgrove	  and	  Sutherland,	  2009)].	  
Historically	   over-­‐expression	   of	   the	   receptor	   Tyr	   kinase	   Her2	   has	   been	   linked	   to	   poor	  
prognosis	  of	  breast	  cancer	  patients	  (Slamon	  et	  al.,	  1987).	  Survival	  of	  Her2	  over-­‐expressing	  
patients	  has	   improved	  with	   the	  development	  of	  drugs	  such	  as	  Trastuzumab	   (Herceptin).	  
Trastuzumab	   is	   a	   recombinant	   humanised	   anti-­‐Her2	  monoclonal	   antibody	   (Carter	   et	   al.,	  
1992).	   Subsequently	   other	   antibody-­‐based	   therapies	   as	   well	   as	   catalytic	   inhibitors	   (e.g.	  
lapatinib)	  of	  Her2	  and	  other	  related	  receptors	  have	  been	  developed.	  Whilst	  such	  therapies	  
improve	   the	  survival	  of	  patients	  over-­‐expressing	  Her2,	  acquisition	  of	   resistance	   to	   these	  
therapies	  is	  frequent	  [reviewed	  in	  (Arteaga	  et	  al.,	  2012;	  Baselga	  and	  Swain,	  2009)].	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Subtype	   Gene	  expression	  signature	   Approximate	  prevalence	   Available	  targeted	  therapy	  
Luminal	  A	  	   ER	  and/or	  PR	  positive	  
Her2	  negative	  
40%	   ER	   modulators	   such	   as	  
tamoxifen	  
Luminal	  B	  	   ER	  and/or	  PR	  positive	  
Her2	  amplified	  
20%	   ER	   modulators	   such	   as	  
tamoxifen	  
Her2-­‐enriched	   Hormone	  receptor	  negative	  
Her2	  amplified	  
10-­‐15%	   Her2	   inhibitors	   such	   as	  
trastuzumab	  	  
Triple	  negative	   Hormone	  receptor	  negative	  
Her2	  negative	  	  
15-­‐20%	   none	  
	  
Table	  1.3	  Breast	  cancer	  classification	  according	  to	  gene	  expression	  profiles	  
Abbreviations	   not	   defined	   in	   text:	   oestrogen	   receptor	   (ER),	   progesterone	   receptor	   (PR).	  
Adapted	  from	  (Sorlie	  et	  al.,	  2001;	  Sorlie	  et	  al.,	  2003)	  for	  the	  gene	  expression	  signatures,	  
prevalence	  data	  adapted	  from	  (Carey	  et	  al.,	  2006;	  Fan	  et	  al.,	  2006a).	  
	  
A	   recent	   study	  by	   the	  Cancer	  Genome	  Atlas	  Network	  determined	   the	  most	   significantly	  
altered	   genes	   in	   breast	   cancer	   patients	   by	   an	   exhaustive	   combination	   of	   copy	   number	  
analysis,	  DNA	  methylation	  analysis,	  exome	  sequencing,	  messenger	  RNA	  arrays,	  microRNA	  
sequencing	   and	   reverse-­‐phase	   protein	   arrays	   (Network,	   2012).	   Data	   is	   summarised	   in	  
Table	  1.4.	  Both	  this	  study	  and	  many	  others	  [recently	  reviewed	  (Miller	  et	  al.,	  2011;	  Polyak	  
and	   Metzger	   Filho,	   2012)]	   have	   found	   that	   phosphoinositide	   3-­‐kinase	   (PI3K)	   pathway	  
mutations	  are	  frequent	  in	  breast	  cancer	  with	  over	  70%	  of	  breast	  cancers	  being	  estimated	  
to	   harbour	   over-­‐activated	   PI3K	   pathway	   signalling.	   Notably,	   whilst	   the	   comprehensive	  
study	  of	  over	  800	  patient	  derived	  tumour	  samples	  revealed	  PI3K	  pathway	  mutations	  to	  be	  
most	   frequent	   in	   luminal	   and	   Her2-­‐enriched	   cancers,	   activity	   of	   the	   pathway	   was	  
conversely	   found	   to	   be	   highest	   in	   triple	   negative	   cancers	   (Network,	   2012).	   This	  
observation	   illustrates	   the	   importance	   of	   this	   pathway	   in	   all	   breast	   cancer	   subtypes.	  
Regulation	   of	   PI3K	   signalling	   and	   the	   consequences	   of	   mutations	   on	   the	   pathway	   are	  
considered	  in	  Section	  1.3.	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Gene	   Protein	  	   Alteration	   Mutation	  frequency	  	  
I.	  Genes	  involved	  in	  the	  PI3K	  Pathway	  
PI3KCA	   PtdIns(4,5)P2	   3-­‐kinase	  
catalytic	  subunit	  
Mutation,	  amplification	   49%	  of	  La	  
32%	  of	  Lb	  
7%	  of	  TN	  
42%	  of	  Her2	  
PI3KR1	   PtdIns(4,5)P2	   3-­‐kinase	  
regulatory	  subunit	  
Mutation	   3%	  of	  all	  
8%	  of	  Her2	  
PTEN	   PtdIns(3,4,5)P3	   3-­‐
phosphatase	   and	   dual-­‐
specificity	   protein	  
phosphatases	  
Mutation,	   deletion	   or	   loss	  
of	  expression	  
13%	  of	  La	  
24%	  of	  Lb	  
35%	  of	  TN	  
19%	  of	  Her2	  
INPP4B	   PtdIns(3,5)P2	  4-­‐phosphatase	   Loss	   9%	  of	  La	  
16%	  of	  Lb	  
30%	  of	  TN	  
30%	  of	  Her2	  
II.	  Genes	  not	  directly	  involved	  with	  the	  PI3K	  Pathway	  
TP53	   P53,	  transcription	  factor	   Inactivation	   12%	  of	  La	  
32%	  of	  Lb	  
84%	  of	  TN	  
75%	  of	  Her2	  
CDK4	   CDK4,	   kinase	   involved	   in	   cell	  
cycle	  
Amplification	   14%	  of	  La	  
25%	  of	  Lb	  
24%	  of	  Her2	  
Cyclin	  D1	   Cyclin	  D1,	  cell	  cycle	  	   Amplification	   29%	  of	  La	  
58%	  of	  Lb	  
38%	  of	  Her2	  
Cyclin	  E1	   Cyclin	  E1,	  cell	  cycle	  	   Amplification	   9%	  of	  TN	  
	  GATA3	   GATA3,	  
transcription	  factor	  
Inactivation	   11%	  
14%	  La	  
MAP3K1	   MAP3K1,	   kinase,	   activation	  
of	  JNK	  mediated	  apoptosis?	  
Inactivation	   14%	  of	  La	  
5%	  of	  Lb	  
MDM2	   MDM2,	   E3	   ligase,	   controls	  
P53	  stability	  
Amplification	   14%	  of	  La	  
31%	  of	  Lb	  
14%	  of	  TN	  
30%	  of	  Her2	  
MYC	   MYC,	  transcription	  factor	   Amplification	   40%	  of	  TN	  
RB1	   RB1,	  cell	  cycle	  suppression	   Inactivation	  
Deletion	  
2%	  of	  all	  
20%	  TN	  
	  
Table	  1.4	  Recent	  advanced	  in	  breast	  cancer	  mutation	  analysis	  	  
Abbreviations	  not	  defined	  in	  text:	  luminal	  A	  (La);	  luminal	  B	  (Lb);	  triple	  negative	  (TN);	  Her2-­‐
enriched	  (Her2).	  Adapted	  from	  (Network,	  2012).	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1.3 	  PI3K-­‐mTOR	  signalling	  
1.3.1 PI3K	  
PI3K	   signalling	  pathway	   is	  one	  of	   the	  many	   tightly	   controlled	  pathways	   that	   cells	  use	   to	  
respond	  to	  external	  messages	  in	  order	  to	  perform	  their	  normal	  functions	  such	  as	  glucose	  
metabolism,	   cell	   survival	   and	  proliferation.	  PI3	  kinases	  are	  divided	   into	   three	  classes,	   as	  
summarised	  in	  Table	  1.5.	  Class	  I	  PI3Ks	  are	  heterodimeric	  containing	  a	  regulatory	  p85	  and	  a	  
catalytic	  p110	  subunit	  [reviewed	  in	  (Vanhaesebroeck	  et	  al.,	  2010)].	  In	  the	  canonical	  Class	  I	  
PI3K	  signalling	  pathway,	  illustrated	  in	  Figure	  1.8,	  PI3K	  is	  activated	  following	  the	  binding	  of	  
growth	  factors	  such	  as	  insulin	  like	  growth	  factor	  1	  (IGF1))	  and	  hormones	  such	  as	  insulin	  to	  
cell	  surface	  receptor	  tyrosine	  kinases	  (RTK).	  Among	  others,	  these	  receptors	  include	  Her2.	  	  
Following	  binding	  of	  the	  ligand	  to	  the	  receptor	  a	  cascade	  of	  events	  comprising	  of	  receptor	  
dimerisation,	   autophosphorylation	   of	   Tyr	   residues	   and	   physical	   association	   of	   the	  
receptors	   with	   many	   cytoplasmic	   substrates	   is	   initiated.	   One	   such	   substrate	   is	   PI3K	  
regulatory	  subunit	  (PI3KR1),	  also	  known	  as	  p85,	  which	  associates	  with	  activated	  RTKs	  via	  
its	   SH2	   (src	   homology)	   domains	   that	   bind	   to	   phospho-­‐tyrosine	   (Escobedo	   et	   al.,	   1991;	  
Skolnik	  et	  al.,	  1991).	  Alternatively,	  p85	  can	  also	  be	  recruited	  to	  the	  plasma	  membrane	  via	  
activated	   G	   protein	   coupled	   receptors	   (GPCR)	   (Stephens	   et	   al.,	   1994)	   or	   via	   adaptor	  
proteins	  that	  act	  as	  intermediates	  between	  the	  activated	  receptor	  and	  p85	  such	  as	  insulin	  
receptor	   substrate	   -­‐1	   (IRS1)	   (Sun	   et	   al.,	   1991).	   Interaction	   of	   the	   PI3K	   catalytic	   subunit	  
p110	  with	   the	  small	  G-­‐protein	  Ras	  also	  contributes	   to	   the	  activation	  of	  PI3K	   (Rodriguez-­‐
Viciana	  et	   al.,	   1994).	  Plasma	  membrane	   recruitment	  brings	  PI3K	   to	  where	   its	   substrates	  
are	  and	  also	  relieves	  the	  inhibitory	  effect	  of	  p85	  on	  p110	  (Myers	  et	  al.,	  1998;	  Stambolic	  et	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al.,	   1998;	   Yu	   et	   al.,	   1998).	   	   Activated	   PI3K	   phosphorylates	   the	  membrane	   phospholipid	  
phosphatidylinositol	   4,5-­‐bisphosphate	   (PtdIns(4,5)P2)	   in	   the	   3-­‐position	   to	   yield	  
phosphatidylinositol	   3,4,5-­‐trisphosphate	   (PtdIns(3,4,5)P3)	   (Whitman	   et	   al.,	   1988	   ).	   The	  
action	  of	  PI3K	   is	   antagonised	  by	   the	   tumour	   suppressor	  PTEN	   (phosphatases	  and	   tensin	  
homolog	   deleted	   on	   chromosome	   10)	   which	   dephosphorylates	   PtdIns(3,4,5)P3	   to	   yield	  











Class	  I	   PtdIns(4,5)P2	   Classically	  activated	  at	  the	  
plasma	  membrane	  
Signalling	  contributes	  to	  for	  
example	  cellular	  proliferation,	  





p85	  isoform	  	  
(p85α,	  p85β,	  	  p55α,	  p55γ	  or	  
p50α)	  for	  p110α,	  β	  or	  δ	  	  	  
	  
p101	  or	  p87	  for	  p110γ	  
Class	  II	   PtdIns,	  
PtdIns(4)P?	  
Intracellular	  membranes	  and	  
plasma	  membrane	  
Functions	  poorly	  characterised,	  
include	  for	  example	  regulation	  







PtdIns	   Intracellular	  membranes	  
Autophagy,	  endocytosis,	  
phagocytosis,	  potentially	  amino	  
acid	  dependent	  activation	  of	  
mTORC1	  
Vps34	   Vps15	  
	  
Table	  1.5	  Classification	  of	  phosphoinositide	  3-­‐kinases	  
Adapted	  from	  (Vanhaesebroeck	  et	  al.,	  2010).	  
The	   creation	   of	   PtdIns(3,4,5)P3	   leads	   to	   the	   recruitment	   of	   proteins	   that	   contain	   a	  
PtdIns(3,4,5)P3	  binding	  pleckstrin	  homology	   (PH)	  domain	   to	   the	  plasma	  membrane.	  Two	  
such	   proteins	   are	   3-­‐phosphoinositide-­‐dependent	   protein	   kinase	   -­‐1	   (PDK1)	   (Alessi	   et	   al.,	  
1997a)	   and	   Akt	   (also	   known	   as	   protein	   kinase	   B,	   PKB)	   (James	   et	   al.,	   1996).	   Plasma	  
membrane	  recruitment	  of	  PDK1	  does	  not	  alter	  its	  catalytic	  activity	  (Currie	  et	  al.,	  1999)	  but	  
allows	   for	   the	   co-­‐localisation	   of	   PDK1	  with	   its	   substrate	  Akt	  whom	   it	   phosphorylates	   at	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Thr308	  leading	  to	  its	  activation	  (Alessi	  et	  al.,	  1997b).	  Akt	  controls	  the	  phosphorylation	  of	  
numerous	   substrates	   thereby	   influencing	   several	   cellular	   processes.	   Akt	   kinases	   are	  
discussed	  in	  more	  detail	  in	  Section	  1.4.	  	  
	  
1.3.2 mTOR	  
The	  mammalian	  target	  of	  rapamycin	  (mTOR)	  is	  a	  central	  integrator	  of	  cellular	  nutrient	  and	  
energy	   levels	   that	   controls	   cell	   growth	   and	   homeostasis.	   mTOR	   is	   the	   mammalian	  
homolog	  of	  yeast	  TOR	  which	  was	  identified	  as	  the	  target	  of	  the	  macrolide	  rapamycin	  that	  
gained	  attention	  due	  to	  its	  anti-­‐proliferative	  properties	  (Brown	  et	  al.,	  1994;	  Heitman	  et	  al.,	  
1991;	   Sabatini	   et	   al.,	   1994;	   Sabers	   et	   al.,	   1995).	   mTOR	   exists	   in	   at	   least	   two	   distinct	  
complexes	  termed	  mTOR	  complex	  1	  (mTORC1)	  and	  mTORC2.	  Both	  complexes	  contain	  the	  
Ser/Thr	   kinase	   mTOR	   and	   an	   accessory	   protein	   termed	   mammalian	   lethal	   with	   sec-­‐13	  
protein	  8	  (mLST8,	  also	  known	  as	  GβL)	  (Jacinto	  et	  al.,	  2004;	  Kim	  et	  al.,	  2003),	  DEP	  domain	  
containing	   mTOR-­‐interacting	   protein	   (Deptor)	   (Peterson	   et	   al.,	   2009)	   and	   Tt1/Tel2	  
complex	   (Kaizuka	  et	   al.,	   2010).	  Components	   that	  are	  unique	   to	  mTORC1	  are	   regulatory-­‐
associated	  protein	  of	  mammalian	  target	  of	  rapamycin	  (Raptor)	  (Hara	  et	  al.,	  2002;	  Kim	  et	  
al.,	  2002),	  and	  proline-­‐rich	  Akt	  substrate	  40	  kDa	  (PRAS40)	  (Sancak	  et	  al.,	  2007;	  Thedieck	  et	  
al.,	  2007;	  Vander	  Haar	  et	  al.,	  2007;	  Wang	  et	  al.,	  2007).	  Rapamycin-­‐insensitive	  companion	  
of	  mTOR	  (Rictor)	  (Jacinto	  et	  al.,	  2004;	  Sarbassov	  et	  al.,	  2004),	  mammalian	  stress-­‐activated	  
map	   kinase-­‐interacting	   protein	   1	   (mSin1)(Frias	   et	   al.,	   2006;	   Jacinto	   et	   al.,	   2006)	   and	  
protein	   observed	   with	   Rictor	   1	   and	   2	   (Protor1/2)	   (Pearce	   et	   al.,	   2007;	   Thedieck	   et	   al.,	  
2007;	   Woo	   et	   al.,	   2007)	   are	   unique	   to	   mTORC2.	   Rapamycin	   can	   be	   used	   to	   delineate	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functions	   of	   the	   two	   complexes,	   as	  mTORC1	   is	   acutely	   sensitive	   to	   rapamycin	   whereas	  
mTORC2	   is	   only	   affected	   by	   chronic	   rapamycin	   treatment.	   mTORC1	   is	   the	   better	  
characterised	   complex	   and	   its	   activity	   is	   regulated	   by	   a	   remarkably	   diverse	   array	   of	  
upstream	  signals.	  Briefly,	  mTORC1	  is	  regulated	  by	  at	  least	  (1)	  growth	  factor	  signalling,	  (2)	  
cellular	   stress,	   (3)	   cellular	   energy	   status,	   (4)	   oxygen	   and	   (5)	   amino	   acids.	   mTORC1	  
integrates	   these	   signals	   to	   control	   cell	   growth	   and	   proliferation	   by	   promoting	   anabolic	  
processes	   (for	   example	   protein	   and	   lipid	   biosynthesis)	   and	   by	   inhibiting	   the	   catabolic	  
process	   of	   autophagy	   [reviewed	   in	   (Laplante	   and	   Sabatini,	   2012)].	   The	   activation	   of	  
mTORC1	  by	  growth	   factor	   signalling	   is	   considered	   in	  more	  detail	  below.	  mTORC2	   is	  also	  
regulated	   by	   growth	   factors	   via	   as-­‐of-­‐yet	   poorly	   understood	   mechanisms.	   Increased	  
PtdIns(3,4,5)P3	   levels	   correlate	   with	   increased	  mTORC2	   activity	   and	   direct	   activation	   of	  
mTORC2	  by	  PtdIns(3,4,5)P3	  has	  been	  suggested	  (Gan	  et	  al.,	  2011).	  mTORC2	  has	  also	  been	  
shown	   to	   associate	   with	   ribosomes	   following	   PI3K	   activation	   and	   the	   activation	   of	  
mTORC2	  is	  suggested	  to	  be	  dependent	  on	  ribosomes,	  but	  not	  protein	  synthesis	  (Zinzalla	  et	  
al.,	  2011).	  By	  phosphorylating	  its	  best-­‐characterised	  substrates	  Akt,	  SGK	  and	  PKC,	  mTORC2	  
controls	  cell	  survival	  and	  proliferation	  and	  cytoskeletal	  organization	  (Laplante	  et	  al.,	  2012).	  
The	  compositions	  of	  the	  mTOR	  complexes,	  and	  an	  overview	  of	  their	  regulation	  and	  cellular	  
functions	  are	  illustrated	  in	  Figure	  1.7.	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Figure	  1.7	  Summary	  of	  mTOR	  complexes,	  their	  regulation	  and	  cellular	  roles	  
Adapted	  from	  (Laplante	  and	  Sabatini,	  2012).	  
	  
Role	  of	  PI3K-­‐PDK1-­‐Akt	  signalling	  in	  the	  growth	  factor	  regulation	  of	  mTORC1	  
As	   illustrated	   in	   Figure	   1.8,	   activation	   of	   Akt	   by	   PDK1	   contributes	   to	   the	   activation	   of	  
mTORC1	   by	   growth	   factors.	   Akt	   phosphorylates	   PRAS40	   leading	   to	   its	   dissociation	   from	  
mTORC1	   thus	   relieving	   the	   inhibitory	  effect	  of	  PRAS40	  on	  mTORC1	   (Sancak	  et	  al.,	  2007;	  
Thedieck	  et	  al.,	  2007;	  Vander	  Haar	  et	  al.,	  2007;	  Wang	  et	  al.,	  2007).	  Furthermore,	  Akt	  also	  
phosphorylates	  and	  inactivates	  tuberous	  sclerosis	  2	  (TSC2,	  also	  called	  tuberin)	  in	  order	  to	  
activate	   mTORC1	   (Inoki	   et	   al.,	   2002;	   Manning	   et	   al.,	   2002a).	   TSC2	   is	   part	   of	   a	  
heterodimeric	   complex	   together	  with	  TSC1.	  The	  TSC1/2	  complex	   functions	  as	  a	  GTPase-­‐
activating	   (GAP)	   for	   the	   Ras	   homolog	   enriched	   in	   brain	   (Rheb)	   GTPase.	   Rheb-­‐GTP	  
stimulates	  mTORC1	  kinase	  activity	  and	  as	  a	  Rheb	  GAP	  TSC1/2	  promotes	  the	  conversion	  of	  
active	  Rheb-­‐GTP	  to	  inactive	  Rheb-­‐GDP	  thereby	  inhibiting	  mTORC1	  (Inoki	  et	  al.,	  2003;	  Tee	  
et	   al.,	   2003).	   TSC1/2	   complex	   is	   phosphorylated	   and	   inactivated	   also	   by	   other	   effector	  































	   22	  
extracellular-­‐signal-­‐regulated	  kinases	  1/2	  (ERK1/2)	  (Laplante	  and	  Sabatini,	  2012;	  Ma	  et	  al.,	  
2005).	   Rheb-­‐GTP	   is	   only	   able	   to	   stimulate	   mTORC1	   in	   the	   presence	   of	   amino	   acids.	  
According	  to	  the	  current	  model,	  amino	  acids	  that	  have	  accumulated	  in	  the	  lysosome	  signal	  
via	   vacuolar	   v-­‐ATPase	   and	   a	   protein	   termed	   Ragulator	   to	   promote	   GTP	   binding	   to	   the	  
heterodimeric	  RagA/B	  GTPase	  and	  GDP	  binding	  to	  RagC/D	  heterodimer	  (Bar-­‐Peled	  et	  al.,	  
2012;	   Kim	   et	   al.,	   2008;	   Sancak	   et	   al.,	   2010;	   Sancak	   et	   al.,	   2008;	   Zoncu	   et	   al.,	   2011).	  
mTORC1	   is	   recruited	   to	   the	   activated	   GTP-­‐RagA/B	   heterodimer	   and	   is	   activated	   at	   the	  
lysosomal	   surface	   by	   GTP-­‐Rheb.	   During	   amino	   acid	   starvation	  mTORC1	   is	   diffuse	   in	   the	  
cytosol	  [reviewed	  in	  (Jewell	  et	  al.,	  2013;	  Laplante	  and	  Sabatini,	  2012)].	  	  
	  
1.3.3 Hyperactivation	  of	  PI3K	  signalling	  in	  breast	  cancer	  
As	  discussed	   in	   Section	   1.2.2,	   activity	   of	   the	   PI3K	  pathway	   is	   frequently	   up-­‐regulated	   in	  
breast	  cancer	  and	  this	  can	  be	  achieved	  by	  a	  number	  of	  ways,	  as	  illustrated	  in	  Figure	  1.9.	  
Briefly,	   frequently	   observed	   alterations	   include,	   but	   are	   not	   limited	   to,	   amplification	   of	  
RTKs,	   loss	  of	  PTEN	  or	   INPP4B	  (inositol	  polyphosphate-­‐4-­‐phosphatase)	  function,	  activating	  
mutations	   of	   p110	   catalytic	   subunit	   of	   PI3K,	   inactivating	   mutations	   of	   p85	   regulatory	  
subunit	   of	   PI3K	   or	   activating	   mutations	   of	   Akt	   or	   Ras.	   Interestingly	   INPP4B,	   which	  
preferentially	   dephosphorylates	   PtdIns(3,4)P2	   to	   yield	   PtdIns(3)P,	   is	   considered	   to	   be	   a	  
tumour	  suppressor	  that	  inhibits	  PI3K	  signalling	  through	  reducing	  Akt	  activation	  suggesting	  
that	   PtdIns(3,4,5)P3	   and	   PtdIns(3,4)P2	  may	   cooperate	   in	   Akt	   activation	   (Gewinner	   et	   al.,	  
2009).	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Figure	  1.8	  An	  overview	  of	  PI3K-­‐mTOR	  signaling	  	  
PI3K	  is	  activated	  downstream	  of	  receptor	  tyrosine	  kinases	  (RTK)	  either	  directly	  or	  via	  the	  
adaptor	   protein	   IRS1.	   PI3K	   is	   also	   stimulated	   by	   the	   small	   G-­‐protein	   Ras.	   PI3K	  
phosphorylates	   the	  membrane	   phospholipid	   PtdIns(4,5)P2	   (PIP2)	   to	   yield	   PtdIns(3,4,5)P3	  
(PIP3).	   The	   reverse	   reaction	   is	   catalysed	   by	   PTEN.	   PtdIns(3,4,5)P3	   generation	   stimulates	  
the	  activation	  of	  Akt	  by	  PDK1	  and	  mTORC2.	  mTORC2	  and	  PDK1	  also	  activate	  SGK	   family	  
members.	  Akt	  contributes	  to	  growth	  factor	  stimulated	  activation	  of	  mTORC1	  by	  relieving	  
the	   inhibitory	  effect	  of	  PRAS40	  on	  mTORC1.	  Akt	  also	  phosphorylates	  TSC2	   to	   inhibit	   the	  
TSC1/2	   complex	   leading	   to	   increased	  association	  of	   the	   small	  G-­‐protein	  Rheb	  with	  GTP.	  
GTP-­‐Rheb	   stimulates	  mTORC1.	   TSC1/2	   is	   also	   negatively	   regulated	   by	   the	   Ras-­‐Raf-­‐MEK-­‐
ERK	   pathway.	   During	   energy	   starvation	   AMP	   activated	   protein	   kinase	   (AMPK),	   which	   is	  
activated	  by	   the	   tumour	  suppressor	  LKB1,	   inhibits	  mTORC1	  by	  positively	   stimulating	   the	  
GAP	   activity	   of	   TSC1/2.	   At	   the	   lysosome	   amino	   acids	   signal	   via	   vacuolar	   v-­‐ATPase	   and	  
Ragulator	   to	   promote	   GTP	   binding	   to	   RagA/B	   and	   GDP	   binding	   to	   RagC/D.	   mTORC1	   is	  
recruited	   to	   the	   activated	   GTP-­‐RagA/B	   heterodimer	   and	   is	   activated	   at	   the	   lysosomal	  
surface	   by	   GTP-­‐Rheb.	   During	   amino	   acid	   starvation	   mTORC1	   is	   diffuse	   in	   the	   cytosol.	  
Tumour	  suppressors	  are	  indicated	  in	  green	  and	  oncogenes	  are	  indicated	  in	  red.	  mTORC2	  is	  
activated	  downstream	  of	  PI3K	  via	  poorly	  defined	  mechanism	  that	  may	  involve	  ribosomes.	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Figure	  1.9	  Up-­‐regulation	  of	  PI3K	  signalling	  	  
PI3K	  pathway	  can	  be	  up-­‐regulated	  by	  activating	  mutations	  or	  over-­‐expression	  of	  receptor	  
tyrosine	   kinases	   (RTK),	   p110	   catalytic	   subunit	   of	   PI3K,	   the	   small	   G-­‐protein	   Ras	   or	   the	  
kinase	  Akt.	  Alternatively	  PI3K	  pathway	  can	  be	  activated	  by	  loss	  of	  function	  or	  expression	  
of	   the	   p85	   regulatory	   subunit	   of	   PI3K,	   the	   PtdIns(3,4,5)P3	   3-­‐phosphatase	   PTEN	   or	   the	  	  
inositol	   polyphosphate-­‐4-­‐phosphatase	   (INPP4).	   Proteins	   that	   are	   frequently	   activated	   in	  
cancer	  are	  in	  red	  and	  those	  whose	  function	  is	  frequently	  lost	  in	  cancer	  are	  in	  green.	  
	  
1.4 	  The	  Akt	  family	  of	  protein	  kinases	  
Members	  of	  the	  Akt	  Ser/Thr	  kinase	  family	  are	  well	  characterised	  as	  downstream	  effectors	  
of	  PI3K	  signalling.	  The	  three	  Akt	  (Akt1/2/3)	  isoforms	  belong	  to	  AGC	  family	  of	  kinases	  and	  
they	   all	   contain	   an	   N-­‐terminal	   PtdIns(3,4,5)P3	   binding	   PH	   domain.	   Akt	   was	   initially	  
discovered	  as	   the	  oncogene	   in	  within	   the	  mouse	   leukemia	  virus	  AKT8	   (Staal,	  1987).	  The	  
generation	  of	  PtdIns(3,4,5)P3	  co-­‐localises	  	  PDK1	  and	  Akt	  kinases	  at	  the	  plasma	  membrane	  
due	  to	  their	  PtdIns(3,4,5)P3	  binding	  PH-­‐domains	  and	   induces	  a	  conformational	  change	   in	  
Akt	  that	  allows	  for	  the	  phosphorylation	  and	  activation	  of	  Akt	  by	  PDK1	  (Alessi	  et	  al.,	  1997b;	  
Calleja	  et	  al.,	  2007;	  Milburn	  et	  al.,	  2003).	  Besides	  the	  PDK1	  site	  (Thr308	  in	  Akt1),	  Akt	  also	  
contains	  a	  second	  growth	  factor	  regulated	  phosphorylation	  site,	  termed	  the	  hydrophobic	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mediated	  by	  mTORC2	  (Sarbassov	  et	  al.,	  2005)	  and	  it	  contributes	  to	  the	  efficient	  activation	  
of	  Akt	  (Hers	  et	  al.,	  2011;	  Najafov	  et	  al.,	  2011).	  A	  number	  of	  direct	  targets	  of	  Akt	  have	  been	  
identified	   and	   consequently	   Akt	   has	   been	   implicated	   in	   a	   number	   of	   cellular	   processes.	  
The	   best-­‐characterised	   substrates	   of	   Akt	   are	   summarised	   in	   Table	   1.6	   [reviewed	   in	  
(Manning	  and	  Cantley	  2007)].	  	  
Target	   Biological	  output	  of	  Akt-­‐mediated	  phosphorylation	  
TSC2	   Activation	  of	  mTORC1:	  cell	  growth	  (promotion	  of	  anabolic	  processes)	  
PRAS40	   "	  
BAD	   Inhibition	  of	  apoptosis	  
Caspase	  9	   "	  
ASK1	   "	  
FoxO	   Inhibition	  of	  apoptosis	  through	  transcriptional	  regulation	  
MDM2	  
Down-­‐regulation	   of	   P53	   leading	   to	   for	   example	   inhibition	   of	   apoptosis	   through	  
transcriptional	  regulation	  	  
Raf1	   Inhibits	  ERK	  signalling	  
eNOS	   Stimulation	  of	  angiogenesis	  
AS160	   Increased	  glucose	  uptake	  
GSK3	   Promotion	  of	  proliferation	  
p21Cip1/WAF1	   Promotion	  of	  progression	  through	  the	  cell	  cycle	  
p27Kip1	   "	  
Chk1	   Blocks	  cell	  cycle	  checkpoint	  
	  
Table	  1.6	  Best	  characterised	  Akt	  substrates	  	  
Only	   the	  most	   extensively	   characterised	   cancer	   relevant	   substrates	   are	   presented	   here.	  
Adapted	  from	  (Hers	  et	  al.,	  2011;	  Manning	  and	  Cantley,	  2007).	  	  
	  
Akt	  and	  cell	  survival	  
To	   promote	   cell	   survival	   Akt	   blocks	   the	   function	   or	   expression	   of	   many	   pro-­‐apoptotic	  
proteins	   (Hers	   et	   al.,	   2011;	   Manning	   and	   Cantley,	   2007).	   Akt	   for	   example	   directly	  
phosphorylates	   and	   inhibits	   the	   pro-­‐apoptotic	   Bcl-­‐2	   family	   member	   BAD	   (Datta	   et	   al.,	  
1997;	   del	   Peso	   et	   al.,	   1997)	   and	   inhibits	  members	   of	   the	  pro-­‐apoptotic	   forkhead	  box	  O	  
(FoxO)	  family	  of	  transcription	  factors.	  Akt	  phosphorylates	  FoxOs	  inducing	  their	  binding	  to	  
the	  adaptor	  protein	  14-­‐3-­‐3	  resulting	  in	  nuclear	  export	  and	  increased	  degradation	  via	  the	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ubiquitin-­‐proteasome	  pathway	   (Aoki	  et	  al.,	   2004;	  Biggs	  et	  al.,	   1999;	  Brunet	  et	  al.,	   1999;	  
Cahill	  et	  al.,	  2001;	  Kops	  et	  al.,	  1999).	  Akt	  also	  promotes	  survival	  by	  negatively	  regulating	  
p53	  levels	  and	  function	  through	  phosphorylation	  of	  the	  E3	  ubiquitin	  ligase	  mouse	  double	  
minute	  2	  homolog	  (MDM2)	  (Mayo	  and	  Donner,	  2001;	  Zhou	  et	  al.,	  2001).	  	  
Akt	  and	  cellular	  growth	  and	  metabolism	  
As	  previously	  described,	  Akt	  positively	  regulates	  mTORC1.	  Through	  phosphorylation	  of	  its	  
direct	  targets	  eukaryotic	  translation	  initiation	  factor	  4E	  (eIF4E)-­‐binding	  protein	  1	  (4E-­‐BP1)	  
and	  ribosomal	  protein	  S6	  kinase	  	  (S6K),	  mTORC1	  regulates	  protein	  translation.	  In	  addition	  
to	  regulation	  of	  protein	  synthesis	  mTORC1	  also	  regulates	  the	  synthesis	  of	   lipids	  required	  
by	  proliferating	  cells	  to	  generate	  sufficient	  membrane	  levels	  (Laplante	  and	  Sabatini,	  2012).	  
Akt	   activation	   also	   stimulates	   glucose	   uptake	   and	   leads	   to	   the	   translocation	   of	   glucose	  
transporter	   4	   (Glut4)	   to	   the	   plasma	   membrane	   (Kohn	   et	   al.,	   1996)	   through	  
phosphorylation	  of	  AS160	  (Sano	  et	  al.,	  2003).	  
Akt	  and	  cell	  proliferation	  
Akt	  contributes	  to	  promotion	  of	  cell	  proliferation	  through	  phosphorylation	  and	  inhibition	  
of	  for	  example	  the	  p27Kip1	  cyclin	  dependent	  kinase	  inhibitor	  (Liang	  et	  al.,	  2002;	  Shin	  et	  al.,	  
2002;	   Viglietto	   et	   al.,	   2002)	   as	   well	   as	   other	   targets	   (Hers	   et	   al.,	   2011;	   Manning	   and	  
Cantley,	   2007).	   Glycogen	   synthase	   3	   (GSK3)	  was	   the	   first	   direct	   target	   of	   Akt	   identified	  
(Cross	   et	   al.,	   1995).	   Phosphorylation	   of	   GSK3	   by	   Akt	   inhibits	   GSK3	   leading	   to	   the	  
stabilisation	   of	   many	   proteins	   that	   play	   key	   roles	   in	   G1-­‐to-­‐S-­‐phase	   cell	   cycle	   transition	  
thereby	   promoting	   progression	   through	   the	   cell	   cycle	   (Hers	   et	   al.,	   2011;	   Manning	   and	  
Cantley,	  2007).	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Somatic	  Akt	  mutations	  in	  cancer	  
Constitutive	  activation	  of	  Akt	   is	  associated	  with	  cancer.	  The	  oncogenic	  Akt	  protein	   from	  
the	   murine	   leukaemia	   retrovirus	   AKT8	   is	   a	   Gag-­‐Akt	   fusion	   protein	   that	   relies	   on	   a	  
constitutive	   membrane	   targeting	   myristoylation	   signal	   for	   being	   transforming	   in	   mice	  
(Ahmed	   et	   al.,	   1993).	   Moreover,	   a	   human	   cancer	   associated	   somatic	   mutation	   causing	  
Akt1	   Glu17Lys	   substitution	   within	   the	   PH	   domain	   causes	   constitutive	   Akt1	   plasma	  
membrane	   association	   and	   activation,	   transforms	   cells	   and	   induces	   leukaemia	   in	   mice	  
(Carpten	  et	  al.,	  2007).	  An	  analogous	  Glu17Lys	  mutation	  has	  also	  been	  reported	  to	  occur	  in	  
Akt2	  and	  Akt3	  (Davies	  et	  al.,	  2008;	  Stephens	  et	  al.,	  2012).	  Recently	  a	  novel	  translocation	  
between	  MAGI3	  and	  Akt3	  was	  described.	  The	  translocation	  leads	  to	  constitutive	  activation	  
of	   Akt3.	   The	   fusion	   protein	   retains	   most	   of	   Akt3	   but	   also	   contains	   MAGI3	   lacking	   its	  
second	   PDZ	   domain	   that	   is	   reported	   to	   bind	   PTEN	   and	   to	   contribute	   to	   the	   inhibitory	  
effect	  of	  PTEN	  on	  the	  PI3K	  pathway	  (Banerji	  et	  al.,	  2012;	  Wu	  et	  al.,	  2000).	  	  
Physiological	  roles	  of	  Akt	  isoforms	  
The	  three	  Akt	  isoforms	  are	  likely	  to	  posses	  some	  redundant	  functions	  but	  they	  also	  have	  
certain	  distinct	  roles.	  Akt1	  knockout	  mice	  have	  a	  decreased	  body	  size	  and	  partial	  neonatal	  
mortality	   phenotypes	   (Chen	   et	   al.,	   2001;	   Cho	   et	   al.,	   2001b;	   Yang	   et	   al.,	   2003).	   Akt2	  
knockout	   mice	   display	   only	   a	   modest	   growth	   defect	   but	   are	   impaired	   in	   the	   ability	   of	  
insulin	  to	  lower	  blood	  glucose	  levels	  due	  to	  defects	  of	  insulin	  action	  on	  liver	  and	  skeletal	  
muscle	  tissue.	  Consequently	  Akt2	  knockouts	  suffer	  from	  a	  type	  2	  diabetes-­‐like	  syndrome	  
(Cho	  et	  al.,	  2001a;	  Garofalo	  et	  al.,	  2003).	  Akt2	  was	  also	  recently	  shown	  to	  suppress	  hepatic	  
glycogenolysis	   (Wan	  et	   al.,	   2013).	  Akt3	   knockout	  mice	  have	  normal	   glucose	  metabolism	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and	  overall	  body	  size	  but	  present	  a	  decrease	  in	  brain	  size	  (Easton	  et	  al.,	  2005;	  Tschopp	  et	  
al.,	  2005).	  
	  
1.5 	  Use	  of	  PI3K	  pathway	  inhibitors	  to	  treat	  cancer	  
Due	   to	   its	   frequent	   aberrant	   activation	   in	   cancers	   and	   central	   role	   in	   the	   control	   of	  
processes	  such	  as	  cell	  survival	  and	  proliferation,	  the	  PI3K	  pathway	  is	  an	  attractive	  target	  
for	  anti-­‐cancer	  therapies.	  Many	  small	  molecule	  PI3K,	  mTOR,	  PDK1	  and	  Akt	  inhibitors	  have	  
been	  developed	  over	  the	  years.	  Whilst	  no	  oncogenic	  PDK1	  mutations	  have	  been	  reported,	  
the	  central	   role	  of	  PDK1	   in	  cancer	  signalling	   is	  evidenced	  by	   the	  observations	   that	  PDK1	  
over-­‐expression	  in	  cells	  causes	  transformation	  (Zeng	  et	  al.,	  2002)	  and	  PDK1	  hypomorphic	  
mice	  are	  protected	  from	  spontaneous	  tumourigenesis	  caused	  by	  reduced	  PTEN	  expression	  
(Bayascas	   et	   al.,	   2005).	   Despite	   this,	   development	   of	   PDK1	   inhibitors	   is	   not	   currently	  
active.	   The	   limited	   anti-­‐tumour	   activity	   of	   PDK1	   inhibitors	   is	   likely	   to	   be	   due	   to	  
insufficiently	  potent	  inhibition	  of	  Akt	  activation	  by	  PDK1	  inhibitors.	  Whilst	  PDK1	  inhibitors	  
potently	  suppress	  the	  activation	  of	  PDK1’s	  cytosolic	   targets	   (including	  SGK	  and	  S6K),	   the	  
efficient	  co-­‐localisation	  of	  Akt	  and	  PDK1	  at	  the	  plasma	  member	  renders	  Akt	  activation	  by	  
PDK1	  very	  efficient	  and	  hard	  to	  fully	  suppress	  with	  PDK1	  inhibitors.	  This	  is	  likely	  to	  explain	  
why	  even	  minimal	   residual	  PDK1	  activity	   is	   sufficient	   to	  cause	  Akt	  activation	   (Najafov	  et	  
al.,	   2011).	   With	   the	   exception	   of	   first-­‐generation	   mTOR	   inhibitors	   including	   rapamycin	  
(sirolimus)	   and	   its	   derivatives,	   no	   drugs	   targeting	   the	   PI3K	   network	   have	   yet	   been	  
approved	   for	   clinical	   use.	   	   Many	   such	   compounds	   are	   currently	   in	   clinical	   trials,	   as	  
summarised	   in	   Table	   1.7.	   For	   example,	   catalytic	  mTOR	   inhibitors,	  which	   unlike	   rapalogs	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inhibit	  both	  mTORC1	  and	  mTORC2	  efficiently,	  have	  yielded	  promising	  pre-­‐clinical	   results	  
[reviewed	  in	  (Willems	  et	  al.,	  2012)].	  
Compound	   Target(s)	   Status	   Company	   Comments	  
Combined	  PI3K–mTOR	  inhibitors	  
BEZ235	   PI3K,	  mTOR	   Phase	  I,	  II	   Novartis	   	  
XL765	   PI3K,	  mTOR	   Phase	  I	   Exelixis/Sanofi-­‐Aventis	   	  
GDC-­‐0980	   PI3K,	  mTOR	   Phase	  I	   Roche/Genentech	   	  
GSK1059615	   PI3K,	  mTOR,	  DNA-­‐PK	   Phase	  I	   GlaxoSmithKline	   	  
PKI-­‐587	   PI3K,	  mTOR	   Phase	  I	   Pfizer	   	  
PF-­‐04691502	   PI3K,	  mTOR	   Phase	  I	   Pfizer	   	  
Pan-­‐PI3K	  inhibitors	  
BKM120	   PI3K	  	   Phase	  I,	  II	   Novartis	   	  
SF1126	   PI3K	  and	  mTOR	   Phase	  I	   Semafore	   	  
PX-­‐866	   PI3K	   Phase	  I	   Oncothyreon	  Inc.	   	  
XL-­‐147	   PI3K	   Phase	  I	   Exelixis/Sanofi-­‐Aventis	   	  
GSK615	  	   PI3K	   Phase	  I	   GlaxoSmithKline	   	  
CH5132799	   PI3K	   Phase	  I	   Chugai	  Pharma	  Europe	  Ltd	   	  
GDC-­‐0941	   PI3K	  (p110α),	  Flt3	   Phase	  I	   Roche/	  Genentech	   	  
BAY	  80-­‐6946	   PI3K	   Phase	  I	   Bayer	   	  
Isoform-­‐specific	  PI3K	  inhibitors	  
Idelalisib	  (CAL-­‐101)	   PI3K	  (p110δ)	   Phase	  I,II,III	   Gilead	  Sciences	   	  
BYL719	   PI3K	  (p110α)	   Phase	  I	   Novartis	   	  
INK1117	   PI3K	  (p110α)	   Phase	  I	   Intellikine	   	  
GSK2636771 	   PI3K	  (p110β)	   Phase	  I	   GlaxoSmithKline	   	  
Akt	  inhibitors	  
Perifosine	  	   Akt,	  	   Phase	  I,	  II,	  III	   AEterna	  Zentaris	  	  
Promiscious.	  No	  effect	   in	  Phase	   III	   colorectal	   cancer	  
trial	   (Bendell	   et	   al.,	   2012).	   Phase	   III	   trials	   for	  
myeloma	  terminated.	  
Triciribine	  (API-­‐2)	   Akt	   Phase	  I	   VioQuest	  Pharmaceuticals	   	  
GDC-­‐0068	   Akt	   Phase	  I	   Roche/Genentech	   	  
AR-­‐67	  (DB-­‐67)	   Akt	   Phase	  I,	  II	   Arno	  Therapeutics	   	  
GSK690693	   Akt	   Phase	  I	   GlaxoSmithKline	   	  
VQD-­‐002	  (API-­‐2)	   Akt	   Phase	  I,	  II	   VioQuest	  Pharmaceuticals	   	  
MK-­‐2206	   Akt	   Phase	  I	   Merck	   	  
AZD5363	   Akt	   Phase	  I,	  II	   AstraZeneca	   	  
mTORC1	  inhibitors	  (rapamycin	  derivatives,	  rapalogs)	  
Sirolimus	   mTORC1	   Phase	  I,	  II	   Wyeth/Pfizer	   	  
Temsirolimus	   mTORC1	   Phase	  I,	  II,	  III	   Wyeth/Pfizer	   Approved	  for	  certain	  cancers	  	  
Everolimus	   mTORC1	   Phase	  I,	  II,	  III	   Novartis	   Approved	  for	  certain	  cancers	  	  
Ridaforolimus	   mTORC1	   Phase	  I,	  II,	  III	   Ariad/Merck	   Minor	  positive	  results	  from	  phase	  III	   (Demetri	  et	  al.,	  2013)	  	  	  
mTORC1/2	  inhibitors	  
AZD8055	   mTORC1/2	   Phase	  I,	  II	   AstraZeneca	   	  
AZD2014	   mTORC1/2	   Phase	  I,	  II	   AstraZeneca	   	  
OSI-­‐027	   mTORC1/2	   Phase	  I	   OSI	  Pharmaceuticals	   Completed,	  no	  active	  trials	  	  
INK-­‐128	   mTORC1/2	   Phase	  I	   Intellikine	   	  
CC-­‐223	   mTORC1/2,	  DNA-­‐PK	   Phase	  I,	  II	   Celgene	   	  
Table	  1.7	  Compounds	  targeting	  the	  PI3K	  pathway	  currently	  in	  clinical	  trials	  
Adapted	  from	  (Rodon	  et	  al.,	  2013;	  Weigelt	  and	  Downward,	  2012)	  and	  data	  retrieved	  from	  
http://www.clinicaltrials.gov/,	  accessed	  July	  2013.	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1.5.1 Feedback	  regulation	  of	  signalling	  networks	  
In	   order	   to	   appropriately	   respond	   to	   signal	   transduction	   cascades	   cells	   must	   have	   the	  
capacity	  to	  down-­‐regulate	  and	  switch	  off	  activated	  signalling	  pathways.	  Phosphatases	  for	  
example	   reverse	   the	   action	   of	   kinases	   and	   consequently	   often	   inactivate	   signalling	  
cascades.	  This	  is	  true	  for	  example	  in	  the	  case	  of	  the	  lipid	  phosphatase	  PTEN	  that	  catalyses	  
the	   reverse	   reaction	   of	   PI3K.	   	   The	   importance	   of	   appropriate	   regulation	   of	   cellular	  
signalling	   is	   highlighted	   by	   the	   notion	   that	   PTEN	   null	   mice	   are	   embryonic	   lethal	   (Di	  
Cristofano	  et	  al.,	  1998;	  Podsypanina	  et	  al.,	  1999;	  Suzuki	  et	  al.,	  1998)	  indicating	  that	  in	  the	  
absence	  of	  this	  negative	  regulator	  development	  fails	  to	  occur	  normally.	  	  	  
Physiological	   responses	   to	   signalling	   networks	   are	   also	   regulated	   and	   fine-­‐tuned	   by	  
feedback	  inhibition	  of	  components	  of	  the	  activated	  networks.	  Such	  feedback	  regulation	  is	  
a	   feature	   of	   both	   normal	   and	   transformed	   cells.	   Negative	   feedback	   is	   a	   universal	  
mechanism	  for	  limiting	  the	  duration	  and	  strength	  of	  signalling	  output.	  In	  cancer	  cells	  relief	  
of	  negative	  feedback	  control	  may	  be	  a	  common	  response	  to	  many	  anti-­‐cancer	  drugs	  that	  
target	  nodes	  of	  signalling	  pathways.	  For	  example	  the	  use	  of	  mTOR	  inhibitors	  has	  revealed	  
that	   inhibition	   of	   mTORC1	   leads	   to	   elevated	   PI3K	   activation	   as	   it	   relieves	   negative	  
feedback.	   Indeed,	   in	   vivo	   mTORC1	   inhibition	   has	   been	   shown	   to	   lead	   to	   Akt	   activation	  
(O'Reilly	  et	  al.,	  2006;	  Sun	  et	  al.,	  2005)	  as	  wells	  as	  ERK	  activation	  (Carracedo	  et	  al.,	  2008).	  	  
When	   active,	   mTORC1	   phosphorylates	   S6K	   that	   subsequently	   phosphorylates	   IRS1/2	  
targeting	   them	   for	   degradation	   causing	   down-­‐regulation	   of	   the	   RTK-­‐PI3K	   signalling	  
(Harrington	   et	   al.,	   2004;	   Haruta	   et	   al.,	   2000;	   Shah	   et	   al.,	   2004).	   mTORC1	   also	   directly	  
phosphorylates	   adaptor	   protein	  Grb10	   enhancing	   its	   stability	   and	   its	   ability	   to	   suppress	  
PI3K	   activation	   (Hsu	   et	   al.,	   2011;	   Yu	   et	   al.,	   2011).	   Pre-­‐clinical	   characterisation	   of	  mTOR	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kinase	   inhibitors	   has	   revealed	   bi-­‐phasic	   regulation	   of	   Akt.	   mTORC1/2	   inhibition	   	   first	  
causes	  a	   transient	   inhibition	  of	  Akt	  due	  to	   loss	  of	  Akt	  Ser473	  phosphorylation	  and	  rapid	  
but	   transient	   inhibition	   of	   Akt	   Thr308	   phosphorylation.	   Sustained	  mTORC1/2	   inhibition,	  
due	  to	  relieved	  feedback	  inhibition,	  however	  leads	  to	  RTK-­‐PI3K	  activation	  and	  subsequent	  
activation	  of	  Akt	  by	  phosphorylation	  of	  Thr308	  by	  PDK1	  (Rodrik-­‐Outmezguine	  et	  al.,	  2011).	  	  
Modulation	   of	   feedback	   inhibition	   is	   also	   associated	   with	   Akt	   inhibitors.	   The	   FoxO	  
transcription	  factors	  comprise	  a	  key	  subset	  of	  Akt	  substrates.	  Many	  FoxO	  targets	  are	  pro-­‐
apoptotic	  and	  via	   inhibition	  of	  FoxOs	  Akt	  plays	  a	  pro-­‐survival	   role.	  FoxOs,	  however,	  also	  
transcriptionally	  up-­‐regulate	  RTKs.	  Akt	  inhibition	  therefore	  relieves	  two	  negative	  feedback	  
components	  of	  the	  PI3K	  pathway.	  Firstly,	  due	  to	  activation	  of	  FoxOs	  Akt	  inhibition	  relieves	  
suppression	  of	  RTK	  expression	  resulting	  in	  increased	  levels	  of	  RTKs	  (Chandarlapaty	  et	  al.,	  
2011).	  Secondly,	  as	  discussed	  in	  Section	  1.3.2,	  Akt	  positively	  regulates	  mTORC1	  via	  PRAS40	  
and	  TSC2.	  Consequently	  Akt	  inhibition	  leads	  to	  reduced	  mTORC1	  activity	  and	  subsequently	  
via	  IRS1/2	  and	  Grb10	  to	  enhanced	  RTK-­‐PI3K	  activation.	  Figure	  1.10	  illustrates	  the	  current	  
understanding	  of	  feedback	  mechanisms	  that	  operate	  within	  the	  PI3K-­‐mTOR	  pathway.	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Figure	  1.10	  Feedback	  regulation	  within	  the	  PI3K	  pathway	  
Receptor	  tyrosine	  kinase	  (RTK)	  activation	  stimulates	  PI3K-­‐AKT	  activity	  causing	  inhibition	  of	  
FoxO-­‐mediated	  RTK	   transcription.	   RTK	   stimulation	   also	   activates	  mTORC1,	  which	  directs	  
inhibitory	  feedback	  to	  the	  pathway	  via	  S6K-­‐IRS1	  and	  Grb10.	  	  	  
	  
1.6 	  The	  SGK	  family	  of	  protein	  kinases	  
Most	  work	  has	  focused	  on	  Akt	  as	  being	  the	  key	  mediator	  of	  cell	  proliferation	  induced	  by	  
activation	   of	   PI3K.	   A	   closely	   related	   enzyme	   termed	   SGK	   (serum-­‐	   and	   glucocorticoid-­‐
regulated	   kinase)	   has	   by	   comparison	   received	   little	   attention.	   Three	   SGK	   isoforms	   exist	  
and	  like	  Akt,	  SGKs	  also	  belong	  to	  the	  AGC	  family	  of	  kinases.	  The	  domain	  structures	  of	  the	  
three	   SGK	   isoforms,	   which	   share	   about	   80%	   identity	   within	   their	   kinase	   domains	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kinase	   domain	   that	   harbours	   their	   T-­‐loop	   phosphorylation	   site	   and	   a	   conserved	   AGC	  
kinase	   C-­‐terminal	   tail	   that	   harbours	   the	   second	   key	   regulatory	   site,	   termed	   the	  
hydrophobic	   motif	   (HM).	   SGK3	   contains	   an	   additional	   phosphoinositide	   binding	   Phox	  
homology	  (PX)	  domain	  [reviewed	  in	  (Pearce	  et	  al.,	  2010b)].	  The	  SGK	  family	  members	  are	  
closely	   related	   to	   Akt	   sharing	   about	   45-­‐55%	   identity	   within	   their	   catalytic	   domains	  
(Webster	   et	   al.,	   1993b).	   SGK	   and	   Akt	   kinase	   phosphorylate	   substrates	   within	   similar	  
consensus	   sequences:	   Arg-­‐Xaa-­‐Arg-­‐Xaa-­‐Xaa-­‐Ser/Thr	   (Alessi	   et	   al.,	   1996;	   Murray	   et	   al.,	  
2005)	  and	  are	  consequently	  likely	  to	  possess	  some	  overlapping	  substrates	  and	  functions.	  
SGK	  kinases	  are	  evolutionarily	   conserved.	  Yeast	  contains	   two	  SGK	  orthologues	  Ypk1	  and	  
Ypk2,	  which	  are	  required	  for	  endocytosis	  and	  proliferation	  (Casamayor	  et	  al.,	  1999;	  deHart	  
et	  al.,	  2002).	  
	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1.11	  The	  serum-­‐	  and	  glucocorticoid-­‐regulated	  kinases	  
SGK	   isoforms	   share	   a	   conserved	   kinase	   domain	   and	   AGC	   kinase	   C-­‐terminal	   tail.	   SGK3	  
additionally	  contains	  a	  phosphoinositide	  binding	  Phox	  homology	  (PX)	  domain.	  The	  T-­‐loop	  
phosphorylation	   sites	   are	   indicated	   in	   red	   and	   the	   hydrophobic	   motif	   (HM)	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Mechanism	  of	  activation	  of	  SGK	  family	  members	  
SGK	  family	  members	  also	  share	  their	  upstream	  activators	  with	  Akt.	  Like	  Akt	  kinases,	  SGKs	  
too	  are	  phosphorylated	  by	  PDK1	  within	  their	  T-­‐loop	  site	  (Thr256	  in	  SGK1)	  (Kobayashi	  and	  
Cohen,	   1999;	   Park	   et	   al.,	   1999)	   and	   by	  mTORC2	  within	   their	   HM	   site	   (Ser422	   in	   SGK1)	  
(Garcia-­‐Martinez	  and	  Alessi,	  2008).	  The	  molecular	  mechanism	  of	  SGK	  activation,	  however,	  
varies	  from	  that	  of	  Akt	  kinases	  because	  SGKs	  do	  not	  possess	  a	  PtdIns(3,4,5)P3	  binding	  PH	  
domain	  and	  therefore	  their	  phosphorylation	  by	  PDK1	  is	  believed	  to	  occur	  in	  the	  cytosol,	  as	  
illustrated	   in	  Figure	  1.12.	  Growth	  factor	  signalling	  activated	  mTORC2	  phosphorylates	  the	  
HM-­‐site	   of	   SGKs	   (Ser422	   in	   SGK1)	   allowing	   the	   phosphorylated	   HM	   to	   interact	   with	   a	  
region	   termed	   the	   PDK1	   interacting	   fragment	   (PIF)-­‐binding	   pocket	   within	   the	   catalytic	  
domain	   of	   PDK1	   (Biondi	   et	   al.,	   2001).	  HM-­‐site	   phosphorylation	   and	   the	   integrity	   of	   PIF-­‐
binding	  pocket	  are	  essential	  for	  the	  phosphorylation	  and	  activation	  of	  SGKs,	  but	  not	  Akt,	  
by	  PDK1.	  This	  is	  genetically	  demonstrated	  by	  studies	  in	  knock-­‐in	  embryonic	  stem	  (ES)	  cells	  
in	  which	  the	  PIF-­‐binding	  pocket	  of	  PDK1	  is	  disrupted	  by	  Leu155Glu	  (Collins	  et	  al.,	  2003)	  or	  
Arg131Met	   (Collins	   et	   al.,	   2005)	  mutations	   that	   prevent	   the	   docking	   of	   phosphorylated	  
HM-­‐residue	  to	  PDK1	  and	  consequently	  SGK	   is	  not	  active	   in	  these	  cells.	  Furthermore,	  the	  
binding	  of	  PDK1	  to	  PtdIns(3,4,5)P3	  is	  not	  required	  for	  the	  activation	  of	  SGK	  by	  PDK1	  in	  vivo	  
(Bayascas	   et	   al.,	   2008)	   or	   for	   T-­‐loop	   phosphorylation	   in	   vitro	   (Biondi	   et	   al.,	   2001).	   The	  
integrity	  of	  the	  PIF-­‐binding	  pocket	   is	  also	  crucial	   for	  the	  phosphorylation	  of	  S6K	  and	  p90	  
ribosomal	   S6	   kinase	   (RSK)	   by	   PDK1	   (Collins	   et	   al.,	   2003;	   Collins	   et	   al.,	   2005).	   The	  
importance	  of	  the	  preceding	  HM-­‐site	  phosphorylation	  for	  SGK	  activation	  is	  highlighted	  by	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the	  fact	  that	  in	  mouse	  embryonic	  fibroblast	  (MEF)	  cells	  that	  lack	  functional	  mTORC2	  due	  
to	  either	  Sin1-­‐,	  mLST8-­‐	  or	  Rictor-­‐deficiency,	  SGK	  is	  not	  phosphorylated	  at	  its	  HM-­‐site	  and	  
consequently	  is	  not	  activated	  (Garcia-­‐Martinez	  and	  Alessi,	  2008).	  
	  
Figure	  1.12	  Comparison	  of	  the	  activation	  of	  Akt	  and	  SGK	  
(A)	  PI3K	  is	  activated	  downstream	  of	  RTKs.	  The	  generation	  of	  PtdIns(3,4,5)P3	  (PIP3)	  by	  PI3K,	  
causes	  the	  recruitment	  of	  Akt	  to	  the	  plasma	  membrane	  and	  a	  conformational	  change	  that	  
enables	   the	   phosphorylation	   of	   Akt	   T-­‐loop	   T308	   by	   PDK1.	   mTORC2-­‐mediated	  
phosphorylation	  of	  the	  HM-­‐site	  S473	  contributes	  towards	  maximal	  activation.	  (B)	  mTORC2	  
is	  activated	  downstream	  of	  PI3K	  and	  phosphorylates	  the	  SGK	  HM-­‐site	  (Ser422)	  providing	  a	  
docking	  site	  for	  PDK1	  that	  then	  phosphorylates	  the	  T-­‐loop	  Thr256.	  Residue	  numbers	  are	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1.6.1 SGK1	  
SGK1	  was	  the	  first	  SGK	  family	  member	  characterised	  and	  was	  initially	  identified	  as	  a	  gene	  
whose	  expression	  is	  regulated	  by	  glucocorticoids	  and	  serum	  (Webster	  et	  al.,	  1993b).	  The	  
SGK1	   gene	   promoter	   contains	   a	   glucocorticoid-­‐response	   element	   that	   is	   bound	   by	  
glucocorticoid	   receptors	   (GR)	   and	   is	   sufficient	   to	   confer	   glucocorticoid	   responsiveness	  
(Webster	   et	   al.,	   1993b).	   SGK1	   expression	   is	   also	   induced	   by	   the	   mineralocorticoid	  
aldosterone	   (Chen	   et	   al.,	   1999;	  Naray-­‐Fejes-­‐Toth	   et	   al.,	   1999)	   as	  well	   as	   serum	  and	   the	  
induction	   in	   response	   to	   serum	   is	   considered	   to	   be	   an	   immediate-­‐early	   transcriptional	  
response	   (Webster	   et	   al.,	   1993a).	   Multiple	   other	   signals	   including,	   but	   not	   limited	   to,	  
gonadotrophins,	   transforming	   gowth	   factor	   beta,	   cytokines,	   excessive	   glucose	   levels,	  
external	   stress	   and	   changes	   to	   cell	   volume	   and	   have	   been	   reported	   to	   control	   SGK1	  
transcription	   [reviewed	   in	   (Lang	   et	   al.,	   2009;	   Lang	   et	   al.,	   2006)].	   By	   contrast,	   SGK2	   and	  
SGK3	  mRNA	  levels	  are	  not	   increased	   in	  response	  to	  serum	  or	  glucocorticoids,	   the	  classic	  
up-­‐regulator	  of	  SGK1	  expression	  (Kobayashi	  et	  al.,	  1999).	  	  
SGK1	  protein	  has	  a	  half-­‐life	  of	  only	  30	  minutes.	  The	  N-­‐terminus	  of	  SGK1	  contains	  a	  motif	  
that	  targets	   it	  ubiquitylation	  mediated	  proteasomal	  degradation	  and	  deletion	  of	  the	  first	  
60	   amino	   acids	   of	   SGK1	   indeed	   greatly	   enhances	   stability	   of	   the	   kinase	   (Bogusz	   et	   al.,	  
2006;	   Brickley	   et	   al.,	   2002;	   Kobayashi	   and	   Cohen,	   1999).	   In	   part	   SGK1	   dictates	   its	   own	  
destruction	  since	  SGK1	  mediated	  phosphorylation	  of	  an	  E3	  ubiquitin	  ligase	  termed	  Neural	  
Precursor	   Cell-­‐Expressed,	  Developmentally	  Down-­‐Regulated	   Protein	   4-­‐2	   (Nedd4-­‐2)	   leads	  
to	   increased	   Nedd4-­‐2	   mediated	   ubiquitylation	   and	   proteasomal	   degradation	   of	   SGK1	  
(Zhou	  and	  Snyder,	  2005).	  Moreover,	  also	  the	  E3	  ubiquiting	  ligase	  CHIP	  has	  been	  reported	  
to	  mediate	   SGK1	   degradation	   (Belova	   et	   al.,	   2006)	   and	   the	  mTORC2	   subunit	   Rictor	   has	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been	   shown	   to	   associate	  with	   Cullin-­‐1	   to	   form	   a	   functional	   E3	   ubiquitin	   ligase	   complex	  
capable	   of	   targeting	   SGK1	   for	   proteasomal	   degradation.	   Phopshorylation	   of	   Rictor	   by	  
activated	  AGC	  kinases	  prevents	  SGK1	  ubiquitylation	  by	  Rictor/Cullin-­‐1	  (Gao	  et	  al.,	  2010).	  
Substrates	  and	  physiological	  functions	  of	  SGK1	  
SGK1	  has	  been	   linked	   to	  multiple	   cellular	   and	  physiological	  processes	   including,	  but	  not	  
limited	  to,	  regulation	  of	  solute	  transport,	  control	  of	  blood	  pressure,	  memory	  consolidation	  
and	  cell	  survival	   [reviewed	   in	   (Lang	  et	  al.,	  2006)].	  SGK1	   is	   thought	  to	  participative	   in	  the	  
pathophysiology	   of	   various	   conditions	   as	   highlighted	   by	   the	   reports	   that	   SGK1	   gene	  
variants	   are	   associated	  with	   for	   example	   elevated	  blood	  pressure	   (Busjahn	   et	   al.,	   2002;	  
Rao	  et	  al.,	  2013),	  increased	  incidence	  of	  ischaemic	  stroke	  and	  type	  II	  diabetes	  (Dahlberg	  et	  
al.,	   2011;	   Schwab	   et	   al.,	   2008)	   and	   increased	   body	  mass	   index	   (Dieter	   et	   al.,	   2004).	   In	  
Caernorhabditis	  elegans	  loss	  of	  SGK-­‐1	  results	  in	  a	  slight	  developmental	  delay,	  smaller	  body	  
size,	   defects	   in	   reproduction,	   increased	   stress	   resistance	   and	   altered	   metabolism	  
highlighted	  by	  increased	  lipid	  storage	  (Hertweck	  et	  al.,	  2004;	  Jones	  et	  al.,	  2009;	  Soukas	  et	  
al.,	  2009).	  
SGK1,	  and	  to	  some	  extent	  also	  other	  SGK	  family	  members,	  have	  been	  reported	  to	  regulate	  
the	  activity	  of	  a	  vast	  number	  of	  channels	  and	  transporters	   including	  sodium,	  potassium,	  
calcium	   and	   chloride	   channels	   and	   amino	   acid	   and	   glucose	   transporters	   	   [reviewed	   in	  
(Lang	   et	   al.,	   2006;	   Lang	   and	  Voelkl,	   2013)].	   The	  mechanistically	   best-­‐characterised	   SGK-­‐
mediated	  regulation	  of	  a	  channel	  is	  that	  of	  the	  epithelial	  sodium	  channel	  (ENaC)	  via	  which	  
SGK1	  contributes	  to	  the	  control	  of	  renal	  tubular	  Na+	  reabsorption.	   Initially	  co-­‐expression	  
of	  SGK1	  with	  ENaC	  in	  Xenopus	  oocytes	  was	  found	  to	  increase	  ENaC	  mediated	  currents	  due	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to	  increased	  levels	  of	  ENaC	  at	  the	  plasma	  membrane	  (Alvarez	  de	  la	  Rosa	  et	  al.,	  1999;	  Chen	  
et	   al.,	   1999;	   Naray-­‐Fejes-­‐Toth	   et	   al.,	   1999).	   Subsequently	   SGK1	   was	   found	   to	  
phosphorylate	   the	  E3	  ubiquitin	   ligase	  Nedd4-­‐2	   that	  downregulates	   levels	  of	  ENaC	  at	   the	  
plasma	  membrane.	  Phosphorylation	  of	  Nedd4-­‐2	  by	  SGK1	  negatively	  regulates	  Nedd4-­‐2	  by	  
reducing	  binding	  of	  Nedd4-­‐2	   to	   ENaC	  and	   inhibiting	  Nedd4-­‐2	   activity	  by	   stimulating	   the	  
binding	  of	  Nedd4-­‐2	   to	  14-­‐3-­‐3	  chaperone	  proteins	   leading	   to	   increased	   levels	  of	  ENaC	  at	  
the	  cell	  surface	  (Bhalla	  et	  al.,	  2005;	  Debonneville	  et	  al.,	  2001;	  Ichimura	  et	  al.,	  2005;	  Snyder	  
et	  al.,	  2002).	  SGK1	  has	  additionally	  been	  suggested	  to	  regulate	  ENaC	  via	  the	  with	  no	  lysine	  
kinase	  4	  (WNK4)	  (Ring	  et	  al.,	  2007)	  and	  transcriptionally	  (Boyd	  and	  Toth,	  2005;	  Zhang	  et	  
al.,	  2007).	  
Many	  observations	  link	  SGK1	  to	  cancer-­‐relevant	  processes.	  SGK1	  is	  for	  example	  suggested	  
to	  phosphorylate	  and	   inhibit	   the	  anti-­‐apoptotic	  FoxO	  transcription	   factors	   (Brunet	  et	  al.,	  
2001).	   SGK1	   has	   also	   been	   linked	   to	   for	   example	   dexamethasone	   and	   GR	   activation	  
associated	  breast	  cancer	  cell	  survival	  (Mikosz	  et	  al.,	  2001;	  Wu	  et	  al.,	  2004)	  and	  in	  multiple	  
myeloma	  SGK1	  has	  been	   identified	  as	  a	   transcriptional	   target	  of	  cytokines	   that	  promote	  
proliferation	   (Fagerli	   et	   al.,	   2011).	   Furthermore,	   a	   role	   for	   SGK1	   in	   cell	   invasion	   and	  
migration,	  which	  are	  two	  highly	  cancer	  relevant	  processes,	  has	  been	  reported	  (Eylenstein	  
et	  al.,	  2011;	  Schmidt	  et	  al.,	  2012a;	  Schmidt	  et	  al.,	  2012b).	  An	  additional	  substrate	  of	  SGK1	  
is	   N-­‐myc	   downstream-­‐regulated	   gene	   1	   (NDRG1)	   and	   2	   (Murray	   et	   al.,	   2004),	   but	   the	  
functional	  significance	  of	  this	  phosphorylation	  event	  remains	  unknown.	  	  
	  
	  
	   39	  
SGK1	  knockout	  mouse	  models	  
Whole	  body	  SGK1	  knockout	  mice	  are	  embryonic	  lethal	  in	  a	  pure	  C57BL/6	  background	  due	  
to	  defects	   in	   angiogenesis	   and	  heart	  development	  presumed	   to	  be	   caused	  by	   increased	  
apoptosis	  in	  SGK1-­‐/-­‐	  endothelial	  and	  vascular	  smooth	  muscle	  cells	  (Catela	  et	  al.,	  2010).	  This	  
observation	  supports	  the	  notion	  that	  SGK1	  could	  be	  a	  pro-­‐survival	  kinase.	  SGK1	  knockout	  
mice,	   however,	   are	   viable	   and	   seemingly	   normal	   in	   129/SvJ	   genetic	   background.	   	   Three	  
different	   SGK1	   knockout	   mouse	  models	   have	   been	   described.	   All	   three	  models	   appear	  
normal	  when	  fed	  a	  standard	  diet.	  The	  first	  described	  constitutive	  SGK1	  knockout	  mouse	  
model	   maintains	   normal	   sodium	   and	   water	   excretion	   under	   normal	   diet	   but	   possesses	  
elevated	   plasma	   aldosterone	   levels	   suggesting	   that	   mechanisms	   controlling	   sodium	  
handling	   and	   cell	   volume	   control	   are	   affected.	   Under	   sodium	   deficient	   diet	   the	   SGK1	  
knockout	  mice	   excrete	  more	  water	   and	   salt	   than	   their	   wild	   type	   counterparts,	   possess	  
highly	  elevated	  aldosterone	   levels	  and	  have	   lowered	  blood	  pressure	  (Wulff	  et	  al.,	  2002).	  
Expression	  of	  α-­‐ENaC	  is	  only	  modestly	  reduced	  in	  these	  mice	  but	  the	  expression	  levels	  of	  
the	  Na+Cl-­‐	   cotransporter	   (NCC)	   are	   drastically	   reduced	   (Vallon	   et	   al.,	   2009;	  Wulff	   et	   al.,	  
2002).	   These	  mice	   are	   resistant	   to	   dexamethasone	   induced	   increases	   in	   blood	   pressure	  
(Boini	  et	  al.,	  2008)	  and	  are	  also	  resistant	  to	  increases	  in	  blood	  pressure	  caused	  by	  high	  salt	  
intake	   in	   combination	   with	   high-­‐fat	   or	   high-­‐fructose	   diet	   that	   cause	   hyperinsulinemia	  
(Huang	  et	   al.,	   2006a;	  Huang	  et	   al.,	   2006b).	  A	   variety	  of	  other	  moderate	   solute	  handling	  
defects	  have	  been	  described	  for	  these	  mice,	  for	  instance	  the	  kidneys	  of	  SGK1-­‐/-­‐	  mice	  fail	  
to	   adequately	   eliminate	   an	   acute	   K+	   load	   (Huang	   et	   al.,	   2004).	   The	   second	   constitutive	  
SGK1	  knockout	  mouse	  model	  also	  displays	  elevated	  urinary	  Na+	  excretion	  when	  placed	  on	  
a	   low	   salt	   diet.	   Surprisingly,	   ENaC	   activity	   is	   increased	   in	   these	   SGK1	   knockout	  mice.	   In	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contrast,	  levels	  of	  active	  form	  of	  γ-­‐ENaC	  are	  reduced	  and	  levels	  of	  NCC	  dimished	  in	  these	  
mice	   (Fejes-­‐Toth	   et	   al.,	   2008).	   The	   third	   SGK1	   mouse	   model,	   which	   is	   a	   conditional	  
knockout,	  again,	  under	  low-­‐salt	  diet,	  exhibits	  reduced	  blood	  pressure	  and	  impaired	  ability	  
to	  reduce	  sodium	  excretion.	  Whilst	  only	  moderate	  decreases	  are	  reported	  for	  ENaC	  levels,	  
the	   levels	   of	   NCC	   are	   drastically	   reduced	   (Faresse	   et	   al.,	   2012).	   Based	   on	   these	  
observations	  it	  appears	  that	  whilst	  SGK1	  is	  involved	  in	  ENaC	  regulation,	  its	  primary	  target	  
may	  be	  NCC	  and	  possibly	  other	   transport	  systems.	  The	  method	  via	  which	  SGK1	  controls	  
NCC	  remains	  elusive	  and	  mechanisms	  involving	  with	  no	  lysine	  kinase	  4	  (WNK4)	  (Rozansky	  
et	  al.,	  2009)	  and	  Nedd4-­‐2	  (Pablo	  Arroyo	  et	  al.,	  2011)	  have	  been	  suggested.	  	  
SGK1	   knockout	   mice	   also	   suffer	   from	   reproductive	   failures	   (Salker	   et	   al.,	   2011)	   and	  
recently	   a	   role	   for	   SGK1	   in	   the	   control	   of	   the	   immune	   system	   was	   described.	   SGK1	   is	  
suggested	   to	   act	   as	   a	   salt-­‐induced	   gene	   whose	   expression	   directs	   the	   induction	   of	  
pathogenic	   TH17	   cells	   that	   contribute	   the	   development	   of	   autoimmune	   diseases	  
(Kleinewietfeld	   et	   al.,	   2013;	  Wu	   et	   al.,	   2013).	   To	   further	   support	   the	   notion	   that	   SGK1	  
might	  be	  involved	  in	  cancer	  signalling,	  SGK1-­‐/-­‐	  mice	  are	  resistant	  to	  chemical	  induction	  of	  
intestinal	   tumours	   (Nasir	  et	  al.,	  2009)	  and	   in	  adenomatous	  polyposis	  coli	   (APC)-­‐deficient	  




SGK2	  is	  the	  least	  studied	  SGK	  isoform.	  SGK2	  contains	  no	  other	  distinctive	  domains	  beyond	  
the	   catalytic	   kinase	   domain	   and	   is	   not	   transcriptionally	   induced	   in	   response	   to	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glucocorticoids	   or	   serum	   in	   cells	   (Kobayashi	   et	   al.,	   1999).	   A	   role	   for	   SGK2	   in	   oncogenic	  
signalling	   has	   been	   suggested.	   An	   RNA	   interference	   (RNAi)	   screen	   of	   human	   cervical	  
carcinoma	  cell	  lines	  and	  human	  papilloma	  virus	  (HPV)	  transformed	  cells	  identified	  SGK2	  as	  
a	  potential	  proliferation	  driver	  (Baldwin	  et	  al.,	  2010).	  SGK2	  knockout	  mice	  were	  described	  
by	  Schnackenberg	  and	  colleagues	  in	  a	  meeting	  abstract	  and	  the	  authors	  suggest	  that	  SGK2	  
is	  not	  critical	  for	  renal	  salt	  and	  water	  homeostasis	  during	  unstressed	  conditions,	  but	  that	  




SGK3	  (also	  called	  SGKL,	  CISK)	  was	  identified	  as	  a	  mediator	  of	  interleukin	  3	  (IL3)	  -­‐dependent	  
survival	   in	   hematopoietic	   cells	   and	   its	   over-­‐expression	   was	   suggested	   to	   inhibit	   FoxO	  
mediated	   transcription	   and	   to	   inhibit	   pro-­‐apoptotic	   Bcl-­‐2	   family	   members	   in	   a	   manner	  
similar	  to	  Akt	  (Liu	  et	  al.,	  2000).	  These	  studies	  did	  not	  analyse	  endogenous	  SGK3.	  Unlike	  the	  
other	  SGKs,	  SGK3	  possesses	  and	  N-­‐terminal	  lipid	  targeting	  domain.	  The	  SGK3	  PX	  domain	  is	  
suggested	   to	   primarily	   bind	   PtdIns(3)P	   and	   to	   localise	   to	   endosomes	   (Jun	   et	   al.,	   2001;	  
Virbasius	  et	  al.,	  2001).	  	  
SGK3	  knockout	  mice	  (C57BL/6	  background)	  display	  impaired	  postnatal	  hair	  growth	  due	  to	  
a	  hair	  bulb	  keratinocyte	  proliferation	  defect	  (Alonso	  et	  al.,	  2005;	  McCormick	  et	  al.,	  2004).	  
SGK3-­‐/-­‐	  mice	  also	  display	  a	  mild	  and	  transient	  growth	  defect,	  normal	   renal	  salt	  handling,	  
subtly	  decreased	  locomotion,	  defective	  mast	  cell	  function,	  increased	  gastric	  acid	  secretion	  
and	  decreased	  intestinal	  glucose	  transport	  (McCormick	  et	  al.,	  2004;	  Pasham	  et	  al.,	  2011;	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Sandu	   et	   al.,	   2005;	   Zemtsova	   et	   al.,	   2010).	   SGK3	   depletion	   also	   further	   worsens	   the	  
glucose	   handling	   phenotype	   of	   Akt2	   knockout	   mice	   (Yao	   et	   al.,	   2011).	   SGK1-­‐/-­‐SGK3-­‐/-­‐	  
double	  knockout	  mice	  (mixed	  129/SvJ:C57BL/6	  background)	  share	  the	  hair	  growth	  defect	  
of	   the	   SGK3	   knockouts	   and	   the	   renal	   salt	   retention	   defect	   of	   SGK1	   knockouts	   without	  
showing	  any	  novel	  more	  severe	  phenotypes	  (Grahammer	  et	  al.,	  2006).	  As	  indicated	  by	  the	  
keratinocyte	   proliferation	   defects	   in	   the	   SGK3	   knockout	  mice,	   SGK3	  might	   play	   roles	   in	  
promoting	   cell	   survival	   and	   proliferation.	   In	   fact,	  many	   PI3KCA-­‐mutant	   cancer	   cell	   lines	  
have	  been	  found	  to	  exhibit	  surprisingly	  low	  levels	  of	  Akt	  activation	  and	  to	  depend	  on	  SGK3	  
for	  their	  viability	  (Vasudevan	  et	  al.,	  2009).	  A	  further	  correlation	  between	  cancer	  signalling	  
and	  SGK3	   is	  provided	  by	  the	  recent	  observations	  that	  SGK3	   is	  transcriptionally	  regulated	  
by	  oestrogen	  and	  elevated	  SGK3	  levels	  are	  found	  in	  ER	  positive	  breast	  cancers	  (Wang	  et	  
al.,	  2011;	  Xu	  et	  al.,	  2012).	  	  
	  
1.7 	  Aims	  of	  the	  study	  
The	  key	  components	  of	  the	  PI3K	  signalling	  pathway,	  PI3K,	  mTOR	  and	  Akt,	  have	  emerged	  
as	  key	  targets	  for	  cancer	  drug	  discovery	  and	  much	  previous	  work	  as	  focused	  on	  the	  role	  of	  
Akt	   as	   a	   major	   mediator	   of	   proliferation-­‐	   and	   survival-­‐promoting	   functions	   of	   PI3K.	   In	  
contrast	   the	   closely	   related	   SGK	   isoforms	   have	   by	   comparison	   received	   little	   attention.	  
Owing	  to	  the	  similarity	  of	  Akt	  and	  SGK	  isoforms	  and	  the	  potential	  that	  these	  kinases	  could	  
possess	  an	  overlapping	  set	  of	  substrates	  and	  functions,	  the	  aim	  of	  this	  PhD	  work	  was	  to	  
elucidate	   whether	   SGK	   isoforms	   could	   compensate	   for	   Akt	   and	   represent	   resistance	  
mechanisms	  to	  Akt	  inhibitors.	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2. Materials	  &	  Methods	  
2.1 	  Materials	  
2.1.1 Commercial	  reagents	  
Acetone,	   ethanol,	   formic	   acid,	   glycerol,	   glycine,	   4-­‐(2-­‐Hydroxyethyl)piperazine-­‐1-­‐
ethanesulfonic	  acid	  (Hepes),	  isopropanol,	  methanol,	  2-­‐mercaptoethanol,	  orthophosphoric	  
acid,	   potassium	   chloride,	   sodium	   chloride,	   sodium	   ethylenediaminetetraacetic	   acid	  
(EDTA),	   magnesium	   acetate,	   sodium	   ethylene	   glycol	   tetraacetic	   acid	   (EGTA),	   sodium	  
fluoride,	   sodium	   β-­‐glycerophosphate,	   sodium	   orthovanadate,	   pentobarbital,	   puromycin,	  
adenosine	   5’-­‐triphosphate	   sodium	   salt	   (ATP),	   anti-­‐HA-­‐agarose,	   ammonium	   bicarbonate,	  
ammonium	   persulphate	   (APS),	   ampicillin,	   benzamidine,	   bovine	   serum	   albumin	   (BSA),	  
bromophenol	   blue	   (BPB),	   dexamethasone,	   doxorubicin,	   dimethyl	   pimelimidate	   (DMP),	  
dimethyl	   sulphoxide	   (DMSO),	   hydrogen	   peroxide,	   iodoacetamide,	   MISSION™	   shRNAs,	  
phenylmethanesulphonylfluoride	   (PMSF),	   Ponceau	   S,	   sodium	   dodecyl	   sulphate	   (SDS),	  
sodium	   tetraborate,	   N,	   N,	   N’,	   N’-­‐Tetramethylethylenediamine	   (TEMED),	  
triethylammonium	   bicarbonate,	   Nonidet	   P40,	   Triton-­‐X-­‐100	   and	   Tween-­‐20	   were	   from	  
Sigma-­‐Aldrich	  (Poole,	  UK).	  	  Sucrose	  and	  Tris(hydroxymethyl)methylamine	  (Tris)	  were	  from	  
BDH	   (Lutterworth,	   UK).	   Cellophane	   films,	   i-­‐Script	   Kit,	   SsoFast™	   EvaGreen®	   Supermix,	  
polymerase	   chain	   reaction	   (PCR)	   plates	   and	   Precision	   Plus	   protein	   markers	   were	   from	  
BioRad	   (Herts,	   UK).	   3-­‐[(3-­‐Cholamidopropyl)dimethylammonio]-­‐1-­‐propanesulfonate	  
(CHAPS)	  was	   from	  Calbiochem	   (Merck	  Biosciences,	  Nottingham,	  UK).	   Insulin-­‐like	   growth	  
factor	   (IGF1)	   was	   from	   Cell	   Signaling	   Technology	   (New	   England	   Biolabs,	   Herts,	   UK).	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Polybrene	  was	   from	  SantaCruz	  Biotechnology	   (Heidelberg,	  Germany).	  Cell	   culture	  dishes	  
and	  flasks,	  cryovials	  and	  Spin-­‐X	  columns	  were	  from	  Corning	  (NY,	  USA).	  Cell	  scrapers	  were	  
from	   Costar	   (Cambridge,	   USA).	   40%	   (w/v)	   29:1	   Acrylamide:Bis-­‐Acrylamide	   solution	   was	  
from	   Flowgen	   Bioscience	   (Nottingham,	   UK).	   Protein	   A-­‐agarose,	   Protein	   G-­‐sepharose,	  
Glutathione-­‐sepharose,	   Enhanced	   chemiluminescence	   (ECL)	   kit,	   Hyperfilm	   MP,	   Protran	  
nitrocellulose	   membrane,	   P81	   paper,	   3mm	   chromatography	   paper	   and	   [γ32P]-­‐labelled	  
ATP	   were	   from	   GE	   Healthcare	   (Piscataway,	   USA).	   Cell	   dissociation	   buffer,	   Dulbecco’s	  
modified	   eagle	  medium	   (DMEM),	   RPMI-­‐1640	  medium,	   Phosphate	   buffered	   saline	   (PBS),	  
Trypsin/EDTA,	   L-­‐glutamine,	   Lipofectamine	   2000,	   non-­‐essential	   amino	   acids,	   sodium	  
pyruvate,	  antibiotic/antimycotic,	  NuPAGE	  Novex	  SDS	  Bis-­‐Tris	  gels,	  NuPAGE	  MOPS	  running	  
buffer,	   NuPAGE	   reducing	   agent,	   NuPAGE	   LDS	   sample	   buffer	   and	   primers	   were	   from	  
Invitrogen	  (Paisley,	  UK).	  Photographic	  developer	  (LX24)	  and	  liquid	  fixer	  (FX40)	  were	  from	  
Kodak	   (Liverpool,	  UK).	  X-­‐ray	   films	  were	   from	  Konica	   (Japan).	  Polyethylenimine	   (PEI)	  was	  
from	  Polysciences	  (Warrington,	  PA).	  Skimmed	  milk	  (Marvel)	  was	  from	  Premier	  Beverages	  
(Stafford,	   UK).	   Plasmid	  Maxiprep	   and	   RNeasy	   kits	   were	   from	  Qiagen	   Ltd	   (Crawley,	   UK).	  
Acetonitrile	   (HPLC	   grade)	   was	   from	   Rathburn	   Chemicals	   (Walkerburn,	   UK).	   Protease	  
inhibitor	   cocktail	   was	   from	   Roche	   (Lewes,	   UK).	   Horseradish	   peroxidase	   (HRP)-­‐	   and	  
Alexafluor-­‐conjugated	   secondary	   antibodies,	   Bradford	   reagent	   and	   Fetal	   Bovine	   Serum	  
(FBS)	  were	   from	   Thermo-­‐scientific	   (Essex,	  UK).	   CellTiter	   96®	  AQueous	  One	   Solution	   Cell	  
Proliferation	   Assay	   (MTS)	   and	   trypsin	   (mass	   spectrometry	   grade)	   were	   from	   Promega	  
(Southhampton,	   UK).	  Matrigel™	   invasion	   chambers	   were	   from	   BD	   Biosciences	   #354483	  
(Oxford,	   UK).	   Reastain	   Quick-­‐Diff	   kit	   was	   from	   Reagena	   (Finland).	   InstantBlue	   protein	  
staining	  solution	  was	  from	  Expedeon	  (Harston,	  UK).	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2.1.2 In-­‐house	  reagents	  
Luria	  Bertani	  (LB)	  broth	  and	  LB	  agar	  plates	  supplemented	  with	  200	  µg/mL	  ampicillin	  were	  
from	  media	   kitchen.	   NDRG1	   (DU1557)	   and	   NEDD4.2	   (DU4004)	   purified	   from	   E.coli	   and	  
Crosstide	  peptide	  were	  from	  the	  Division	  of	  Signal	  Transduction	  Therapy	  (DSTT).	  
	  
2.1.3 Antibodies	  
In-­‐house	   antibodies	   (Table	   2.1)	   were	   raised	   in	   sheep	   and	   affinity	   purified	   on	   the	  
appropriate	  antigen	  by	  the	  DSTT.	   In-­‐house	  antibodies	  were	  used	  at	  1	  µg/mL	  in	  5%	  (w/v)	  
skimmed	  milk	  in	  TBST	  and	  the	  in-­‐house	  phospho-­‐specific	  antibodies	  were	  used	  at	  1	  µg/mL	  
in	   5%	   (w/v)	   BSA	   -­‐TBST	   supplemented	   with	   10	   µg/mL	   non-­‐phospho	   peptide	   to	   increase	  
specificity.	  Commercial	  antibodies	  (Table	  2.2)	  were	  used	  at	  1:1000	  dilutions.	  The	  α-­‐ENaC	  
antibody	  was	  a	  gift	  from	  Dr	  S.	  Wilson	  (University	  of	  Dundee).	  
Antibody	   Immunogen	   Sheep	  	   Bleed	  
Akt1	   Full-­‐length	  human	  Akt1	   S742B	   3rd	  	  
GST	   GST	  (expressed	  from	  pGEX4T)	   S902A	   2nd	  	  
HA	   HA	  (YPYDVPDYA)	   mouse	   -­‐	  
NDRG1	   Full-­‐length	  human	  NDRG1	   S276B	   3rd	  	  
PRAS40	   Full-­‐length	  human	  PRAS40	   S115B	   1st	  	  
PRAS40	  pThr246	   Human	  PRAS40	  [240-­‐251]	  (CRPRLNT*SDFQK)	   S114B	   2nd	  	  
Protor-­‐1	   Full-­‐length	  human	  Protor-­‐1	   S020C	   3rd	  	  
Protor-­‐2	   Full-­‐length	  human	  Protor-­‐2	   S136C	   3rd	  	  
Rictor	  (mouse)	   Mouse	  Rictor	  [6-­‐20]	  RGRSLKNLRIRGRND	   S274C	   1st	  	  
S6K1	   Human	  S6K1	  [25-­‐44]	  (AGVFDIDLDQPEDAGSEDEL)	   S417B	   2nd	  	  
SGK1+2	   Full-­‐length	  human	  SGK1	   S062D	   3rd	  	  
SGK2	   Human	  SGK2	  [333-­‐346]	  (KSIGCTPDTVASSS)	  	   S036D	   3rd	  
SGK3	   SGK3	  PX	  domain	  (residues	  1-­‐130	  of	  human	  SGK3)	   S037D	   3rd	  	  
Sin1	   Full-­‐length	  human	  Sin1	   S008C	   2nd	  	  
	  
Table	  2.1	  In-­‐house	  antibodies	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Antibody	   Catalog	  #	   Source	   Species	   Blocking	  buffer	  
Akt	  pThr308	  	   4056	   CST	   Rabbit	   BSA	  
Akt	  pSer473	   9271	   CST	   Rabbit	   BSA	  
γ-­‐ENaC	   E4902	   Sigma	   Rabbit	   milk	  
Flotillin-­‐1	   sc-­‐25506	   Santa	  Cruz	   Rabbit	   milk	  
FoxO1	   2880	   CST	   Rabbit	   BSA	  
FoxO3	   2497	   CST	   Rabbit	   BSA	  
FoxO1/FoxO3	  pThr24/pThr32	   9464	   CST	   Rabbit	   BSA	  
FoxO1	  pSer256	   9461	   CST	   Rabbit	   BSA	  
FoxO3	  pSer253	   9466	   CST	   Rabbit	   BSA	  
GAPDH	   2118	   CST	   Rabbit	   BSA	  
GSK3a/ß	  pSer21/9	  	   9331	   CST	   Rabbit	   BSA	  
GSK3α/β	  	   44-­‐610	   Invitrogen	   Mouse	   BSA	  
IGF	  Receptor	  β	   3027	   CST	   Rabbit	   BSA	  
IGFR	  pTyr1135/1136	   3024	   CST	   Rabbit	   BSA	  
mTOR	   SC-­‐1549	   Santa	  Cruz	   Goat	   milk	  
NDRG1	  Thr346	  	   5482	   CST	   Rabbit	   BSA	  
S6	  	   2217	   CST	   Rabbit	   BSA	  
S6	  pSer235/Ser236	  	   4856	   CST	   Rabbit	   BSA	  
S6K	  pThr229	   9379	   CST	   Rabbit	   BSA	  
S6K	  pThr389	  	   9234	   CST	   Rabbit	   BSA	  
SGK	  pT-­‐loop	  	   9379	   CST	   Rabbit	   BSA	  
Pan-­‐SGK	   S5188	   SIGMA	   Rabbit	   milk	  
PTEN	   5384	   CST	   Rabbit	   BSA	  
SGK	  pHydrophobic	  motif	   sc-­‐16745	   Santa	  Cruz	   Rabbit	   BSA	  
TSC2	   3612	   CST	   Rabbit	   BSA	  
TSC2	  pThr1462	   3617	   CST	   Rabbit	   BSA	  
	  
Table	  2.2	  Commercial	  antibodies	  
	  
2.1.4 Plasmids	  
Dr	  M.	  Deak,	  Dr	  M.	   Peggie	   and	  Mr	   T.	  Macartney	   performed	   the	   cloning,	   subcloning	   and	  
mutagenesis	  of	  the	  constructs	  described	  in	  this	  thesis.	  Constructs	  used	  are	  shown	  in	  Table	  
2.3.	  All	   constructs	   encoded	   the	  human	  version	  of	   the	   gene.	   The	  mammalian	  expression	  
vector,	  pEBG6P,	  was	  generated	  by	  Dr	  M.	  Deak.	  This	   is	  a	  modified	  version	  of	  the	  pEBG2T	  
vector	  (Sanchez	  et	  al.,	  1994)	  that	  allows	  the	  expression	  of	  proteins	  with	  an	  N-­‐terminal	  GST	  
tag	   followed	   by	   a	   PreScission	   cleavage	   site.	   A	  mammalian	   expression	   vector	   under	   the	  
control	  of	  the	  cytomegalovirus	  promoter	  called	  pCMV5A	  was	  also	  utilised,	  encoding	  an	  N-­‐
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terminal	   hemagglutinin	   (HA)-­‐tag	   (Andersson	   et	   al.,	   1989).	   For	   retroviral	   transduction	   of	  
cells	  pBABE	  vector	  encoding	  puromycin	  selectable	  marker	  was	  used.	  The	  pBABE	  vector	  is	  
based	  on	  the	  Moloney	  murine	   leukemia	  virus	  (MoLV)	  and	  the	  genes	  are	  expressed	  from	  
the	  MoLV	  long	  terminal	  repeat	  (LTR)	  (Morgenstern	  and	  Land,	  1990).	  	  
Construct	   Clone	  number	   Vector	  
GST-­‐Akt1	   DU2005	   pEBG	  
GST-­‐Akt1	  K179A	  (Kinase	  inactive	  [KI])	   DU6191	   pEBG	  
GST-­‐SGK1	   DU124	   pEBG	  
GST-­‐SGK1	  K127A	  (KI)	   DU125	   pEBG	  
GST-­‐ΔN-­‐SGK1	  (61-­‐431)	   DU142	   pEBG	  
GST-­‐ΔN-­‐SGK1	  (61-­‐431)	  K127A	  (residue	  number	  for	  full	  length)	  (KI)	   DU143	   pEBG	  
GST-­‐ΔN-­‐SGK1	  (61-­‐431)	  T256A	  (residue	  number	  for	  full	  length)	   DU144	   pEBG	  
GST-­‐ΔN-­‐SGK1	  (61-­‐431)	  S422A	  (residue	  number	  for	  full	  length)	   DU145	   pEBG	  
HA-­‐SGK1	   DU153	   pCMV5A	  
HA-­‐ΔN-­‐SGK1	  (61-­‐431)	   DU38226	   pBABE	  
HA-­‐ΔN-­‐SGK1	  (61-­‐431)	   DU163	   pCMV5A	  
HA-­‐ΔN-­‐SGK1	  (61-­‐431)	  K127A	  (residue	  number	  for	  full	  length)	  (KI)	   DU41768	   pBABE	  
GST-­‐SGK2	   DU176	   pEBG	  
HA-­‐SGK2	   DU181	   pCMV5A	  
GST-­‐SGK3	  	   DU410	   pEBG	  
GST-­‐SGK3	  K191A	  (KI)	   DU2257	   pEBG	  
HA-­‐SGK3	   DU442	   pCMV5A	  
HA-­‐SGK3	  shRNA	  #D	  resistant	   DU44496	   pBABE	  
HA-­‐SGK3	  K191A	  (KI)	  shRNA	  #D	  resistant	   DU44538	   pBABE	  
	  
Table	  2.3	  Constructs	  
	  
2.1.5 Inhibitors	  
Inhibitors	  used	  in	  this	  thesis	  are	  shown	  in	  Table	  2.4.	  Compounds	  were	  dissolved	  in	  DMSO	  
and	  stored	  at	  -­‐80°C.	  The	  National	  Centre	  for	  Protein	  Kinase	  Profiling	  (http://www.kinase-­‐
screen.mrc.ac.uk)	  performed	  specificity	   screens.	   In-­‐house	   inhibitors	  were	  synthesised	  by	  
Dr	   N.	   Shripo.	   DSTT	   SGKi1	   and	   DSTT	   SGKi2	   (unpublished,	   structures	   not	   disclosed)	   were	  
obtained	  from	  collaborations	  with	  pharmaceutical	  companies.	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Inhibitor	   Target	   Source	   Reference	  
AZD5363	   Akt	   AstraZeneca	   (Davies	  et	  al.,	  2012)	  
AZD8055	   mTOR	   Axon	  MedChem	   (Chresta	  et	  al.,	  2010)	  
DSTT	  SGKi1	   SGK	   DSTT	   Unpublished	  
DSTT	  SGKi2	   SGK/Akt	   DSTT	   Unpublished	  
EMD638683	   SGK	   Merck	   (Ackermann	  et	  al.,	  2011)	  
GDC-­‐0941	   Class	  I	  PI3K	   In-­‐house	   (Folkes	  et	  al.,	  2008)	  
GSK2334470	  	   PDK1	   In-­‐house	   (Najafov	  et	  al.,	  2011)	  
MK-­‐2206	   Akt	   In-­‐house	   (Hirai	  et	  al.,	  2010)	  
PF-­‐4708671	   S6K	   Tocris	   (Pearce	  et	  al.,	  2010a)	  
PI-­‐103	   Class	  I	  PI3Ks	  &	  mTOR	   In-­‐house	   (Fan	  et	  al.,	  2006b)	  
Rapamycin	   mTORC1	   Calbiochem	   (Vezina	  et	  al.,	  1975)	  
	  
Table	  2.4	  Inhibitors	  
	  
2.1.6 Buffers	  
Tris	  lysis	  buffer:	  50	  mM	  Tris-­‐HCl	  pH	  7.5,	  1	  mM	  EGTA,	  1	  mM	  EDTA,	  1%	  (v/v)	  Triton-­‐X100,	  1	  
mM	  sodium	  orthovanadate,	  10	  mM	  sodium-­‐ß-­‐glycerophosphate,	  50	  mM	  sodium	  fluoride,	  
10	  mM	   sodium	   pyrophosphate,	   0.27	  M	   sucrose,	   0.15	  M	  NaCl,	   0.1%	   2-­‐mercaptoethanol	  
and	   either	   1	   mM	   benzamidine	   and	   0.1	   mM	   phenylmethylsulphonylfluoride	   (PMSF)	   or	  
complete	   protease	   inhibitor	   cocktail.	   For	   large-­‐scale	   immunoprecipitations	   Triton-­‐X100	  
was	  replaced	  with	  the	  milder	  detergent	  CHAPS	  (0.3%	  [w/v]).	  
HEPES	   lysis	   buffer:	   (for	  mTOR	   kinase	   assays)	   40	  mM	  Hepes	   pH	   7.5,	   1	  mM	   EDTA,	   0.3%	  
(w/v)	  CHAPS,	  0.5	  mM	  sodium	  orthovanadate,	  10	  mM	  sodium-­‐ß-­‐glycerophosphate,	  50	  mM	  
sodium	  fluoride,	  10	  mM	  sodium	  pyrophosphate,	  0.27	  M	  sucrose,	  0.12	  M	  NaCl	  and	  1	  mM	  
benzamidine	  and	  0.1	  mM	  PMSF.	  
Lysis	  buffer	  inhibits	  proteases,	  kinases,	  phosphatases	  and	  other	  divalent	  cation-­‐dependent	  
enzymes	  ensuring	  that	  the	  phosphorylation	  and	  expression	  levels	  of	  proteins	  are	  fixed	  at	  
the	   levels	   in	  which	  they	  are	  found	   in	  vivo.	  Benzamidine	  and	  PMSF	  or	  complete	  protease	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inhibitor	   tablets	   prevent	   the	   action	   of	  metallo,	   aspartic,	   cysteine	   and	   serine	   proteases.	  
EDTA	  chelates	  Mg2+	  and	  EGTA	  chelates	  Ca2+.	  Sodium	  fluoride,	  sodium-­‐ß-­‐glycerophosphate	  
and	  sodium	  pyrophosphate	  are	  Ser/Thr	  phosphatase	  inhibitors.	  Sodium	  orthovanadate	  is	  
Tyr	   phosphatase	   inhibitor.	   Sodium	   orhovanadate	   was	   prepared,	   as	   recommended	   by	  
manufacturer,	  by	  repeated	  rounds	  of	  boiling	  and	  cooling	  until	  the	  solution	  was	  colourless	  
at	  pH10	  at	  room	  temperature	  to	  ensure	  that	  it	  is	  in	  the	  monomeric	  state	  that	  favours	  Tyr	  
phosphatase	  inhibition.	  
Buffer	  A:	  50	  mM	  Tris-­‐HCl	  pH	  7.5,	  0.1	  mM	  EGTA,	  and	  0.1%	  2-­‐mercaptoethanol	  
Hepes	  kinase	  buffer:	  (for	  mTOR	  kinase	  assays)	  25	  mM	  Hepes	  pH	  7.5,	  50	  mM	  KCl	  
Tris	  buffered	  saline	  (TBS):	  50	  mM	  Tris-­‐HCl	  pH	  7.5,	  0.15	  M	  NaCl	  
5x	   sodium	   dodecyl	   sulfate	   (SDS)	   sample	   buffer:	   5%	   (w/v)	   SDS,	   5%	   (v/v)	   2-­‐
mercaptoethanol,	  250	  mM	  Tris-­‐HCl	  pH	  6.8,	  32.5%	  (v/v)	  Glycerol,	  bromophenol	  blue	  
Tris-­‐glycine	  SDS	  running	  buffer:	  25mM	  Tris-­‐HCl	  pH	  8.3,	  192mM	  Glycine,	  0.1%	  (w/v)	  SDS	  
Tris-­‐glycine	  transfer	  buffer:	  48mM	  Tris-­‐HCl,	  39mM	  Glycine,	  20%	  (v/v)	  Methanol	  
	  
2.1.7 Cell	  lines	  
Wild-­‐type	   and	   knockout	   Rictor	  mouse	   embryonic	   fibroblasts	   (MEF)	   (Shiota	   et	   al.,	   2006)	  
were	   provided	   by	   Prof.	  M.	  Magnuson	   (Vanderbilt	   University	   School	   of	  Medicine,	   USA).	  
Generation	   of	   Protor-­‐1/Protor-­‐2	   wild	   type	   and	   double	   knockout	   MEFs	   is	   described	   in	  
(2.2.34).	  BT-­‐474,	  BT-­‐549,	  CAMA-­‐1,	  HCC-­‐1806,	  HCC-­‐1187,	  HCC-­‐1937,	  JIMT-­‐1,	  MDA-­‐MB-­‐157,	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MDA-­‐MB-­‐231,	  MDA-­‐MB-­‐436,	   SUM-­‐52-­‐PE,	   T47D	   and	   ZR-­‐75-­‐1	   cell	   lines	  were	   provided	   by	  
AstraZeneca	   (Alderley	   Park,	  Macclesfield,	   UK).	   All	   other	   cell	   lines	   were	   supplied	   by	   the	  
MRC	  Protein	  Phosphorylation	  and	  Ubiquitylation	  Unit	  (University	  of	  Dundee).	  	  
	  
2.1.8 Animals	  
Mice	  obtained	  from	  Taconic-­‐Artemis	  (Cologne,	  Germany)	  were	  maintained	  under	  specific	  
pathogen-­‐free	  conditions	  and	  routine	  animal	  tail	  and	  ear	  notching	  was	  carried	  out	  by	  staff	  
in	  the	  College	  of	  Life	  Science	  Transgenic	  Unit	  (University	  of	  Dundee).	  Mrs	  G.	  Fraser	  carried	  
out	  genotyping	  from	  tail	  biopsies.	  All	  procedures	  were	  carried	  out	  in	  accordance	  with	  the	  
regulations	  set	  by	  the	  University	  of	  Dundee	  and	  the	  United	  Kingdom	  Home	  Office.	  
	  
2.1.9 Instruments	  
Centrifuge	  tubes,	  rotors	  and	  centrifuges	  were	  from	  Beckmann	  (Palo	  Alto,	  USA).	  Trans-­‐Blot	  
Cells,	   iQ5	   real	   time	   PCR	   detection	   system	   and	   gel	   dryer	   apparatus	   were	   from	   BioRad	  
(Herts,	   UK).	   SpeedVac	   was	   from	   CHRIST	   (Osterode,	   Germany).	   Thermomixer	   IP	   shakers	  
were	   from	   Eppendorf	   (Cambridge,	   UK).	   The	   Biofuge	  microcentrifuge	  was	   from	   Haraeus	  
Instruments	   (Osterode,	   Germany).	   pH	   meters	   were	   from	   Horiba	   (Kyoto,	   Japan).	   X-­‐Cell	  
SureLock	   Mini-­‐cell	   electrophoresis	   systems	   and	   X-­‐Cell	   II	   Blot	   modules	   were	   from	  
Invitrogen	   (Paisley,	   UK).	   Polytron	   was	   from	   Kinematica	   (Brinkmann,	   CT,	   USA).	   X-­‐omat	  
autoradiography	   cassettes	   were	   from	   Kodak	   (Liverpool,	   UK).	   The	   Konica	   automatic	   film	  
processor	  was	  from	  Konica	  Corporation	  (Japan).	  Li-­‐Cor	  OdysseyTM	  Infrared	  Imaging	  System	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was	  from	  Li-­‐Cor	  Biosciences	  (Cambridge,	  UK).	  CO2	  incubators	  were	  from	  Mackay	  and	  Lynn	  
(Dundee,	   UK).	   Tissue	   culture	   class	   II	   safety	   cabinets	   were	   from	  Medical	   Air	   Technology	  
(Oldham,	   UK).	   The	   PCR	   thermocycler	   (PTC-­‐200)	   was	   from	   MJ	   Research.	   The	   96-­‐well	  
Versamax	  plate	   reader	  was	   from	  Molecular	  Devices	   (Wokingham,	  UK).	  Proxeon	  EasynLC	  
chromatography	   system,	   LTQ-­‐Orbitrap	   Classic	   mass	   spectrometer	   and	   Nanodrop	   were	  
from	   Thermo	   Scientific	   (Essex,	   UK).	   Scintillation	   counter	   (Tri-­‐Carb	   2800	   TR)	   was	   from	  
Perkin-­‐Elmer.	  	  
	  
2.2 	  Methods	  
2.2.1 Transformation	  of	  chemically	  competent	  Escherichia	  coli	  (E.coli)	  
Calcium	   competent	   E.coli	   DH5α	   (Inoue	   et	   al.,	   1990)	   cells	   were	   provided	   by	   the	   DSTT.	  
Approximately	  10-­‐50	  ng	  DNA	  was	  added	  to	  50	  µl	  of	  competent	  cells	  and	  incubated	  on	  ice	  
for	  5	  min.	  Cells	  were	  then	  subjected	  to	  heat	  shock	  at	  42°C	  water	  bath	  for	  90	  seconds	  to	  
induce	  the	  uptake	  of	  DNA	  and	  briefly	  placed	  back	  on	  ice.	  Cells	  were	  streaked	  onto	  LB	  agar	  
plates	  containing	  200	  µg/mL	  ampicillin	  and	  plates	  incubated	  at	  37°C	  overnight.	  
	  
2.2.2 Purification	  of	  plasmids	  from	  E.coli	  
Transformed	  DH5α	  E.coli	  were	  cultured	   in	  200	  mL	  LB	  containing	  200	  µg/mL	  ampicillin	  at	  
37°C	  while	  shaking	  at	  200	  rpm	  overnight.	  Cells	  were	  pelleted	  by	  centrifugation	  at	  6000	  g	  
for	   15	   min	   at	   4°C.	   Plasmid	   DNA	   was	   purified	   using	   the	   Qiagen	   plasmid	   Maxiprep	   kit	  
according	  to	  the	  manufacturer’s	  instructions.	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2.2.3 Measurement	  of	  DNA	  and	  RNA	  concentration	  
DNA	   and	   RNA	   concentrations	   were	   measured	   using	   NanoDrop	   as	   per	   manufacturer’s	  
instructions.	  RNA	  and	  DNA	  absorb	  at	  260	  nM.	  Absorbance	  was	  also	  measured	  at	  280	  nM	  
because	  calculation	  of	  260/280	  ratio	  allows	  estimation	  of	  purity.	  Ratios	  of	  greater	  than	  1.8	  
are	  accepted	  as	  pure.	  Lower	  ratios	  may	  indicate	  the	  presence	  of	  phenol,	  protein	  or	  other	  
contaminants.	  
	  
2.2.4 DNA	  mutagenesis	  
Site-­‐directed	   mutagenesis	   was	   performed	   using	   QuikChange	   kit	   (Stratagene)	   and	   KOD	  
polymerase	  (Novagen).	  Mutations	  were	  verified	  by	  sequencing.	  
	  
2.2.5 DNA	  sequencing	  
Sequencing	  was	   performed	   by	   DNA	   Sequencing	   and	   Services	   (www.dnaseq.co.uk)	   using	  
Applied	   Biosystems	   Big-­‐Dye	   v.	   3.1	   chemistry	   on	   an	   Applied	   Biosystems	   model	   3730	  
automated	  capillary	  DNA	  sequencer.	  	  
	  
2.2.6 Cell	  culture	  
All	  procedures	  were	  carried	  out	  in	  aseptic	  conditions	  meeting	  biological	  safety	  category	  2	  
regulations.	  Cells	  were	  maintained	  at	  37°C	  in	  a	  5%	  CO2	  water	  saturated	  incubator.	  For	  the	  
passaging	  of	  cells,	  cells	  were	  washed	  with	  PBS	  and	  then	  incubated	  with	  Trypsin/EDTA	  to	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detach	  the	  cells.	  Detached	  cells	  were	  resuspended	  in	  cell	  culture	  medium	  and	  split	  at	  a	  1:2	  
–	  1:20	  ratios	  for	  continued	  culture.	  	  All	  breast	  cancer	  cell	  lines	  were	  cultured	  in	  RPMI-­‐1640	  
and	  human	  embryonic	  kidney	  293	   (HEK293),	  HeLa	  and	  MEF	  cells	   in	  Dulbecco’s	  modified	  
eagle	   medium	   (DMEM).	   All	   cell	   lines	   were	   grown	   in	   the	   presence	   of	   10%	   (v/v)	   foetal	  
bovine	  serum	  (FBS),	  2	  mM	  L-­‐glutamine,	  100	  U/mL	  penicillin	  and	  0.1	  mg/mL	  streptomycin.	  
For	   primary	   MEF	   culture	   medium	   was	   additionally	   also	   supplemented	   with	   1x	   non-­‐
essential	  amino	  acids	  and	  1	  mM	  sodium	  pyruvate.	  
	  
2.2.7 Freezing	  /	  thawing	  cells	  
Detached	   cells	   were	   centrifuges	   at	   1000	   rpm	   for	   5	   min	   and	   resuspended	   in	   growth	  
medium	  supplemented	  with	  10%	  DMSO.	  1	  mL	  aliquots	  were	  stored	   in	  cryovials	  at	   -­‐80°C	  
prior	   to	   long-­‐term	   storage	   in	   liquid	   nitrogen.	   Cells	   were	   thawed	   in	   a	   37°C	   water	   bath,	  
resuspended	  in	  growth	  medium	  and	  allowed	  to	  adhere	  overnight	  prior	  to	  medium	  change.	  
	  
2.2.8 Transfection	  of	  cells	  using	  polyethylenimine	  (PEI)	  
Cells	  were	  transiently	   transfected	  using	   the	  polyethylenimine	   (PEI)	  method	   (Durocher	  et	  
al.,	  2002).	  1	  mg/mL	  PEI	   stock	  was	  prepared	   in	  20	  mM	  Hepes	   (pH	  7).	   For	   transfection	  of	  
cells	  grown	  on	  10	  cm	  dishes,	  5	  µg	  of	  DNA	  was	  mixed	  with	  20	  µL	  1mg/mL	  PEI	  and	  1	  mL	  
serum-­‐free	  DMEM	  and	  left	  for	  15	  min	  at	  room	  temperature	  before	  being	  added	  to	  cells.	  
Cells	  were	  harvested	  36	  hrs	  post	  transfection.	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2.2.9 Treatment	  of	  cells	  with	  growth	  factors,	  hormones	  or	  inhibitors	  	  
In	   IGF1	  stimulation	  experiments	  cells	  were	  deprived	  of	  serum	  for	  16	  hrs	   to	   induce	  basal	  
conditions	  prior	  to	  stimulation	  of	  the	  PI3K	  pathway	  with	  50	  ng/mL	  IGF1	  for	  30	  min.	  Where	  
indicated	  a	  30	  min	   incubation	  of	   cells	  with	   inhibitors	  preceded	   the	  addition	  of	   IGF1.	   50	  
µg/mL	  stock	  of	  IGF1	  was	  prepared	  in	  20	  mM	  citrate	  pH	  3.	  	  For	  the	  induction	  of	  SGK1,	  cells	  
were	   treated	  with	  0.2	  µM	  dexamethasone	   for	  2.5	  hrs.	  Dexamethasone	  was	  dissolved	   in	  
ethanol	  and	  diluted	  in	  DMEM	  to	  prepare	  1	  mM	  stock.	  Inhibitors,	  along	  with	  the	  equivalent	  
volume	  of	  DMSO	  as	  a	  control,	  were	  added	   to	   the	  cell	   culture	  medium	  and	   incubated	  at	  
37°C	   and	   5%	   CO2	   for	   the	   times	   indicated	   in	   the	   figure	   legends.	   For	   chronic	   inhibitor	  
treatments	  growth	  medium	  was	  changed	  to	  fresh	   inhibitor	  or	  DMSO	  containing	  medium	  
approximately	  every	   three	  days.	  Where	  cells	  subjected	  to	  chronic	   treatments	  needed	  to	  
be	  trypsinised	  and	  re-­‐seeded,	  the	  compounds	  were	  added	  directly	  to	  the	  cell	  suspension	  
at	  the	  time	  of	  plating.	  
	  
2.2.10 	  RNA	  interference	  by	  small	  hairpin	  RNAs	  (shRNA)	  	  
To	  knockdown	  the	  expression	  of	  SGK1	  and	  SGK3,	  the	  MISSION™	  shRNA	  system	  obtained	  
from	   Sigma-­‐Aldrich	   was	   utilised.	   All	   shRNAs	   used	   were	   in	   lentiviral	   pLKO1-­‐puro	   vector.	  
Sequences	  of	  the	  shRNAs	  used	  are	  shown	  in	  Table	  2.5.	  Scrambled	  shRNA	  cloned	  into	  the	  
same	   pLK0.1	   vector	   was	   used	   as	   a	   negative	   control.	   To	   generate	   lentiviral	   particles,	  
HEK293T	  cells	  grown	  on	  10	  cm	  dishes	  were	  transfected	  with	  3	  µg	  of	  the	  shRNA-­‐encoding	  
plasmid	   (pLK0.1),	   3	   µg	   of	   pCMV	   delta	   R8.2	   (packaging	   plasmid,	   Addgene)	   and	   3	   µg	   of	  
pCMV-­‐VSV-­‐G	   (envelope	   plasmid,	   Addgene)	   using	   36	   µL	   PEI.	   72	   hours	   post-­‐transfection	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virus-­‐containing	  medium	  was	   collected	   and	   filtered	  with	   a	   0.45	   µm	   filter.	   2	  mL	   of	   viral	  
supernatant	   was	   used	   to	   infect	   cells	   cultured	   in	   6-­‐well	   plates	   with	   8	   µg/mL	   polybrene.	  
After	  24	  hours,	   the	  virus-­‐containing	  medium	  was	   replaced	  with	   fresh	  medium	  and	  after	  
next	   24	   hours	   cells	   were	   seeded	   for	   experiments.	   Protein	   knockdown	   was	   assayed	   by	  
immunoblotting	  at	  72	  hours	  post	  infection.	  No	  puromycin	  selection	  was	  used	  as	  in	  initial	  
optimisation	  experiments	  infection	  efficiency	  was	  found	  to	  be	  near	  100%.	  
shRNA	  	   TRC	  number	   Sequence	  
SGK1	  A	   TRCN0000040175	   CCGGCGGAATGTTCTGTTGAAGAATCTCGAGATTCTTCAACAGAACATTC
CGTTTTTG	  
SGK1	  B	   TRCN0000040177	   CCGGCATGTCTTCTTCTCCTTAATTCTCGAGAATTAAGGAGAAGAAGACA
TGTTTTTG	  
SGK1	  C	   TRCN0000010432	   CCGGCAATTCTCATCGCTTTCATGACTCGAGTCATGAAAGCGATGAGAAT
TGTTTTTG	  
SGK1	  D	   TRCN0000196562	   CCGGGCAATCTTATTGCACACTGTTCTCGAGAACAGTGTGCAATAAGATT
GCTTTTTTG	  
SGK1	  E	   TRCN0000194957	   CCGGCTGGAAGCTTAGCAATCTTATCTCGAGATAAGATTGCTAAGCTTCC
AGTTTTTTG	  
SGK3	  A	   TRCN0000001517	   CCGGGCGAGACCCTAGTTAAGAGAACTCGAGTTCTCTTAACTAGGGTCTC
GCTTTTT	  
SGK3	  B	   TRCN0000001518	   CCGGGCAGGACTAAACGAATTCATTCTCGAGAATGAATTCGTTTAGTCCT
GCTTTTT	  
SGK3	  C	   TRCN0000001519	   CCGGGAACGTAATGTGCTCTTGAAACTCGAGTTTCAAGAGCACATTACGT
TCTTTTT	  
SGK3	  D	   TRCN0000001520	   CCGGGCATTCGTTGGTTTCTCTTATCTCGAGATAAGAGAAACCAACGAAT
GCTTTTT	  
SGK3	  E	   TRCN0000001521	   CCGGGCCGAGATGTTGCTGAAATGTCTCGAGACATTTCAGCAACATCTCG
GCTTTTT	  
scrambled	   	   CCTAAGGTTAAGTCGCCCTCGCTCTAGCGAGGGCGACTTAACCTTAGG	  
	  
Table	  2.5	  shRNA	  sequences	  
	  
2.2.11 	  Transduction	  with	  pBABE	  constructs	  for	  stable	  over-­‐expression	  
To	   generate	   retroviral	   particles	  HEK293T	   cells	   grown	  on	   10	   cm	  dishes	  were	   transfected	  
with	  6	  µg	  of	  pBABE	  construct,	  3.8	  µg	  pCMV-­‐Gag-­‐Pol	  (packaging	  plasmid,	  Addgene)	  and	  2.2	  
µg	  pCMV-­‐VSVG	  (envelope	  plasmid,	  Addgene)	  using	  36	  µL	  Lipofectamine	  2000	  according	  to	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manufacturer’s	   instructions.	   72	   hours	   post-­‐transfection	   virus-­‐containing	   medium	   was	  
collected	  and	  filtered	  with	  a	  0.45	  µm	  filter.	  2	  mL	  of	  viral	  supernatant	  was	  used	  to	   infect	  
cells	  cultured	  in	  6-­‐well	  plates	  with	  8	  µg/mL	  polybrene.	  After	  24	  hours,	  the	  virus-­‐containing	  
medium	  was	  replaced	  with	  fresh	  medium	  and	  after	  next	  24	  hours	  transduced	  cells	  were	  
selected	  in	  the	  presence	  of	  2	  µg/mL	  puromycin.	  
	  
2.2.12 	  Rescue	  of	  shRNA	  mediated	  knockdown	  
For	   rescue	  experiments	   cells	  were	   retrovirally	   transduced	   to	   stably	  express	  wild	   type	  or	  
kinase	  inactive	  SGK	  constructs.	  For	  rescue	  of	  SGK1	  knockdown	  wild-­‐type	  and	  catalytically	  
inactive	  (K127A)	  SGK1	  lacking	  the	  N-­‐terminal	  1–60	  amino	  acids	  (ΔN-­‐SGK1)	  were	  subcloned	  
into	  pBABE-­‐puro-­‐HA	  retroviral	  vector.	  ΔN-­‐SGK1	  lacks	  an	  N-­‐terminal	  degradation	  motif	  that	  
targets	   SGK1	   for	   proteasomal	   degradation	   and	   allows	   for	   higher	   levels	   of	   SGK1	   over-­‐
expression	  (Bogusz	  et	  al.,	  2006).	  For	  rescue	  of	  SGK1	  knockdown	  no	  silent	  mutations	  were	  
introduced	   into	   the	   constructs	   as	   one	   of	   the	   shRNAs	   (SGK1	   shRNA	   #D)	   targeted	   the	   3’	  
untranslated	   region	   (UTR)	   of	   the	   SGK1	   gene.	   	   Following	   selection	   and	   western	   blot	  
confirmation	  of	  kinase	  over-­‐expression,	  cells	  were	  infected	  with	  either	  SGK1	  shRNA	  #D	  or	  
scrambled	  shRNA.	  For	  rescue	  of	  SGK3	  knockdown	  three	  silent	  mutations	  (A1449C,	  C1452T	  
and	   T1455C,	   residue	   numbers	   correspond	   to	   nucleotide	   numbers	   in	   the	   construct	  
sequence)	   that	   alter	   the	   nucleotide	   sequence	   but	   not	   the	   amino	   acid	   sequence	   of	   the	  
expressed	   protein	   were	   introduced	   into	   full	   length	   wild-­‐type	   and	   catalytically	   inactive	  
(K191A)	   SGK3	   in	  order	   to	   create	   SGK3	   shRNA	  #D	   resistant	   constructs.	   	   	   SGK3	   shRNA	  #D	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resistant	   SGK3	   constructs	   were	   subcloned	   pBABE-­‐puro-­‐HA	   retroviral	   vector	   and	   rescue	  
experiments	  were	  performed	  as	  described	  above	  for	  SGK1.	  
	  
2.2.13 	  Cell	  growth	  assays	  
Cells	   (3,000-­‐4,000	   /	   well)	   were	   seeded	   into	   the	   inner	   60	   wells	   of	   96-­‐well	   plates	   and	  
allowed	  to	  attach	  overnight.	  For	  inhibitor	  treatments,	  cells	  were	  treated	  in	  triplicates	  with	  
increasing	  concentrations	  (0.01,	  0.03,	  0.1,	  0.3,	  1,	  3,	  10	  µM)	  of	  inhibitors	  diluted	  in	  DMSO.	  
72	  or	  96	  hours	  later	  cell	  viability	  was	  determined	  using	  CellTiter	  96®	  Non-­‐Radioactive	  Cell	  
Proliferation	  Assay	  (MTS),	  according	  to	  manufacturer’s	   instructions.	  Results	  were	  plotted	  
with	   a	   best-­‐fit	   sigmoidal	   variable	   slope	   dose	   response	   curve	   and	   GI50	   values	   were	  
calculated	  using	  GraphPad	  Prism	  5.0.	  	  
The	   capacity	   for	   proliferation	   following	   shRNA	   mediated	   knockdown	   of	   SGK1	   was	  
determined	  by	  seeding	  2,000	  cells	  /	  well	  into	  the	  inner	  60	  wells	  of	  96-­‐well	  plates	  48	  hours	  
post	   transduction	  with	   lentiviral	   shRNAs.	  MTS	  assay	  was	   then	  performed	  24,	  48,	  72,	  96,	  
120	  and	  144	  hours	  post	  seeding.	  Results	  are	  presented	  as	  fold	  change	  in	  absorbance	  over	  
the	  five-­‐day	  period	  relative	  to	  the	  assay	  start-­‐point	  (24	  hours	  post	  seeding	  or	  day	  0).	  
	  MTS	  assay	   is	   a	   colorimetric	  assay	   for	   the	  determination	  of	  numbers	  of	   viable	   cells.	   The	  
reagent	  contains	  a	  stable	  solution	  of	  tetrazolium	  compound	  [3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐
5-­‐(3-­‐carboxymethoxyphenyl)-­‐2-­‐(4-­‐sulfophenyl)-­‐2H-­‐tetrazolium,	   inner	   salt;	   MTS]	   and	   an	  
electron-­‐coupling	   reagent	   (phenazine	  ethosulfate;	  PES).	  Metabolically	   active,	   viable	   cells	  
reduce	  the	  MTS	  tetrazolium	  compound	  into	  a	  soluble	  and	  colored	  formazan	  product	  that	  
	   58	  
absorbs	  at	  490	  nm.	  The	  MTS	  assay	  is	  an	  improved	  version	  of	  the	  older	  MTT	  assay	  that	  also	  
utilises	  the	  conversion	  of	  a	  tetrazolium	  compound	  into	  a	  formazan	  (Mosmann,	  1983).	  
	  
2.2.14 	  Cell	  invasion	  assays	  
The	   ability	   of	   cells	   to	   invade	  was	   tested	   in	   a	   growth-­‐factor-­‐reduced	  Matrigel™	   invasion	  
chamber	  according	  to	  manufacturer’s	  instructions.	  Briefly,	  cells	  were	  serum-­‐deprived	  for	  2	  
hours,	  detached	  with	  enzyme-­‐free	  cell-­‐dissociation	  buffer	  and	  2.5	  x	  105	  cells	  suspended	  in	  
RPMI-­‐1640	   containing	   1%	   (w/v)	   BSA	   were	   added	   to	   the	   upper	   chambers	   and	  
chemoattractant	  (RPMI-­‐1640	  containing	  10%	  (v/v)	  FBS)	  was	  added	  to	  the	  lower	  wells.	  The	  
chambers	   were	   kept	   at	   37°C	   in	   5%	   CO2	   for	   20	   hours.	   Cells	   that	   did	   not	   invade	   were	  
removed	  from	  the	  upper	  face	  of	  the	  filters	  and	  cells	  that	  had	  migrated	  to	  the	  lower	  face	  of	  
the	  filters	  were	  fixed	  and	  stained	  with	  Reastain	  Quick-­‐Diff	  kit	  according	  to	  manufacturer’s	  
instructions	  and	  images	  (×10)	  were	  captured.	  	  
The	   growth-­‐factor-­‐reduced	   Matrigel™	   invasion	   chambers	   contain	   polyethylene	  
terephthalate	  (PET)	  membrane	  with	  8	  micron	  pores	  and	  a	  layer	  of	  growth	  factor	  reduced	  
Matrigel	  Matrix.	  Matrigel	   is	   a	   solubilized	   tissue	   basement	  membrane	  matrix	   containing	  
laminin,	  collagen	  type	  IV,	  heparan	  sulfate	  proteoglycan,	  entactin	  and	  growth	  factors	  (Taub	  
et	  al.,	  1990).	  Reduced	  growth	  factor	  Matrigel	  contains	  reduced	  amounts	  of	  growth	  factors	  
that	  may	   influence	  the	   invasive	  properties	  of	  cells	   	   (Vukicevic	  et	  al.,	  1992).	  The	  Matrigel	  
layer	  occludes	   the	  8	  micron	  pores	  of	   the	  membrane	   thereby	  blocking	  non-­‐invasive	   cells	  
from	  migrating	  through	  the	  membrane.	  Cells	  that	   invade	  through	  the	  Matrigel	   layer	  and	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the	  pores	   in	  response	  to	  the	  growth	  factor	  containing	  chemoattractant	  present	  beneath	  
the	  membrane	  are	  considered	  to	  be	  invasive	  in	  this	  in	  vitro	  setting.	  
	  
2.2.15 	  Cell	  lysis	  
Cells	  were	  rinsed	  with	  PBS	  and	  lysed	  on	  ice	  using	  lysis	  buffer.	  Lysates	  were	  snap-­‐frozen	  in	  
liquid	  nitrogen	  and	  stored	  at	  -­‐80°C.	  Lysates	  were	  clarified	  by	  centrifugation	  at	  18,000	  g	  for	  
15	  min	  at	  4°C	  and	  the	  supernatants	  were	  used	  for	  experiments.	  
	  
2.2.16 	  Quantification	  of	  protein	  concentration	  with	  Bradford	  assay	  
The	  protein	   concentration	  of	   lysates	  was	   estimated	  using	   the	  Bradford	   assay	   (Bradford,	  
1976).	   Binding	   of	   coomassie	   dye	   to	   protein	   in	   an	   acidic	   medium	   shifts	   the	   absorption	  
maximum	  from	  465	  to	  595	  nm.	  A	  standard	  curve	  was	  generated	  by	  plotting	  absorbance	  
against	  BSA	  standards.	   Lysate	  samples	  diluted	   in	  water	  were	  assayed	   in	   triplicates	  using	  
200	  µL	  of	  Bradford	  reagent	  per	  sample	  and	  absorbance	  at	  595	  nM	  was	  measured.	  Sample	  
concentrations	  were	  calculated	  using	  the	  standard	  curve.	  
	  
2.2.17 	  Purification	  of	  GST-­‐tagged	  proteins	  from	  HEK293	  cells	  
24	  hours	  post-­‐transfection,	  HEK293	  cells	   that	  had	  been	   transfected	  with	  GST-­‐Akt1,	  GST-­‐
ΔN-­‐SGK1	  or	  GST-­‐SGK3	  were	  serum	  starved	  for	  16	  hrs.	  Cells	  were	  treated	  with	  1	  µM	  PI-­‐103	  
for	   30	   min	   (for	   inactive	   and	   dephosphorylated	   Akt1	   or	   SGK1	   for	   use	   as	   substrates	   in	  
mTORC2	  kinase	  assays)	  or	  stimulated	  with	  50	  ng/mL	  IGF1	  for	  30min	  (for	  active	  Akt1,	  SGK1	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or	  SGK3)	  and	  harvested	  in	  Tris-­‐Triton	  lysis	  buffer.	  For	  the	  purification	  of	  dephosphorylated	  
Akt1	   and	   SGK1	   phosphatase	   inhibitors	   were	   omitted	   from	   the	   lysis	   buffer.	   20	   µl	   of	  
glutathione-­‐sepharose	  beads	  were	  used	  per	  5	  mg	  of	  lysate	  to	  bind	  the	  GST-­‐tagged	  protein	  
at	   4°C	   for	   2	   hrs	   on	   a	   rotating	   platform.	   The	   beads	  were	  washed	   twice	  with	   lysis	   buffer	  
containing	   0.5	   M	   NaCl,	   twice	   in	   normal	   lysis	   buffer	   and	   twice	   in	   Buffer	   A.	   GST-­‐tagged	  
proteins	   were	   eluted	   from	   the	   resin	   by	   resuspension	   in	   an	   equal	   amount	   of	   Buffer	   A	  
containing	   0.27	   M	   sucrose	   and	   20	   mM	   glutathione	   (pH	   7.5)	   for	   10	   minutes	   at	   room	  
temperature.	  Supernatants	  were	   filtered	   through	  a	  0.22	  µm	  Spin-­‐X	  column	  and	  aliquots	  
snap-­‐frozen	   and	   stored	   at	   -­‐80°C.	   Concentration	   of	   purified	   proteins	   was	   estimated	   by	  
Bradford	  assay	  and	  their	  purity	  was	  estimated	  by	  SDS-­‐PAGE.	  
	  
2.2.18 	  Covalent	  coupling	  of	  antibodies	  
For	   the	   coupling	   of	   antibodies,	   protein	   G-­‐sepharose	   and	   protein	   A-­‐agarose	   beads	  were	  
used.	   Protein	  G,	   isolated	   from	  Group	  G	  Streptococci,	   binds	   to	   the	   Fc	   region	   of	   IgG-­‐class	  
antibodies	   and	   has	   a	   high	   affinity	   for	   antibodies	   generated	   in	   many	   species,	   including	  
sheep.	  Protein	  A,	  which	  originates	  from	  Staphylococcus	  aureus,	  also	  binds	  Fc	  region	  of	  IgG-­‐
class	   antibodies,	   particularly	   those	   generated	   in	   rabbit.	   Covalent	   coupling	   of	   antibodies	  
was	  carried	  out	  using	  dimethyl	  pimelimidate	  (DMP),	  a	  homo-­‐bifunctional	  imidoester	  that	  
reacts	  with	  primary	  amine	  groups,	  as	  the	  cross-­‐linker.	  Protein	  A-­‐	  or	  G-­‐beads	  were	  washed	  
in	  PBS	  followed	  by	  incubation	  of	  1	  µL	  or	  resin	  per	  1	  µg	  of	  antibody	  for	  1-­‐2	  hrs	  at	  4°C.	  Beads	  
were	   then	   washed	   twice	   with	   PBS	   followed	   by	   three	   washes	   with	   0.1	   M	   sodium	  
tetraborate	   pH	   9.3.	   Beads	   were	   then	   mixed	   twice	   for	   30	   min	   in	   sodium	   tetraborate	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containing	   20	   mM	   DMP	   at	   room	   temperature	   followed	   by	   four	   washes	   with	   50	   mM	  
glycine	  pH	  2.5	  to	  remove	  any	  non-­‐covalently	  coupled	  antibody	  and	  two	  washes	  with	  0.2	  M	  
Tris-­‐HCl	  pH	  8.	  Beads	  were	  mixed	  with	  0.2	  M	  Tris-­‐HCl	  pH	  8	  at	  4°C	  overnight	  to	  quench	  any	  
residual	  DMP,	  before	  storage	  in	  PBS	  at	  4°C.	  
	  
2.2.19 	  Immunoprecipitation	  of	  proteins	  
3	  µL	  of	  covalently	  coupled	  antibody	  or	  for	  larger	  sample	  quantities	  1	  µL	  of	  antibody	  beads	  
/	  1	  mg	  of	   lysate	  was	  mixed	  with	  the	   lysate	  for	  1-­‐4	  hrs	  at	  4°C	  on	  a	  rotating	  wheel.	  Beads	  
were	  then	  washes	  twice	  with	  lysis	  buffer	  containing	  0.5	  M	  NaCl	  and	  twice	  with	  lysis	  buffer	  
containing	  0.15	  M	  NaCl	  followed	  by	  2	  washes	  with	  buffer	  A.	  Reducing	  agent	  was	  omitted	  
from	  the	  washes.	  To	  elute	  immunoprecipitates,	  beads	  were	  resuspended	  in	  2x	  SDS	  sample	  
buffer	  (or	  2x	  NuPAGE	  LDS	  sample	  buffer	  for	  mass	  spectrometry)	  lacking	  reducing	  agent	  for	  
10	  min	   prior	   to	   filtering	   through	   Spin-­‐X	   columns	   to	   remove	   the	   antibody-­‐bound	   beads.	  
Reducing	  agent	  was	  added	  to	  the	  eluted	  samples	  and	  the	  samples	  were	  heated.	  	  
	  
2.2.20 	  Resolution	  of	  protein	  samples	  via	  SDS-­‐PAGE	  
Sodium	  dodecyl	  sulphate	  polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  resolves	  proteins	  
based	   on	   their	   apparent	   molecular	   weight.	   The	   anionic	   detergents	   SDS	   and	   lithium	  
dodecyl	   sulphate	   (LDS)	   bind	   to	   proteins	   giving	   them	   a	   net	   negative	   charge	   that	   is	  
proportional	  to	  the	  molecular	  mass	  of	  the	  protein.	  Consequently,	  the	  speed	  of	  migration	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of	  proteins	  through	  a	  PAGE	  matrix	  is	  a	  linear	  function	  of	  the	  logarithm	  of	  their	  molecular	  
weight.	  	  
Resolving	   gels	   contained	   375	   mM	   Tris-­‐HCl	   (pH	   8.6),	   0.1%	   SDS	   and	   8-­‐10%	   acrylamide.	  
TEMED	  and	  ammonium	  persulphate	  (APS)	  were	  used	  to	   initiate	  polymerisation.	  Stacking	  
gels	  contained	  125	  mM	  Tris	  HCl	  pH	  6.8,	  0.1%	  SDS,	  4%	  acrylamide,	  TEMED	  and	  APS.	  
Samples	  were	  prepared	  either	  in	  1x	  LDS	  sample	  buffer	  and	  1x	  sample	  reducing	  agent	  (for	  
use	  with	  pre-­‐cast	  NuPAGE	  4-­‐12%	  Bis-­‐Tris	   gels)	   or	   in	   1x	   SDS	   sample	  buffer	   (for	   use	  with	  
homemade	  gels)	  and	  heated	  at	  heated	  at	  90°C	  for	  5	  min.	  5-­‐20	  µg	  of	  lysate	  or	  10-­‐30	  µL	  of	  
immunoprecipitates	  were	   loaded	  per	   lane	  along	  with	  protein	   standards.	   Electrophoresis	  
was	  carried	  out	  at	  80	  V	  until	  the	  protein	  markers	  started	  to	  resolve	  and	  then	  the	  voltage	  
was	  increased	  to	  160	  –	  180	  V	  until	  the	  dye	  front	  reached	  the	  end	  of	  the	  resolving	  gel.	  
	  
2.2.21 	  Coomassie	  staining	  of	  polyacrylamide	  gels	  
Polyacrylamide	   gels	   were	   stained	   in	   Instant	   Blue	   staining	   solution	   for	   1-­‐2	   hrs	   and	  
destained	  with	  MilliQ	  water.	  
	  
2.2.22 	  Dessication	  of	  polyacrylamide	  gels	  and	  autoradiography	  
For	  drying,	  gels	  were	   incubated	   in	  5%	  glycerol	   for	  10	  min	  and	  sandwiched	  between	  two	  
sheets	  of	  pre-­‐wet	  cellophane.	  The	  gel	  was	  then	  dried	  in	  a	  GelAir	  Dryer	  for	  1.5	  hrs.	  Dried	  
gels	  were	  exposed	  to	  Hyperfilm	  MP	  for	  1-­‐24	  hrs	   in	  an	  X-­‐Omat	  autoradiography	  cassette.	  
Films	  were	  developed	  using	  a	  Konica	  auto-­‐developer.	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2.2.23 	  Transfer	  of	  proteins	  onto	  nitrocellulose	  membranes	  
Gels	   were	   sandwiched	   between	   nylon	   sponges,	   Whatman	   3	   mm	   filter	   papers	   and	  
nitrocellulose	  membrane	  all	  soaked	  in	  transfer	  buffer.	  The	  transfer	  cell	  was	  submerged	  in	  
transfer	  buffer	  and	  transfer	  was	  carried	  out	  at	  at	  750	  mA	  for	  1	  hour.	  
	  
2.2.24 	  Immunoblotting	  
After	  transfer,	  membranes	  were	  stained	  with	  Ponceau	  S	  and	  destained	  in	  distilled	  water	  in	  
order	   to	   visualise	   the	   transferred	   proteins.	   Non-­‐specific	   binding	   of	   antibodies	   was	  
prevented	  by	  incubating	  the	  membranes	  with	  5%	  (w/v)	  skimmed	  milk	  in	  TBST	  for	  1	  hour	  at	  
room	  temperature.	  Membranes	  were	   then	   incubated	  with	  primary	  antibodies	  diluted	   in	  
either	   5%	   (w/v)	   skimmed	  milk	   or	   BSA	   in	   TBST	   at	   4°C	   for	   16	   hrs.	  Membranes	  were	   next	  
washed	  three	  times	  for	  10	  minutes	  with	  TBST.	  Horseradish	  peroxidase	  (HRP)-­‐conjugated	  
secondary	  antibodies	  diluted	  at	  1:2500	  in	  5%	  (w/v)	  skimmed	  milk	  in	  TBST	  were	  incubated	  
with	   the	  membranes	   for	   1	   hr	   at	   room	   temperature	   and	   the	  membranes	   were	   washed	  
three	   more	   times	   with	   TBST.	   Membranes	   were	   incubated	   with	   the	   enhanced	  
chemiluminescence	  (ECL)	  substrate	  and	  exposed	  to	  X-­‐ray	  films	  for	  various	  lengths	  of	  time.	  
Films	  were	  developed	  using	  a	  Konica	  automatic	  developer. Where	  indicated,	  signals	  were	  
visualised	  using	  the	  OdysseyTM	  Infrared	  Imaging	  System	  instead	  of	  ECL.	  The	  procedure	  was	  
the	  same	  but	  the	  secondary	  antibodies	  were	  labelled	  with	  either	  IRD800	  or	  Alexa680	  dyes	  
and	  the	  signal	  captured	  and	  quantified	  with	  an	  Odyssey	  Infrared	  Imaging	  System.	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2.2.25 	  Processing	  protein	  bands	  for	  analysis	  by	  mass	  spectrometry	  
To	   minimise	   contamination	   with	   proteins	   such	   as	   keratin,	   samples	   were	   handled	   in	   a	  
laminar	  flow	  hood.	  Gels	  were	  cut	  into	  small	  pieces.	  The	  pieces	  were	  sequentially	  washed	  
for	   10	   min	   in	   0.5	   mL	   water,	   50%	   (v/v)	   acetonitrile,	   0.1	   M	   NH4HCO3	   and	   50%	   (v/v)	  
acetonitrile/50	  mM	  NH4HCO3.	  The	  last	  step	  was	  repeated	  until	  the	  pieces	  were	  colourless.	  
Colourless	   gel	   pieces	   were	   incubated	   with	   0.3	   mL	   acetonitrile	   for	   15	   min	   at	   room	  
temperature	  followed	  by	  drying	  in	  a	  Speed-­‐Vac	  at	  45°C.	  Dried	  gel	  pieces	  were	  incubated	  
with	  30	  µL	  25	  mM	  Triethylammonium	  bicarbonate	  buffer	   containing	  5	  µg/mL	   trypsin	  at	  
30°C	  for	  16	  hrs	  on	  a	  shaking	  platform.	  Next	  an	  equal	  volume	  of	  acetonitrile	  was	  added	  and	  
the	   peptides	   obtained	   from	   the	   digestion	   were	   extracted	   for	   15	   min	   on	   a	   shaking	  
platform.	  The	  supernatant	  was	  dried	  in	  a	  clean	  tube	  at	  45°C	  using	  Speed-­‐Vac.	  To	  extract	  
further	   peptides,	   100	   µL	   of	   50%	   (v/v)	   acetonitrile	   supplemented	  with	   2.5%	   (v/v)	   formic	  
acid	  was	   added	   to	   the	   gel	   pieces	   and	   incubated	   for	   15	  min	   at	   room	   temperature	   on	   a	  
shaking	  platform.	  The	  supernatant	  was	  combined	  with	  the	  first	  dried	  peptide	  extract	  and	  
dried	  using	  Speed-­‐Vac.	  Dried	  peptides	  were	  stored	  at	  -­‐20°C.	  
	  
2.2.26 	  Mass	  spectrometry	  
Liquid	   chromatography–mass	   spectrometry	   (LC-­‐MS)	  was	   performed	   by	  Dr.	   D.	   Campbell,	  
and	   Mr.	   R.	   Gourlay.	   Tryptic	   peptides	   were	   subjected	   to	   LC-­‐MS/MS	   using	   a	   Proxeon	  
EasynLC	   chromatography	   system	   coupled	   with	   a	   Thermo	   LTQ-­‐Orbitrap	   Classic	   mass	  
spectrometer.	  Results	  were	  searched	  against	  the	  SwissProt	  or	  IPI	  mouse	  databases	  using	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Mascot	   (www.matrixscience.com).	   Data	   analysis	   was	   performed	   using	   Online	  MassSpec	  
Data	  Analysis	  Tool	  (http://www.proteinguru.com/MassSpec/OLMAT).	  
	  
2.2.27 	  mTORC2	  kinase	  assays	  
Lysates	  were	  generated	  in	  Hepes-­‐CHAPS	  lysis	  buffer.	  1-­‐4	  mg	  of	  lysate	  was	  pre-­‐cleared	  by	  
incubation	  with	  5	  µL	  pre-­‐immune	  IgG.	  This	  was	  followed	  by	  incubation	  with	  5	  µg	  of	  Sin1	  
antibody	  or	  pre-­‐immune	  IgG	  at	  4°C	  for	  1.5	  hrs.	  All	  antibodies	  were	  covalently	  coupled	  to	  
protein	   G-­‐sepharose.	   Immunoprecipitates	   were	   washed	   four	   times	   with	   Hepes-­‐CHAPS	  
lysis	  buffer	  and	  twice	  with	  Hepes	  kinase	  buffer.	  Assays	  were	  carried	  out	  in	  a	  final	  volume	  
of	  40	  µL	  Hepes	  kinase	  buffer	  containing	  1	  µg	  of	  substrate	  (GST-­‐Akt1	  or	  GST-­‐ΔN-­‐SGK1)	  and	  
kinase	   reactions	   were	   initiated	   upon	   addition	   of	   0.1	   mM	   ATP	   and	   10	   mM	  Magnesium	  
acetate.	   Reactions	  were	   carried	   out	   for	   30	  min	   at	   30°C	   and	   terminated	   by	   SDS	   sample	  
buffer.	   Samples	   were	   heated	   to	   70°C	   for	   5	   min,	   passed	   through	   a	   Spin-­‐X	   column	   and	  
subjected	  to	  immunoblot	  analysis.	  
	  
2.2.28 	  Kinase	  assays	  employing	  a	  protein	  substrate	  
Indicated	  amounts	  of	  kinases	  were	  incubated	  with	  1	  µg	  of	  purified	  protein	  substrate	  in	  the	  
presence	   of	   0.1	  mM	   [γ32P]-­‐ATP	   and	   10	  mM	  Magnesium	   acetate	   in	   Buffer	   A	   at	   30°C	   for	  
times	  indicated	  in	  the	  figure	  legends.	  Reactions	  were	  terminated	  with	  SDS	  sample	  buffer.	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2.2.29 	  Kinase	  assays	  employing	  a	  peptide	  substrate	  
In	   vitro	   kinase	   activities	   were	   measured	   using	   Cerenkov	   counting	   of	   incorporation	   of	  
radioactive	  32P	  from	  [γ32P]-­‐labelled	  ATP	  into	  a	  peptide	  substrate.	  The	  following	  conditions	  
were	   used:	   10	  mM	  Magnesium	   acetate,	   0.1	  mM	   [γ32P]-­‐	   ATP,	   30	   µM	  CROSStide	   peptide	  
(GRPRTSSFAEG)	  in	  Buffer	  A	  in	  a	  final	  volume	  of	  50	  µL.	  Control	  reactions	  contained	  a	  kinase	  
inactive	  mutant	   or	   an	   IgG	   immunoprecipitate.	   Reactions	  were	   incubated	   at	   30°C	   for	   30	  
min	  and	  terminated	  by	  adding	  10	  µL	  of	  0.5M	  EDTA	  to	  the	  reactions.	  40	  µL	  of	  the	  reactions	  
were	  spotted	  onto	  P81	  phosphocellulose	  paper.	  Papers	  were	  washed	  five	  times	  in	  75	  mM	  
orthophosphoric	  acid	  to	  remove	  any	  radioactivity	  not	  associated	  with	  the	  phosphorylated	  
peptide.	   Papers	   were	   then	   incubated	   in	   acetone	   for	   3	   min	   and	   air-­‐dried.	   Cerenkov	  
counting	  of	  the	  papers	  was	  done	  on	  a	  scintillation	  counter.	  Kinase	  activity	  was	  expressed	  
as	  specific	  activity	  (units	  of	  activity	  per	  mg	  of	  protein).	  One	  unit	  of	  protein	  kinase	  activity	  is	  
the	   amount	   of	   enzyme	   that	   catalyses	   the	   incorporation	   of	   1	   nmole	   phosphate	   into	   the	  
substrate	  in	  1	  min.	  
For	   IC50	   determination	   active	   GST-­‐ΔN-­‐SGK1	   and	   GST-­‐SGK3	   were	   purified	   from	   HEK293	  
cells.	  1	  µg	  of	  the	  kinase	  was	  assayed	  for	  30	  min	  at	  30°C	  on	  96	  well	  plates	  in	  the	  presence	  
or	  absence	  of	  inhibitor	  (0.1	  nM	  -­‐	  30	  µM)	  in	  triplicates	  in	  a	  50 µL	  assay	  mixture.	  Reactions	  
were	  terminated	  and	  the	  reaction	  products	  were	  subjected	  to	  Cerenkov	  counting.	  Results	  
were	  plotted	  with	  a	  best-­‐fit	  sigmoidal	  variable	  slope	  dose	  response	  curve	  and	  IC50	  values	  
were	   calculated	   using	   GraphPad	   Prism	   5.0.	   	   The	   data	   were	   presented	   as	   %	   activity	  
remaining	  in	  comparison	  to	  DMSO	  control.	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2.2.30 	  RNA	   isolation,	   cDNA	   preparation	   and	   analysis	   of	   transcripts	   by	  
quantitative	  reverse	  transcription-­‐PCR	  (qRT-­‐PCR)	  
Total	   RNA	   was	   isolated	   from	   cells	   using	   the	   RNeasy	   kit	   (Qiagen)	   according	   to	  
manufacturer’s	   instructions.	   cDNA	   was	   prepared	   from	   1	  µg	   of	   RNA	   using	   i-­‐Script	   Kit	  
(BioRad)	   according	   to	   manufacturer’s	   instructions.	   qRT-­‐PCR	   was	   performed	   in	   96-­‐well	  
plate	   format	   using	   iQ5™	   Real	   Time	   PCR	   detection	   system	   (BioRad).	   Each	   20	  µL	   reaction	  
included	  1%	  cDNA,	  0.5	  µM	  primers	  and	  10	  µL	  SsoFast™	  EvaGreen®	  Supermix	  (BioRad).	  The	  
supermix	  contained	  a	  heat-­‐activated	  Sso7d-­‐fusion	  polymerase,	  EvaGreen®	  fluorescent	  dye	  
that	  is	  similar	  to	  SYBER®green,	  dNTPs	  and	  MgCl2.	  	  The	  plate	  was	  subjected	  to	  the	  following	  
thermal	  cycle:	  95°C	  for	  3	  min,	  40	  cycles	  of	  95°C	  for	  20	  sec	  and	  57°C	  for	  45	  sec;	  then	  95°C	  
for	  1	  min,	  55°C	  for	  1	  min	  followed	  by	  80	  cycles	  at	  0.5°C	  increments	  for	  10	  sec	  up	  to	  95°C	  in	  
order	  to	  determine	  the	  melt	  curve.	  The	  melting	  curve	  allows	  the	  detection	  of	  non-­‐specific	  
products	  and	  primer	  dimers.	  A	  single	  melting	  peak	   indicates,	  but	  does	  not	  prove,	   that	  a	  
single	   product	   is	   being	   produced.	   The	   primer	   sequences	   are	   shown	   in	   Table	   2.6.	   Two	  
independent	   samples	   were	   assayed	   with	   each	   sample	   assayed	   in	   duplicate.	   Data	   were	  
normalised	   to	   an	   internal	   standard	   gene	  18S.	   For	   the	   comparison	  of	   SGK	   isoform	   levels	  
across	   a	   panel	   of	   breast	   cancer	   cell	   lines	   data	   were	   presented	   as	   relative	   levels	   in	  
comparison	   to	   the	   SGK	   isoform	  mRNA	   levels	   in	  HEK293	   cells.	   For	   all	   other	   experiments	  
data	  were	   presented	   as	   relative	   levels	   in	   comparison	   to	   control	   treatment.	   The	   relative	  
gene	  expression	   levels	   in	  comparison	  to	  control	  conditions	  were	  calculated	  according	   to	  
the	  2 -­‐ΔΔCT	  method	  (Livak	  and	  Schmittgen,	  2001).	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Primer	  name	   Sequence	  (5’	  -­‐>	  3’)	  
Human	  SGK1	  sense	   CATAGGAGTTATTGGCAAT	  
Human	  SGK1	  antisense	   CTTCCATCTCACTAACCA	  
Human	  SGK2	  sense	   CTTTGTTATTAGGGATAGTCA	  
Human	  SGK2	  antisense	   GAAGTGAATGGTTTGTCT	  
Human	  SGK3	  sense	   ATATTCTCTTGGCAGGAA	  
Human	  SGK3	  antisense	   AATGGCTCATTAAATCAGTT	  
Human	  18S	  sense	   CTAGAATTACCACAGTTATCC	  
Human	  18S	  antisense	   CTAGAATTACCACAGTTATCC	  
	  
Table	  2.6	  qRT-­‐PCR	  primer	  sequences	  
	  
2.2.31 	  Injection	  of	  mice	  with	  IGF1	  
IGF1	   injections	  were	  carried	  out	  by	  Dr	  K.	  Sakamoto	  and	  Dr	  L.	  Pearce.	  Mice	  were	  starved	  
for	  3	  hrs	  before	  being	  terminally	  anaesthetised	  using	  pentobarbital.	  This	  was	  followed	  by	  
an	   intravenous	   injection	   through	   the	   inferior	   vena	   cava	   of	   either	   saline	   or	   0.5 µg	   per	  
gram	  of	  body	  weight	  of	  IGF1.	  Tissues	  were	  excised	  after	  5	  min.	  
	  
2.2.32 	  Lysis	  of	  mouse	  tissues	  
Mouse	  tissues	  were	  rapidly	  excised,	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C	  until	  use.	  
Tissues	   were	   weighed	   and	   homogenised	   in	   a	   10-­‐fold	   excess	   of	   ice-­‐cold	   Tris-­‐CHAPS	   or	  
Hepes-­‐CHAPS	   lysis	   buffer	   using	   a	   polytron.	   Lysates	   were	   clarified	   by	   centrifugation	   at	  
3,000	  rpm	  for	  15	  min	  at	  4°C	  and	  supernatants	  then	  further	  centrifuged	  at	  18,000	  g	  for	  20	  
min	  at	  4°C.	  Lysates	  were	  aliquoted,	  snap	  frozen	  and	  stored	  at	  -­‐80°C.	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2.2.33 	  Kidney	  membrane	  preparation	  
Mouse	  kidneys	  were	  homogenized	  in	  10-­‐fold	  excess	  of	  Tris	   lysis	  buffer	   lacking	  detergent	  
with	  a	  Polytron.	  Nuclei	  and	  debris	  were	  pelleted	  by	  centrifugation	  at	  1,500	  g	   for	  5	  min.	  
The	  procedure	  was	  repeated	  at	  3,000	  g	  for	  10	  min	  and	  the	  low-­‐speed	  supernatants	  were	  
next	  centrifuged	  at	  100,000	  g	  for	  1	  h.	  The	  pellet	  was	  washed	  with	  1	  volume	  of	  lysis	  buffer	  
and	  centrifuged	  again	  at	  100,000	  g	  for	  15	  min	  to	  remove	  any	  remaining	  cytosolic	  particles.	  
The	  pellet	  was	  then	  resuspended	  in	  lysis	  buffer	  supplemented	  with	  1%	  (v/v)	  Nonidet	  P40	  
and	  centrifuged	  at	  16,500	  g	   for	  10	  min.	  Protein	  content	  of	   the	  membrane	  and	  cytosolic	  
fractions	  was	  quantified	  and	  the	  preparations	  were	  resuspended	  in	  SDS	  sample	  buffer.	  
	  
2.2.34 	  Mouse	  embryonic	  fibroblast	  (MEF)	  generation	  
Female	  mice	   at	   13	   days	   gestation	  were	   culled,	   the	   uterine	   horn	   removed	   and	   embryos	  
placed	   in	  PBS.	  Embryo	  heads	  were	  used	   to	  confirm	  the	  genotype	  by	  PCR	   (performed	  by	  
Mrs	  G.	  Fraser).	  After	  removing	  internal	  organs	  embryos	  were	  chopped	  and	  incubated	  with	  
trypsin	   at	   37°C,	   5%	  CO2	   for	   5-­‐10	  min.	   Cells	  were	   centrifuged	   at	   800	   rpm	   for	   5	  min	   and	  
resuspended	   in	   primary	  MEF	  media	   (Section	   2.2.6).	   After	   24	   hrs,	   cells	  were	   trypsinised,	  
resuspended	  in	  primary	  MEF	  media	  and	  filtered.	  These	  cells	  were	  designated	  as	  passage	  1	  
(P1).	   MEFs	   were	   immortalised	   by	   continues	   passaging	   and	   were	   considered	   to	   be	  
immortalised	  once	  the	  cells	  were	  proliferating	  at	  a	  rate	  similar	  to	  primary	  MEFs.	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2.2.35 	  Statistical	  analysis	  
Statistical	  significance	  was	  assessed	  by	  one-­‐way	  analysis	  of	  variance	  (ANOVA)	  followed	  by	  
Tukey’s	   multiple	   comparison	   tests	   using	   GraphPad	   Prism	   5.0.	   	   All	   the	   experiments	  
presented	   in	   this	   thesis	  were	  performed	  at	   least	   two	  or	   three	   times	  with	   similar	   results	  
obtained	   on	   each	   occasion.	   Error	   bars	   indicate	   the	   standard	   deviation	   (SD)	   or	   standard	  
error	  of	  the	  mean	  (SEM),	  as	  indicated	  in	  figure	  legends.	  
	  
2.2.36 	  Bioinformatics	  
Sequence	  alignments	  were	  undertaken	  using	  Clustal	  Omega	  (Sievers	  et	  al.,	  2011)	  and	  the	  
alignments	  were	  annotated	  using	  Jalview	  2	  (Waterhouse	  et	  al.,	  2009).	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3. Optimisation	   of	   the	   detection	   of	   endogenous	   SGK	   and	  
study	  of	  the	  role	  of	  Protor	  in	  the	  regulation	  of	  SGK	  
	  
3.1. Introduction	  
The	  major	  initial	  aim	  of	  this	  PhD	  project	  was	  to	  develop	  and	  characterise	  novel	  antibodies	  
that	  would	  enable	  reliable	  and	  specific	  detection	  of	  endogenous	  SGK.	  Furthermore,	  when	  
I	  started	  this	  project,	  there	  were	  no	  well-­‐characterised	  antibodies	  available	  to	  monitor	  T-­‐
loop	  phosphorylation	  of	  endogenous	  SGKs.	  	  
Previous	  work	  carried	  out	  in	  our	  laboratory	  had	  identified	  Protor-­‐1	  and	  Protor-­‐2	  as	  novel	  
constitutive	  components	  of	  mTORC2	  (Pearce	  et	  al.,	  2007).	  Additionally,	  two	  other	  groups	  
independently	  identified	  both	  Protor-­‐1	  and	  Protor-­‐2	  as	  mTORC2	  components	  (Thedieck	  et	  
al.,	   2007;	  Woo	   et	   al.,	   2007).	   As	   cell-­‐based	   experiments	   had	   failed	   to	   provide	   any	   clues	  
about	   the	   function	   of	   these	   proteins,	   Protor-­‐1,	   Protor-­‐2	   and	   Protor-­‐1/2	   deficient	   mice	  
were	   generated	   in	   the	   laboratory.	  Work	   carried	   out	   by	   Dr	   Laura	   Pearce	   indicated	   that	  
mice	  lacking	  Protor-­‐1	  have	  a	  defect	   in	  the	  activation	  of	  SGK	  in	  kidney.	  In	  the	  kidney,	  but	  
not	   in	  other	  tissues	  studied,	   loss	  of	  Protor-­‐1	  resulted	  in	  reduced	  phosphorylation	  of	  SGK	  
hydrophobic	  motif	  and	  reduced	  phosphorylation	  of	  the	  SGK	  substrate	  NDRG1.	  Analysis	  of	  
Protor-­‐2	   knockout	   mice	   carried	   out	   by	   Dr	   L.	   Pearce	   failed	   to	   yield	   any	   observable	  
differences	  between	  the	  wild	  type	  and	  Protor-­‐2	  knockout	  animals	  indicating	  that	  the	  two	  
Protor	   isoforms	  may	  have	  different	  functions.	  To	  ensure	  that	  no	  compensation	  occurred	  
between	   the	   two	   Protor	   isoforms,	   I	   studied	   Protor-­‐1/2	   double	   knockout	   mice	   with	   a	  
particular	  focus	  on	  the	  activation	  of	  SGK.	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In	  this	  chapter	  I	  first	  describe	  the	  validation	  of	  antibody	  tools	  that	  allow	  reliable	  detection	  
of	  endogenous	  SGKs.	  Using	  the	  improved	  methods	  to	  study	  endogenous	  SGK	  I	  (1)	  validate	  
the	   compromised	   activation	   of	   SGK	   in	   the	   kidney	   using	   Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	   double	  
knockout	  mice	  as	  a	  model	  and	  (2)	  show	  that	  Protor	  is	  not	  universally	  required	  for	  mTORC2	  
mediated	  activation	  of	  SGK.	  To	  answer	  this	  question	   I	  describe	  the	  generation	  of	  mouse	  
embryonic	  fibroblasts	  (MEF)	  lacking	  both	  Protor	  isoforms.	  
	  
3.2. Results	  
3.2.1. Characterisation	  of	  SGK	  antibodies	  
In	  order	   to	  have	   state-­‐of-­‐the-­‐art	   tools	   to	   study	  SGKs,	   antibodies	  designed	  against	   SGK1,	  
SGK2	  and	  SGK3	  were	  raised	  by	  the	  DSTT	  (Figure	  3.1).	  These	  antibodies	  were	  characterised	  
for	   their	  ability	   to	  recognise	  over-­‐expressed	  HA-­‐tagged	  SGK	   isoforms	  by	   immunoblotting	  
(Figure	  3.2A-­‐C)	   and	   to	   immunoprecipitate	  HA-­‐SGK	   isoforms	   (Figure	  3.2D-­‐F).	  An	   anti-­‐SGK	  
antibody	   obtained	   from	   Sigma	   was	   also	   characterised	   (Figure	   3.2G).	   Other	   commercial	  
antibodies	   tested	   (appendix	   1)	  were	  poorly	   reactive	   against	   over-­‐expressed	   SGK	  and	  no	  
further	  work	  was	  carried	  out	  with	  them	  (data	  not	  shown).	  
All	   DSTT	   antibodies	   tested	   recognised	   and	   immunoprecipitated	   the	   over-­‐expressed	  
isoform	   that	   they	   were	   raised	   against.	   Clear	   differences	   between	   the	   bleeds	   were	  
observed	   in	   the	   immunoblot	   analysis	   whereas	   for	   each	   antibody	   all	   bleeds	  
immunoprecipitated	  HA-­‐SGKs	   equally	  well	   (Figure	   3.2A-­‐F).	   Antibodies	   generated	   against	  
SGK2	  and	  SGK3	  (S036D	  and	  S037D,	  respectively)	  were	  isoform-­‐specific	  whereas	  the	  anti-­‐
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SGK1	   antibody	   (S062D)	   also	   recognised	   SGK2.	   	   The	   best	   bleeds	  were	   chosen	   for	   future	  




Figure	  3.1	  Schematic	  summary	  of	  SGK	  antibodies	  characterised	  	  
(A)	   Schematic	   representation	   of	   SGK	   isoforms	   and	   the	   regions	   against	   which	   the	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Figure	  3.2	  Testing	  of	  SGK	  antibodies	  in	  over-­‐expression	  system	  
(A)	  HEK293	  cells	  were	  transfected	  with	  indicated	  vectors	  and	  10	  µg	  of	  lysate	  was	  analysed	  
by	   immunoblotting	   (IB)	   with	   indicated	   bleeds	   of	   S062D	   SGK1	   or	   anti-­‐HA	   antibodies.	  
Asterisk	  indicates	  the	  best	  bleed.	  (B)	  as	  in	  (A)	  except	  S036D	  SGK2	  antibody	  was	  used.	  (C)	  
as	   in	   (A)	  except	  SGK3	  S037D	  antibody	  was	  used.	   (D)	  as	   in	   (A)	  except	  1	  mg	  of	   lysate	  was	  
immunoprecipitated	   (IP)	   with	   indicated	   bleeds	   of	   S062D	   antibody	   and	   the	  
immunoprecipitates	  were	  analysed	  by	  immunoblotting	  with	  anti-­‐HA	  antibody.	  (E)	  as	  in	  (D)	  
except	  S036D	  was	  used	  for	  immunoprecipitations.	  (F)	  as	  in	  (D)	  except	  S037D	  was	  used	  for	  
immunoprecipitations.	   (G)	   as	   in	   (A)	   except	   10	   µg	   (5	   µg	   for	   HA-­‐SGK2)	   of	   lysate	   was	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To	  test	  the	  ability	  of	  the	  antibodies	  to	  detect	  endogenous	  SGKs,	  a	  preliminary	  expression	  
analysis	   of	   mouse	   tissues	   was	   undertaken.	   Endogenous	   SGK	   was	   immunoprecipitated	  
from	  a	  range	  of	  tissues	  derived	  from	  wild	  type	  C57BL/6J	  mice	  with	  the	  pan-­‐SGK	  antibody	  
obtained	  from	  Sigma	  and	  the	  immunoprecipitates	  were	  analysed	  by	  immunoblotting	  with	  
DSTT	   S062D	   antibody	   that	   based	   on	   results	   presented	   in	   Figure	   3.2	   was	   expected	   to	  
recognise	  at	   least	   SGK1	  and	  SGK2.	  As	   shown	   in	  Figure	  3.3,	   SGK	  protein	  was	  detected	   in	  
kidney	  and	  liver	  and	  low	  levels	  of	  a	  species	  that	  migrated	  higher	  were	  detected	  in	  spleen	  
and	  testis.	  As	  it	  was	  unclear	  which	  isoforms	  were	  detected,	  next	  SGK	  immunoprecipitates	  
from	  kidney,	   liver,	   spleen	  and	   testes	  extracts	  were	  analysed	  by	  mass	  spectrometry.	  SGK	  
was	  immunoprecipitated	  from	  the	  four	  tissues	  with	  the	  Sigma	  pan-­‐SGK	  antibody	  and	  the	  
results	   revealed	   that	   SGK2	  was	   the	  most	   abundant	   isoform	   in	   kidney	   and	   liver	  whereas	  
SGK3	  was	  the	  most	  abundant	  isoform	  in	  spleen	  and	  testes	  (Figure	  3.4A	  and	  Table	  3.1).	  To	  
further	  test	  the	  DSTT	  SGK	  antibodies,	  immunoprecipitations	  with	  all	  three	  DSTT	  antibodies	  
were	  performed	  from	  kidney	   lysates.	  Whilst	  all	   three	  SGK	  isoforms	  were	  detected,	  SGK2	  
was	  again	  most	  efficiently	   immunoprecipitated	  (Figure	  3.4B,	  Table	  3.1).	  The	  endogenous	  
immunoprecipitations	  also	   revealed	   that	   the	  Sigma	  S5188	  antibody	   immunoprecipitated	  
all	  SGK	  isoforms,	  S062D	  immunoprecipitated	  SGK2	  (based	  on	  over-­‐expression	  experiments	  
S062D	   would	   also	   be	   expected	   to	   immunoprecipitate	   SGK1	   if	   SGK1	   were	   expressed	   at	  
sufficiently	   high	   levels),	   S036D	   immunoprecipitated	   only	   SGK2	   and	   S037D	  
immunoprecipitated	  only	  SGK3	  (Figure	  3.4	  and	  Table	  3.1).	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Figure	  3.3	  Analysis	  of	  SGK	  isoform	  expression	  in	  mouse	  tissues	  
SGK	  was	   immunoprecipitated	  (IP)	  with	  Sigma	  S5188	  antibody	  or	  pre-­‐immune	  IgG	  from	  1	  
mg	   of	   tissue	   lysates	   and	   analysed	   by	   immunoblotting	   (IB)	  with	   S062D	   antibody.	   Arrows	  
indicate	  the	  approximate	  sizes	  at	  which	  different	  isoforms	  are	  expected	  to	  run.	  
	  
	  
Figure	  3.4	  Immunoprecipitation	  of	  endogenous	  SGK	  for	  analysis	  by	  mass	  spectrometry	  
(A)	  Endogenous	  SGK	   isoforms	  were	   immunoprecipitated	   (IP)	  with	  Sigma	  S5188	  antibody	  
from	  40	  mg	  of	  the	  indicated	  tissue	  lysates	  derived	  from	  wild	  type	  C57BL/6J	  mice	  for	  in-­‐gel	  
digestion	   and	   analysis	   by	   mass	   spectrometry.	   (B)	   5%	   of	   the	   immunoprecipitates	   were	  
analysed	   by	   immunoblotting	   (IB)	   with	   Sigma	   S5188	   anti-­‐SGK	   antibody.	   (C)	   Endogenous	  
SGK	  isoforms	  were	  immunoprecipitated	  with	  the	  indicated	  DSTT	  anti-­‐SGK	  antibodies	  from	  
40	  mg	  of	  kidney	   lysate	   for	   in-­‐gel	  digestion	  and	  analysis	  by	  mass	   spectrometry.	   (D)	  As	   in	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Tissue	  
	  






Kidney	  	   Sigma	  S5188	   SGK2	   2730	   61%	  
Kidney	   Sigma	  S5188	   SGK3	   1057	   51%	  
Kidney	   Sigma	  S5188	   SGK1	   103	   14%	  
Kidney	   SGK1	  S062D	   SGK2	   249	   31	  %	  
Kidney	   SGK2	  S036D	   SGK2	   526	   41%	  
Kidney	   SGK3	  S037D	   SGK3	   440	   31%	  
Liver	   Sigma	  S5188	   SGK2	   1172	   56%	  
Liver	   Sigma	  S5188	   SGK3	   806	   48%	  
Liver	   Sigma	  S5188	   SGK1	   21	   9%	  
Spleen	   Sigma	  S5188	   SGK3	   1447	   53%	  
Testis	   Sigma	  S5188	   SGK3	   2474	   57%	  
Testis	   Sigma	  S5188	   SGK1	   60	   5%	  
	  
Table	   3.1	   Summary	   of	   endogenous	   SGK	   immunoprecipitations	   analysed	   by	   mass	  
spectrometry	  
	  
Data	   obtained	   from	   the	   large-­‐scale	   mass	   spectrometry	   analysis	   indicated	   that	   no	  
contaminating	   kinases	   were	   immunoprecipitated	   with	   endogenous	   SGKs	   under	   any	  
conditions	   tested	   (appendix	   2).	   Consequently	   the	   SGK	   antibodies	   are	   suitable	   for	  
endogenous	   kinase	   assays.	   Results	   presented	   in	   Figure	   3.4	   and	   Table	   3.1	   indicate	   that	  
SGK2	  is	  the	  most	  abundant	  isoform	  in	  whole	  kidney	  and	  liver	  lysates.	  To	  manually	  confirm	  
that	   all	   the	   SGK2	   peptides	   identified	   in	   the	  mass	   spectrometry	   were	   indeed	   unique	   to	  
SGK2,	   a	   sequence	   alignment	   of	   mouse	   SGKs	   was	   prepared	   and	   the	   peptides	   identified	  
were	   matched	   onto	   the	   sequence	   alignment.	   As	   shown	   in	   Figure	   3.5,	   the	   sequence	  
alignment	  analysis	  confirmed	  that	  the	  peptides	  were	  indeed	  unique	  to	  SGK2.	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Figure	  3.5	  Sequence	  alignment	  of	  mouse	  SGK	  isoforms	  	  
Sequence	   alignment	   of	   mouse	   SGK1	   (Uniprot	   accession	   number:	   Q9WVC6),	   SGK2	  
(Q9QZS5)	  and	  SGK3	  (Q9ERE3)	  was	  undertaken	  using	  Clustal	  Omega	  (Sievers	  et	  al.,	  2011)	  
and	   the	   alignment	   was	   annotated	   using	   Jalview	   2	   (Waterhouse	   et	   al.,	   2009).	   SGK2	  
peptides	   identified	   in	   immunoprecipitations	   (IP)	   performed	  with	   SIGMA	  S5188	   antibody	  
and	  DSTT	  S062D	  antibody	  are	  underlined	  in	  blue	  and	  red,	  respectively.	  
	  
3.2.2. Validation	  of	  an	  SGK	  phospho-­‐T-­‐loop	  antibody	  
As	   the	   amino	   acid	   sequences	   encompassing	   the	   T-­‐loop	  of	   S6K	   and	   SGK	   are	   very	   similar	  
(Figure	   3.6A),	   a	   phospho-­‐specific	   pan-­‐PDK1	   site	   antibody,	   which	   recognises	   the	  
phosphorylated	  T-­‐loop	  of	  S6K	  (Collins	  et	  al.,	  2005),	  was	  tested	  for	   its	  ability	  to	  recognise	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antibody	   efficiently	   recognised	   IGF1	   stimulated	   phosphorylation	   of	   GST-­‐ΔN-­‐SGK1	   in	  
HEK293	   cell	   lysates	   (Figure	   3.6B).	   No	   immunoreactivity	   was	   observed	   when	   cells	   were	  
transfected	  with	  a	  construct	  in	  which	  Thr256	  was	  mutated	  into	  alanine.	  Because	  SGK1	  is	  
sequentially	  phosphorylated,	  first	  by	  mTORC2	  at	  the	  HM-­‐site	  and	  subsequently	  by	  PDK1	  at	  
the	  T-­‐loop,	  mutation	  of	  the	  HM-­‐site	  Ser422	  into	  alanine	  would	  also	  be	  expected	  to	  inhibit	  
Thr256	  phosphorylation	  (Biondi	  et	  al.,	  2001),	  and	  this	  was	  indeed	  observed	  (Figure	  3.6B).	  	  
Validation	   of	   the	   pan-­‐PDK1	   site	   antibody	   allowed	   characterisation	   of	   the	   effects	   of	  
GSK2334470,	  a	  novel	  PDK1	   inhibitor	   (Najafov	  et	  al.,	  2011),	  on	  T-­‐loop	  phosphorylation	  of	  
all	  SGK	  isoforms.	  HEK293	  cells	  were	  transiently	  transfected	  with	  GST-­‐ΔN-­‐SGK1,	  GST-­‐SGK2	  
or	  GST-­‐SGK3	  and	   the	   impact	  of	  GSK2334470	  on	   IGF1-­‐induced	  phosphorylation	  of	   the	  T-­‐
loop	   was	   analysed	   by	   immunoblotting	   (Figure	   3.6C).	   IGF1	   induced	   T-­‐loop	   and	   NDRG1	  
phosphorylation	  were	  decreased	  in	  response	  to	  GSK2334470	  in	  a	  dose-­‐dependent	  manner	  
indicating	  that	  PDK1	  inhibition	  suppressed	  activation	  of	  all	  the	  three	  SGK	  isoforms	  (Figure	  
3.6C).	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Figure	  3.6	  Recognition	  of	  SGK	  T-­‐loop	  phosphorylation	  	  
(A)	   Sequences	   surrounding	   the	   T-­‐loop	   site	   of	   human	   SGK1	   (Uniprot	   accession	   number:	  
O00141),	   SGK2	   (Q9HBY8),	   SGK3	   (Q96BR1),	   S6K1	   (P23443)	   and	   S6K2	   (Q9UBS0)	   were	  
aligned	  using	  Clustal	  Omega	  (Sievers	  et	  al.,	  2011)	  and	  the	  alignment	  was	  annotated	  using	  
Jalview	   2	   (Waterhouse	   et	   al.,	   2009).	   Arrow	   indicates	   the	   T-­‐loop	   residue	   that	   is	  
phosphorylated	   by	   PDK1.	   (B)	   24	   hours	   post	   transfection	   with	   the	   indicated	   constructs	  
HEK293	  cells	  were	  serum	  starved	  for	  16	  hours,	  stimulated	  with	  50	  ng/ml	  IGF1	  for	  30	  min,	  
lysed	   and	   analysed	   by	   immunoblotting	   (IB)	   with	   the	   indicated	   antibodies.	   Residue	  
numbers	  are	   for	   full-­‐length	  SGK1.	   (C)	  HEK293	  cells	  were	   transfected	  with	  GST–ΔN-­‐SGK1,	  
GST–SGK2	  or	  GST–SGK3.	   24	  hours	   post-­‐transfection,	   cells	  were	   serum-­‐starved	  overnight	  
and	   treated	   with	   the	   indicated	   concentrations	   of	   GSK2334470	   for	   30	   min	   prior	   to	  
stimulation	  with	  50	  ng/mL	  IGF1	  for	  30	  min.	  Lysates	  were	  analysed	  by	  immunoblotting	  with	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3.2.3. Study	  of	  the	  role	  of	  Protor	  in	  SGK	  activation	  in	  kidney	  
Work	  carried	  out	  by	  Dr	  L.	  Pearce,	  a	  previous	  PhD	  student	  in	  the	  laboratory,	  suggested	  that	  
activation	   of	   SGK	   is	   compromised	   in	   kidney	   in	   the	   absence	   of	   the	  mTORC2	   component	  
Protor-­‐1.	  The	  related	  AGC	  kinases	  Akt,	  S6K	  and	  PKCα were	  normally	  activated	  in	  both	  fed	  
IGF1	  injected	  Protor-­‐1	  deficient	  mice.	  	  Based	  on	  further	  preliminary	  work	  carried	  out	  by	  Dr	  
L.	   Pearce,	   loss	   of	   the	   closely	   related	   protein	   Protor-­‐2	   did	   not	   result	   in	   any	   noticeable	  
defects	   in	  the	  activation	  of	  any	  of	  the	  AGC	  kinases	  tested	  (Pearce	  et	  al.,	  2011).	  With	  the	  
aid	   of	   the	   development	   of	   antibodies	   that	   efficiently	   recognised	   endogenous	   SGK	  
isoforms,	   I	  undertook	   further	  analysis	   in	  Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	  double	  knockout	  mice	   that	  
were	  generated	  in	  order	  to	  ensure	  that	  no	  compensation	  between	  the	  two	  isoforms	  took	  
place.	  Dr	   L.	   Pearce	   generated	   and	  maintained	   the	   Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	   double	   knockout	  
mice	   on	   a	   pure	   C57BL/6J	   background	   and	   found	   that	   the	   double-­‐knockout	   mice	   were	  
viable,	   born	   at	   the	   expected	   Mendelian	   frequency	   and	   did	   not	   display	   any	   overt	  
phenotype	  (Pearce	  et	  al.,	  2011).	  	  
The	   phosphorylation	   state	   of	   Akt,	   its	   substrate	   PRAS40,	   as	  well	   as	   of	   the	   reported	   SGK	  
substrate	  NDRG1,	  was	  examined	  in	  kidney,	   liver	  and	   lung	  tissues	  obtained	  from	  fed	  wild	  
type	  and	  Protor-­‐1−/−Protor-­‐2-­‐/-­‐mice	   (Figure	  3.7).	  No	  significant	  differences	  were	  detected	  
in	  Akt	  or	  PRAS40	  phosphorylation	  between	  the	  wild	  type	  and	  double	  knockout	  mice	  in	  any	  
of	   the	   tissues	   examined	   (Figure	   3.7).	   Consistent	   with	   previous	   work	   performed	   in	   the	  
laboratory,	   there	   was	   a	   substantial	   reduction	   in	   the	   phosphorylation	   of	   NDRG1	   in	   the	  
kidney,	  but	  not	  in	  the	  liver	  or	  lung	  tissues	  of	  Protor	  double	  knockout	  mice	  (Figure	  3.7).	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Figure	  3.7	  NDRG1	  phosphorylation	  is	  reduced	  in	  kidney	  of	  fed	  Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	  mice	  
Whole	   kidney,	   liver	   and	   lung	   lysates	   prepared	   from	   wild	   type	   and	   Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	  
mice	  were	   analysed	   by	   immunoblotting	   (IB)	  with	   the	   indicated	   antibodies.	   Dr	   L.	   Pearce	  
prepared	  the	  samples	  and	  undertook	  part	  of	  the	  immunoblot	  analysis.	  
	  
To	  further	  validate	  the	  importance	  of	  Protor	  in	  the	  regulation	  of	  SGK	  activation	  in	  kidney,	  
wild	  type	  and	  Protor	  double	  knockout	  mice	  were	   injected	  with	   IGF1	  to	  activate	  the	  PI3K	  
pathway.	   Kidney	   and	   liver	   extracts	   derived	   from	   these	   animals	   were	   probed	   using	  
antibodies	  that	  recognise	  SGK	  phosphorylated	  at	   its	  hydrophobic	  motif	   (Ser422	   in	  SGK1)	  
and	  validation	  of	  the	  T-­‐loop	  antibody	  allowed	  for	  the	  detection	  of	  phosphorylated	  SGK	  T-­‐
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loop	   residue	   (Thr256	   in	   SGK1).	   Although	   SGK1	   hydrophobic	   motif	   phosphorylation	   was	  
stimulated	   upon	   IGF1	   treatment	   in	   wild-­‐type	   mice,	   phosphorylation	   of	   this	   site	   was	  
markedly	   reduced	   in	   the	   kidney	   of	   Protor-­‐1−/−Protor-­‐2−/−	   mice	   (Figure	   3.8A).	   Consistent	  
with	   phosphorylation	   of	   Ser422	   being	   required	   for	   the	   subsequent	   phosphorylation	   of	  
Thr256	  (Biondi	  et	  al.,	  2001;	  Garcia-­‐Martinez	  and	  Alessi,	  2008),	  there	  was	  also	  diminished	  
phosphorylation	   of	   Thr256	   in	   the	   double	   knockouts.	   The	   loss	   of	   HM-­‐site	   and	   T-­‐loop	  
phosphorylation	   would	   result	   in	   a	   lack	   of	   SGK	   activation,	   which	   would	   account	   for	   the	  
much-­‐reduced	  phosphorylation	  of	  NDRG1.	  There	  was	  no	  significant	  difference	  in	  the	  IGF1-­‐
induced	  phosphorylation	  of	  Akt	  Ser473	  or	  Thr308	  or	  that	  of	  PRAS40	  in	  the	  kidney	  of	  the	  
double	   knockout	   mice	   (Figure	   3.8A).	   Phosphorylation	   of	   SGK	   HM-­‐site	   was	   similarly	  
stimulated	   by	   IGF1	   in	   liver	   samples	   derived	   from	  both	  wild	   type	   and	   Protor-­‐1/2	   double	  
knockout	   mice.	   No	   T-­‐loop	   phosphorylation	   of	   SGK	   was	   detected	   in	   liver	   and	   the	  
stimulatory	  effect	  of	  IGF1	  on	  NDRG1	  phosphorylation	  was	  weak.	  As	  expected,	  loss	  of	  the	  
two	   Protor	   isoforms	   did	   not	   influence	   IGF1	   stimulated	   phosphorylation	   of	   Akt	   or	   its	  
substrate	  PRAS40	  in	  liver	  (Figure	  3.8B).	  Total	  levels	  of	  SGK	  protein	  were	  similar	  in	  the	  wild	  
type	  and	  double	  knockout	  mice	  in	  both	  tissues	  examined	  (Figure	  3.8).	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Figure	  3.8	  SGK	  phosphorylation	  is	  defective	  in	  the	  kidneys	  of	  Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	  mice	  
Wild	   type	   and	   Protor-­‐1-­‐/-­‐Protor-­‐2−/−	   mice	   deprived	   of	   food	   for	   3	   hours	   were	   injected	  
intravenously	  with	   IGF1	   (0.5	   μg/g)	   or	   saline	   solution	   for	   5	  min.	  Whole	   kidney	   and	   liver	  
lysates	  were	  analysed	  by	  immunoblotting	  (IB)	  with	  the	  indicated	  antibodies.	  SGK	  antibody	  
used	  was	  Sigma	  S5188.	  Dr	  L.	  Pearce	  carried	  out	  the	  IGF1	  injections	  and	  undertook	  part	  of	  
the	  immunoblot	  analysis.	  
	  
Given	   the	   ability	   of	   the	   Sigma	   SGK	   antibody	   to	   efficiently	   and	   selectively	  
immunoprecipitate	   endogenous	   SGK	   from	   kidney,	   the	   catalytic	   activity	   of	   SGK	  
immunoprecipitated	  from	  IGF1	  stimulated	  wild	  type	  and	  double	  knockout	  kidney	   lysates	  
was	   compared	   (Figure	   3.9).	   IGF1	   increased	   the	   activity	   of	   endogenous	   SGK	   by	  
approximately	   two-­‐fold	   in	   wild	   type	   mice.	   	   SGK	   immunoprecipitated	   from	   kidney	   of	  
Protor-­‐1-­‐/-­‐Protor2-­‐/-­‐	  mice	  showed	  a	  significantly	  blunted	  increase	  in	  activity	  as	  a	  response	  
to	  IGF1	  stimulation	  confirming	  the	  defect	  in	  SGK	  activation	  in	  this	  tissue.	  The	  total	  levels	  of	  
SGK	  were	  not	  altered	  between	  the	  two	  genotypes	  (Figure	  3.9).	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Figure	  3.9	  IGF1	  induced	  SGK	  activation	  is	  defective	  in	  Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	  kidneys	  
(A)	   Wild	   type	   and	   Protor-­‐1-­‐/-­‐Protor-­‐2−/−	   mice	   deprived	   of	   food	   for	   3	   hours	   were	  
intravenously	   injected	   with	   IGF1	   (0.5	   μg/g)	   or	   saline	   for	   5	   min.	   Endogenous	   SGK	   was	  
immunoprecipitated	  (IP)	  from	  5	  mg	  of	  kidney	  lysate	  using	  Sigma	  S5188	  antibody	  and	  the	  
catalytic	  activity	  was	  measured	  using	  Crosstide	  peptide.	  Each	  bar	  represents	  the	  mean	  ±	  
S.D.	  specific	  activity	  of	  two	  independent	  samples.	  Immunoprecipitates	  were	  subjected	  to	  
immunoblot	   (IB)	   analysis	   with	   DSTT	   S062D	   antibody.	   Lysates	   were	   also	   subjected	   to	  
immunoblot	  analysis	  with	  other	  indicated	  antibodies.	  Statistical	  significance	  was	  assessed	  
by	   ANOVA	   followed	   by	   Tukey's	   multiple	   comparison	   tests	   using	   GraphPad	   Prism	   5.0.	  
*P<0.05,	  **P<0.01.	  	  
	  
3.2.4. Membrane	  abundance	  of	  ENaC	  is	  not	  affected	  by	  the	  loss	  of	  Protor	  
The	  best-­‐characterised	  role	  of	  any	  SGK	  isoform	  in	  vivo	  is	  that	  of	  SGK1	  in	  the	  kidney.	  Whilst	  
SGK1	  knockout	  mice	  have	  no	  overt	  phenotype	  on	  a	  standard	  diet,	  when	  challenged	  with	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[reviewed	  in	  (Lang	  et	  al.,	  2009;	  Lang	  and	  Shumilina,	  2013).	  At	  least	  in	  part	  SGK1	  stimulates	  
sodium	   transport	   into	   epithelial	   cells	   by	   enhancing	   the	   stability	   and	   plasma	  membrane	  
abundance	  of	  the	  epithelial	  sodium	  channel	  ENaC.	  As	  SGK	  activity	  is	  reduced	  in	  kidneys	  of	  
Protor-­‐1−/−Protor-­‐2−/−	  mice,	   levels	   of	   ENaC	   at	   the	  membrane	   could	   also	   be	   lowered.	   To	  
address	   this,	   membrane	   fractions	   were	   prepared	   from	   wild	   type	   and	   Protor	   double	  
knockout	  kidneys.	  However,	  similar	  levels	  of	  ENaCα	  and	  ENaCγ	  subunits	  were	  observed	  in	  
membrane	  fractions	  derived	  from	  wild	  type	  and	  Protor-­‐1−/−Protor-­‐2−/−	  mice	  (Figure	  3.10).	  
Therefore	   Protor	   isoforms	   are	   not	   essential	   for	   regulating	   ENaC	   abundance	   at	   the	  
membrane,	  at	  least	  in	  basal	  conditions.	  
	  	  	  	  	  	  	  	  	  	   	  
Figure	  3.10	  Expression	  of	  ENaC	  subunits	  in	  kidney	  membrane	  fractions	  of	  wild-­‐type	  and	  
Protor-­‐1−/−	  Protor-­‐2−/−	  mice	  
Membrane	   and	   cytosolic	   fractions	  were	   prepared	   from	  wild-­‐type	   and	   Protor-­‐1−/−Protor-­‐
2−/−	  mouse	  kidney	  by	  ultra-­‐centrifugation	  and	  subjected	  to	  immunoblot	  (IB)	  analysis	  with	  
the	  specified	  antibodies.	  Flotillin-­‐1	  is	  a	  membrane	  and	  GAPDH	  a	  cytosolic	  protein.	  
	  
3.2.5. Generation	  and	  characterisation	  of	  Protor	  double	  knockout	  MEFs	  
To	  study	  the	  role	  of	  Protor	   in	  the	  regulation	  of	  SGK	  activity	  outside	  of	  kidney,	  MEF	  cells	  
were	   generated	   from	   wild	   type	   and	   Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	   mice.	   Due	   to	   difficulty	   in	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of	   Protor	   isoforms	   at	   protein	   level	  was	   confirmed	  by	   immunoprecipitations	   followed	  by	  
immunoblotting	  (Figure	  3.11).	  	  
	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  3.11	  Generation	  of	  Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	  double	  knockout	  MEFs	  
(A)	  Protor-­‐1	  was	  immunoprecipitated	  (IP)	  from	  1	  mg	  of	  wild	  type	  and	  Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐
MEF	  lysate	  and	  immunoblotting	  (IB)	  was	  carried	  out	  using	  the	  same	  antibody.	  (B)	  Protor-­‐2	  
was	  immunoprecipitated	  from	  3	  mg	  of	  wild	  type	  and	  Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	  MEF	  lysate	  and	  
immunoblotting	  was	  carried	  out	  using	  the	  same	  antibody.	  
	  
Next	   the	   phosphorylation	   of	   NDRG1	   was	   examined	   in	   MEF	   cells.	   Both	   IGF1,	   which	  
activates	   the	  PI3K	  pathway,	  and	  the	  glucocorticoid	  dexamethasone,	  which	   induces	  SGK1	  
expression,	   stimulated	  NDRG1	  phosphorylation	   in	  wild	   type	  MEFs	  but	   failed	   to	  do	   so	   in	  
Rictor	   deficient	   MEFs	   (Figure	   3.12A-­‐B)	   confirming	   the	   importance	   of	   the	   integrity	   of	  
mTORC2	   for	   SGK	   activation	   in	   this	   cell	   type.	   	   IGF1	   and	   dexamethasone	   induced	   a	  
significant	   phosphorylation	   and	   an	   electrophoretic	   band-­‐shift	   of	  NDRG1	  protein	   in	   both	  
wild	   type	   and	   Protor-­‐1−/−Protor-­‐2−/−	   MEFs	   indicating	   that	   SGK	   is	   normally	   activated	   in	  

























	   88	  
activation	   of	   all	   SGK	   isoforms	   whereas	   dexamethasone	   is	   reported	   to	   induce	   the	  
expression	  of	  only	  SGK1	  isoform	  (Kobayashi	  et	  al.,	  1999).	  
	  
Figure	  3.12	  Loss	  of	  Protor	  does	  not	  impair	  mTORC2	  dependent	  NDRG1	  phosphorylation	  
in	  MEFs	  
(A)	   Wild	   type	   and	   Rictor	   deficient	   MEFs	   were	   serum-­‐starved	   overnight	   and	   stimulated	  
with	   50	   ng/mL	   of	   IGF1	   for	   30	  min	   prior	   to	   lysis	   and	   immunoblot	   (IB)	   analysis	   with	   the	  
indicated	   antibodies.	   (B)	   Wild	   type	   and	   Rictor	   deficient	   MEFs	   were	   serum-­‐starved	  
overnight	   and	   stimulated	   with	   0.2	   µM	   dexamethasone	   for	   2.5	   hrs	   prior	   to	   lysis	   and	  
immunoblot	  analysis.	  (C)	  as	   in	  (A)	  except	  wild	  type	  and	  Protor-­‐1−/−Protor-­‐2−/−	  MEFs	  were	  
used.	  (D)	  As	  in	  (B)	  except	  wild	  type	  and	  Protor-­‐1−/−Protor-­‐2−/−	  MEFs	  were	  used.	  
	  
3.2.6. Loss	  of	  Protor	  does	  not	  affect	  the	  catalytic	  activity	  of	  SGK	  in	  MEFs	  
As	  monitoring	  NDRG1	  phosphorylation	  is	  an	  indirect	  measurement	  of	  SGK	  activity	  and	  the	  
possibility	   that	   another	   kinase	   could	   be	   responsible	   for	   its	   phosphorylation	   cannot	   be	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developed.	  Wild	  type	  and	  Protor-­‐1−/−Protor-­‐2−/−	  MEFs	  were	  transduced	  to	  stably	  express	  
HA-­‐ΔN-­‐SGK1	   using	   retroviral	   expression	   system	   based	   on	   pBABE-­‐plasmid.	   Expression	   of	  
full	  length	  SGK1	  was	  undetectable	  (data	  not	  shown).	  ΔN-­‐SGK1	  lacks	  N-­‐terminal	  residues	  1-­‐
60	   that	   target	   SGK1	   for	   proteasomal	   degradation	   (Bogusz	   et	   al.,	   2006;	   Kobayashi	   and	  
Cohen,	  1999).	  HA-­‐ΔN-­‐SGK1	  was	  immunoprecipitated	  from	  MEFs	  and	  its	  kinase	  activity	  was	  
assayed.	   	  Neither	   the	   catalytic	   activity	  of	  HA-­‐ΔN-­‐SGK1	  nor	   the	   levels	  of	   SGK1	  Ser422	  or	  
Thr256	  phosphorylation	  were	  affected	  by	  the	  absence	  of	  Protor	  isoforms	  (Figure	  3.13).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  3.13	  Activity	  of	  HA-­‐ΔN-­‐SGK1	  is	  similar	  in	  wild	  type	  and	  Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	  MEFs	  
Lysates	   were	   prepared	   from	  wild	   type	   and	   Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	   MEFs	   stably	   expressing	  
HA-­‐ΔN-­‐SGK1	  or	  HA-­‐empty	  vector.	   Immunoprecipitates	  (IP)	  were	  prepared	  using	  anti-­‐HA-­‐
agarose	  from	  1	  mg	  of	  lysate	  and	  catalytic	  activity	  was	  measured	  against	  Crosstide	  peptide.	  
Each	  bar	  represents	  the	  mean±S.D.	  activity	  of	  two	  separate	  samples.	  Immunoprecipitates	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Since	  studying	  stably	  expressed	  HA-­‐ΔN-­‐SGK1	   is	  non-­‐physiological,	   the	  ability	  of	  different	  
antibodies	  to	  immunoprecipitate	  endogenous	  SGK	  for	  kinase	  assays	  from	  MEFs	  was	  next	  
tested.	   Immunoprecipitates	   were	   prepared	   using	   either	   DSTT	   S062D	   or	   Sigma	   S5188	  
antibodies	   from	   wild	   type	   and	   Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	   MEFs.	   Results	   obtained	   with	   both	  
antibodies	   indicated	   that	   the	   absence	   of	   Protor	   isoforms	  does	   not	   affect	   the	   activity	   of	  
endogenous	   SGK	   in	   MEFs	   (Figure	   3.14A-­‐B).	   Immunoblot	   analysis	   revealed	   that	   SGK	  
migrated	   as	   several	   species	   in	   the	   immunoprecipitations	   indicating	   that	   either	   several	  
isoforms	  or	  variants	  were	  immunoprecipitated.	  	  
Next	   the	   endogenous	   SGK	   kinase	   assays	   from	  wild	   type	   and	   the	   Protor	   deficient	  MEFs	  
were	  repeated	  using	  the	  DSTT	  S062D	  SGK	  antibody	  to	  immunoprecipitate	  SGK	  from	  cells	  
treated	  with	  DMSO	  or	  1µM	  PI-­‐103	  to	  inactivate	  PI3	  and	  mTOR	  kinases	  (Fan	  et	  al.,	  2006b).	  
Endogenous	  SGK	  activity	  was	  sensitive	  to	  treatment	  with	  PI-­‐103	  and	  again	  no	  differences	  
were	   observed	   between	   wild	   type	   and	   Protor	   deficient	  MEFs.	  Moreover,	   levels	   of	   SGK	  
HM-­‐site	   and	   T-­‐loop	   phosphorylation	   were	   not	   affected	   by	   the	   loss	   of	   Protor	   isoforms	  
(Figure	  3.14C).	  Immunoblot	  analysis	  of	  the	  lysates	  confirmed	  that	  PI-­‐103	  impaired	  NDRG1	  
phosphorylation	   and	   mTORC2	   activity,	   as	   assessed	   by	   monitoring	   Akt	   Ser473	  
phosphorylation	  (Figure	  3.14D).	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Figure	  3.14	  Loss	  of	  Protor	  does	  not	  affect	  the	  activity	  of	  endogenous	  SGK	  in	  MEFs	  
(A)	   SGK	  was	   immunoprecipitated	   (IP)	   from	   3	  mg	   of	  wild	   type	   and	   Protor-­‐1−/−Protor-­‐2−/−	  
MEFs	   lysate	  with	   DSTT	   S062D	   antibody	   or	   pre-­‐immune	   IgG	   and	   catalytic	   activity	   of	   the	  
immunoprecipitates	   was	   measured	   against	   Crosstide	   peptide.	   Each	   bar	   represents	   the	  
mean±S.D.	   specific	   activity	   of	   two	   separate	   samples.	   Immunoprecipitates	   were	   also	  
analysed	  by	   immunoblotting	   (IB)	  with	   the	   indicated	  antibody.	   (B)	  as	   in	   (A)	  except	  Sigma	  
S5188	  anti-­‐SGK	  was	  used	  for	  immunoprecipitations.	  (C)	  as	  in	  (A)	  expect	  cells	  were	  treated	  
with	  1µM	  PI-­‐103	  or	  DMSO	  vehicle	   control	   for	  1	  h	  before	   lysis	   and	   immunoprecipitation	  
with	   DSTT	   S062D	   SGK	   antibody	   or	   pre-­‐immune	   IgG.	   Immunoprecipitates	   were	   also	  
subjected	   to	   immunoblot	   analysis	   with	   indicated	   antibodies.	   (D)	   as	   in	   (C)	   except	   cell	  
lysates	  were	  subjected	  to	  immunoblot	  analysis	  with	  indicated	  antibodies.	  
	  
3.2.7. Protor	  isoforms	  are	  dispensable	  for	  the	  activity	  of	  mTORC2	  in	  vitro	  
The	  evidence	  thus	  far	  implies	  that	  Protor-­‐1	  is	  important	  for	  the	  HM-­‐site	  phosphorylation	  
and	  activation	  of	   SGK	   in	   the	   kidney.	   Therefore,	   the	   importance	  of	   Protor	   for	   the	   kinase	  
activity	  of	  mTORC2	  in	  kidney	  tissue	  was	  next	  examined.	  mTORC2	  was	  immunoprecipitated	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using	   Sin1	   antibody	   from	   either	   fed	   (Figure	   3.15A-­‐B)	   or	   IGF1-­‐injected	   (Figure	   3.15C-­‐D)	  
wild-­‐type	  or	  Protor-­‐1−/−Protor-­‐2−/−	  double	  knockout	  mouse	  kidney	  or	  liver	  lysates,	  and	  its	  
ability	  to	  phosphorylate	  GST-­‐Akt1	  or	  GST-­‐SGK1	   in	  vitro	  was	  assessed.	  GST-­‐Akt1	  and	  GST-­‐
SGK1	   used	   as	   substrates	   in	   these	   assays	   were	   purified	   from	   HEK293	   cells	   that	   were	  
deprived	  of	  serum	  overnight	  and	  incubated	  for	  a	  further	  1	  hour	  with	  1	  µM	  PI-­‐103	  prior	  to	  
lysis	   to	   ensure	   that	   dephosphorylated	   forms	   of	   SGK1	   and	   Akt1	  were	   isolated.	   Dr	   Laura	  
Pearce	  had	  previously	  optimised	  mTORC2	  kinase	   assays	   and	   found	   them	   to	  be	   linear	   in	  
respect	   to	   time	   and	   consequently	   the	   assays	  were	   carried	   out	   for	   30	  minutes	  which	   is	  
within	  the	   linear	  part	  of	  these	  assays	  (personal	  communication).	  Loss	  of	  Protor	   isoforms	  
did	   not	   have	   a	   significant	   impact	   on	   the	   ability	   of	   immunoprecipitated	   mTORC2	   to	  
phosphorylate	  GST–Akt1	   or	   GST–SGK1	   in	   cell	   free-­‐assays.	   Similar	   results	  were	   observed	  
using	  both	  kidney	  and	  liver	  lysates.	  Furthermore,	  similar	  results	  were	  also	  obtained	  when	  
mTORC2	  was	   immunoprecipitated	   from	  wild	   type	   or	   Protor-­‐1−/−Protor-­‐2−/−	  MEFs	   (Figure	  
3.15).	   Dr	   L.	   Pearce	   had	   previous	   obtained	   similar	   results	   by	   comparing	   wild	   type	   and	  
Protor-­‐1	  single	  knockouts.	  	  These	  findings	  indicate	  that	  despite	  the	  importance	  of	  Protor-­‐1	  
for	  activation	  of	  SGK	  in	  the	  kidney,	  Protor	  isoforms	  are	  dispensable	  for	  regulating	  intrinsic	  
mTORC2	  kinase	  activity.	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Figure	  3.15	  Protor	  isoforms	  are	  not	  required	  for	  mTORC2	  kinase	  activity	  in	  vitro	  
(A)	  Immunoprecipitates	  (IP)	  were	  prepared	  using	  either	  pre-­‐immune	  IgG	  or	  Sin1	  antibody	  
from	   fed	   wild-­‐type	   or	   Protor-­‐1−/−Protor-­‐2−/−	   kidney	   or	   liver	   lysates	   and	   their	   ability	   to	  
phosphorylate	  GST-­‐Akt1	  in	  vitro	  was	  assayed.	  Reactions	  were	  analysed	  by	  immunoblotting	  
(IB)	   with	   the	   indicated	   antibodies.	   (B)	   As	   in	   (A),	   except	   GST–ΔN-­‐SGK1	   was	   used	   as	  
substrate.	   (C)	   As	   in	   (A),	   except	   immunoprecipitates	  were	   prepared	   from	   kidney	   or	   liver	  
lysates	   from	  mice	   injected	  with	   IGF1	   for	   5	  min.	   (D)	   As	   in	   (C),	   except	  GST–ΔN-­‐SGK1	  was	  
used	  as	  substrate.	  (E)	  as	  in	  (A),	  except	  immunoprecipitates	  were	  prepared	  from	  wild-­‐type	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3.3. Discussion	  
SGK2	  is	  the	  most	  highly	  expressed	  SGK	  isoform	  in	  the	  whole	  kidney	  	  
Immunoprecipitation	  and	  mass	  spectrometry	  analysis	  of	  endogenous	  SGKs	  revealed	  that	  
SGK2	   was	   the	   most	   abundant	   isoform	   detected	   in	   the	   whole	   kidney	   and	   liver	   lysates.	  
Consistent	  with	   this,	  SGK2	   gene	  expression	  has	  been	   reported	   to	  be	  particularly	  high	   in	  
epithelial	  tissues	  such	  as	  kidney	  and	  liver	  (Kobayashi	  et	  al.,	  1999).	  SGK2	  is	  the	  least	  studied	  
SGK	  family	  member	  and	  the	  finding	  that	  it	  is	  so	  robustly	  expressed	  in	  the	  kidney	  warrants	  
it	  more	  careful	  attention	  in	  the	  future.	  In	  Xenopus	  oocyte	  co-­‐expression	  studies	  that	  have	  
compared	   all	   the	   three	   SGK	   isoforms,	   SGK2	   is	   commonly	   able	   to	   perform	   the	   same	  
functions	   as	   SGK1	   (and	   SGK3)	   [reviewed	   in	   (Lang	   et	   al.,	   2006)].	   For	   example,	   all	   SGK	  
isoforms	  are	  able	  to	  stimulate	  the	  epithelial	  sodium	  channel	  ENaC	  (Friedrich	  et	  al.,	  2003).	  
It	   is	   important	   to	   note	   that	   kidney	   is	   a	   complex	   organ	   with	   highly	   specialised	   tissue	  
architecture	  and	  a	  weakness	  of	  the	  biochemical	  analysis	  presented	   in	  this	  chapter	   is	   the	  
use	   of	   whole	   kidney	   lysate.	   One	   previous	   study	   has	   addressed	   the	   renal	   expression	   of	  
SGK2	  mainly	  by	   looking	  at	   the	   transcript	   and	  by	   immunofluorescence,	  which	   is	   critically	  
dependent	   on	   highly	   specific	   antibodies.	   The	   findings	   indicate	   that	   SGK2	   is	   robustly	  
expressed	   in	   the	  proximal	   straight	   tubule	  and	   thick	  ascending	   limb	  of	   the	   loop	  of	  Henle	  
and	  that	  SGK2	  is	  expressed	  in	  proximal	  tubule	  cells	  that	  also	  express	  the	  Na+/H+	  exchanger	  
3	   (NHE3).	   Unlike	   SGK1,	   SGK2	   mRNA	   expression	   in	   renal	   tissue	   is	   not	   affected	   by	   the	  
mineralocorticoid	  aldosterone.	  In	  vitro	  experiments	  indicate	  that	  SGK2	  can	  regulate	  NHE3,	  
suggesting	  that	  in	  vivo	  SGK2	  could	  play	  a	  role	  in	  the	  control	  of	  sodium	  transport	  through	  
NHE3	  in	  the	  proximal	  tubule	  (Pao	  et	  al.,	  2010).	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SGK2	   knockout	   mice	   have	   not	   been	   characterised	   in	   peer-­‐reviewed	   literature.	   Findings	  
presented	  by	  Schnackenberg	  and	  colleagues	  in	  a	  meeting	  abstract	  suggest	  that	  SGK2	  is	  not	  
critical	  for	  renal	  homeostasis	  during	  unstressed	  conditions,	  but	  that	  SGK2	  can	  compensate	  
for	   the	   loss	  of	  SGK1	  during	  salt	  deprivation	   (Schnackenberg	  et	  al.,	  2007).	  During	  normal	  
diet	   the	   renal	   function	   of	   SGK2-­‐/-­‐	   mice	   as	   well	   as	   SGK1-­‐/-­‐SGK2-­‐/-­‐	   double	   knockouts	   is	  
reported	  to	  be	  similar	  to	  wild	  type	  mice.	  Unlike	  SGK1	  knockout	  mice,	  SGK2	  knockout	  mice	  
do	  not	  display	  a	  salt	  wasting	  phenotype	  when	  fed	  a	  low	  sodium	  diet.	  SGK1-­‐/-­‐SGK2-­‐/-­‐	  double	  
knockout	   mice,	   however,	   are	   reported	   to	   display	   a	   more	   severe	   defect	   in	   renal	  
reabsorption	   of	   water,	   sodium	   and	   potassium	   than	   SGK1	   single	   knockout	   mice	  
(Schnackenberg	   et	   al.,	   2007).	   Since	   the	   SGK1	   single	   and	   SGK1/3	   double	   knockout	  mice	  
display	  near	   identical	   renal	  phenotypes	   (Grahammer	  et	  al.,	   2006),	   it	   appears	   that	   SGK2,	  
which	  has	  received	  very	  little	  attention,	  may	  play	  more	  important	  roles	  in	  the	  kidney	  than	  
SGK3.	  
	  
Loss	  of	  Protor-­‐1	  impairs	  SGK	  activation	  in	  kidney	  
Although	  previous	  work	  carried	  out	  by	  Dr	  L.	  Pearce	  had	  not	  detected	  any	  obvious	  increase	  
in	  Protor-­‐2	  expression	   in	  Protor-­‐1-­‐/-­‐	  mice	  and	  no	   impairment	  of	  NDRG1	  phosphorylation	  
had	  been	  detected	  in	  the	  kidneys	  of	  Protor-­‐2-­‐/-­‐	  mice,	  Protor-­‐1-­‐/-­‐Protor-­‐2-­‐/-­‐	  double	  knockout	  
mice	  were	  generated	   in	  order	   to	   address	  whether	   compensation	  occurred	  between	   the	  
two	   Protor	   isoforms.	   Analysis	   of	   tissues	   derived	   from	   the	   double	   knockout	   mice	  
emphasises	  that	  Protor-­‐1,	  rather	  than	  Protor-­‐2,	  is	  key	  for	  regulating	  SGK	  activation	  in	  the	  
kidney.	   The	   defects	   in	   SGK	   and	   NDRG1	   phosphorylation	   in	   Protor-­‐1/2	   double	   knockout	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kidneys	  appeared	  identical	  to	  those	  previously	  seen	  in	  Protor-­‐1	  single	  knockouts.	  In	  both	  
genotypes	   Akt	   was	   normally	   activated	   in	   all	   tissues	   examined.	   The	   function	   of	   NDRG1	  
protein	  and	  the	  consequence	  of	  its	  phosphorylation	  by	  SGK	  remain	  elusive	  and	  are	  further	  
discussed	  in	  Chapter	  4.	  
Characterisation	   of	   antibodies	   that	   allow	   reliable	   detection	   of	   endogenous	   SGK	   made	  
crucial	  contributions	  to	  the	  study	  of	  the	  importance	  of	  Protor	  in	  the	  regulation	  of	  SGK.	  The	  
measurement	   of	   endogenous	   SGK	   kinase	   activity	   in	   kidney	   lysates	   revealed	   that	   the	  
stimulatory	   effect	   of	   IGF1	   on	   endogenous	   SGK	   activity	   is	   significantly	   blunted	   in	   the	  
absence	  of	  Protor.	   Furthermore,	  detection	  of	   the	  phosphorylated	  T-­‐loop	  of	  endogenous	  
SGK	   in	   the	   kidney	   confirmed	   the	   expected	   consequence	   that	   loss	   of	  mTORC2	  mediated	  
HM-­‐site	   phosphorylation	   would	   have	   on	   SGK	   T-­‐loop	   phosphorylation.	   As	   discussed	   in	  
Section	   1.6,	   phosphorylation	   of	   SGK	  HM-­‐site	   creates	   a	   docking	   site	   for	   PDK1	   leading	   to	  
subsequent	  SGK	  T-­‐loop	  phosphorylation	  and	  activation	  (Biondi	  et	  al.,	  2001;	  Collins	  et	  al.,	  
2003;	   Collins	   et	   al.,	   2005;	   Garcia-­‐Martinez	   and	   Alessi,	   2008).	   Results	   presented	   in	   this	  
chapter	   represent	   the	   first	   confirmation	   of	   this	   at	   endogenous	   kinase	   activity	   level.	  
Moreover,	  detection	  of	  endogenous	  total	  SGK	  protein	  conclusively	  excluded	  the	  possibility	  
that	  the	  defects	  previously	  observed	  in	  NDRG1	  and	  SGK	  HM-­‐site	  phosphorylation	  could	  be	  
due	   to	   reduced	   expression	   of	   SGK	   protein	   in	   the	   kidneys	   of	   Protor-­‐1	   deficient	   mice.	  
Reduced	  stability	  of	  SGK	  due	  to	  loss	  of	  Protor-­‐1	  had	  been	  a	  possible	  explanation	  especially	  
given	  that	  Rictor,	  the	  direct	  binding	  partner	  of	  Protor	  (Pearce	  et	  al.,	  2007),	  had	  just	  been	  
described	   to	   regulate	   the	   stability	  of	   SGK1	  by	   forming	  an	  E3	   ligase	   complex	   (Gao	  et	   al.,	  
2010).	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Protor-­‐1/2	  double	  knockout	  MEF	  cells	  were	  generated	  in	  order	  to	  have	  an	  additional	  tool	  
to	   further	  address	  the	   importance	  of	  Protor	   in	  the	  regulation	  of	  SGK.	  Studies	  with	  MEFs	  
clearly	  indicated	  that	  whilst	  NDRG1	  phosphorylation	  in	  this	  cell	  type	  is	  critically	  dependent	  
upon	   mTORC2	   integrity	   following	   both	   stimulation	   of	   the	   PI3K	   pathway	   and	  
dexamethasone	   induction	  of	  SGK1	   expression,	   Protor	   isoforms	  do	  not	   contribute	   to	   the	  
activation	   of	   SGK	   in	   MEFs.	   Dr	   L.	   Pearce	   obtained	   similar	   results	   with	   Protor-­‐1	   single	  
knockout	  MEFs.	  Furthermore,	  measurement	  of	  endogenous	  SGK	  kinase	  activity	  in	  Protor-­‐
1/2	  deficient	  MEFs	   revealed	  no	  differences	  between	  the	  wild	   type	  and	  double	  knockout	  
cells.	  	  
The	  most	   extensively	   characterised	   role	   of	   SGK	   in	   vivo	   is	   that	   of	   SGK1	   in	   the	   kidney,	   in	  
particularly	   in	   the	   aldosterone-­‐sensitive	   distal	   nephron	   in	   the	   activation	   of	   ENaC.	   A	   key	  
mechanism	  via	  which	  SGK1	  induction	  in	  response	  to	  aldosterone	  is	  believed	  to	  stimulate	  
Na+	   entry	   into	   the	   epithelial	   cells	   is	   via	   increased	   expression	   of	   ENaC	   in	   the	   luminal	  
membrane,	   as	   discussed	   in	   Section	   1.6.1.	   No	   defects	   were	   observed	   in	   the	   plasma	  
membrane	   abundance	   of	   ENaC	   in	   the	   absence	   of	   Protor	   isoforms.	   This	   observation	   is,	  
however,	   not	   entirely	   surprising.	   Firstly,	   the	   animals	   were	   fed	   a	   standard	   diet	   and	   the	  
defects	  in	  Na+	  handling	  of	  SGK1	  deficient	  mice	  are	  only	  seen	  when	  animals	  are	  fed	  a	  low-­‐
salt	  diet.	  Secondly,	  as	  discussed	  in	  Section	  1.6.1,	  the	  defects	  seen	  in	  ENaC	  expression	  even	  
in	  the	  SGK1	  knockout	  mice	  are	  mild	  (Faresse	  et	  al.,	  2012;	  Fejes-­‐Toth	  et	  al.,	  2008;	  Wulff	  et	  
al.,	  2002).	  Therefore	  it	  is	  not	  unsurprising	  that	  the	  loss	  of	  Protor-­‐1	  did	  not	  influence	  ENaC	  
abundance	   under	   the	   conditions	   studied.	   Furthermore,	   it	   should	   be	   noted	   that	   the	  
mechanisms	   by	   which	   SGK1	   deficiency	   lead	   to	   salt	   wasting	   remain	   somewhat	   elusive.	  
Besides	  regulation	  of	  ENaC,	  recent	  findings	  also	  indicate	  that	  SGK1	  dependent	  regulation	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of	   the	  Na+Cl-­‐	   co-­‐transporter	  NCC	   is	   likely	   to	  be	   important	   for	   renal	   sodium	  homeostasis	  
(Faresse	  et	  al.,	  2012;	  Fejes-­‐Toth	  et	  al.,	  2008;	  Vallon	  et	  al.,	  2009).	  	  
	  
Protor-­‐1	  may	  function	  as	  a	  scaffold	  protein	  that	  presents	  SGK	  to	  mTORC2	  in	  the	  kidney	  
The	  precise	  mechanism	  by	  which	  Protor-­‐1	  regulates	  the	  efficient	  activation	  of	  SGK	  in	  the	  
kidney	  remains	  unknown.	  Overall,	   little	   is	  known	  about	  the	  functions	  of	  Protor	   isoforms.	  
Protor-­‐1	   has	   been	   proposed	   to	   control	   Platelet-­‐derived	   growth	   factor	   receptor	   beta	  
(PDGFRβ)	   expression	   via	   as-­‐of-­‐yet	   uncharacterised	   mechanisms	   (Woo	   et	   al.,	   2007).	   It	  
would	   be	   interesting	   to	   analyse	   PDGFRβ expression	   levels	   in	   Protor	   deficient	   mice	   and	  
MEFs.	  Protor-­‐2	  has	  been	  suggested	  to	  reduce	  apoptosis	  as	  knockdown	  of	  Protor-­‐2	  in	  HeLa	  
cells	   modestly	   increased	   TNAα and	   cycloheximide	   induced	   apoptosis	   (Thedieck	   et	   al.,	  
2007).	  A	  role	   in	   the	  de-­‐stabilisation	  of	  certain	  mRNA	  transcripts	  has	  also	  been	  proposed	  
for	  Protor-­‐2	  (Holmes	  et	  al.,	  2012).	  	  
Interestingly,	   recently	   Protor-­‐2	   was	   linked	   to	   the	   regulation	   of	   PKCδ activation	   and	  
fibroblast	  migration	   (Gan	  et	   al.,	   2012).	   Lysophosphatidic	   acid	   (LPA)	   stimulates	   sustained	  
PKCδ HM-­‐site	   phosphorylation	   via	   the	   small	   G-­‐protein	   Gα12	   and	   mTORC2.	   LPA	   also	  
induces	  the	  expression	  of	  E3	  ubiquitin	   ligase	  RFFL	   leading	  to	  Protor-­‐2	  ubiquitylation	  and	  
degradation	   and	   subsequently	   increased	   PKCδ HM-­‐site	   phosphorylation.	   Consequently	  
Protor-­‐2	   is	   suggested	   to	   be	   a	   suppressor	   of	   LPA	   and	   mTORC2-­‐mediated	   PKCδ HM-­‐site	  
phosphorylation	  (Gan	  et	  al.,	  2012).	  	  This	  study	  also	  utilised	  the	  Protor-­‐1/2	  deficient	  MEFs	  
whose	  generation	  is	  described	  in	  this	  thesis.	  LPA	  failed	  to	  induce	  migration	  of	  Protor-­‐1/2	  
deficient	  MEFs	  but	  re-­‐introduction	  of	  Protor-­‐2	  to	  the	  double	  knockout	  MEFs	  restored	  LPA	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responsiveness	  of	  cell	  migration	  by	  suppressing	  basal	  migration	  (Gan	  et	  al.,	  2012).	  	  These	  
observations	  together	  with	  the	  data	  presented	  in	  this	  chapter	  and	  in	  (Pearce	  et	  al.,	  2011)	  
indicate	   that	   the	   roles	   of	   Protor-­‐1	   and	   Protor-­‐2	   are	   different	   but	   that	   both	   may	   be	  
involved	  in	  the	  regulation	  of	  phosphorylation	  of	  a	  specific	  subset	  of	  mTORC2	  substrates.	  	  
SGK	  activation	  and	  downstream	  signalling	  were	  markedly	  reduced	  in	  kidneys	  derived	  from	  
Protor	   double	   knockouts	   and	   similar	   observations	   had	   previously	   been	   made	   in	   the	  
Protor-­‐1	  single	  knockouts.	  However,	  it	  is	  clear	  that	  mTORC2	  isolated	  from	  Protor	  deficient	  
tissues	  and	  MEFs	  phosphorylated	  GST-­‐Akt1	  and	  GST-­‐ΔN-­‐SGK1	  normally	  in	  vitro.	  Therefore	  
it	   is	  unlikely	  that	  Protor-­‐1	  is	  required	  for	  the	  intrinsic	  kinase	  activity	  of	  mTORC2	  towards	  
SGK.	  	  
Neither	  Protor	   isoform	  possesses	  obviously	  recognisable	  functional	  domains	  nor	  do	  they	  
have	   any	  obvious	  orthologues	   in	   lower	   eukaryotic	   species	   such	   as	  Drosophila	   and	   yeast	  
(Pearce	  et	  al.,	  2007).	  Protor	  isoforms	  are	  non-­‐essential	  for	  the	  overall	  function	  of	  mTORC2	  
as	  highlighted	  by	  the	  fact	  that	  in	  mice	  whole-­‐body	  loss	  of	  the	  critical	  mTORC2	  components	  
mTOR,	  Rictor,	  mLST8	  or	  Sin1	  causes	  embryonic	  lethality	  (Gangloff	  et	  al.,	  2004;	  Guertin	  et	  
al.,	  2006;	  Murakami	  et	  al.,	  2004;	  Shiota	  et	  al.,	  2006;	  Yang	  et	  al.,	  2006).	  S.	  Cerevisiae	  TORC2	  
contains	   two	   proteins	   termed	   Avo2	   and	   Bit61	   that	   are	   non-­‐essential	   components	   of	  
TORC2	  (Loewith	  et	  al.,	  2002;	  Wullschleger	  et	  al.,	  2006).	  Avo2	  and	  Bit61	  appear	  to	  act	  as	  
adaptors	  that	  bind	  the	  yeast	  TORC2	  substrates	  Slm1	  and	  Sl2m	  (Audhya	  et	  al.,	  2004;	  Fadri	  
et	  al.,	  2005).	  Avo2	  and	  Bit61,	  however,	  do	  not	  share	  any	  detectable	  identity	  with	  the	  two	  
Protor	  isoforms	  (Pearce	  et	  al.,	  2007).	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Recently,	   a	   substrate	   binding	   adaptor	   role	  was	   described	   for	   the	  mTORC2	   subunit	   Sin1	  
that	   was	   found	   to	   interact	   with	   PKC	   isoforms	   and	   Akt	   (Cameron	   et	   al.,	   2011).	   HM-­‐site	  
phosphorylation	   of	   SGK	   was	   not	   addressed	   in	   this	   study.	   Furthermore,	   the	   mTORC1	  
component	   Raptor	   binds	   mTORC1	   substrates	   such	   as	   S6K1	   and	   4EBP1	   (Nojima	   et	   al.,	  
2003).	  Association	  of	  Raptor	  with	  S6K	  and	  4EBP1,	  however,	  is	  necessary	  for	  the	  capacity	  of	  
isolated	  mTORC1	  to	  phosphorylate	  these	  substrates	  in	  vitro	  as	  a	  point	  mutation	  within	  the	  
substrate	   proteins	   significantly	   reduces	   their	   phosphorylation	   by	   mTORC1	   in	   cell	   free	  
assays	  (Nojima	  et	  al.,	  2003).	  Given	  that	  loss	  of	  Protor	  isoforms	  did	  not	  have	  any	  impact	  on	  
the	   ability	   of	   immunoprecipitated	   mTORC2	   to	   phosphorylate	   SGK1	   or	   Akt	   in	   cell	   free	  
assays,	  one	  possibility	   is	  that	  Protor-­‐1	  may	  act	  as	  a	  scaffolding	  component	  that	  presents	  
SGK	  to	  mTORC2	  in	  the	  kidney	  perhaps	  by	  ensuring	  their	  co-­‐localisation.	  
Both	   the	  kinase	  activity	  measurements	  and	  analysis	  of	  SGK	  and	  NDRG1	  phosphorylation	  
revealed	   that	   SGK	   activity	   is	   not	   completely	   lost	   in	   the	   absence	   of	   Protor	   in	   the	   kidney	  
thereby	  suggesting	  that	  Protor	  contributes	  towards	  the	  efficient	  activation	  of	  SGK	  but	  that	  
in	  its	  absence	  some	  SGK	  activity	  does	  remain.	  This	  observation	  is	  consistent	  with	  the	  lack	  
of	   effect	   that	   Protor	   deficiency	   had	   on	   isolated	   mTORC2	   kinase	   assays	   and	   further	  
strengthens	  the	  hypothesis	  that	  Protor	  may	  be	  crucial	  for	  distributing	  SGK	  and	  mTORC2	  to	  
a	  specific	  subcellular	   localisation	  rather	  than	  for	  the	  ability	  of	  mTORC2	  to	  phosphorylate	  
SGK.	  In	  the	  absence	  of	  Protor-­‐1	  SGK	  and	  mTORC2	  would	  still	  come	  to	  proximity	  by	  passive	  
diffusion	  allowing	   the	  HM-­‐site	  phosphorylation	  of	   SGK	   to	   take	  place	  albeit	   at	  a	   reduced	  
efficiency.	   Co-­‐localisation	   of	   mTORC2	   with	   its	   substrate	   would	   be	   analogous	   for	   the	  
function	  of	  the	  S.	  Cerevisiae	  TORC2	  subunits	  Avo2	  and	  Bit61	  which	  bring	  mTORC2	  to	  the	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plasma	  membrane	  where	  the	  substrates	  Slm1	  and	  Slm2	  exist	  (Audhya	  et	  al.,	  2004;	  Fadri	  et	  
al.,	  2005).	  	  
Preliminary	  immunoprecipitations	  studies	  performed	  by	  Dr	  L.	  Pearce	  using	  over-­‐expressed	  
SGK	  isoforms	  in	  HEK293	  cells	  suggested	  that	  Protor-­‐1	  could	  interact	  with	  SGKs.	  I,	  however,	  
failed	   to	   detect	   either	   Protor	   isoform	   in	   large-­‐scale	   endogenous	   SGK	  
immunoprecipitations	   undertaken	   from	   mouse	   tissues	   lysed	   with	   the	   mild	   detergent	  
CHAPS.	  Many	   kinase-­‐substrate	   interactions	   are	   transient	   and	   it	   is	   entirely	   plausible	   that	  
Protor	   and/or	   other	   mTORC2	   components	   could	   be	   lost	   from	   SGK	   during	   the	  
immunoprecipitations	  process.	  	  	  	  
Why	  should	  a	  scaffolding	  role	  for	  Protor-­‐1	  only	  be	  critical	  for	  efficient	  SGK	  activation	  in	  the	  
kidney	  remains	  unsolved.	  One	  possibility	  is	  that	  SGK	  variants	  expressed	  in	  the	  kidney	  are	  
particularly	   dependent	   on	   Protor-­‐1	   for	   the	   efficient	   activation.	   	   For	   example,	   for	   SGK1	  
differentially	   regulated	   transcriptional	   variants	   that	   alter	   the	   SGK1	  N-­‐terminus,	  which	   is	  
particularly	  important	  for	  controlling	  the	  localisation	  of	  SGK1,	  have	  been	  described	  (Pao	  et	  
al.,	  2007;	  Simon	  et	  al.,	  2007)	  and	  SGK1	  has	   indeed	  been	  suggested	  to	   localise	  to	  various	  
subcellular	   compartments	   including	   mitochondria,	   endoplasmic	   reticulum,	   plasma	  
membrane,	  nucleus	  and	  cytoplasm	  (Arteaga	  et	  al.,	  2006;	  Bogusz	  et	  al.,	  2006;	  Brickley	  et	  
al.,	   2002;	   Engelsberg	   et	   al.,	   2006;	   Lang	   et	   al.,	   2009;	   Pao	   et	   al.,	   2007).	   Protor-­‐1	   is	  most	  
highly	  expressed	  in	  the	  kidney	  at	  both	  the	  mRNA	  and	  protein	  level	  (Johnstone	  et	  al.,	  2005;	  
Pearce	  et	  al.,	  2007;	  Shan	  et	  al.,	  2003)	  highlighting	  that	  a	  key	  role	  for	  the	  protein	  may	  have	  
evolved	  specifically	  in	  this	  tissue.	  It	  would	  certainly	  be	  interesting	  to	  study	  the	  subcellular	  
distribution	   of	   SGK	   and	   Protor-­‐1	   proteins	  within	   different	   regions	   of	   the	   kidney.	   Ideally	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such	  studies	  would	  be	  done	  utilising	  the	  knockout	  mice	  available	  in	  order	  to	  demonstrate	  
the	  specificity	  of	  the	  antibodies	  used.	  	  
Whilst	  differences	   in	  SGK	   isoform	  expression	  might	  be	   important	   for	   their	   regulation	  by	  
Protor-­‐1,	   it	   is	   important	   to	  note	   that	   the	  endogenous	  mass	  spectrometry	  analysis	   found	  
both	   kidney	   and	   liver	   to	   possess	   a	   very	   similar	   distribution	   of	   SGK	   isoforms	  with	   SGK2	  
being	   most	   abundant	   in	   whole	   tissue	   lysates	   derived	   from	   both	   sources,	   whereas	   an	  
important	   role	   for	  Protor-­‐1	  was	  only	  seen	   in	   the	  kidney.	  The	  effect	  of	  Protor-­‐1	  on	  SGK1	  
was	   addressed	   by	   analysing	   the	   dexamethasone	   induced	   NDRG1	   phosphorylation	   in	  
Protor	   deficient	   MEFs	   and	   by	   measuring	   the	   kinase	   activity	   of	   over-­‐expressed	   SGK1	   in	  
MEFs.	  By	  contrast,	  the	  endogenous	  kinase	  activity	  studies	  in	  MEFs	  were	  likely	  to	  measure	  
the	   contribution	   of	   a	   range	   of	   SGK	   isoforms/variants	   as	   the	   immunoprecipitated	   SGK	  
protein	  was	  seen	  to	  migrate	  as	  several	  bands.	  These	  notions	  suggest	  that	  the	  difference	  
between	  kidney	  and	  other	  organs	  and	  MEFs	  is	   likely	  to	  be	  due	  to	  more	  complex	  reasons	  
than	  just	  differential	  expression	  of	  SGK	  isoforms.	  
It	   is	  also	  worthwhile	   to	  note	   that	  whilst	   IGF1	   induced	  SGK	  HM-­‐site	  phosphorylation	  was	  
detected	  in	  the	  liver,	  and	  was	  found	  to	  be	  normal	  in	  Protor	  deficient	  mice,	  endogenous	  T-­‐
loop	  phosphorylation	  was	  not	  detected	   in	  this	  tissue	  and	  the	  stimulatory	  effects	  of	   IGF1	  
on	  NDRG1	  phosphorylation	  were	  weak	  in	  the	  both	  kidney	  and	  liver.	  Overall	  kidney	  is	  the	  
only	   tissue	   in	   which	   most	   significant	   NDRG1	   phosphorylation	   was	   seen	   (Pearce	   et	   al.,	  
2011).	   It	  would	   be	   valuable	   to	   study	   the	   phosphorylation	   status	   of	  wider	   range	   of	   SGK	  
substrates	   in	   the	   absence	   of	   Protor	   isoforms	   and	   to	   study	   the	   phosphorylation	   of	   SGK	  
substrates	   following	   stimulation	   with	   dexamethasone	   and	   aldosterone.	   In	   conclusion,	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Protor-­‐1	   is	   important	  for	  the	  efficient	  mTORC2-­‐mediated	  activation	  of	  SGK	   in	  the	  kidney	  
and	  it	  is	  clear	  that	  further	  work	  is	  required	  to	  understand	  the	  tissue-­‐specific	  nature	  of	  the	  




4. Elevated	  SGK1	  predicts	  resistance	  of	  breast	  cancer	  cells	  
to	  Akt	  inhibitors	  
	  
4.1. Introduction	  
Over	  70%	  of	  breast	  cancers	  possess	  mutations	  that	  trigger	  activation	  of	  the	  PI3K	  pathway	  
(Miller	   et	   al.,	   2011).	   Given	   the	   pivotal	   role	   of	   PI3K	   signalling	   in	   controlling	   cell	   growth,	  
survival	   and	   proliferation,	   key	   components	   of	   this	   pathway,	   PI3K,	   mTOR	   and	   Akt,	   are	  
promising	   targets	   for	  cancer	  drug	  discovery	   (Engelman,	  2009;	  Liu	  et	  al.,	  2009).	  Although	  
most	  work	  has	  focused	  on	  Akt	  as	  being	  the	  major	  mediator	  of	  cell	  proliferation	  induced	  by	  
activation	  of	   PI3K,	   the	   closely	   related	   SGK	   isoforms	  have,	   by	   comparison,	   received	   little	  
attention.	   Although	   there	   are	   subtle	   differences	   in	   the	   optimal	   substrate	   specificity	  
requirements	   of	   SGK	   and	   Akt	   kinases,	   both	   enzymes	   phosphorylate	   substrates	  within	   a	  
similar	  Arg-­‐Xaa-­‐Arg-­‐Xaa-­‐Xaa-­‐Ser/Thr	  (Xaa	  is	  any	  amino	  acid)	  consensus	  sequence	  (Alessi	  et	  
al.,	   1996;	  Murray	   et	   al.,	   2005).	   Moreover,	   Akt	   and	   SGK	   also	   share	   the	   same	   upstream	  
activators,	  mTORC2	   and	   PDK1.	   Consequently	   it	   is	   likely	   that	   Akt	   and	   SGK	   could	   possess	  
similar	   functions	   such	   as	   promoting	   proliferation	   and	   survival	   of	   cancer	   cells.	   There	   are	  
currently	  223	  clinical	  trials	  to	  evaluate	  the	  efficacy	  of	  Akt	   inhibitors	  for	  the	  treatment	  of	  
cancer	  (http://www.clinicaltrials.gov/).	  The	  ability	  to	  predict	  which	  tumours	  will	  be	  most	  
responsive	  to	  Akt	  inhibitors	  is	  an	  important	  question.	  Owing	  to	  the	  similarity	  of	  SGK	  and	  




to	  investigate	  whether	  tumour	  cells	  displaying	  high	  levels	  of	  SGK	  would	  be	  more	  resistant	  
to	  Akt	  inhibitors	  than	  tumours	  lacking	  SGK.	  	  
Work	   carried	   out	   at	   AstraZeneca	   had	   identified	   a	   correlation	   between	   the	   sensitivity	   of	  
breast	  cancer	  cells	  to	  Akt	  inhibition	  and	  SGK1	  mRNA	  levels.	  In	  this	  chapter	  I	  describe	  the	  
verification	   that	   a	   number	   of	   Akt	   inhibitor	   resistant	   breast	   cancer	   cell	   lines	   possess	  
elevated	   levels	   of	   SGK1	  at	  both	  mRNA	  and	  protein	   levels.	   I	   present	   evidence	   that	   SGK1	  
represents	   a	   major	   driver	   of	   proliferation	   in	   these	   cells	   and	   that	   in	   contrast,	   the	   Akt	  
inhibitor	  sensitive	  cells	  analysed	  display	  low	  or	  undetectable	  levels	  of	  SGK1	  protein.	  I	  also	  
demonstrate	   that	   in	   the	   absence	   of	   significant	   SGK1	   activity,	   Akt	   can	   mediate	   the	  
phosphorylation	   of	   NDRG1,	  which	   has	   previously	   been	   reported	   to	   be	   an	   SGK1-­‐specific	  
substrate	   (Murray	   et	   al.,	   2004).	   The	   findings	   presented	   in	   this	   chapter	   indicate	   that	  
monitoring	   SGK1	   levels	   as	   well	   the	   effect	   that	   administration	   of	   Akt	   inhibitors	   has	   on	  
NDRG1	  phosphorylation	  could	  have	  utility	   in	  predicting	  the	  sensitivity	  of	   tumours	  to	  Akt	  
inhibitors.	   The	   results	   also	   suggest	   that	   SGK	   inhibitors	   or	   dual	   Akt-­‐SGK	   inhibitors	  might	  
have	  utility	  for	  treating	  cancers	  displaying	  elevated	  SGK	  activity.	  
	  
4.2. Results	  
4.2.1. Identification	  of	  Akt	  inhibitor	  sensitive	  and	  resistant	  cell	  lines	  
Two	   structurally	   and	   mechanistically	   distinct	   Akt	   inhibitors	   that	   are	   both	   currently	   in	  
clinical	  trials	  were	  utilised	  to	  study	  the	  role	  of	  Akt	  and	  SGK	  in	  breast	  cancer	  cells.	  MK-­‐2206	  




not	   entirely	   understood.	   Inhibition	   of	   Akt	   by	   MK-­‐2206	   and	   related	   compounds	   is	  
dependent	   on	   the	   presence	   of	   the	   PtdIns(3,4,5)P3	   binding	   PH-­‐domain	   and	   is	   not	  
competitive	   with	   ATP	   (Barnett	   et	   al.,	   2005).	   These	   compounds	   disrupt	   the	   membrane	  
localisation	  of	  Akt	  and	  are	  believed	  to	  induce	  a	  closed	  conformation	  of	  Akt	  that	  occludes	  
the	  binding	  sites	  of,	  PDK1,	  mTORC2	  and	  substrates	  (Cherrin	  et	  al.,	  2010).	  As	  expected	  for	  a	  
non-­‐ATP	  competitive	  compound,	  MK-­‐2206	  does	  not	  significantly	  inhibit	  any	  kinases	  in	  an	  
in	   vitro	   selectivity	   screen	   (Figure	   4.1).	  AZD5363	   is	   an	  ATP-­‐competitive	  Akt	   inhibitor	   that	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Whole	   transcriptome	   analysis	   performed	   at	   AstraZeneca	   indicated	   that	   there	   is	   a	  
correlation	  between	  AZD5363	  sensitivity	  and	  SGK1	  mRNA	  levels	  (Figure	  4.3).	  This	  analysis	  
revealed	  that	  there	  was	  a	  group	  of	  AZD5363-­‐sensitive	  cell	  lines	  with	  low	  SGK1	  mRNA	  (BT-­‐
474,	  CAMA-­‐1,	  ZR-­‐75-­‐1,	  T47D,	  HCC-­‐1187	  and	  HCC-­‐1569)	  and	  a	  group	  of	  resistant	  cell	  lines	  
with	   high	   SGK1	   mRNA	   (HCC-­‐1937,	   MDA-­‐MB-­‐436,	   BT-­‐549,	   MDA-­‐MB-­‐157,	   MDA-­‐MB-­‐231,	  
HCC-­‐1806	  and	  JIMT-­‐1).	  There	  were	  eight	  cell	   lines	  that	  displayed	  intermediate	  sensitivity	  
towards	  AZD5363,	  six	  having	  low	  SGK1	  mRNA	  (SUM-­‐52-­‐PE,	  MDA-­‐MB-­‐453,	  SK-­‐BR-­‐3,	  MCF-­‐7,	  
MDA-­‐MB-­‐468	  and	  HCC-­‐1419)	  and	  two	  with	  elevated	  SGK1	  mRNA	  (BT-­‐20	  and	  HCC-­‐1954).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	   	  
Figure	  4.3	  Correlation	  of	  breast	  cancer	  cell	  sensitivity	  to	  AZD5363	  with	  SGK1	  expression	  
21	  breast	  cancer	  cell	  lines	  were	  screened	  in	  a	  72	  h	  MTS	  proliferation	  assay.	  Cell	  lines	  with	  
a	  GI50	  value	  of	  <0.4	  μM	  were	  classified	  as	  sensitive	  (green),	  with	  a	  GI50	  value	  of	  0.4	  –	  4	  µM	  
as	  intermediately	  sensitive	  (orange)	  and	  with	  GI50	  value	  of	  >4	  μM	  as	  resistant	  (red).	  SGK1	  
gene	  expression	  from	  whole	  transcriptome	  analysis	  (Affymetrix	  U133)	  was	  scaled	  relative	  
to	   the	   expression	   range	   across	   a	   panel	   of	   500	   cell	   lines	   where	   0=minimum	   and	  













































































Five	  sensitive	  (BT-­‐474,	  CAMA-­‐1,	  ZR-­‐75-­‐1,	  T47D	  and	  HCC-­‐1187),	  one	  intermediate	  (SUM-­‐52-­‐
PE)	   and	   the	   seven	   resistant	   (HCC-­‐1937,	  MDA-­‐MB-­‐436,	   BT-­‐549,	  MDA-­‐MB-­‐157,	  MDA-­‐MB-­‐
231,	   HCC-­‐1806	   and	   JIMT-­‐1)	   cell	   lines	   were	   chosen	   for	   further	   analysis.	   The	   known	  
mutations	   in	   these	   cells	   are	   listed	   in	   Appendix	   3.	   As	   shown	   in	   Figure	   4.4,	   sensitivity	   of	  
these	  cells	  to	  AZD5363	  was	  confirmed	  by	  exposing	  the	  cells	  to	   increasing	  concentrations	  
(1	  nM	  –	  10	  µM)	  of	  AZD5363	  for	  72	  hours	  followed	  by	  MTS	  assay.	  Data	  presented	  in	  Figure	  
4.5	   and	   Table	   4.1	   also	   confirms	   that	   the	   cell	   lines	   studied	   displayed	   similar	   sensitivity	  
towards	   the	   structurally	   and	   mechanistically	   distinct	   allosteric	   Akt	   inhibitor	   MK-­‐2206.	  
Interestingly,	  the	  resistant	  cell	  lines	  are	  all	  triple	  negative	  and	  all	  of	  the	  sensitive	  cell	  lines	  
with	   the	   exception	   of	   HCC-­‐1187	   cells,	   which	   are	   triple	   negative,	   are	   hormone	   receptor	  
positive	  (Appendix	  3)	  .	  As	  discussed	  in	  the	  Chapter	  1,	  currently	  no	  targeted	  therapies	  exist	  







Figure	  4.4	  Dose	  response	  curves	  of	  breast	  cancer	  cell	  lines	  to	  AZD5363	  
Cells	  were	  exposed	  to	  DMSO	  or	  1	  nM	  –	  10	  μM	  AZD5363	  for	  72	  hrs	  and	  cell	  viability	  was	  
determined	  using	  MTS	   assay.	  Data	  were	   fitted	   to	   sigmoidal	   dose	   response	   curves	   using	  
GraphPad	  Prism	  5.0.	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Figure	  4.5	  Dose	  response	  curves	  of	  breast	  cancer	  cells	  to	  MK-­‐2206	  
Cells	  were	  exposed	  to	  DMSO	  or	  1	  nM	  –	  10	  μM	  MK-­‐2206	  for	  72	  hrs	  and	  cell	  viability	  was	  
determined	  using	  MTS	  assay.	  Data	  were	   fitted	   to	   sigmoidal	  dose–response	   curves	  using	  
GraphPad	  Prism	  5.0.	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Table	  4.1	  GI50	  values	  of	  Akt	  inhibitors	  
Cells	  were	  exposed	  to	  DMSO	  or	  1	  nM	  -­‐	  10	  μM	  AZD5363	  or	  MK-­‐2206	  for	  72	  hours	  and	  cell	  
viability	  was	   determined	   using	  MTS	   assay.	  Data	  were	   fitted	   to	   sigmoidal	   dose	   response	  
curves	  and	  GI50	  values	  and	  95%	  confidence	  intervals	  (CI)	  were	  calculated	  using	  GraphPad	  
Prism	  5.0.	  Where	  GI50	  values	  exceeded	  20	  μM,	  data	  fitted	  poorly	  to	  dose	  response	  curves,	  
and	  therefore	  no	  exact	  GI50	  values	  or	  95%	  CIs	  are	  stated	  for	  these	  samples.	  	  
	  
4.2.2. Analysis	  of	  Akt	  inhibitor	  sensitive	  and	  resistant	  cell	  lines	  
Next	   the	   relative	  mRNA	   expression	   levels	   of	   all	   three	   SGK	   isoforms	   in	   the	   Akt	   inhibitor	  
sensitive	  and	  resistant	  cell	  lines	  were	  determined	  using	  quantitative	  reverse	  transcription	  
PCR	   (qRT-­‐PCR)	   (Figure	   4.6).	   This	   revealed	   that	   the	   Akt	   inhibitor	   resistant	   cell	   lines	  
displayed	  higher	  levels	  of	  SGK1	  mRNA	  than	  the	  sensitive	  cell	   lines.	  Levels	  of	  SGK2	  mRNA	  
were	  variable	  between	  sensitive	  and	  resistant	  cells	  and	  SGK3	  mRNA	  levels	  were	  present	  at	  










GI50	  95%	  CI	  
BT-­‐474	   0.20	   0.15	  -­‐	  0.25	   0.14	   0.12	  -­‐	  0.16	  
CAMA-­‐1	   0.58	   0.48	  -­‐	  0.70	   0.04	   0.03	  -­‐	  0.06	  
ZR-­‐75-­‐1	   0.69	   0.45	  -­‐	  1.1	   1.5	   0.94	  -­‐	  2.4	  
T47D	   0.09	   0.06	  -­‐	  0.14	   0.14	   0.1	  -­‐	  0.2	  
HCC-­‐1187	   0.88	   0.57	  -­‐	  1.4	   0.61	   0.46	  -­‐	  0.8	  
SUM52PE	   0.18	   0.15	  -­‐	  0.23	   1.1	   0.93	  -­‐	  1.2	  
HCC-­‐1937	   >	  20	   -­‐	   >	  20	   -­‐	  
MDA-­‐MD-­‐436	   9.7	   6.3-­‐	  14.9	   14.9	   7.2	  -­‐	  31	  
BT-­‐549	   4.5	   3.3	  -­‐	  6.1	   >	  20	   -­‐	  
MDA-­‐MB-­‐157	   >	  20	   -­‐	   >	  20	   -­‐	  
HCC-­‐1806	   >	  20	   -­‐	   >	  20	   -­‐	  
MDA-­‐MB-­‐231	   >	  20	   -­‐	   >	  20	   -­‐	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  4.6	  Comparison	  of	  SGK	  mRNA	  levels	  in	  Akt	  inhibitor	  sensitive	  and	  resistant	  cells	  
Total	  mRNA	  was	   isolated	   from	   cells	   and	   SGK	   isoform	  mRNA	   levels	  were	   determined	   by	  
qRT-­‐PCR.	   The	   data	   were	   normalised	   to	   an	   internal	   18S	   control	   and	   are	   presented	   as	  
relative	   levels	   in	  comparison	  with	  control	   cells	   (HEK293).	  Results	   represent	   the	  means	  ±	  
S.E.M.	  of	  two	  independent	  samples	  each	  assayed	  in	  duplicate.	  
	  
Next	  an	  immunoblot	  analysis	  was	  carried	  out	  to	  compare	  the	  relative	  expression	  levels	  of	  
SGK1	  and	  SGK3	  protein	  as	  well	  as	  phosphorylation	   levels	  of	  NDRG1	  across	  the	  cell	   lines.	  
Four	  of	  the	  Akt	  inhibitor	  resistant	  cell	  lines	  (HCC-­‐1937,	  MDA-­‐MB-­‐436,	  BT-­‐549	  and	  JIMT-­‐1)	  













































































































NDRG1	  phosphorylation.	  All	  of	  these	  cell	  lines	  possess	  mutations	  that	  activate	  PI3K.	  HCC-­‐
1937,	  MDA-­‐MB-­‐436	  and	  BT-­‐549	  cells	  were	  null	  for	  PTEN	  expression	  whereas	  JIMT-­‐1	  cells	  
have	  an	  activating	  mutation	  in	  the	  catalytic	  subunit	  of	  PI3K	  (C420R)	  (Koninki	  et	  al.,	  2010).	  
Two	   of	   the	   remaining	   Akt	   inhibitor	   resistant	   cell	   lines	   (HCC-­‐1806	   and	   MDA-­‐MB-­‐231),	  
although	   not	   displaying	   obvious	   elevation	   of	   SGK1	   protein,	   nevertheless	   exhibited	  
significant	  phosphorylation	  of	  NDRG1.	  The	  final	  Akt	  inhibitor	  resistant	  cell	  line	  investigated	  
(MDA-­‐MB-­‐157)	   showed	   low	   levels	   of	   NDRG1	   phosphorylation	   and	   no	   detectable	   SGK1	  
protein	  suggesting	  that	  SGK	  signalling	   is	  not	  activated	   in	   these	  cells.	  Consistent	  with	  the	  
mRNA	  expression	  data,	  SGK3	  protein	   levels	  were	  more	  variable	  across	   the	  sensitive	  and	  
resistant	  cell	  lines	  (Figure	  4.7).	  	  
In	  addition,	  Akt	  expression	  and	  activity	  was	  monitored	  by	  assessing	  Akt	  Thr308	  and	  Ser473	  
phosphorylation	   as	   well	   as	   phosphorylation	   of	   the	   Akt	   substrates	   PRAS40,	   GSK3	   and	  
FoxO1/3.	  All	  Akt	  inhibitor	  sensitive	  and	  five	  out	  of	  the	  seven	  resistant	  cell	  lines	  (HCC-­‐1937,	  
MDA-­‐MB-­‐436,	  BT-­‐459,	  HCC-­‐1806	  and	  JIMT-­‐1)	  displayed	  significant	  Akt	  Thr308/Ser473	  and	  
PRAS40	  phosphorylation,	  confirming	  that	  Akt	  signalling	  is	  active	  in	  these	  cells.	  In	  contrast,	  
resistant	  MDA-­‐MB-­‐157	  and	  HCC-­‐1806	  cells	  had	  very	  low	  levels	  of	  Akt	  Thr308/Ser473	  and	  
undetectable	  PRAS40	  phosphorylation	  suggesting	  that	  Akt	  signalling	  is	  weak	  in	  these	  cells.	  
Levels	  of	  GSK3	  and	  FoxO1/3	  phosphorylation	  were	  more	  variable	  across	  all	   the	  cell	   lines	  
examined.	  Levels	  of	  mTORC1	  activity	  were	  estimated	  by	  monitoring	  phosphorylation	  of	  S6	  
protein.	   Similar	   levels	  of	   S6	  phosphorylation	  were	  detected	   in	  all	   cell	   lines,	  except	  HCC-­‐




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  4.7	  Immunoblot	  analysis	  of	  Akt	  inhibitor	  sensitive	  and	  resistant	  cells	  	  
Total	   protein	   was	   isolated	   from	   cells	   and	   analysed	   by	   immunoblotting	   (IB)	   with	   the	  















































































4.2.3. SGK1	  knockdown	  impairs	  proliferation	  of	  Akt	  inhibitor	  resistant	  cells	  
SGK1	  has	  a	  short	  half-­‐life	  (Brickley	  et	  al.,	  2002),	  making	   it	  straightforward	  to	  knockdown	  
SGK1	   protein	   expression	   using	   RNA	   interference.	   Five	   independent	   lentiviral	   shRNAs	  
reduced	   the	  expression	  of	   SGK1	  protein	   to	  near	  undetectable	   levels	   in	   the	  Akt	   inhibitor	  
resistant	   cell	   lines	   displaying	   high	   levels	   of	   SGK1	   protein	   (BT-­‐549,	  MDA-­‐MB-­‐436,	   JIMT-­‐1	  
and	  HCC-­‐1937	  (Figure	  4.8A).	  Consistent	  with	  the	  efficient	  knockdown	  of	  SGK1	  protein,	  all	  
shRNAs	  also	  markedly	   reduced	  NDRG1	  phosphorylation	   in	   the	   resistant	  cell	   lines	   (Figure	  
4.8A).	   Strikingly,	   knockdown	   of	   SGK1	   protein	  markedly	   impaired	   proliferation	   of	   all	   Akt	  
inhibitor	   resistant	   cell	   lines	   examined	   (Figure	   4.8B).	   In	   contrast,	   transduction	   of	   Akt	  
inhibitor	   sensitive	   cells	   (BT-­‐474,	   T47D	  and	  ZR-­‐75-­‐1)	  with	   SGK1	   shRNAs	  had	  no	  effect	  on	  
NDRG1	  phosphorylation	  or	  proliferation	  (Figure	  4.9).	  	  
To	   confirm	   that	   inhibition	   of	   proliferation	   following	   SGK1	   knockdown	   in	   Akt	   inhibitor	  
resistant	  cells	  was	  indeed	  mediated	  by	  a	  SGK1	  deficiency,	  a	  rescue	  experiment	  was	  carried	  
out.	   Endogenous	   SGK1	   expression	   was	   knocked	   down	   in	   BT-­‐549	   cells	   stably	   over-­‐
expressing	  wild	  type	  or	  kinase	  inactive	  SGK1.	  This	  experiment	  revealed	  that	  in	  BT-­‐549	  cells	  
lacking	   endogenous	   SGK1,	   proliferation	   and	  NDRG1	   phosphorylation	   can	   be	   rescued	   by	  




	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  4.8	  SGK1	  knockdown	  impairs	  proliferation	  of	  Akt	  inhibitor	  resistant	  cells	  
(A)	  The	   indicated	  Akt	   inhibitor	   resistant	  cells	  were	  transduced	  with	  SGK1	  and	  scrambled	  
shRNAs.	  Cells	  were	  lysed	  72	  hours	  post	   infection	  and	  the	  lysates	  were	  analysed	  with	  the	  
indicated	   antibodies	   by	   immunoblotting	   (IB).	   (B)	   Akt	   inhibitor	   resistant	   cells	   were	  
transduced	   with	   lentiviral	   SGK1	   and	   scrambled	   shRNAs.	   Equal	   numbers	   of	   cells	   were	  
seeded	  onto	  96-­‐well	  plates	  48	  hours	  post	  infection	  and	  allowed	  to	  adhere	  overnight.	  Cell	  
proliferation	  was	   then	  determined	  over	  a	  5-­‐day	  period	  by	   carrying	  out	  MTS	  assay	  at	  24	  
hour	   intervals.	   Each	   data	   point	   is	   the	   average	   MTS	   assay	   of	   samples	   assayed	   in	  
triplicate±S.D.	  The	  data	  are	  presented	  as	  fold	  change	  relative	  to	  day	  0	  values	  (day	  0	  equals	  













































































































































































Figure	  4.9	  SGK1	  knockdown	  does	  not	  affect	  proliferation	  of	  Akt	  inhibitor	  sensitive	  cells	  
(A)	  Akt	   inhibitor	  sensitive	  cells	  were	   transduced	  with	  SGK1	  and	  scrambled	  shRNAs.	  Cells	  
were	   lysed	   72	   hours	   post	   infection	   and	   the	   lysates	   were	   analysed	   with	   the	   indicated	  
antibodies	  by	   immunoblotting	   (IB).	   (B)	  Akt	   inhibitor	  sensitive	  cells	  were	  transduced	  with	  
SGK1	  and	  scrambled	  shRNAs.	  Equal	  numbers	  of	  cells	  were	  seeded	  onto	  96-­‐well	  plates	  48	  
hours	   post	   infection	   and	   allowed	   to	   adhere	   overnight.	   Cell	   proliferation	   was	   then	  
determined	  over	  a	  5-­‐day	  period	  by	  carrying	  out	  MTS	  assay	  at	  24	  hour	  intervals.	  Each	  data	  
point	   is	   the	   average	   MTS	   assay	   of	   samples	   assayed	   in	   triplicate±S.D.	   The	   data	   are	  






































































































































Figure	  4.10	  Rescue	  of	  SGK1	  knockdown	  induced	  proliferation	  defect	  
BT-­‐549	  cells	  stably	  expressing	  HA–ΔN-­‐SGK1	  wild	  type	  (wt)	  or	  kinase-­‐inactive	  (ki)	  constructs	  
were	   transduced	  with	   SGK1	   shRNA	   #D	   or	   scrambled	   shRNA.	   (A)	   Equal	   numbers	   of	   cells	  
were	   seeded	  48	  hours	   post	   shRNA	   infection	  onto	   96-­‐well	   plates	   and	   allowed	   to	   adhere	  
overnight.	  Cell	  proliferation	  was	  then	  determined	  by	  carrying	  out	  the	  MTS	  assay	  over	  a	  5-­‐
day	   period	  with	   cells	   assayed	   at	   24	   hour	   intervals.	   Each	   data	   point	   is	   the	   average	  MTS	  
assay	  of	  samples	  assayed	  in	  triplicate	  ±	  S.D.	  The	  data	  are	  presented	  as	  fold	  change	  relative	  
to	  day	  0	  values	  (day	  0	  equals	  24	  h	  post-­‐seeding).	  (B)	  Cells	  were	  lysed	  72	  h	  post	  infection	  










































































4.2.4. SGK1	  knockdown	  reduces	  the	  invasive	  ability	  of	  BT-­‐549	  cells	  
SGK1	  has	  previously	  been	  reported	  to	  be	  important	  for	  the	  ability	  of	  various	  cell	  types	  to	  
migrate	  (Eylenstein	  et	  al.,	  2011;	  Schmidt	  et	  al.,	  2012a;	  Schmidt	  et	  al.,	  2012b).	  Therefore,	  
the	  effect	  of	  SGK1	  knockdown	  on	  the	  ability	  of	  highly	  invasive	  BT-­‐549	  cells	  to	  invade	  into	  
three-­‐dimensional	   Matrigel	   matrix	   in	   a	   transwell	   invasion	   assay	   was	   next	   determined.	  
Knockdown	  of	   SGK1	  by	   two	   independent	   shRNAs	  markedly	   reduced	   the	   invasiveness	   of	  
BT-­‐549	  cells	  in	  this	  assay	  (Figure	  4.11A).	  To	  confirm	  that	  the	  impaired	  invasion	  was	  due	  to	  
SGK1	  knockdown,	  a	  rescue	  experiment	  was	  performed.	  Over-­‐expression	  of	  wild	  type,	  but	  
not	   kinase	   inactive	   SGK1,	   restored	   invasiveness	   of	   SGK1	   shRNA-­‐infected	   cells	   back	   to	  







Figure	  4.11	  SGK1	  knockdown	  reduces	  the	  invasive	  ability	  of	  BT-­‐549	  cells	  
(A)	  BT-­‐549	  cells	  were	  transduced	  with	  SGK1	  or	  scrambled	  shRNAs.	  Cells	  were	  plated	  for	  a	  
transwell	   invasion	   assay	   48	   hours	   post	   infection	   in	   triplicates	   using	   10%	   FBS	   as	   a	  
chemoattractant.	  Cells	  that	  had	  invaded	  through	  to	  the	  lower	  face	  of	  the	  filters	  were	  fixed	  
and	   photographed	   (×10	   magnification).	   Invasive	   cells	   were	   counted	   and	   the	   data	   are	  
presented	  as	  the	  mean	  number	  of	  migrated	  cells	  ±	  S.D.	  (B)	  BT-­‐549	  cells	  stably	  expressing	  
HA–ΔN-­‐SGK1	  wild	  type	  (wt)	  or	  kinase-­‐inactive	  (ki)	  constructs	  were	  transduced	  with	  SGK1	  
shRNA	  #D	  or	  scrambled	  shRNA	  and	  48	  h	  post	   infection	  cells	  were	  plated	   for	  a	   transwell	  
invasion	   assay	   as	   in	   (A).	   Statistical	   significance	   was	   assessed	   by	   ANOVA	   followed	   by	  
Tukey's	  multiple	   comparison	   test	  using	  GraphPad	  Prism	  5.0.	  ***P<0.001	  compared	  with	  
the	  scrambled	  control;	  ns,	  not	  significant.	  	  
	  
4.2.5. SGK1	  knockdown	  does	  not	  affect	  Akt	  signalling	  
To	   assess	   whether	   SGK1	   depletion	   influences	   Akt	   signalling,	   phosphorylation	   status	   of	  
PRAS40	  and	  Akt	  Thr308	  and	  Ser573	  was	  assessed	  at	  48	  and	  72	  hours	  post-­‐infection	  with	  











































phosphorylation	   (Figure	   4.12).	   Furthermore,	   the	   effect	   of	   SGK1	   knockdown	   on	  
phosphorylation	  of	  other	  key	  Akt	  substrates,	  FoxO1/3,	  GSK3	  and	  TSC2	  was	  also	  assessed.	  
Although	  SGK1	  has	  been	  suggested	  to	  phosphorylate	  GSK3	  (Sakoda	  et	  al.,	  2003)	  and	  FoxOs	  
(Brunet	   et	   al.,	   2001),	   SGK1	   knockdown	   in	   BT-­‐549	   cells	   had	   no	   effect	   on	   the	  
phosphorylation	  of	  these	  proteins	  (Figure	  4.12).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  
Figure	  4.12	  Knockdown	  of	  SGK1	  does	  not	  affect	  Akt	  signalling	  
BT-­‐549	  cells	  were	  transduced	  with	  SGK1	  and	  scrambled	  shRNAs.	  Cells	  were	  lysed	  at	  48	  and	  



















































4.2.6. Akt	  inhibitor	  resistant	  cells	  are	  sensitive	  to	  mTOR	  inhibition	  
mTOR	  is	  a	  critical	  activator	  of	  SGK1.	  Therefore	  the	  sensitivity	  of	  the	  Akt	  inhibitor	  resistant	  
cells	   to	  the	  mTOR	  kinase	   inhibitor	  AZD8055	  (Chresta	  et	  al.,	  2010)	  was	  next	   investigated.	  
BT-­‐549,	  JIMT-­‐1	  and	  MDA-­‐MB-­‐436	  were	  treated	  with	  increasing	  doses	  (1	  nM	  –	  10	  µM)	  of	  
AZD8055	   for	   72	   hours.	   AZD8055	   suppressed	   the	   proliferation	   of	   the	   three	  Akt	   inhibitor	  
resistant	   cell	   lines	   tested	   (Figure	   4.13).	   The	  GI50	   values	   determined	  were	   approximately	  
~0.2	   μM	   for	   BT-­‐549,	   ~0.1	   μM	   for	   JIMT-­‐1,	   and	   ~0.2	   μM	   for	   MDA-­‐MB-­‐436.	   Moreover,	  
AZD8055	  also	  suppressed	  phosphorylation	  of	  the	  T-­‐loop	  (Thr256)	  and	  hydrophobic	  motif	  
(Ser422)	   of	   endogenous	   SGK1	   and	  phosphorylation	   of	  NDRG1	   in	   the	   three	  Akt	   inhibitor	  




Figure	  4.13	  Cells	  with	  elevated	  SGK1	  levels	  are	  sensitive	  to	  mTOR	  inhibitor	  AZD8055	  
The	   indicated	   Akt	   inhibitor	   resistant	   cells	   were	   exposed	   to	   DMSO	   or	   increasing	  
concentrations	   (1	   nM	   –	   10	  µM)	   of	   AZD8055	   and	   72	   hours	   post	   inhibitor	   treatment	   cell	  
viability	  was	   determined	   using	  MTS	   assay.	  Data	  were	   fitted	   to	   sigmoidal	   dose	   response	  
curves	  using	  GraphPad	  Prism	  5.0.	  The	  results	  are	  the	  means	  ±	  S.D.	  of	  a	  triplicate	  assay	  and	  
are	  normalized	  to	  the	  DMSO	  control	  that	  was	  set	  to	  100%.	  	  
	  




































































Figure	  4.14	  	  mTOR	  inhibitor	  AZD8055	  inhibits	  the	  activation	  of	  SGK1	  	  
Cells	  were	   treated	  with	   the	   indicated	   doses	   of	   the	   AZD8055	  mTOR	   inhibitor	   for	   1	   hour	  
followed	  by	  lysis	  and	  immunoblot	  (IB)	  analysis	  with	  the	  indicated	  antibodies.	  	  
	  
4.2.7. Akt	  can	  mediate	  NDRG1	  phosphorylation	  in	  the	  absence	  of	  SGK	  	  
Interestingly,	  two	  Akt	  inhibitor	  sensitive	  cell	  lines	  examined	  (BT-­‐474	  and	  CAMA-­‐1)	  and	  one	  
cell	   line	   displaying	   high	   sensitivity	   to	   MK-­‐2206	   and	   intermediate	   sensitivity	   towards	  
AZD5363	   (SUM-­‐52-­‐PE)	   despite	   possessing	   low	   SGK1	  mRNA/protein	   displayed	   significant	  
phosphorylation	   of	  NDRG1	   (Figure	   4.7).	  On	   a	   long	   exposure,	   several	   other	   Akt	   inhibitor	  
sensitive	  cells	  displayed	  observable	  phosphorylation	  of	  NDRG1	  (Figure	  4.7).	  One	  possibility	  
to	  account	  for	  this	  would	  be	  if	  NDRG1	  were	  phosphorylated	  by	  Akt	  rather	  than	  by	  SGK	  in	  
the	  Akt	  inhibitor	  sensitive	  cells.	  
To	  test	  this,	  Akt	  inhibitor	  sensitive	  cell	  lines	  (BT-­‐474,	  CAMA-­‐1,	  T47D,	  SUM-­‐52-­‐PE,	  ZR-­‐75-­‐1	  
and	   HCC-­‐1187)	   were	   treated	   with	   DMSO	   or	   10	   nM	   -­‐	   1	   µM	   MK-­‐2206	   for	   1	   hour	   and	  
analysed	  by	  immunoblotting.	  As	  expected,	  Akt	  inhibition	  decreased	  PRAS40	  and	  FoxO1/3	  
phosphorylation	   in	   all	   cell	   lines	   examined.	  MK-­‐2206	  also	   suppressed	  phosphorylation	  of	  









































































phosphorylation	  was	  insensitive	  to	  MK-­‐2206	  only	  in	  HCC-­‐1187	  cells.	  To	  confirm	  the	  effect	  
that	  Akt	  inhibition	  has	  on	  NDRG1	  phosphorylation	  in	  Akt	  inhibitor	  sensitive	  cells,	  BT-­‐474,	  
CAMA-­‐1	   and	   T47D	   cells	   were	   also	   treated	   with	   the	   distinct	   AZD5363	   Akt	   inhibitor	   and	  
identical	  results	  were	  obtained	  (Figure	  4.16).	  These	  results	   indicate	  that	  phosphorylation	  
of	  NDRG1	   is	  mediated	  by	  Akt	   in	   the	  absence	  of	   significant	  SGK	   levels.	   In	  HCC-­‐1187	  cells	  
either	  SGK	  or	  another	  kinase	  would	  be	  expected	  to	  mediate	  NDRG1	  phosphorylation.	  	  
	  
	  
Figure	  4.15	  MK-­‐2206	  inhibits	  NDRG1	  phosphorylation	  in	  Akt	  inhibitor	  sensitive	  cells	  
Cells	   were	   treated	   with	   the	   indicated	   doses	   of	   MK-­‐2206	   for	   1	   hour	   prior	   to	   lysis	   and	  























































































































































Figure	  4.16	  AZD5363	  inhibits	  NDRG1	  phosphorylation	  in	  Akt	  inhibitor	  sensitive	  cells	  
Cells	  were	  treated	  with	  the	   indicated	  doses	  of	  AZD5363	  for	  1	  hour	  followed	  by	   lysis	  and	  
immunoblot	  (IB)	  analysis	  with	  the	  indicated	  antibodies.	  
	  
The	  effect	  of	  MK-­‐2206	  on	  PRAS40	  and	  NDRG1	  phosphorylation	  was	  also	  tested	  in	  six	  Akt	  
inhibitor	   resistant	   cell	   lines	   (MDA-­‐MB-­‐436,	   JIMT-­‐1,	   BT-­‐549,	   HCC-­‐1937,	   HCC-­‐1806,	  MDA-­‐
MB-­‐231)	   (Figure	   4.17).	   As	   expected,	   Akt	   inhibition	   with	   MK-­‐2206	   induced	  
dephosphorylation	  of	  PRAS40	  in	  all	  cell	  lines	  tested.	  Phosphorylation	  of	  FoxO1/3	  was	  also	  
sensitive	  to	  MK-­‐2206	  in	  these	  cells.	  In	  contrast,	  NDRG1	  phosphorylation	  was	  insensitive	  to	  
MK-­‐2206	   in	   the	  Akt	   inhibitor	   resistant	   cells.	  Only	   in	  HCC-­‐1937	   cells	   a	  minor	  decrease	   in	  
NDRG1	  phosphorylation	  was	  seen	   in	  response	  to	  high	  (1	  µM)	  concentration	  of	  MK-­‐2206	  
indicating	  that	  in	  these	  cells	  Akt	  may	  contribute	  towards	  NDRG1	  phosphorylation	  (Figure	  
4.17).	  These	  results	  were	  confirmed	  by	  treating	  two	  of	  the	  Akt	  inhibitor	  resistant	  cell	  lines	  
(BT-­‐549	   and	   MDA-­‐MB-­‐436)	   also	   with	   the	   distinct	   Akt	   inhibitor	   AZD5363.	   As	   expected,	  
AZD5363	  also	  had	  no	  effect	  on	  NDRG1	  phosphorylation	   in	   the	  cells	   tested	   (Figure	  4.18).	  	  
Notably,	   AZD5363	   induced	   hyper-­‐phosphorylation	   of	   Akt	   in	   all	   cell	   lines,	   as	   previously	  





































































Figure	   4.17	   NDRG1	   phosphorylation	   is	   resistant	   to	  MK-­‐2206	   in	   Akt	   inhibitor	   resistant	  
cells	  
Cells	  were	  treated	  with	  the	   indicated	  doses	  of	   the	  MK-­‐2206	  for	  1	  hour	   followed	  by	   lysis	  























































































































































Figure	   4.18	   NDRG1	   phosphorylation	   is	   resistant	   to	   AZD5363	   in	   Akt	   inhibitor	   resistant	  
cells	  
Cells	  were	  treated	  with	  the	   indicated	  doses	  of	   the	  AZD5363	  for	  1	  hour	   followed	  by	   lysis	  
and	  immunoblot	  (IB)	  analysis	  with	  the	  indicated	  antibodies.	  
	  
To	  further	  study	  the	  regulation	  of	  NDRG1	  phosphorylation	  outside	  of	  breast	  cancer	  cells,	  
the	   effect	   of	   MK-­‐2206	   on	   IGF1	   induced	   NDRG1	   phosphorylation	   was	   assessed	   in	   HeLa	  
(Figure	  4.19)	  and	  HEK293	  (Figure	  4.20)	  cells.	  HeLa	  cells	  are	  reported	  to	  display	  detectable	  
levels	  of	  SGK1	  protein	  and	  to	  possess	  SGK1	  knockdown	  sensitive	  NDRG1	  phosphorylation	  
(Murray	   et	   al.,	   2004).	   Consistent	   with	   this,	   NDRG1	   phosphorylation	   was	   resistant	   to	  
treatment	   with	   the	   Akt	   inhibitor	   MK-­‐2206	   in	   HeLa	   cells	   (Figure	   4.19).	   In	   contrast,	   in	  
HEK293	  cells	  NDRG1	  phosphorylation	  was	  sensitive	  to	  MK-­‐2006	  treatment	  (Figure	  4.20A).	  
Transfection	   of	   GST-­‐ΔN-­‐SGK1	   into	   HEK293	   cells	   induced	   MK-­‐2206	   resistant	   NDRG1	  
phosphorylation	   (Figure	  4.20B).	  These	  observations	   indicate	   that	  SGK1	  mediated	  NDRG1	  
phosphorylation	  is,	  as	  expected	  resistant	  to	  Akt	  inhibition.	  Furthermore,	  HEK293	  cells	  are	  













































phosphorylation	  is	  mediated	  by	  Akt	  or	  possibly	  by	  a	  combination	  of	  Akt	  and	  SGK.	  Notably,	  
in	  both	  HeLa	  and	  HEK293	  cells	   IGF1	  induced	  PRAS40	  phosphorylation	  was	  only	  modestly	  
inhibited	   by	   MK-­‐2206.	   	   As	   shown	   in	   Figure	   4.19	   and	   Figure	   4.20,	   monitoring	   Akt	  
Thr308/Ser473	   phosphorylation	   and	   assessing	   S6K	   activity	   by	   blotting	   for	   phospho-­‐S6K	  
and	  phospho-­‐S6	  confirmed	  that	  Akt	  was	  efficiently	  inhibited	  in	  these	  cells.	  
	  
	  	  	  	  	   	  
Figure	  4.19	  NDRG1	  phosphorylation	  is	  resistant	  to	  MK-­‐2206	  in	  HeLa	  cells	  
HeLa	  cells	  were	  serum	  starved	  overnight	  and	  treated	  with	  the	  indicated	  doses	  of	  MK-­‐2206	  
for	   30	   minutes	   prior	   to	   stimulation	   with	   50	   ng/ml	   IGF1	   for	   30	   min.	   Cell	   lysates	   were	  
























	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   4.20	   NDRG1	   phosphorylation	   is	   resistant	   to	   MK-­‐2206	   in	   HEK293	   cells	   over-­‐
expressing	  SGK1	  
(A)	  HEK293	   cells	  were	   serum	  starved	  overnight	   and	   treated	  with	   the	   indicated	  doses	  of	  
MK-­‐2206	  for	  30	  minutes	  prior	  to	  stimulation	  with	  50	  ng/ml	   IGF1	  for	  30	  min.	  Cell	   lysates	  
were	   analysed	   by	   immunoblotting	   (IB)	  with	   the	   indicated	   antibodies.	   (B)	   24	   hours	   post	  
transfection	   with	   GST-­‐ΔN-­‐SGK1,	   HEK293	   cells	   were	   serum	   starved	   for	   16	   hours	   and	  
treated	  with	  the	  indicated	  doses	  of	  MK-­‐2206	  for	  30	  minutes	  followed	  by	  stimulation	  with	  
50	   ng/ml	   IGF1	   for	   30	   min.	   Cell	   lysates	   were	   analysed	   by	   immunoblotting	   with	   the	  














































Akt	  has	  been	  reported	  to	  phosphorylate	  NDRG1	   in	  vitro,	  albeit	  much	  less	  efficiently	  than	  
SGK1	   (Murray	   et	   al.,	   2004).	   To	   confirm	   this,	   the	   abilities	   of	  ΔN-­‐SGK1	   and	   Akt1	   purified	  
from	  HEK293	  cells	  to	  phosphorylate	  NDRG1	  in	  vitro	  were	  compared	  in	  parallel	  using	  equal	  
activities	  of	  each	  kinase.	  As	  previously	   reported,	  both	  kinases	  phosphorylated	  NDRG1	   in	  
vitro,	   but	   SGK1	   did	   this	   more	   efficiently	   than	   Akt	   (Figure	   4.21).	   Similar	   results	   were	  
observed	  with	  phosphorylation	  of	  Nedd4.2	  that	  was	  also	  included	  in	  the	  experiment.	  
	  
	  
Figure	  4.21	  Phosphorylation	  of	  NDRG1	  in	  vitro	  by	  SGK	  and	  Akt	  
5	  µg	  of	  NDRG1	  or	  Nedd4.2	  purified	  from	  E.coli	  was	  incubated	  with	  equal	  activity	  of	  either	  
wild	  type	  (wt)	  or	  kinase	  dead	  (kd)	  full	  length	  GST-­‐Akt1	  (245	  ng)	  (A)	  or	  GST-­‐ΔN-­‐SGK1	  (175	  
ng)	   (B)	   purified	   from	   HEK293	   cells	   in	   the	   presence	   of	   0.1	   mM	   [γ32P]-­‐ATP	   and	   10	   mM	  
magnesium	  acetate	   for	   the	   indicated	  times.	   	  Assays	  were	  terminated	  by	  addition	  of	  SDS	  
sample	   buffer.	   Proteins	   were	   detected	   by	   Coomassie	   staining	   (lower	   panel)	   and	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Elevated	  SGK1	  expression	   in	  breast	  cancer	  cells	  correlates	  with	  SGK1-­‐	  rather	  than	  Akt-­‐
driven	  proliferation	  
Results	  presented	  in	  this	  chapter	  demonstrate	  that	  SGK1	  can	  mediate	  innate	  resistance	  of	  
breast	  cancer	  cells	  to	  Akt	  inhibitors	  and	  therefore	  elevation	  of	  SGK1	  expression	  represents	  
one	  mechanism	   predicting	   Akt	   inhibitor	   resistance.	   In	   the	   Akt	   inhibitor	   resistant	   breast	  
cancer	  cell	   lines	  displaying	  elevated	  SGK1	  (BT-­‐549,	  JIMT-­‐1,	  MDA-­‐MB-­‐436	  and	  HCC-­‐1937),	  
knockdown	  of	  SGK1	  markedly	  suppressed	  cell	  proliferation.	  Rescue	  experiment	  performed	  
in	  BT-­‐549	  cells	  demonstrated	  that	  the	  impaired	  proliferation	  was	  due	  to	  SGK1	  deficiency	  
and	   not	   due	   to	   off-­‐target	   effects.	   SGK1	   expression	   is	   induced	   by	   the	   glucocorticoid	  
dexamethasone	   that	   is	   routinely	   used	   to	   reduce	   inflammation	   and	   to	   mitigate	  
chemotherapy	   associated	   nausea	   in	   cancer	   patients	   (Volden	   and	   Conzen,	   2013).	   This	  
raises	  the	  possibility	  that	  administration	  of	  steroid	  hormones	  to	  cancer	  patients	  receiving	  
Akt	  inhibitors	  might	  have	  the	  potential	  to	  induce	  SGK1	  in	  tumour	  cells	  and	  thereby	  induce	  
resistance	   to	  Akt	   inhibitors.	  Glucocorticoid	   receptor	   (GR)	  activation	  has	  different	  effects	  
depending	   on	   cell	   type.	   For	   example	   in	   lymphocytes	   glucocorticoids	   induce	   apoptosis	  
(Distelhorst,	   2002)	  whereas	   in	  mammary	   epithelial	   cells	   (MEC)	   glucocorticoids	   are	   anti-­‐
apoptotic	   (Moran	  et	  al.,	  2000;	  Schorr	  and	  Furth,	  2000)	  and	   in	  a	  xenograft	  model	  of	   lung	  
cancer	   glucocorticoids	   induce	   resistance	   to	   apoptosis	   caused	   by	   cisplatin	   (Herr	   et	   al.,	  
2003).	  Based	  on	  over-­‐expression	  studies,	  glucocorticoid	  associated	  apoptosis	  resistance	  is	  
suggested	   to	   be	   mediated	   by	   SGK1	   in	   MECs	   (Mikosz	   et	   al.,	   2001).	   Moreover,	   SGK1	  




caused	  by	  chemotherapy	  in	  breast	  cancer	  cells	  (Wu	  et	  al.,	  2004).	  These	  observations	  and	  
data	  presented	  in	  this	  chapter	  emphasise	  the	  key	  role	  that	  SGK1	  activity	  can	  play	  in	  driving	  
the	   expansion	   and	   survival	   of	   tumour	   cells.	   Indeed,	   by	   promoting	   induction	   of	   SGK1,	  
steroid	  treatment	  could	  have	  the	  potential	  to	  promote	  many	  cancers.	  
Pro-­‐proliferative	   and	   pro-­‐survival	   roles	   have	   been	   described	   for	   SGK1	   also	   outside	   of	  
breast	   cancers.	   Most	   notably,	   SGK1	   knockout	   mice	   are	   resistant	   to	   chemically	   induced	  
colonic	   carcinogenesis	   (Nasir	   et	   al.,	   2009)	   and	   spontaneous	   intestinal	   tumour	  
development	  in	  the	  APC	  deficient	  apcmin/+	  mice	  (Wang	  et	  al.,	  2010).	  Additionally,	  SGK1	  has	  
been	  suggested	  to	  mediate	   interleukin	  6	   (IL6)	  dependent	  survival	   in	  cholangiocarcinoma	  
cells	  in	  which	  SGK1	  knockdown	  sensitises	  cells	  to	  chemotherapy	  and	  similar	  observations	  
have	   been	   demonstrated	   for	   IL2	   mediated	   survival	   of	   renal	   cancer	   cells	   (Amato	   et	   al.,	  
2007;	  Meng	  et	  al.,	  2005).	  Further	  evidence	  for	  SGK1	  acting	  as	  a	  cytokine	  responsive	  pro-­‐
survival	   gene	   comes	   from	   studies	   with	   multiple	   myeloma	   cells.	   In	   these	   cells	   SGK1	   is	  
induced	   as	   a	   response	   to	   IL6,	   IL21	   and	   tumour	   necrosis	   factor	  α	   and	   SGK1	   knockdown	  
inhibits	   proliferation	   and	   is	   associated	   with	   reduced	   expression	   of	   cell	   cycle	   promoting	  
genes	   suggesting	   that	   SGK1	   can	   influence	   cell	   cycle	   progression	   (Fagerli	   et	   al.,	   2011).	  
Additionally,	   androgen	   stimulates	   SGK1	   expression	   and	   based	   on	   over-­‐expression	   and	  
knockdown	  studies	  SGK1	  is	  reported	  to	  promote	  androgen	  mediated	  survival	  of	  prostate	  
cancer	  cells	   (Shanmugam	  et	  al.,	  2007).	  SGK1	  expression	  has	  been	  proposed	  to	  be	  down-­‐
regulated	  in	  some	  cancer	  types,	  such	  as	  prostate	  (Rauhala	  et	  al.,	  2005),	  ovarian	  (Chu	  et	  al.,	  
2002)	  and	  hepatocellular	  carcinoma	  (Chung	  et	  al.,	  2002).	  It	  should	  be	  noted	  that	  without	  
further	   functional	   characterisation	   correlating	   expression	   levels	   with	   physiological	  




SGK1	  appears	  to	  promote	  proliferation	  via	  mechanisms	  that	  are	  distinct	  from	  Akt	  	  
The	   Akt	   inhibitor	   resistant	   cell	   lines	   that	   possess	   elevated	   SGK1	   displayed	   similar	   Akt	  
signalling	   to	   Akt	   inhibitor	   sensitive	   cells	   and	   in	   all	   cell	   lines	   examined	   Akt	   inhibitors	  
similarly	   reduced	   phosphorylation	   of	   the	   Akt	   substrates	   examined	   (PRAS40,	   FoxO1/3).	  
Therefore	  resistance	  of	  the	  cells	  displaying	  elevated	  SGK1	  to	  Akt	  inhibitors	  cannot	  simply	  
be	   explained	   by	   lack	   of	   Akt	   activity.	   SGK1	   knockdown	   impaired	   the	   capacity	   of	   Akt	  
inhibitor	   resistant	   breast	   cancer	   cells	   to	   proliferate	   and	   SGK1	   carrying	   out	   functions	  
commonly	  attributed	  to	  Akt	  could	  account	  for	  this.	  Assessing	  the	  phosphorylation	  status	  
of	   Akt	   and	   a	   subset	   of	   its	   substrates	   that	   are	   linked	   to	   pro-­‐survival	   and	   proliferative	  
functions,	   namely	   FoxO1/3,	   GSK3,	   PRAS40	   and	   TSC2,	   revealed	   no	   differences	   between	  
SGK1	  and	  scrambled	  shRNA	  infected	  BT-­‐549	  cells.	  Therefore	  it	  appears	  unlikely	  that	  SGK1	  
supports	  cell	  proliferation	  via	  phosphorylating	  these	  substrates,	  at	  least	  in	  BT-­‐549	  cells.	  	  
The	   first	   report	   to	   identify	   FoxO3	   as	   a	   target	   of	   SGK1	   utilised	   in	   vitro	   phosphorylation	  
assays	  and	  over-­‐expression	  studies	  and	   reported	   that	  both	  SGK1	  and	  Akt	  phosphorylate	  
Thr32	   and	   SGK1	   additionally	   preferentially	   phosphorylates	   Ser315	   whereas	   Akt	   favours	  
Ser253	  (Brunet	  et	  al.,	  2001).	  I	  did	  not	  examine	  FoxO3	  Ser315	  phosphorylation	  and	  failed	  to	  
reliably	   detect	   total	   FoxO3	   protein.	   It	   would	   of	   course	   be	   valuable	   to	   monitor	   Ser315	  
phosphorylation	  and	  total	  FoxO3	  levels	  in	  the	  cells	  studied.	  Since	  the	  initial	  report	  of	  SGK1	  
mediated	   phosphorylation	   of	   FoxOs,	   a	   number	   of	   studies	   have	   reported	   similar	  
observations.	   For	   instance,	   over-­‐expression	   of	   SGK1	   has	   been	   reported	   to	   prevent	   de-­‐
attachment	   induced	  de-­‐phosphorylation	  of	   FoxO3	   Thr32	   (Shelly	   and	  Herrera,	   2002)	   and	  




FoxO3	   Thr32	   phosphorylation	   (You	   et	   al.,	   2004).	   Also,	   dexamethasone	   induced	   FoxO3	  
Thr32	  phosphorylation	  in	  breast	  epithelial	  cells	  has	  been	  shown	  to	  be	  partially	  blunted	  by	  
siRNA-­‐mediated	  knockdown	  of	  SGK1	  (Wu	  et	  al.,	  2006)	  and	  based	  on	  immunofluorescence	  
and	   reporter	   expression	   assays	   combined	   with	   SGK1	   knockdown,	   SGK1	   has	   been	  
suggested	   to	   regulate	   FoxO3	   in	   colon	   cancer	   cells	   (Dehner	   et	   al.,	   2008).	   In	   chemically	  
induced	  colon	  tumours	  isolated	  from	  wild	  type	  and	  SGK1	  knockout	  mice,	  tumours	  isolated	  
from	  the	  knockouts	  displayed	  higher	  total	  levels	  of	  FoxO3.	  The	  knockouts	  also	  were	  more	  
resistant	  to	  chemically	  induced	  carcinogenesis	  (Nasir	  et	  al.,	  2009).	  	  
Over-­‐expressed	   SGK1	   can	   also	   phosphorylate	   GSK3	   (Sakoda	   et	   al.,	   2003).	   Notably,	  
embryonic	  stem	  (ES)	  cells,	   in	  which	  activation	  of	  SGK,	  but	  not	  of	  Akt,	   is	  blunted	  due	  to	  a	  
PIF-­‐binding	  pocket	  mutation	  of	  PDK1,	  display	  normal	  phosphorylation	  of	  GSK3	  and	  FoxO1	  
indicating	  that	  Akt	  is	  likely	  to	  be	  the	  predominant	  kinase	  regulating	  the	  phosphorylation	  of	  
these	   substrates,	   at	   least	   in	   the	   absence	   of	   SGK	   activity	   (Collins	   et	   al.,	   2003).	   Based	   on	  
results	  presented	  in	  this	  chapter,	  Akt	  appears	  to	  be	  the	  key	  kinase	  for	  FoxO1/3	  Thr24/32	  
phosphorylation	   in	   the	   breast	   cancer	   cell	   lines	   examined.	   Further	   work	   is	   required	   to	  
address	   to	  which	   extinct	   SGKs	  might	   contribute	   to	   FoxO	  phosphorylation	   in	   various	   cell	  
types.	  
Given	  that	  SGK1	  did	  not	  appear	  to	  simply	  replace	  Akt	   in	  the	  Akt	   inhibitor	  resistant	  cells,	  
the	  mechanisms	   via	  which	   SGK1	  promotes	  proliferation	  of	   these	   cells	   remain	  unknown.	  
Many	  proposed	  SGK1	  substrates,	  some	  of	  which	  are	  discussed	  below,	  could	  contribute	  to	  




level	  is	  lacking.	  Nevertheless,	  a	  number	  of	  studies,	  as	  outlined	  above,	  have	  identified	  SGK1	  
as	  a	  promoter	  of	  survival	  and	  proliferation.	  	  
Over-­‐expressed	  SGK1	  phosphorylates	  mitogen-­‐activated	  protein	  kinase	  kinase	  4	  (MAP2K4)	  
(also	  known	  as	  JNKK1,	  MKK4	  SEK1)	  at	  Ser80	  (Kim	  et	  al.,	  2007).	  siRNA-­‐mediated	  knockdown	  
of	  SGK1	   in	  breast	  cancer	  cells	   impairs	  stress	   induced	  phosphorylation	  of	  SEK1	  and	  SEK1-­‐
JNK	  signalling,	   indicating	  that	  MAP2K4	  may	  be	  a	  bona	  fide	  substrate	  of	  SGK1	  (Kim	  et	  al.,	  
2007).	  	  The	  same	  site	  also	  phosphorylated	  by	  Akt	  (Park	  et	  al.,	  2002).	  SGK1	  or	  Akt	  mediated	  
phosphorylation	   of	   MAP2K4	   inhibits	   JNK	   activation	   thereby	   down-­‐regulating	   stress	  
activated	  MAPK	   signalling	   that	   promotes	   apoptosis	   (Kim	  et	   al.,	   2007;	   Park	   et	   al.,	   2002).	  
Inhibition	  of	  MAP2K4	  through	  SGK1	  may	  be	  one	  of	  the	  cytoprotective	  effects	  of	  SGK1	  and	  
it	  would	  be	  interesting	  to	  examine	  MAP2K4	  Ser80	  phosphorylation	  status	  in	  the	  cell	  lines	  
studied	  in	  this	  chapter.	  	  
SGK1	  has	  been	   linked	   to	  activation	  of	   the	  Nuclear	   factor-­‐κB	   (NF-­‐κB)	   transcription	   factor	  
via	  phosphorylation	  of	  the	  IκB	  kinase	  (IKK)	  complex	  that	  is	  important	  for	  the	  activation	  of	  
NF-­‐κB.	  NF-­‐κB	  regulates	  transcription	  of	  many	  pro-­‐proliferative	  and	  –survival	  genes	  (Karin,	  
2006).	  SGK1	  has	  been	  shown	  to	  phosphorylate	  the	  IκB	  kinase	  α	  (IKKα)	   in	  vitro	  and	  SGK1	  
knockdown	   reduces	   IGF1	   induced	   IKKα	   phosphorylation	   (Tai	   et	   al.,	   2009).	   Furthermore,	  
aldosterone	  stimulated	  IKKα/β	  dependent	  NF-­‐κB	  transcriptional	  activity	  in	  renal	  collecting	  
duct	  principal	  cells	  is	  partially	  sensitive	  to	  SGK1	  knockdown	  (Leroy	  et	  al.,	  2009)	  and	  NF-­‐κB	  
activation	  in	  response	  to	  mineralocorticoids	   is	  blunted	  in	  SGK1	  knockout	   lung	  fibroblasts	  
(Vallon	   et	   al.,	   2006).	   SGK1	   has	   also	   been	   suggested	   to	   mediate	   glucocorticoid	   induced	  




Recently	   the	   physiological	   importance	   of	   SGK1-­‐NF-­‐κB	   signalling	   for	   cell	   survival	   was	  
demonstrated	   in	  Xenopus	  embryos	  (Endo	  et	  al.,	  2011).	  SGK1	  knockdown	   in	  the	  embryos	  
caused	   defective	   development	   due	   to	   excessive	   apoptosis,	   a	   phenotype	   rescued	   by	   re-­‐
expression	   of	   SGK1.	   SGK1	   knockdown	   in	   the	   embryos	   was	   associated	   with	   decreased	  
expression	  of	  NF-­‐κB	  targets	  and	  increased	  expression	  of	  death-­‐inducing	  signalling	  complex	  
(DISC)	  components.	  Mechanistically	  SGK1	  is	  suggested	  to	  induce	  NF-­‐κB	  targets	  that	  cause	  
a	  subsequent	  decrease	  of	  DISC	  gene	  expression	  (Endo	  et	  al.,	  2011).	  
As	   previously	   discussed,	   SGK1	   regulates	   a	   large	   number	   of	   channels	   and	   transporters	  
[reviewed	  in	  (Lang	  and	  Shumilina,	  2013)].	  For	  instance,	  stimulation	  glucose	  and	  amino	  acid	  
transporters	   by	   SGK1	   may	   aid	   cancer	   cells	   to	   meet	   their	   energy	   demands.	   SGK1	   also	  
stimulates	   the	   potassium	   channel	   Kv1.3	   and	   growth	   factor	   stimulated	   activity	   of	  
potassium	   channels	   is	   correlated	   with	   cell	   proliferation	   in	   multiple	   cell	   lines,	   including	  
breast	   cancer	   cells	   and	   Kv1.3	   blockers	   have	   been	   reported	   to	   disrupt	   IGF1	   induced	  
proliferation	  (Gamper	  et	  al.,	  2002;	  Lang	  et	  al.,	  2006).	  K+	  channels	  are	  also	  critical	  for	  the	  
maintenance	  of	  negative	  membrane	  potential	   that	   is	  necessary	   for	  Ca2+	  entry	   into	  cells.	  
Ca2+	   is	   critical	   for	   many	   cellular	   functions	   such	   as	   progression	   through	   the	   cell	   cycle.	  
Intracellular	  Ca2+	  levels	  can	  be	  raised	  either	  through	  mobilisation	  from	  intracellular	  stores	  
or	   entry	   across	   the	   cell	   membrane	   (Roderick	   and	   Cook,	   2008).	   Release	   of	   Ca2+	   from	  
intracellular	   stores	   activates	   the	   Ca2+	   release-­‐activated	   Ca2+	   channel	   (CRAC)	   leading	   to	  
store	  operated	  Ca2+	  entry	   (SOCE).	  CRAC	   is	   composed	  of	  Orai	  pore	   forming	  subunits	   that	  
are	   activated	   by	   Ca2+	   sensing	   STIM1/2	   proteins	   upon	   depletion	   of	   Ca2+	   from	   the	  




(Lang	  et	  al.,	   2012)]	  and	  additionally	  Ora1	  and	  STIM1	  have	  been	   shown	   to	  be	  critical	   for	  
breast	  cancer	  cell	  migration	  and	  metastasis	   (Yang	  et	  al.,	  2009).	  SGK1	  stimulates	  SOCE	  at	  
least	  partially	  via	  inhibition	  of	  Nedd4-­‐2	  and	  via	  NF-­‐κB	  activation	  mediated	  transcriptional	  
up-­‐regulation	   of	  Ora1	   and	   STIM1	   expression	   (Eylenstein	   et	   al.,	   2011;	   Eylenstein	   et	   al.,	  
2012).	  SGK1	  knockout	  bone	  marrow	  derived	  mast	  cells	  (BMMC)	  express	  decreased	  levels	  
of	  Ora1	  and	  STIM1	  and	  only	  in	  wild	  type	  BMMCs	  stimulation	  of	  the	  PI3K	  pathway	  induces	  
nuclear	   translocation	   of	   the	   NF-­‐κB	   p65	   subunit	   and	   STIM1	   and	   Ora1	   gene	   expression	  
(Eylenstein	  et	  al.,	  2012).	  	  	  
SGK1	  is	  critical	  for	  the	  invasive	  ability	  of	  BT-­‐549	  cells	  
Metastasis	   represents	   the	   major	   cause	   of	   cancer-­‐related	   mortality	   and	   the	   ability	   to	  
migrate	   and	   invade	   is	   critical	   for	   metastasis.	   Cell	   migration	   and	   invasion	   are	   multistep	  
processes	   that	   involve	   the	   formation	   of	   F-­‐actin	   rich	   protrusions	   at	   the	   leading	   edge	  
followed	  by	  contraction	  of	  the	  trailing	  edge.	   Invasive	  protrusions	  (invadopodia)	  have	  the	  
capacity	  to	  degrade	  matrix	  and	  to	  thus	  overcome	  barriers	  of	  migration.	  Invadiopodia	  are	  
also	   involved	   in	   direction	   sensing	   and	   chemotaxis	   [reviewed	   in	   (Bravo-­‐Cordero	   et	   al.,	  
2012)].	  	  
Breast	  cancer	  cell	  migration	   in	  vitro	  and	  breast	  cancer	  metastasis	   in	  vivo	  are	  dependent	  
upon	   Ca2+	   signalling	   and	   in	   particular	   on	   Orai	   and	   STIM1	   that	   regulate	   focal	   adhesion	  
turnover	   in	  migrating	   cells	   (Yang	   et	   al.,	   2009).	  As	   discussed	   above,	  Ora1	   and	   STIM1	  are	  
regulated	   by	   SGK1	   (Eylenstein	   et	   al.,	   2011;	   Eylenstein	   et	   al.,	   2012).	   SGK1	   dependent	  
stimulation	   of	   SOCE	   is	   important	   for	   cell	  migration	   as	   SGK1	   deficient	   BMMCs	   display	   a	  




sarcoplasmic/endoplasmic	   reticulum	   Ca2+-­‐ATPase	   inhibitor	   that	   stimulates	   SOCE	   by	  
causing	   Ca2+	   release	   from	   intracellular	   stores	   (Eylenstein	   et	   al.,	   2011).	   Therefore	   it	   is	  
possible	  that	  the	   impaired	  ability	  of	  BT-­‐549	  breast	  cancer	  cells	   to	   invade	  following	  SGK1	  
depletion	  could	  be	  at	   least	  partially	  accounted	   for	  by	  disturbances	   to	  Ca2+	  uptake.	  SGK1	  
dependent	   migration	   and	   invasion	   have	   also	   recently	   also	   been	   linked	   to	   control	   of	  
vinculin	  phosphorylation	  and	  membrane	  androgen	  receptors	  (Schmidt	  et	  al.,	  2012a).	  
Akt	  can	  mediate	  NDRG1	  phosphorylation	  in	  the	  absence	  of	  significant	  SGK	  activity	  
Results	   presented	   in	   this	   chapter	   emphasise	   that	   caution	   is	   required	   when	   employing	  
NDRG1	  as	  a	  surrogate	  marker	   for	  SGK1	  activity.	   In	   the	  cell	   lines	  displaying	  high	   levels	  of	  
SGK1,	   NDRG1	   phosphorylation	   is	   insensitive	   to	   Akt	   inhibitors	   and	   knockdown	   of	   SGK1	  
inhibits	   NDRG1	   phosphorylation.	   By	   contrast,	   NDRG1	   phosphorylation	   is	   suppressed	   by	  
Akt	  inhibitors,	  but	  not	  by	  SGK1	  knockdown,	  in	  several	  cell	  lines	  displaying	  high	  Akt	  activity	  
and	  low	  SGK1	  indicating	  that,	  at	  least	  in	  these	  cells,	  Akt,	  rather	  than	  SGK1,	  phosphorylates	  
NDRG1.	  In	  agreement	  with	  previous	  studies	  (Murray	  et	  al.,	  2004),	  Akt	  can	  phosphorylate	  
NDRG1	  in	  vitro,	  albeit	  less	  efficiently	  than	  SGK1.	  SGK1	  has	  been	  reported	  to	  phosphorylate	  
NDRG1	   at	   three	   C-­‐terminal	   residues	   (Thr328,	   Ser330	   and	   Thr346)	   and	   NDRG2	   in	   the	  
corresponding	   residues.	   Phosphorylation	   of	   NDRG1	   by	   SGK1	   primes	   NDRG1	   for	   further	  
phosphorylation	  by	  GSK3	  at	  another	  three	  residues	  (Ser342,	  Ser352	  and	  Ser362)	  (Murray	  
et	  al.,	  2004).	  The	  precise	  molecular	  function	  of	  NDRG1	  is	  unknown	  and	  consequently	  the	  
role	  of	  its	  phosphorylation	  by	  SGK1/Akt	  and	  GSK3	  remains	  uncharacterised.	  	  
NDRG1	  expression	  is	  regulated	  via	  multiple	  mechanisms	  including	  up-­‐regulation	  by	  stress	  




al.,	   1998),	   DNA	   damage,	   elevated	   p53	   (Kurdistani	   et	   al.,	   1998),	   and	   hypoxia	   (Le	   and	  
Richardson,	  2004;	  Park	  et	  al.,	   2000)	  and	  down-­‐regulation	  by	   the	  proto-­‐oncogene	  N-­‐myc	  
(Shimono	  et	  al.,	  1999).	  Both	  oncogenic	  and	  tumour	  suppressive	  roles	  have	  been	  proposed	  
for	   NDRG1.	   Whilst	   decreased	   NDRG1	   expression	   has	   been	   described	   in	   a	   number	   of	  
tumour	   types,	   including	   breast	   cancer,	   increased	   NDRG1	   expression	   has	   also	   been	  
described	   in	   a	   number	   of	   cancers	   (Melotte	   et	   al.,	   2010).	   It	   is	   unclear	   whether	   these	  
contrasting	  observations	  could	  be	  due	  to	  tissue-­‐specific	  functions	  of	  NDRG1.	  Furthermore,	  
as	  the	  precise	  molecular	  function(s)	  of	  NDRG1	  remain	  poorly	  characterised,	  it	  is	  difficult	  to	  
correlate	  expression	  levels	  with	  cellular	  and	  physiological	  outcomes.	  	  
Several	   studies	   have	   correlated	   the	   levels	   of	   NDRG1	   expression	   with	   invasiveness	   and	  
proliferation	   (Melotte	   et	   al.,	   2010).	   For	   example,	   ectopic	   over-­‐expression	   of	   NDRG1	   in	  
MDA-­‐MB-­‐468	   breast	   cancer	   cells	   is	   reported	   to	   suppress	   in	   vitro	   invasiveness	  
(Bandyopadhyay	   et	   al.,	   2004)	   and	   ectopic	   over-­‐expression	   of	   NDRG1	   in	   cultured	  MCF-­‐7	  
breast	  cancer	  cells	  is	  reported	  to	  suppress	  proliferation	  rate	  (Kurdistani	  et	  al.,	  1998).	  The	  
effect	  of	  SGK1	  knockdown	  on	  reducing	  the	  proliferation	  rate	  of	  Akt	  inhibitor	  resistant	  cell	  
lines	   and	   the	   invasive	   ability	   of	   BT-­‐549	   cells	   could	   therefore	   be	   also	   at	   least	   partially	  
mediated	  via	  altered	  function	  of	  NDRG1	  due	  to	  its	  de-­‐phosphorylation.	  In	  future	  it	  would	  
be	  of	   interest	  to	  dissect	  the	  precise	  molecular	  role(s)	  that	  phosphorylation	  of	  NDRG1	  by	  
SGK1/Akt	   and	   GSK3	   plays.	   NDRG1	   has	   additionally	   been	   linked	   to	   regulation	   of	   NF-­‐κB	  
(Hosoi	  et	  al.,	  2009)	  and	  therefore	  the	  effects	  that	  accumulating	  evidence	  shows	  that	  SGK1	  






Elevated	  SGK1	  might	  be	  deployed	   to	  predict	   resistance	  of	  breast-­‐cancer-­‐derived	  cells	   to	  
Akt	   inhibitors.	  This	   finding	  will	  be	  of	   relevance	   to	   the	  numerous	  clinical	   trials	  evaluating	  
the	   therapeutic	  potential	  of	  Akt	   inhibitors	   for	   the	   treatment	  of	  cancer.	   In	   future	  work	   it	  
would	  be	   important	   to	  gauge	  whether	   the	  cancers	  most	   responsive	   to	  Akt	   inhibitors	  do	  
indeed	  possess	  low	  levels	  of	  SGK1	  protein/mRNA.	  
It	  would	  also	  be	   important	   to	  establish	  whether	  potent	  and	   selective	   inhibitors	  of	   SGK1	  
would	  inhibit	  proliferation	  of	  tumour	  cells	  displaying	  elevated	  SGK1	  activity.	  Moreover,	  as	  
Akt	   and	   SGK1	   are	   related	   kinases,	   it	  might	   be	   feasible	   to	   develop	   inhibitors	   that	   target	  
both	  enzymes.	  It	  should	  be	  noted	  that	  mechanisms	  other	  than	  enhanced	  SGK1	  activity	  are	  
also	   likely	   to	   contribute	   to	   the	   resistance	   to	   Akt	   inhibitors.	   Indeed,	   one	   of	   the	   Akt-­‐
inhibitor-­‐resistant	  cell	   lines	  analysed	   (MDA-­‐MB-­‐157)	  displayed	  both	   low	  SGK1	   levels	  and	  
NDRG1	  phosphorylation.	  This	  emphasises	  the	  importance	  of	  future	  work	  to	  profile	  a	  much	  
larger	   number	   of	   breast	   and	   other	   types	   of	   cancer	   cells	   to	   establish	   the	   proportion	   of	  
different	   tumours	   that	   are	   resistant	   to	  Akt	   inhibitors	   and	   also	   display	   elevated	   SGK1	   as	  
well	   as	   elevated	   NDRG1	   phosphorylation	   that	   is	   not	   suppressed	   by	   Akt	   inhibitors.	  
Monitoring	  NDRG1	  phosphorylation	   responses	   following	  administration	  of	  Akt	   inhibitors	  
could	  represent	  an	  effective	  general	  biomarker	  to	  assess	  SGK1	  activity	  in	  tumour	  cells.	  As	  
illustrated	   in	   Figure	   4.22,	   results	   presented	   in	   this	   chapter	   indicate	   that	   breast	   cancers	  
most	  likely	  to	  be	  sensitive	  to	  Akt	  inhibitors	  would	  be	  those	  displaying	  high	  Akt,	  low	  SGK1	  
mRNA/protein	  and	  in	  which	  phosphorylation	  of	  NDRG1	  is	  suppressed	  by	  Akt	  inhibitors.	  In	  




phosphorylation	  is	  not	  suppressed	  by	  Akt	  inhibitors	  are	  likely	  to	  be	  more	  resistant	  to	  Akt	  
inhibitors.	  Such	  tumours	  might	  be	  better	  treated	  with	  signal	  transduction	  suppressors	  that	  
reduce	   SGK1	   activity,	   such	   as	   mTOR	   inhibitors.	   Finally,	   more	   work	   is	   also	   needed	   to	  
determine	  whether	  administration	  of	  steroids	  to	  patients	  has	  the	  potential	  to	  induce	  SGK1	  
expression	  and	  cause	  resistance	  to	  Akt	  inhibitors.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Figure	   4.22	   Differential	   sensitivity	   of	   NDRG1	   phosphorylation	   to	   Akt	   inhibitors	   in	   Akt	  








































5. Sustained	  Akt	  inhibition	  leads	  to	  bi-­‐phasic	  up-­‐regulation	  
of	  SGK3	  
5.1. Introduction	  
Results	  presented	   in	  Chapter	  4	  demonstrate	  that	  breast	  cancer	  cells	  expressing	  elevated	  
levels	   of	   SGK1	  protein	   and	  mRNA	  are	   intrinsically	   resistant	   to	  Akt	   inhibitors	   and	   that	   in	  
these	   cells	   SGK1	   is	   a	   key	   proliferation	   driver.	  Moreover,	   results	   presented	   in	   Chapter	   4	  
also	   indicate	   that	  Akt	   can	  mediate	  NDRG1	  phosphorylation	   in	   the	  absence	  of	   significant	  
SGK	  activity.	  Careful	  consideration	  of	  feedback	  regulation	  that	  governs	  signal	  transduction	  
cascades	   is	   emerging	   as	   a	   critical	   area	   of	   cancer	   drug	   discovery.	   Comprehensive	  
understanding	   of	   the	   long-­‐term	   consequences	   of	   inhibiting	   components	   of	   the	   PI3K	  
pathway	   will	   aid	   in	   rational	   development	   of	   therapies	   that	   effectively	   turn	   off	   this	  
signalling	  network	  and	  minimise	  the	  up-­‐regulation	  of	  intrinsic	  resistance	  mechanisms.	  Due	  
to	   their	   similarities,	   SGK	   family	  members	   are	   obvious	   candidates	   for	   kinases	   that	   could	  
compensate	   for	   the	   loss	   of	   Akt.	   Therefore	   I	   decided	   to	   study	   whether	   chronic	   Akt	  
inhibition	  could	  lead	  to	  emergence	  of	  compensatory	  signalling	  mediated	  by	  SGKs.	  
In	  this	  chapter	  I	  describe	  a	  novel	  method	  of	  feedback	  regulation	  that	  operates	  within	  the	  
PI3K	  pathway.	  I	  show	  that	  in	  Akt	  inhibitor	  sensitive	  cells	  sustained	  Akt	  inhibition	  leads	  to	  
recovery	   of	  NDRG1	  phosphorylation,	  which	   is	   due	   to	   an	   elevation	   in	   the	   levels	   and	   the	  
catalytic	   activity	   of	   SGK3.	   I	   present	   evidence	   indicating	   that	   downstream	   of	   Akt	   the	  





exposure	   to	   sustained	  Akt	   inhibition	   reduces	   the	  efficiency	  of	  Akt	   inhibitors	   in	   cells	   and	  
present	   data	   that	   implies	   that	   the	   induction	  of	   SGK3	   is	   responsible	   for	   the	   reduction	   in	  
cells’	  sensitivity	  to	  Akt	  inhibitors.	  	  
Finally,	   I	   also	   present	   preliminary	   data	   implying	   that	   the	   model	   of	   activation	   of	  
endogenous	  SGK3	  by	  PI3K,	  PDK1	  and	  mTORC2,	  as	  outlined	  in	  the	  introduction,	  may	  need	  
to	  be	  re-­‐evaluated.	  mTORC2	  mediated	  HM-­‐site	  phosphorylation	   is	  not	  necessary	   for	   the	  
activation	   of	   Akt	   and	   accordingly	   Akt	   is	   insensitive	   to	   chronic	   mTORC1/2	   inhibition.	   In	  
contrast,	   several	   studies	   have	   demonstrated	   that	   for	   SGK	   and	   S6K	   HM-­‐site	  
phosphorylation	  is	  required	  for	  subsequent	  T-­‐loop	  phosphorylation	  and	  activation	  (Pearce	  
et	  al.,	  2010b).	  This	  model	  is	  based	  upon	  studies	  that	  have	  analysed	  SGK1	  isoform.	  Unlike	  
SGK1,	  SGK3,	  however,	  contains	  a	  phosphoinositide	  binding	  PX	  domain.	  Interestingly,	  data	  
that	   I	   present	   in	   this	   Chapter	   suggests	   that	   SGK3	   is	   insensitive	   to	   long	   term	  mTORC1/2	  
inhibition.	   This	   suggests	   that	   the	   PX	   domain	   of	   SGK3	   may	   render	   activation	   of	   SGK3	  
analogous	  to	  that	  of	  the	  PH	  domain	  containing	  Akt.	  	  
	  
5.2. Results	  
5.2.1. Sustained	  Akt	   inhibition	   causes	   recovery	  of	  NDRG1	  phosphorylation	  
and	  elevation	  of	  SGK3	  	  
In	   order	   to	   investigate	   whether	   treatment	   of	   Akt	   inhibitor	   sensitive	   cells	   with	   Akt	  
inhibitors	   for	   a	   long	   period	   of	   time	   could	   induce	   activation	   of	   SGK	   isoforms,	   BT-­‐474,	  





days)	   (Figure	   5.1).	   Long-­‐term	   treatment	   of	   the	   three	   cell	   lines	  with	   the	   two	   structurally	  
and	  mechanistically	  distinct	  Akt	  inhibitors,	  MK-­‐2206	  and	  AZD5363,	  strikingly	  revealed	  that	  
whilst	   Akt	   remained	   inhibited	   throughout	   the	   experiment,	   as	   assessed	  by	   sustained	  de-­‐
phosphorylation	   of	   the	   Akt	   substrate	   PRAS40,	   phosphorylation	   of	   NDRG1	   protein	   was	  
sensitive	  to	  an	  acute	  one	  hour	  treatment	  with	  both	  Akt	  inhibitors	  but	  was	  largely	  restored	  
by	  24	  hours	  and	  was	  completely	  insensitive	  to	  five	  and	  ten	  days	  of	  Akt	  inhibition	  (Figure	  
5.1).	   Furthermore,	   as	   expected,	   MK-­‐2206	   induced	   sustained	   de-­‐phosphorylation	   of	   Akt	  
Thr308	   and	   Ser473,	   whilst	   AZD5363	   induced	   sustained	   hyper-­‐phosphorylation	   at	   both	  
sites	  (Figure	  5.1).	  Strikingly,	  monitoring	  levels	  of	  SGK	  isoforms	  throughout	  the	  time-­‐course	  
revealed	  a	  clear	  increase	  in	  the	  levels	  of	  SGK3	  following	  five	  and	  ten	  days	  of	  Akt	  inhibition.	  








Figure	  5.1	  Sustained	  Akt	   inhibition	   leads	  to	  recovery	  of	  NDRG1	  phosphorylation	  and	   is	  
associated	  with	  elevation	  of	  SGK3	  levels	  in	  Akt	  inhibitor	  sensitive	  cell	  lines	  
(A)	  The	  indicated	  Akt	  inhibitor	  sensitive	  cells	  were	  treated	  with	  MK-­‐2206	  (0.3	  µM	  for	  BT-­‐
474	  and	  1	  µM	  for	  CAMA-­‐1	  and	  ZR-­‐75-­‐1	  cells)	  for	  the	  indicated	  time	  points	  or	  for	  10	  days	  
with	   DMSO.	   All	   cells	   were	   seeded	   at	   the	   same	   time	   and	   treatment	   commenced	   in	   a	  
staggered	  fashion.	  For	  DMSO	  control,	  24	  hour	  and	  1	  hour	  samples	  approximately	  1x104,	  
for	  5	  day	  treatment	  approximately	  1x105	  and	  for	  10	  day	  treatment	  approximately	  1x106	  
cells	   were	   seeded	   per	   well	   of	   a	   6-­‐well	   plate.	   Growth	  medium	  was	   replaced	   with	   fresh	  
medium	  containing	  either	  DMSO	  or	  inhibitor	  on	  days	  3,	  6	  and	  8.	  Cells	  were	  harvested	  all	  
at	   the	   same	   time	   at	   approximately	   80%	   confluency	   and	   the	   lysates	   were	   analysed	   by	  
immunoblotting	  (IB)	  with	  the	  indicated	  antibodies.	  (B)	  As	  in	  (A)	  except	  cells	  were	  treated	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5.2.2. Akt	  inhibition	  up-­‐regulates	  SGK3	  protein	  and	  mRNA	  levels	  
In	  order	  to	  further	  analyse	  the	  increase	  in	  SGK3	  protein	  levels,	  ZR-­‐75-­‐1	  cells	  were	  treated	  
with	   the	   two	  distinct	  Akt	   inhibitors	   for	   0,	   2,	   4,	   6,	   8	   and	  10	  days	   and	   the	   levels	  of	   SGK3	  
protein	  were	  monitored	  by	  quantitative	   immunoblotting	  using	   Li-­‐Cor	   system.	   This	   time-­‐
course	  analysis	  confirmed	  the	  initial	  observation	  that	  NDRG1	  phosphorylation	  is	  resistant	  
to	   chronic	   Akt	   inhibition	   and	   that	   sustained	   Akt	   inhibition	   is	   associated	   with	   increased	  
SGK3	   levels	   (Figure	   5.2A-­‐B).	   Throughout	   the	   time-­‐course	   Akt	   remained	   inhibited,	   as	  
assessed	  by	  sustained	  de-­‐phosphorylation	  of	  the	  Akt	  substrates	  PRAS40	  and	  FoxO1/3,	  and	  
sustained	   down-­‐regulation	   of	   mTORC1	   signalling,	   as	   monitored	   by	   following	   S6	  
phosphorylation	   (Figure	   5.2A-­‐B).	   Both	   Akt	   inhibitors	   led	   to	   approximately	   two-­‐fold	   up-­‐
regulation	  of	  SGK3	  protein	  levels	  after	  two	  days	  of	  Akt	   inhibition	  and	  by	  four/six	  days	  of	  
Akt	  inhibition	  SGK3	  protein	  up-­‐regulation	  was	  around	  four-­‐fold	  and	  it	  plateaued	  at	  these	  
levels.	   Levels	   of	   both	   SGK1	   and	   SGK2	   remained	   unaltered	   throughout	   the	   experiment	  
(Figure	  5.2A-­‐B).	  	  
In	   parallel,	   qRT-­‐PCR	   analysis	  was	   undertaken	   to	   assess	   the	   levels	   of	   SGK	   isoform	  mRNA	  
levels	  following	  sustained	  Akt	  inhibition.	  Following	  two	  days	  of	  Akt	  inhibition	  SGK3	  mRNA	  
levels	   were	   elevated	   by	   approximately	   two-­‐to-­‐three-­‐fold.	   At	   later	   time-­‐points	  
approximately	   five-­‐to-­‐eight-­‐fold	   up-­‐regulation	   in	   comparison	   to	   basal	   (DMSO	   control)	  
levels	  was	  detected.	  mRNA	  levels	  of	  the	  related	  SGK1	  and	  SGK2	  isoforms	  were	  not	  altered	  






	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  5.2	  Chronic	  Akt	  inhibition	  up-­‐regulates	  SGK3	  protein	  levels	  approximately	  4-­‐fold	  
(A)	  ZR-­‐75-­‐1	  cells	  seeded	  onto	  6-­‐well	  plates	  in	  duplicates	  were	  treated	  with	  1	  µM	  MK-­‐2206	  
for	  2,	  4,	  6,	  8	  or	  10	  days	  or	  with	  DMSO	  for	  10	  days.	  All	  cells	  were	  seeded	  at	  the	  same	  time	  
and	   treatment	   commenced	   in	   a	   staggered	   fashion.	   Growth	  medium	  was	   replaced	   with	  
fresh	   inhibitor	  or	  DMSO	  containing	  medium	  on	  days	  3	  and	  8.	  On	  day	  5	  all	  cells	  were	  re-­‐
plated	  in	  the	  presence	  of	  MK-­‐2206	  or	  DMSO.	  All	  samples	  (approximately	  80%	  confluent)	  
were	  harvested	  at	   the	  same	  time.	  For	  SGK3	  and	  GAPDH	  quantitative	  Li-­‐Cor	   immunoblot	  
(IB)	   analysis	   was	   undertaken	   and	   the	   data	   are	   presented	   as	   relative	   SGK3	   levels	   over	  
GAPDH	   levels	  ±	  S.D.	  Basal	   levels	  were	  set	   to	  1.	   	   (B)	  as	   in	   (A)	  except	  1	  µM	  AZD5363	  was	  
used. (C)	  as	  in	  (A)	  except	  total	  mRNA	  was	  isolated	  and	  SGK	  mRNA	  levels	  were	  determined	  
by	  qRT-­‐PCR.	   The	  data	  were	  normalised	   to	   an	   internal	   18S	   control	   and	  are	  presented	  as	  
relative	  levels	  in	  comparison	  with	  control	  cells	  (DMSO).	  Results	  represent	  the	  means	  ±	  S.D	  





















































































































































5.2.3. SGK3	  levels	  return	  to	  basal	  following	  re-­‐activation	  of	  Akt	  
Next	  an	  inhibitor	  washout	  experiment	  was	  performed	  in	  order	  to	  assess	  the	  effect	  of	  re-­‐
activating	  Akt	   on	   SGK3	   levels.	   ZR-­‐75-­‐1	   cells	  were	   first	   treated	  with	   the	  ATP-­‐competitive	  
Akt	  inhibitor	  AZD5363	  for	  four	  days	  in	  order	  to	  up-­‐regulate	  SGK3.	  The	  inhibitor	  was	  then	  
washed	  out	  and	   fresh	  growth	  medium	   lacking	   the	   inhibitor	  was	  added	   for	  2	  –	  72	  hours	  
(Figure	  5.3).	  This	  revealed	  that	  Akt	  was	  rapidly	  re-­‐activated	  as	  phosphorylation	  of	  the	  Akt	  
substrate	   PRAS40	   reached	   normal	   levels	   already	   two	   hours	   after	   the	   inhibitor	   was	  
removed.	   Recovery	   of	   mTORC1	   activity,	   however,	   took	   longer	   and,	   as	   assessed	   by	   S6	  
phosphorylation,	   was	   apparent	   12	   hours	   after	   the	   inhibitor	   was	   removed.	   SGK3	   levels	  
were	   partially	   decreased	   12	   hours	   after	   the	   inhibitor	   washout	   and	   had	   returned	   to	  
approximately	  basal	  levels	  (similar	  to	  DMSO	  control)	  24	  hours	  after	  the	  washout.	  Notably,	  
AZD5363	  induced	  Akt	  hyper-­‐phosphorylation	  returned	  to	  basal	  levels	  only	  48	  hours	  after	  
the	  washout	   (Figure	  5.3).	  As	   SGK3	   levels	   return	   to	  basal	   following	  Akt	   re-­‐activation,	   the	  






	  	  	  	  	  	  	  	  	  	   	  
Figure	  5.3	  SGK3	  up-­‐regulation	  by	  Akt	  inhibition	  is	  reversible	  
ZR-­‐75-­‐1	  cells	  grown	  on	  6-­‐well	  plates	  were	  pre-­‐treated	  with	  1	  µM	  AZD5363	  for	  4	  days	  to	  
up-­‐regulate	   SGK3	   levels.	   In	   parallel	   control	   cells	   were	   maintained	   in	   the	   presence	   of	  
DMSO.	   For	   inhibitor	   pre-­‐treated	   wells	   approximately	   5x105	   and	   for	   DMSO	   pre-­‐treated	  
wells	   approximately	  1x105	   cells	  were	   seeded	  per	  well.	   Inhibitor	   containing	  medium	  was	  
replaced	  with	  fresh	  growth	  medium	  lacking	  the	  inhibitor	  for	  2,	  4,	  12,	  24,	  48	  or	  72	  hours.	  
For	   cells	  with	  0	  hour	  washout	  growth	  medium	  was	   replaced	  with	   fresh	  growth	  medium	  
containing	   1	  µM	  AZD5363	   for	   72	   hours.	   All	   cells	   were	   lysed	   at	   the	   same	   time	   and	   the	  
lysates	  were	  analysed	  with	  the	  indicated	  antibodies	  by	  immunoblotting	  (IB).	  	  
	  
5.2.4. Chronic	  Akt	  inhibition	  leads	  to	  increased	  SGK3	  catalytic	  activity	  	  
As	  shown	  in	  Figure	  5.1,	  whilst	  in	  Akt	  inhibitor	  sensitive	  cells	  NDRG1	  phosphorylation	  was	  
sensitive	  to	  an	  acute	  one-­‐hour	  treatment	  with	  Akt	  inhibitors,	  it	  had	  started	  recovering	  by	  
24	   hours	   of	   Akt	   inhibition.	   Elevated	   SGK3	   protein	   levels	   were,	   however,	   only	   detected	  
following	  five	  and	  ten	  days	  of	  Akt	  inhibition	  (Figure	  5.1)	  and	  more	  careful	  analysis	  of	  SGK3	  
up-­‐regulation	  revealed	  that	  maximum	  levels	  of	  SGK3	  protein	  were	  reached	  following	  four-­‐







































to-­‐six	  days	  of	  Akt	  inhibition	  (Figure	  5.2).	  To	  determine	  whether	  Akt	  inhibition	  modulated	  
SGK3	   in	   a	   biphasic	  manner	  by	  1)	   first	   leading	   to	   elevated	   SGK3	  activity	   and	  2)	   secondly	  
leading	  to	  elevated	  SGK3	  levels,	  the	  catalytic	  activity	  of	  endogenous	  SGK3	  was	  monitored	  
following	  Akt	  inhibition	  for	  1,	  12,	  24,	  48	  and	  96	  hours	  (Figure	  5.4).	  Immunoprecipitation	  of	  
endogenous	   SGK3	   also	   enabled	   the	   detection	   of	   phospho-­‐SGK3.	   The	   two	   key	  
phosphorylation	   sites	   on	   SGK3	   are	   the	   HM-­‐site	   Ser486,	   which	   is	   phosphorylated	   by	  
mTORC2,	  and	  the	  T-­‐loop	  site	  Thr320,	  which	  is	  phosphorylated	  by	  PDK1.	  	  
Acute	   (one	   hour)	   Akt	   inhibition	   with	   MK-­‐2206	   did	   not	   alter	   SGK3	   kinase	   activity,	  
phosphorylation	   or	   protein	   levels	   but	   inhibited	   NDRG1	   phosphorylation	   (Figure	   5.4).	  
Following	  12	  and	  24	  hours	  of	  Akt	  inhibition	  a	  moderate,	  approximately	  two-­‐fold,	  increase	  
in	  SGK3	  kinase	  activity	  was	  observed	  and	  the	  increase	  in	  SGK3	  activity	  was	  accompanied	  
with	   a	  moderate	   increase	   in	   both	  HM-­‐site	   and	   T-­‐loop	  phosphorylation	   of	   SGK3	  without	  
marked	  effects	  on	  total	  SGK3	  levels	  (Figure	  5.4).	  Furthermore,	  as	  previously	  shown	  for	  the	  
24-­‐hour	   treatment	   (Figure	   5.1),	   at	   these	   time	   points	   a	   partial	   recovery	   of	   NDRG1	  
phosphorylation	  was	  also	  observed.	  Following	  48	  and	  96	  hours	  of	  Akt	   inhibition	  a	  more	  
substantial	   increase	   in	   SGK3	   kinase	   activity	   was	   detected	   (approximately	   three-­‐to-­‐four-­‐
fold)	  accompanied	  by	  markedly	  increased	  levels	  of	  SGK3	  total	  protein	  as	  well	  as	  SGK3	  HM-­‐
site	   and	   T-­‐loop	  phosphorylation.	  Moreover,	   following	   48	   and	   96	   hours	   of	   Akt	   inhibition	  
levels	  of	  NDRG1	  phosphorylation	  had	  fully	  recovered.	  Phosphorylation	  of	  Akt	  itself	  and	  of	  







Figure	  5.4	  Sustained	  Akt	  inhibition	  stimulates	  SGK3	  catalytic	  activity	  	  
ZR-­‐75-­‐1	   cells	  were	   seeded	  onto	   15-­‐cm	  dishes,	   allowed	   to	   adhere	  overnight	   and	   treated	  
with	  1	  µM	  MK-­‐2206	  for	  the	  indicated	  time	  points	  or	  with	  DMSO	  for	  96	  hours.	  For	  DMSO	  
control,	   1,	   12	   and	   24	   hour	   samples	   approximately	   1x106	   and	   for	   48	   hour	   and	   96	   hour	  
samples	  approximately	  1x107	  and	  2x107,respectively	  cells	  were	  seeded	  per	  dish.	  All	  cells	  
were	   approximately	   80%	   confluent	   at	   the	   time	   of	   lysis.	   Endogenous	   SGK3	   was	  
immunoprecipitated	   (IP)	   from	   2	   mg	   of	   fresh	   lysate	   and	   SGK3	   catalytic	   activity	   was	  
measured	  using	  Crosstide	  substrate	  peptide.	  Results	  represent	  the	  means	  ±	  S.E.M.	  of	  two	  
independent	   samples	   each	   assayed	   in	   duplicates.	   Lysates	   and	   immunoprecipitates	  were	  













































mTORC2	   inhibition	   is	   expected	   to	   suppress	   SGK3	   HM-­‐site	   phosphorylation	   leading	   to	  
subsequent	   loss	   of	   also	   SGK3	   T-­‐loop	   phosphorylation	   and	   SGK3	   activity	   (Biondi	   et	   al.,	  
2001;	  Garcia-­‐Martinez	  and	  Alessi,	  2008;	  Kobayashi	  and	  Cohen,	  1999).	  To	   test	   this,	   SGK3	  
activity	  and	  levels	  were	  stimulated	  by	  chronic	  Akt	  inhibition	  and	  the	  sensitivity	  of	  SGK3	  to	  
1-­‐hour	  treatment	  with	  mTOR	  inhibitor	  AZD8055	  was	  assessed	  (Figure	  5.5).	  96	  hours	  of	  Akt	  
inhibition	  in	  ZR-­‐75-­‐1	  cells	  with	  MK-­‐2206	  markedly	  increased	  SGK3	  activity,	  T-­‐loop	  and	  HM-­‐
site	   phosphorylation	   and	   total	   levels	   as	   well	   as	   induced	   Akt	   inhibitor	   resistant	   NDRG1	  
phosphorylation	  (Figure	  5.5).	  	  Acute	  treatment	  with	  AZD8055	  reduced	  SGK3	  kinase	  activity	  






	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  5.5	  Increase	  in	  kinase	  activity	  is	  sensitive	  to	  acute	  mTOR	  kinase	  inhibition	  
ZR-­‐75-­‐1	   cells	  were	   seeded	  onto	   15-­‐cm	  dishes,	   allowed	   to	   adhere	  overnight	   and	   treated	  
with	  1	  µM	  MK-­‐2206	  or	  DMSO	  for	  96	  hours.	  Prior	  to	  lysis	  MK-­‐2206	  pre-­‐treated	  cells	  were	  
exposed	   to	   1	   µM	   AZD8055	   or	   DMSO	   for	   1	   hour.	   Endogenous	   SGK3	   was	  
immunoprecipitated	   (IP)	   from	   2	   mg	   of	   fresh	   lysate	   and	   SGK3	   catalytic	   activity	   was	  
measured	  using	  Crosstide	  substrate	  peptide.	  Results	  represent	  the	  means	  ±	  S.E.M.	  of	  two	  
independent	   samples	   each	   assayed	   in	   duplicate.	   Lysates	   and	   immunoprecipitates	   were	  
analysed	  by	  immunoblotting	  (IB)	  with	  the	  indicated	  antibodies.	  	  	  
	  













































5.2.5. Akt	   inhibitor	   resistant	   NDRG1	   phosphorylation	   is	   sensitive	   to	  
inhibition	  of	  the	  up-­‐stream	  regulators	  of	  SGKs	  
In	  Akt	  inhibitor	  sensitive	  cells	  a	  striking	  correlation	  between	  the	  increase	  in	  SGK3	  activity	  
and	   the	   emergence	   of	   Akt	   inhibitor	   resistant	   phosphorylation	   of	   NDRG1	   was	   observed	  
(Figure	   5.1;	   Figure	   5.4)	   suggesting	   that	   in	   these	   cells	   SGK3	   could	   be	   the	   kinase	   that	  
phosphorylates	   NDRG1	   in	   the	   absence	   of	   Akt	   activity.	   To	   address	   this	   possibility,	   the	  
sensitivity	   of	   Akt	   inhibitor	   resistant	   NDRG1	   phosphorylation	   to	   inhibition	   of	   the	   PI3K	  
pathway	   at	   different	   nodes	   was	   assessed	   (Figure	   5.6).	   Akt	   inhibitor	   resistant	   NDRG1	  
phosphorylation,	   as	  well	   as	   SGK3	   activation,	  was	   induced	  by	   10	   days	   of	   treatment	  with	  
MK-­‐2206	  in	  CAMA-­‐1	  and	  ZR-­‐75-­‐1	  cells.	  Akt	  inhibitor	  resistant	  NDRG1	  phosphorylation	  was	  
in	  both	  cell	  lines	  sensitive	  to	  one-­‐hour	  treatment	  with	  the	  PDK1	  inhibitor	  GSK2334470	  and	  
mTOR	   inhibitor	   AZD8055	   but	   not	   to	   the	   mTORC1	   selective	   inhibitor	   rapamycin	   (Figure	  
5.6).	   These	   results	   are	   consistent	   with	   an	   SGK	   isoform	   being	   responsible	   for	  mediating	  
phosphorylation	  of	  NDRG1	  in	  these	  cells	  in	  the	  absence	  of	  Akt	  activity.	  In	  contrast	  to	  the	  
PDK1	   and	   mTOR	   inhibitors,	   the	   Class	   I	   PI3K	   inhibitor	   GDC-­‐0941	   caused	   only	   a	   partial	  







Figure	  5.6	  Akt	  inhibitor	  resistant	  NDRG1	  phosphorylation	  is	  sensitive	  to	  inhibition	  of	  the	  
upstream	  regulators	  of	  SGK	  	  
CAMA-­‐1	  and	  ZR-­‐75-­‐1	  cells	  were	  maintained	  in	  the	  presence	  of	  1	  µM	  MK-­‐2206	  or	  DMSO	  for	  
10	  days	  prior	  to	  seeding	  onto	  6-­‐well	  plates	  in	  the	  presence	  of	  1	  µM	  MK-­‐2206	  or	  DMSO.	  48	  
hours	  later	  DMSO	  pre-­‐treated	  cells	  were	  exposed	  to	  1	  µM	  MK-­‐2206	  or	  DMSO	  for	  1	  hour	  
and	  MK-­‐2206	  pre-­‐treated	  cells	  were	  exposed	  to	  1	  µM	  GDC-­‐0941,	  1	  µM	  GSK-­‐233470,	  1	  µM	  
AZD8055,	   100	   nM	   Rapamycin	   or	   DMSO	   for	   1	   hour.	   Lysates	   were	   analysed	   by	  
immunoblotting	  (IB)	  with	  the	  indicated	  antibodies.	  	  
	  
5.2.6. Akt	  inhibitor	  resistant	  NDRG1	  phosphorylation	  is	  mediated	  by	  SGK3	  	  
The	   sensitivity	   of	   Akt	   inhibitor	   resistant	   NDRG1	   phosphorylation	   to	   the	  mTOR	   catalytic	  
inhibitor	   AZD8055	   and	   to	   the	   PDK1	   inhibitor	   GSK2334470,	   but	   not	   to	   the	   mTORC1	  
inhibitor	   rapamycin,	   is	   consistent	  with	  NDRG1	   phosphorylation	   being	  mediated	   by	   SGK,	  





















































































































Akt	   inhibitor	   resistant	   NDRG1	   phosphorylation	   and	   up-­‐regulation	   of	   SGK3	   and	   to	  
determine	  whether	  SGK3	  is	  the	  SGK	  isoform	  responsible	  for	  phosphorylation	  of	  NDRG1	  in	  
the	  absence	  of	  Akt	  activity,	  a	  number	  of	  SGK3	  shRNAs	  were	  tested.	  SGK3	  shRNAs	  #B,	  #D	  
and	  #E	  were	  most	  efficient	  in	  reducing	  the	  levels	  of	  SGK3	  protein	  in	  both	  CAMA-­‐1	  and	  ZR-­‐
75-­‐1	  cells	  (Figure	  5.7)	  and	  these	  shRNAs	  were	  selected	  for	  further	  experiments.	  	  
	  
	  	  	   	  
Figure	  5.7	  Evaluation	  of	  SGK3	  shRNAs	  
CAMA-­‐1	  and	  ZR-­‐75-­‐1	  cells	  were	   infected	  with	  SGK3	  or	  scrambled	  shRNAs.	  72	  hours	  post	  
infection	  cell	  lysates	  were	  analysed	  by	  immunoblotting	  (IB)	  with	  the	  indicated	  antibodies.	  
	  
To	  test	  whether	  SGK3	  mediated	  phosphorylation	  of	  NDRG1	  in	  the	  absence	  of	  Akt	  activity,	  
SGK3	  was	  up-­‐regulated	  in	  CAMA-­‐1	  and	  ZR-­‐75-­‐1	  cells	  by	  chronic	  Akt	  inhibition	  with	  either	  
MK-­‐2206	  (Figure	  5.8A,C)	  or	  AZD5363	  (Figure	  5.8B,D)	  and	  the	  cells	  were	  then	  infected	  with	  
either	   scrambled	   or	   SGK3	   shRNAs.	   The	   elevated	   SGK3	   protein	   was	   efficiently	   knocked	  
down	  to	  undetectable	  levels	  with	  each	  of	  the	  three	  independent	  SGK3	  shRNAs	  and	  SGK3	  
knockdown	   was	   accompanied	   by	   complete	   loss	   of	   Akt	   inhibitor	   resistant	   NDRG1	  

























































	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  5.8	  Akt	  inhibitor	  resistant	  NDRG1	  phosphorylation	  is	  mediated	  by	  SGK3	  
(A,	  C)	  CAMA-­‐1	  and	  ZR-­‐75-­‐1	   cells	  were	  maintained	   in	   the	  presence	  of	  1	  µM	  MK-­‐2206	  or	  
DMSO	   for	   10	   days	   prior	   to	   infection	   with	   scrambled	   or	   SGK3	   shRNAs	   in	   the	   sustained	  
presence	  of	  either	  1	  µM	  MK-­‐2206	  or	  DMSO.	  72	  hours	  post	   infection	  DMSO	  pre-­‐treated	  
cells	  were	  exposed	  to	  1	  µM	  MK-­‐2206	  or	  DMSO	  for	  1	  hour	  and	  MK-­‐2206	  pre-­‐treated	  cells	  
were	  exposed	  to	  DMSO	  for	  1	  hour.	  Lysates	  were	  analysed	  by	  immunoblotting	  (IB)	  with	  the	  





















































































































































































Next	  the	  effect	  of	  SGK3	  knockdown	  on	  basal	  NDRG1	  phosphorylation	  in	  CAMA-­‐1	  and	  ZR-­‐
75-­‐1	  cells	  was	  assessed.	  SGK3	  was	  knocked	  down	  with	  the	  three	  independent	  shRNAs	  in	  
cells	  pre-­‐treated	  for	  48	  hours	  with	  either	  DMSO	  (active	  Akt)	  or	  MK-­‐2206	  (in-­‐active	  Akt).	  In	  
the	   presence	   of	   Akt	   activity	   SGK3	   knockdown	   did	   not	   affect	   NDRG1	   phosphorylation	   in	  
CAMA-­‐1	  cells,	   in	  contrast	  Akt	  inhibitor	  resistant	  NDRG1	  phosphorylation	  was	  sensitive	  to	  
SGK3	  knockdown	  (Figure	  5.9A).	   	   In	  ZR-­‐75-­‐1	  cells	  SGK3	  knockdown	  had	  a	  partial	  effect	  on	  
basal	   NDRG1	   phosphorylation	   and	   induced	   complete	   loss	   of	   NDRG1	   phosphorylation	   in	  
cells	   treated	  with	  MK-­‐2206	   for	  48	  hours	   (Figure	  5.9B).	  This	  observation	   indicates	   that	   in	  
ZR-­‐75-­‐1	  cells	  basal	  NDRG1	  phosphorylation	   is	   likely	   to	  be	  mediated	  by	  a	  combination	  of	  
Akt	  and	  SGK3.	  SGK3	  knockdown	  did	  not	  affect	  phosphorylation	  of	  Akt	  or	  the	  Akt	  substrate	  
PRAS40	  in	  either	  of	  the	  cell	  lines	  studied	  (Figure	  5.9).	  
	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  5.9	  Effect	  of	  SGK3	  knockdown	  on	  basal	  NDRG1	  phosphorylation	  	  
48	  hours	  post	   infection	  with	  scrambled	  or	  SGK3	  shRNAs	  the	   indicated	  cells	  were	  seeded	  
onto	  6-­‐well	  plates	  and	  allowed	  to	  adhere	  overnight	  prior	  to	  exposure	  to	  1	  µM	  MK-­‐2206	  or	  
























































































To	  verify	  that	  the	  loss	  of	  Akt	  inhibitor	  resistant	  NDRG1	  phosphorylation	  was	  due	  to	  SGK3	  
knockdown,	  a	  rescue	  experiment	  was	  carried	  out.	  ZR-­‐75-­‐1	  cells	  were	  transduced	  to	  stably	  
express	  HA-­‐tagged	  wild	  type	  (wt)	  and	  kinase	  inactive	  (ki)	  SGK3	  that	  was	  engineered	  to	  be	  
resistant	  to	  SGK3	  shRNA	  #D.	  The	  resistant	  construct	  possesses	  three	  silent	  mutations	  that	  
alter	  the	  nucleotide	  but	  not	  the	  expressed	  amino	  acid	  sequence	  thus	  making	  the	  construct	  
resistant	  to	  RNA	  interference.	   In	  ZR-­‐75-­‐1	  cells	  stably	  expressing	  wild	  type	  but	  not	  kinase	  
inactive	   shRNA	   resistant	   SGK3,	   Akt	   inhibitor	   resistant	   NDRG1	   phosphorylation	   was	   not	  
affected	  by	  SGK3	  knockdown	  (Figure	  5.10).	  This	  result	  confirmed	  that	  the	  effect	  of	  SGK3	  
knockdown	  on	  Akt	  inhibitor	  resistant	  NDRG1	  phosphorylation	  was	  specific.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   5.10	  Rescue	  of	   SGK3	   knockdown	   induced	   loss	   of	  Akt	   inhibitor	   resistant	  NDRG1	  
phosphorylation	  	  
ZR-­‐75-­‐1	  cells	  stably	  expressing	  SGK3	  shRNA	  #D	  resistant	  HA-­‐SGK3	  wild-­‐type	  (wt)	  or	  kinase	  
inactive	   (ki)	  were	  maintained	   in	   the	  presence	  of	   either	   1	  µM	  AZD5363	  or	  DMSO	   for	   10	  
days	  prior	  to	  infection	  with	  SGK3	  shRNA	  #D	  or	  scrambled	  shRNA	  in	  the	  sustained	  presence	  
of	  either	  1	  µM	  AZD5363	  or	  DMSO.	  72	  hours	  post	  infection	  cells	  were	  lysed	  and	  analysed	  
















































5.2.7. In	  vitro	  characterization	  of	  SGK	  inhibitors	  
Results	  obtained	  from	  SGK3	  knockdown	  studies	  demonstrate	  that	  in	  CAMA-­‐1	  and	  ZR-­‐75-­‐1	  
cells	  SGK3	  mediates	  NDRG1	  phosphorylation	  in	  the	  absence	  of	  Akt.	  Therefore	  the	  effects	  
of	   potential	   SGK3	   inhibitors	   in	   cultured	   cells	   can	   be	   determined	   by	   monitoring	   Akt	  
inhibitor	   resistant	   NDRG1	   phosphorylation.	   Three	   SGK	   inhibitors	   were	   obtained	   and	  
initially	   characterised	   in	   vitro.	   One	   of	   the	   inhibitors,	   EMD638683,	   has	   been	   published	  
(Ackermann	   et	   al.,	   2011).	   Two	   of	   the	   inhibitors,	   DSTT	   SGKi1	   and	   DSTT	   SGKi2,	   were	  
obtained	  from	  the	  DSTT	  collaboration	  with	  pharmaceutical	  companies.	  The	  structures	  of	  
these	   compounds	   are	   not	   disclosed.	   DSTT	   SGKi1	   was	   expected	   to	   be	   an	   SGK	   specific	  
inhibitor	  and	  DSTT	  SGKi2	  was	  expected	  to	  be	  a	  dual	  Akt/SGK	  inhibitor.	  In	  order	  to	  test	  the	  
specificities	   of	   these	   inhibitors,	   the	   effects	   of	   1	   µM	   of	   these	   compounds	   upon	   the	  
activities	  of	  141	  protein	  kinases	  in	  vitro	  were	  tested	  (Figure	  5.11-­‐13).	  	  
EMD638683	  did	  not	  inhibit	  any	  kinases	  other	  than	  SGK1	  by	  more	  than	  50%	  being	  the	  most	  
specific	  compound.	  1	  µM	  EMD638683,	  however,	  only	  inhibited	  SGK1	  by	  86%	  (Figure	  5.11).	  
In	   contrast,	  1	  µM	  DSTT	  SGKi1	   inhibited	  SGK1	  by	  95%	  but	  was	   less	   selective.	  1	  µM	  DSTT	  
SGKi1	  inhibited	  31	  kinases	  by	  more	  than	  50%	  and	  15	  kinases	  by	  more	  than	  75%.	  Amongst	  
the	  most	  inhibited	  kinases	  were	  (in	  decreasing	  order	  of	  inhibition):	  GSK3β,	  DYRK1A,	  CLK2,	  
PIM1	  and	  SGK1	  (Figure	  5.12).	  DSTT	  SGKi2	  was	  the	  least	  selective	  compound	  as	  1	  µM	  DSTT	  
SGKi2	  inhibited	  49	  kinases	  by	  more	  than	  50%	  and	  32	  kinases	  by	  more	  than	  75%.	  Amongst	  
the	   most	   inhibited	   kinases	   were	   (in	   decreasing	   order	   of	   inhibition):	   Akt1,	   S6K1,	   MSK1,	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345(F# =)2&1# )91:*,# >19?.%# -9)2(.(9)+# ?9=,2# M&# &Q;&-.&2# .9# ()2=-&# -9:;,&.&# ,9++# 9<#
BTZ4!# ;%9+;%910,*.(9)7# T3$$# 345(F# ?*+# -9:;*1&2# 2(1&-.,0# +(2&AM0A+(2&# ?(.%# .%&# P'.A
+&,&-.(/&# ()%(M(.91# P[TN6"6# ()# [ZAVNA!# -&,,+# *)2# ()# *,+9#JTPAJYAO6"# -&,,+# .%*.# ;9++&++#
&,&/*.&2#345!#,&/&,+7#$%&#-&,,+#?&1&#.1&*.&2#?(.%#!#A#!I#µJ#T3$$#345(F#*)2#P[TN6"6#<91#
9)&#%9=17#!#µJ#P[TUINN#?*+#=+&2#*+#*#;9+(.(/&#-9).19,7#Y9.%# ()%(M(.91+# ,&2# .9#&<<(-(&).#
()%(M(.(9)# 9<# P'.# *+# 2&.&1:()&2# M0# *# 29+&A2&;&)2&).# 1&2=-.(9)# ()# XZP3OI#
;%9+;%910,*.(9)#*)2#%0;&1A;%9+;%910,*.(9)#9<#P'.#(.+&,<#HC(>=1&#N7!UL7#P+#2&:9)+.1*.&2#()#

























































































;%9+;%910,*.(9)# ()#JTPAJYAO6"# -&,,+7# 8)# -9).1*+.#T3$$# 345(F# ,&2# .9# *# 29+&A2&;&)2&).#
2&-1&*+&#()#BTZ4!#;%9+;%910,*.(9)#()#JTPAJYAO6"#-&,,+#()2(-*.()>#.%*.#*.#*19=)2#6#K#!I#
µJ#-9)-&).1*.(9)+# (.# ()%(M(.&2#345!7# 8)#[ZAVNA!#-&,,+@#%9?&/&1@#M9.%#P[TN6"6#*)2#T3$$#
345(F# -*=+&2# *# 29+&A2&;&)2&).# 1&2=-.(9)# ()# BTZ4!# ;%9+;%910,*.(9)# HC(>=1&# N7!UL7#
S9)+(+.&).#?(.%#3456#;%9+;%910,*.(9)#M&()>#:&2(*.&2#M0#M9.%#P'.#*)2#3456# ()#[ZAVNA!#






















































































































































3456# *)2# P'.# *1&# 1&,*.&2# '()*+&+# 1&>=,*.&2# M0# .%&# +*:&# =;+.1&*:# *-.(/*.91+# *)2#
+=+.*()&2# P'.# ()%(M(.(9)# -*=+&+# =;A1&>=,*.(9)# 9<# 3456# ,&/&,+# *)2# *-.(/(.07# $%&1&<91&# .%&#
*M(,(.0#9<#3456#.9#-9:;&)+*.&# <91#P'.A21(/&)#-&,,=,*1#;19,(<&1*.(9)#?*+#)&Q.#&Q*:()&2# ()#
.%&# P'.# ()%(M(.91# +&)+(.(/&# SPJPA!# *)2# [ZAVNA!# -&,,+7# S&,,+# ?&1&# .1*)+2=-&2# ?(.%# .?9#
()2&;&)2&).#3456#+%ZBP+#91#?(.%#+-1*:M,&2#+%ZBP#*)2#.%&#&<<&-.#9<#3456#')9-'29?)#
9)# .%&# +&)+(.(/(.0# 9<# SPJPA!# *)2# [ZAVNA!# -&,,+# .9# M9.%# J5AFFI"# *)2# P[TN6"6# ?*+#
*++&++&2# ()#*#G"A%9=1#29+&# 1&+;9)+&#*++*0# HC(>=1&#N7!GL7#3456#')9-'29?)#2(2#)9.#%*/&#










HAL# SPJPA!# -&,,+# ?&1&# .1*)+2=-&2# ?(.%# 3456# 91# +-1*:M,&2# +%ZBP+7# VF# %9=1+# ;9+.#
()<&-.(9)#-&,,+#?&1&#+&&2&2#9).9#G"A?&,,#;,*.&+#*)2#*,,9?&2#.9#*2%&1&#9/&1)(>%.#;1(91#.9#
&Q;9+=1&#.9#!#)J#K#!I#µJ#9<#J5AFFI"7#G"#%9=1+#,*.&1#-&,,#/(*M(,(.0#?*+#2&.&1:()&2#=+()>#


































































SPJPA!# *)2# [ZAVNA!# -&,,+# ?&1&# +=M^&-.&2# .9# !I# 2*0+# P'.# ()%(M(.(9)# ?(.%# .%&# P$XA
-9:;&.(.(/&# ()%(M(.91#P[TN6"6# ()#912&1#.9#=;A1&>=,*.&#34567#P[TN6"6#?*+#.%&)#?*+%&2#














!"#$%&'()@S'U%&N.%&>.J&/.'R".D' .D&'AL.' "/D"E".-%'AO5(767' "/?$0&1' 0&FF' 0$F.$%&'?&%"M&?'
%&1"1.>/0&'.-'AL.'"/D"E".-%1'
HAL#SPJPA!#-&,,+#?&1&#:*().*()&2#()#.%&#;1&+&)-&#9<#!#µJ#P[TN6"6#91#TJ3W#<91#!I#2*0+7#
$%&# ()%(M(.91# ?*+# ?*+%&2# 9=.@# -&,,+# ?&1&# +&&2&2# 9).9# G"A?&,,# ;,*.&+# *)2# *,,9?&2# .9#
*2%&1&# 9/&1)(>%.# ;1(91# .9# &Q;9+=1&# .9# ()-1&*+()># -9)-&).1*.(9)+# H!# )J# K# !I# µJL# 9<#
P[TN6"67#G"#%9=1+# ,*.&1#-&,,#/(*M(,(.0#?*+#*++&++&2#=+()>#J$3#*++*07#T*.*#?&1&#<(..&2#.9#
29+&K1&+;9)+&# -=1/&+# =+()>#41*;%X*2# X1(+:# N7I7# $%&# 1&+=,.+# *1&# .%&#:&*)+# _# 37T7# 9<# *#
.1(;,(-*.&#*++*0#*)2#*1&#)91:*,(+&2#.9#.%&#TJ3W#-9).19,#.%*.#?*+#+&.#.9#!II`7##HBL#P+#()#





























































































!"#$%&' ()@*' U%&N.%&>.J&/.'R".D' AO5(767' ?-&1' /-.' >F.&%' D-R' UV7=' -%'J;WI' "/D"E"."-/'
>22&0.1'0&FF',%-F"2&%>."-/'
HAL#SPJPA!#-&,,+#?&1&#:*().*()&2#()#.%&#;1&+&)-&#9<#!#µJ#P[TN6"6#91#TJ3W#<91#!I#2*0+7#





()# HAL# &Q-&;.# X865# ()%(M(.91#4TSAIGO!#?*+#=+&27# HCL# *+# ()# HAL# &Q-&;.# [ZAVNA!# -&,,+#?&1&#
=+&27#H5L#*+#()#HBL#&Q-&;.#[ZAVNA!#-&,,+#?&1&#=+&27#
#







































































































;9;=,*.(9)L#91#TJ3W# H;*1&).*,#;9;=,*.(9)L# <91#!I#2*0+#;1(91# .9# ()<&-.(9)#?(.%# ()2(-*.&2#
+%ZBP+# ()# .%&# +=+.*()&2# ;1&+&)-&# 9<# &(.%&1# !# µJ# P[TN6"6# 91# TJ3W7# VF# %9=1+# ;9+.#
()<&-.(9)#P[TN6"6#?*+#?*+%&2#9=.#*)2#-&,,+#?&1&#+&&2&2#9).9#G"A?&,,#;,*.&+#*)2#*,,9?&2#
.9# *2%&1&# 9/&1)(>%.# ;1(91# .9# &Q;9+=1&# .9# !# )J# K# !I#µJ# P[TN6"67# G"# %9=1+# ,*.&1# -&,,#
/(*M(,(.0#?*+#*++&++&2#=+()>#J$3#*++*07#T*.*#?&1&# <(..&2# .9#29+&K1&+;9)+&# -=1/&+#=+()>#







































































































$%&# 2*.*# .%=+# <*1# (:;,(&2# .%*.# =;A1&>=,*.(9)# 9<# 3456# *+# *# 1&+;9)+&# .9# -%19)(-# P'.#




.9# 3456# +%ZBP# aT7# $%&# -&,,+# ?&1&# ;1&A.1&*.&2# ?(.%# P[TN6"6# *)2@# *+# ;1&/(9=+,0@# .%&#
()%(M(.91# ?*+# ?*+%&2# 9<<# *)2# .%&# -&,,+# ?&1&# +=M^&-.&2# .9# *# G"A%9=1# 29+&# 1&+;9)+&#
&Q;&1(:&).#?(.%# .%&# .?9#P'.# ()%(M(.91+7# EQ;1&++(9)# 9<#?(,2# .0;&# M=.# )9.# '()*+&# ()*-.(/&#











[ZAVNA!# -&,,+# +.*M,0#&Q;1&++()>#DPK3456#?(,2A.0;&# H?.L#91# '()*+&A()*-.(/&# H'(L# -9)+.1=-.+#
2&+(>)&2#.9#M&#1&+(+.*).#.9#3456#+%ZBP#aT#?&1&#:*().*()&2#()#.%&#;1&+&)-&#9<#&(.%&1#!#






























































$%&# 2*.*# .%=+# <*1# ;1&+&).&2# (:;,(&+# .%*.# P'.# *-.(/(.0# 29?)A1&>=,*.&+# 3456# ,&/&,+# *)2#
*-.(/(.07# 8)# 912&1# .9# >*()# ()+(>%.+# ().9# .%&#:9,&-=,*1#:&-%*)(+:+# /(*# ?%(-%# P'.# *-.(/(.0#
()<,=&)-&+#3456#,&/&,+#*)2#*-.(/(.0@#[ZAVNA!#-&,,+#?&1&#.1&*.&2#<91#<(/&#2*0+#?(.%#*#1*)>&#9<#
()%(M(.91+#.%*.#.*1>&.#.%&#X865#;*.%?*0#*.#2(<<&1&).#)92&+7#Y&+(2&+#.%&#P'.#()%(M(.91+@#J5A
FFI"# *)2# P[TN6"6@# *,+9# X865# ()%(M(.91# 4TSAIGO!@# XT5!# ()%(M(.91# 435AF66OOVI@# :$WZ#
()%(M(.91#P[TUINN#*)2#:$WZS!#()%(M(.91#Z*;*:0-()#()2=-&2#*)#()-1&*+&#()#3456#;19.&()#
,&/&,+#?%&1&*+#)&(.%&1#3"5#()%(M(.91#XCAOVIU"V!#)91#345#()%(M(.91#EJT"6U"U6#,&2#.9#*)#
()-1&*+&# ()# 3456# ,&/&,+# HC(>=1&# N7FOYL7# 3.1('()>,0@# .%&# ()%(M(.91+# .%*.# ()2=-&2# ()-1&*+&2#
3456#;19.&()#,&/&,+#-9)/&1>&2#9)#:$WZS!#()%(M(.(9)7#P+#EJT"6U"U6#(+#)9.#/&10#;9.&).#()#
-&,,+# HC(>=1&# N7!"L@# *# %(>%# 6I# µJ# -9)-&).1*.(9)# ?*+# =+&27# b('&?(+&@# M&-*=+&# .%&# 3"5#
()%(M(.91#XCAOVIU"V!#9),0#*<<&-.+#3"#;%9+;%910,*.(9)#()#DE5AFG6#-&,,+#*.#*19=)2#6#K#!I#µJ#
HX&*1-&#&.#*,7@#FI!I*L@#!I#µJ#9<#XCAOVIU"V!#?*+#=+&27##
b9)>A.&1:# .1&*.:&).# 9<# [ZAVNA!# -&,,+#?(.%# P'.# ()%(M(.91+# ()2=-&2#P'.# ()%(M(.91# 1&+(+.*).#
BTZ4!# ;%9+;%910,*.(9)# ?%(,+.# -9).19,# 9)&A%9=1# .1&*.:&).+# ()%(M(.&2# BTZ4!#
;%9+;%910,*.(9)7# P+# &Q;&-.&2@# *-=.&# .1&*.:&).# ?(.%# X865# ()%(M(.91# 4TSAIO!# ()%(M(.&2#
;%9+;%910,*.(9)#9<#P'.@#XZP3OI@#3"#*)2#BTZ4!7#3=1;1(+()>,0@#BTZ4!#;%9+;%910,*.(9)#?*+#
)9.#+&)+(.(/&#.9#+=+.*()&2#!FIA%9=1#.1&*.:&).#?(.%#4TSAIGO!#&/&)#.%9=>%#.%&#.1&*.:&).#
()%(M(.&2# ;%9+;%910,*.(9)# 9<# P'.@# XZP3OI# *)2# 3"7# XT5!# ()%(M(.91# 435F66OOVI# ()%(M(.&2#
P'.# $A,99;# H$%16IUL@# XZP3OI@# 3"# *)2#BTZ4!# ;%9+;%910,*.(9)# <9,,9?()># M9.%# !# *)2# !FI#
%9=1+7# $%&# =+&# 9<# :$WZ# '()*+&# ()%(M(.91# P[TUINN# 1&/&*,&2# *# ;1&/(9=+,0# 2&+-1(M&2# M(A





P[TUINN# ()%(M(.&2# ;%9+;%910,*.(9)# 9<# P'.# *.# M9.%# .%&#DJA+(.&# *)2# .%&# $A,99;# *)2# *,+9#
()%(M(.&2# ;%9+;%910,*.(9)# 9<# .%&# P'.# +=M+.1*.&# XZP3OI7# 3=+.*()&2# P[TUINN@# %9?&/&1@#
-*=+&2#2&A;%9+;%910,*.(9)#9<#P'.#DJA+(.&# H3&1OV6L#M=.# ,&2# .9#%0;&1A;%9+;%910,*.(9)#9<#
P'.# $A,99;@# *# ;*1.(*,# 1&-9/&10# 9<# XZP3OI# ;%9+;%910,*.(9)# *)2# %(>%# ,&/&,+# 9<# BTZ4!#
;%9+;%910,*.(9)7#$%&#&,&/*.&2#BTZ4!#;%9+;%910,*.(9)#:*0#M&#2=&#.9#P[TUINN#()2=-&2#
%0;&1A*-.(/*.(9)# 9<# P'.7# Z*;*:0-()# (+# *)# :$WZS!# +&,&-.(/&# ()%(M(.91# M=.# ,9)>A.&1:#
1*;*:0-()# .1&*.:&).# ,&*2+# .9# :$WZSF# ()%(M(.(9)# 2=&# .9# 2(+1=;.(9)# 9<# .%&# ().&>1(.0# 9<#
:$WZSF#-9:;,&Q#H3*1M*++9/#&.#*,7@#FIINL7#P+#&Q;&-.&2@#*-=.&#.1&*.:&).#?(.%#1*;*:0-()#
9),0# *<<&-.&2# 3"# ;%9+;%910,*.(9)7# b9)>A.&1:# 1*;*:0-()# .1&*.:&).# *,+9# ()%(M(.&2# 3"#
;%9+;%910,*.(9)#*)2#:92&+.,0#&,&/*.&2#;%9+;%910,*.(9)#9<#P'.#$A,99;7#3=1;1(+()>,0@#*-=.&#
.1&*.:&).# ?(.%# 3"5# ()%(M(.91# XCAOVIU"V!# 9),0# 1&/&*,&2# *# :()91# &<<&-.# 9)# 3"#
;%9+;%910,*.(9)#M=.#+=+.*()&2#!FI#%9=1#XCAOVIU"V!#.1&*.:&).#&<<(-(&).,0#+=;;1&++&2#3"#
;%9+;%910,*.(9)7# XCAOVIU"V!# %*2# )9# &<<&-.# 9)#P'.@# XZP3OI#91#BTZ4!#;%9+;%910,*.(9)7#
Y9.%#*-=.&#*)2# ,9)>A.&1:# .1&*.:&).+#?(.%#345# ()%(M(.91#EJT"6U"U6#%*2#;*1.(*,#&<<&-.+#
9)#BTZ4!#;%9+;%910,*.(9)#*)2#2(2#)9.#*<<&-.#P'.@#XZP3OI#91#3"#;%9+;%910,*.(9)###HC(>=1&#
N7FOL7###
8)#912&1# .9# .&+.#?%&.%&1# .%&#/*1(9=+# ()%(M(.91+#9<# .%&#X865#;*.%?*0#?9=,2# +=;;1&++#P'.#
()%(M(.91#1&+(+.*).#BTZ4!#;%9+;%910,*.(9)@#.%&#,9)>A.&1:#&Q;&1(:&).#?*+#*,+9#;&1<91:&2#
()# .%&# +=+.*()&2#;1&+&)-&#9<#&(.%&1#J5AFFI"#91#P[TN6"6# HC(>=1&#N7FNL7# 3=1;1(+()>,0@#P'.#
()%(M(.91#1&+(+.*).#BTZ4!#;%9+;%910,*.(9)#?*+#9),0#+&)+(.(/&#.9#+=+.*()&2#.1&*.:&).#?(.%#






















































































































































































HAL# [ZAVNA!# -&,,+# ?&1&# &Q;9+&2# .9# TJ3W@# !# µJ#J5AFFI"# *,9)&# 91# !# µJ#J5AFFI"# ()#





3.1('()>,0@# 3456A:&2(*.&2# BTZ4!# ;%9+;%910,*.(9)# ?*+# 1&+(+.*).# .9# -%19)(-# :$WZS!\F#
()%(M(.(9)7# $9# *221&++# .%(+# 9M+&1/*.(9)# <=1.%&1@# *# '()*+&# *++*0# ?*+# )&Q.# =)2&1.*'&)# ()#
912&1# .9# :&*+=1&# .%&# -*.*,0.(-# *-.(/(.0# 9<# 3456# <9,,9?()># -%19)(-# P'.\:$WZ# ()%(M(.(9)#
HC(>=1&#N7F"L7#[ZAVNA!#-&,,+#?&1&#.1&*.&2#?(.%#TJ3W@#!#µJ#P'.# ()%(M(.91#J5AFFI"@#!#µJ#
:$WZS!\F#()%(M(.91#P[TUINN#91#*#-9:M()*.(9)#9<#J5AFFI"#*)2#P[TUINN#<91#!FI#%9=1+7#
3(:(,*1# .9# *# ;1&/(9=+# &Q;&1(:&).# H3&&# C(>=1&# N7NL@# -&,,+# &Q;9+&2# .9# +=+.*()&2#J5AFFI"#












































































































































.1&*.:&).# ?&1&# *,+9# +=M^&-.&2# .9# *)# *-=.&# !# %9=1# P[TUINN# .1&*.:&).# ()# 912&1# .9#
2(<<&1&).(*.&#M&.?&&)# .%&#&<<&-.+# .%*.# -%19)(-#*)2#*-=.&#:$WZ# ()%(M(.(9)#%*/&#9)#3456#
*-.(/(.07# P+# ;1&/(9=+,0# +%9?)# HC(>=1&# N7NL@# +=+.*()&2#P'.# ()%(M(.(9)# ,&2# .9# &,&/*.&2# 3456#
*-.(/(.0#*)2#DJA+(.&#*)2#$A,99;#;%9+;%910,*.(9)#*+#?&,,#*+#BTZ4!#;%9+;%910,*.(9)# .%*.#
?&1&# *,,# +&)+(.(/&# .9# *-=.&# !# %9=1# .1&*.:&).#?(.%#P[TUINN# HC(>=1&# N7F"L7# 8)# *>1&&:&).#
?(.%# .%&# 2&.&-.(9)# 9<# BTZ4!# ;%9+;%910,*.(9)# =)2&1# -9)2(.(9)+# ()# ?%(-%# M9.%# P'.# *)2#
:$WZ#*1&# ()%(M(.&2#HC(>=1&#N7FNL@#3456#;9++&++&2#%(>%# ,&/&,+#9<#-*.*,0.(-#*-.(/(.0#2&+;(.&#
.%&# -9:M()*.(9)# 9<# +=+.*()&2# P'.# *)2# :$WZ# ()%(M(.(9)# HC(>=1&# N7F"L7# d)2&1# .%&+&#
-9)2(.(9)+@# $A,99;# ;%9+;%910,*.(9)# 9<# 3456# ?*+# *.# +(:(,*1# ,&/&,+# *+# ?(.%# P'.# ()%(M(.(9)#
*,9)&@#M=.#DJA+(.&#;%9+;%910,*.(9)#?*+#+(>)(<(-*).,0#()%(M(.&2#()2(-*.()>#.%*.#.%&#$A,99;#9<#
3456# -*)#M&# ;%9+;%910,*.&2# ()2&;&)2&).,0# 9<# .%&#DJA+(.&7# # 3=+.*()&2#:$WZ# ()%(M(.(9)#
*,9)&#,&2#.9#&,&/*.&2#.9.*,#,&/&,+#9<#3456#;19.&()#?(.%9=.#()<,=&)-()>#3456#'()*+&#*-.(/(.0#
91#;%9+;%910,*.(9)7#P+#*#-9).19,@#.%&#$A,99;#*)2#DJA+(.&#;%9+;%910,*.(9)#9<#3"5#?&1&#*,+9#
:9)(.91&27# DJA+(.&# ;%9+;%910,*.(9)# (+# *# ;1&A1&R=(+(.&# <91# $A,99;# ;%9+;%910,*.(9)# *)2#
*-.(/*.(9)# 9<# 3"5# e1&/(&?&2# ()# HX&*1-&# &.# *,7@# FI!IML7# 3=+.*()&2# P'.# ()%(M(.(9)#:92&+.,0#
()%(M(.&2# 3"5# DJA+(.&# ;%9+;%910,*.(9)# *)2# $A,99;# ;%9+;%910,*.(9)# 1&<,&-.()># .%&# &<<&-.#
.%*.# P'.# ()%(M(.91+# %*/&# 9)# ()%(M(.()>#:$WZS!7# P+# &Q;&-.&2@# +=+.*()&2#:$WZ# ()%(M(.(9)#
*,9)&#*)2# ()#-9:M()*.(9)#?(.%#+=+.*()&2#P'.# ()%(M(.(9)# ,&2# .9#-9:;,&.&# ,9++#9<#3"5#DJA
+(.&#*)2#$A,99;#;%9+;%910,*.(9)7#B9.*M,0@#*#+.19)>#M*)2#.%*.#:(>1*.&2#,9?&1#.%*)#3"5#?*+#
2&.&-.&2# ()# 3"5# $A,99;# (::=)9M,9.# *)*,0+(+7# $%(+# M*)2# :(>%.# 1&;1&+&).# $A,99;#








[ZAVNA!# -&,,+#?&1&# +&&2&2#9).9# !NA-:#2(+%&+@# *,,9?&2# .9# *2%&1&#9/&1)(>%.# *)2# .1&*.&2#
?(.%#TJ3W@#!#µJ#J5AFFI"@#!#µJ#P[TUINN#91#*#-9:M()*.(9)#9<#!#µJ#J5AFFI"#*)2#!#µJ#
P[TUINN# <91# !FI# %9=1+7# C91# TJ3W# -9).19,# *;;19Q(:*.&,0# !Q!IV@# J5AFFI"# .1&*.:&).#
FQ!IV@# P[TUINN# .1&*.:&).# OQ!IV# *)2# J5AFFI"\P[TUINN# .1&*.:&).# UQ!IV# -&,,+# ?&1&#
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